

Disclaimer

The following report(s) provides findings from an FDA initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelssystem.org.

Overview for Request: cder_mpl1r_wp298, Report 2

Request ID: cder_mpl1r_wp298_nsdp_v01

Request Description: In this report, we characterized dispensing and administration patterns of 33 New Molecular Entities (NMEs) approved from August 1, 2018, to December 31, 2018, stratified by age and sex in the Sentinel Distributed Database (SDD).

Sentinel Routine Querying Module: Cohort Identification and Descriptive Analysis module (CIDA), version 14.2.0.

Data Source: We distributed this request to 13 Sentinel Data Partners (DPs) on June 23, 2025. We included aggregate results from all 13 DPs in this report. The study period included data from January 1, 2018, to December 31, 2024. Please see Appendix A for a list of available data dates for each Data Partner. Report 1 includes NMEs approved January 1, 2018 to July 31, 2018.

Study Design: We identified individuals initiating any of the 33 NMEs of interest. We described demographic and clinical characteristics for individuals initiating each NME based on history recorded in the six months prior to initiation of treatment with the relevant drug. The analyses characterized dispensing patterns by examining cumulative exposure episode duration, first exposure episode duration, all exposure episode durations, days supplied per dispensing, and lengths of gaps between episodes, overall and stratified by age group and sex. This was a type five analysis in the Query Request Package (QRP) documentation.

Exposures of Interest: Our exposures of interest were NMEs approved between August 1, 2018, and December 31, 2018, administered or dispensed in any care setting. These were defined using Healthcare Common Procedure Coding System (HCPCS) procedure codes and National Drug Codes (NDCs). Please see Appendix B for a list of non-proprietary and proprietary names of medical products and Appendix C for a list of procedure codes used to define exposures in this request. All valid exposure episodes were included.

Cohort Eligibility Criteria: We defined index exposure as the first qualifying administration or dispensing of a given NME to an individual during the study period. We required individuals to be enrolled in health plans with both medical and drug coverage for at least 183 days prior to their index exposure, during which gaps in coverage of up to 45 days were allowed. The following age groups were included: 0-17, 18-24, 25-40, 41-64, 65+ years.

Baseline Characteristics: We described demographic characteristics such as sex, age, and calendar year on the day of each index NME exposure. We also described 33 clinical characteristics based on history recorded in the six months prior to the index exposure. The set of clinical characteristics included 26 chronic conditions and seven lifestyle-related conditions. Chronic conditions were defined using Centers for Medicare and Medicaid Services' (CMS) Chronic Conditions Data Warehouse¹ (CCW) algorithms and included: acute myocardial infarction, Alzheimer's disease, Non-Alzheimer's Dementia, atrial fibrillation, diabetes mellitus, heart failure, hyperlipidemia, hypertension, depression, ischemic heart disease, rheumatoid arthritis/osteoarthritis, stroke/transient ischemic attack (TIA), breast cancer, colorectal cancer, prostate cancer, lung cancer, endometrial cancer, acquired hypothyroidism, anemia, asthma, benign prostatic hyperplasia, chronic kidney disease, chronic obstructive pulmonary disease (COPD) and bronchiectasis, glaucoma, osteoporosis, and liver disease. Lifestyle-related conditions included: obesity, overweight, smoking, alcohol abuse or dependence, drug abuse or dependence, history of cardiac arrest, and history of coronary angioplasty or bypass. International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS) procedure codes, Healthcare Common Procedure Coding System (HCPCS) procedure codes, Current Procedural Terminology, Fourth Edition (CPT-4) procedure codes, and NDCs were used to define the clinical characteristics. Please see Appendix D for a list of diagnosis and procedure codes, Appendix E for a list of non-proprietary and proprietary names of medical products used to define baseline characteristics in this request.

Please refer to Appendices F, G, and H for the specifications of parameters used in this request, baseline characteristics used in this request, and a design diagram.

Limitations: Algorithms used to define exposures and inclusion criteria are imperfect; thus, it is possible that there may be misclassification. Therefore, data should be interpreted with this limitation in mind.

Notes: Please contact the Sentinel Operations Center (info@sentinelssystem.org) for questions and to provide comments/suggestions for future enhancements to this document. For more information on Sentinel's routine querying modules, please refer to the documentation (<https://dev.sentinelssystem.org/projects/SENTINEL/repos/sentinel-routine-querying-tool-documentation/browse>).

¹Chronic Conditions Data Warehouse. Condition Categories -Chronic Conditions Data Warehouse. <https://www.ccwdata.org/web/guest/condition-categories>

Table of Contents

<u>Glossary</u>	List of Terms to Define the Cohort Identification and Descriptive Analysis (CIDA) Found in this Report
<u>Table 1a</u>	Aggregated Characteristics of mogamulizumab-kpkc in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 1b</u>	Aggregated Characteristics of patisiran in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 1c</u>	Aggregated Characteristics of segesterone acetate and ethinyl estradiol vaginal system in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 1d</u>	Aggregated Characteristics of migalastat in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 1e</u>	Aggregated Characteristics of stiripentol in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 1f</u>	Aggregated Characteristics of cenegermin-bkbj in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 1g</u>	Aggregated Characteristics of lanadelumab in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 1h</u>	Aggregated Characteristics of eravacycline in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 1i</u>	Aggregated Characteristics of doravirine in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 1j</u>	Aggregated Characteristics of moxetumomab pasudotox-tdfk in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 1k</u>	Aggregated Characteristics of fremanezumab-vfrm in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 1l</u>	Aggregated Characteristics of duvelisib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 1m</u>	Aggregated Characteristics of galcanezumab-gnlm in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 1n</u>	Aggregated Characteristics of dacomitinib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 1o</u>	Aggregated Characteristics of cemiplimab-rwlc in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 1p</u>	Aggregated Characteristics of sarecycline in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 1q</u>	Aggregated Characteristics of omadacycline in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 1r</u>	Aggregated Characteristics of elapegademase-lvlr in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 1s</u>	Aggregated Characteristics of inotersen in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 1t</u>	Aggregated Characteristics of talazoparib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 1u</u>	Aggregated Characteristics of baloxavir marboxil in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 1v</u>	Aggregated Characteristics of lorlatinib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 1w</u>	Aggregated Characteristics of revefenacin in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 1x</u>	Aggregated Characteristics of rifamycin in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Table of Contents

<u>Table 1y</u>	Aggregated Characteristics of emapalumab-lzsg in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 1z</u>	Aggregated Characteristics of glasdegib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 1aa</u>	Aggregated Characteristics of larotrectinib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 1ab</u>	Aggregated Characteristics of amifampridine in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 1ac</u>	Aggregated Characteristics of gilteritinib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 1ad</u>	Aggregated Characteristics of prucalopride in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 1ae</u>	Aggregated Characteristics of calaspargase pegol-mknl in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 1af</u>	Aggregated Characteristics of tagraxofusp-erzs in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 1ag</u>	Aggregated Characteristics of ravulizumab in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 2a</u>	Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 2b</u>	Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 2c</u>	Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex
<u>Table 2d</u>	Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex
<u>Table 2e</u>	Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group
<u>Table 2f</u>	Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group
<u>Table 3a</u>	Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 3b</u>	Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 3c</u>	Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex
<u>Table 3d</u>	Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex
<u>Table 3e</u>	Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group
<u>Table 3f</u>	Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group
<u>Table 4a</u>	Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 4b</u>	Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 4c</u>	Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex
<u>Table 4d</u>	Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

Table of Contents

<u>Table 4e</u>	Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group
<u>Table 4f</u>	Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group
<u>Table 5a</u>	Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 5b</u>	Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 5c</u>	Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex
<u>Table 5d</u>	Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex
<u>Table 5e</u>	Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group
<u>Table 5f</u>	Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group
<u>Table 6a</u>	Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 6b</u>	Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 6c</u>	Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex
<u>Table 6d</u>	Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex
<u>Table 6e</u>	Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group
<u>Table 6f</u>	Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group
<u>Table 7a</u>	Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 7b</u>	Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex
<u>Table 7c</u>	Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group
<u>Table 8a</u>	Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 8b</u>	Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex
<u>Table 8c</u>	Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group
<u>Table 9</u>	Summary of Reasons Treatment Episodes Ended for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 10</u>	Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1a</u>	Patient Entry into Study by Month for mogamulizumab-kpkc in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1b</u>	Patient Entry into Study by Month for patisiran in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1c</u>	Patient Entry into Study by Month for segesterone acetate and ethinyl estradiol vaginal system in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Table of Contents

<u>Figure 1d</u>	Patient Entry into Study by Month for migalastat in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1e</u>	Patient Entry into Study by Month for stiripentol in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1f</u>	Patient Entry into Study by Month for cenegermin-bkbj in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1g</u>	Patient Entry into Study by Month for lanadelumab in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1h</u>	Patient Entry into Study by Month for eravacycline in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1i</u>	Patient Entry into Study by Month for doravirine in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1j</u>	Patient Entry into Study by Month for moxetumomab pasudotox-tdfk in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1k</u>	Patient Entry into Study by Month for fremanezumab-vfrm in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1l</u>	Patient Entry into Study by Month for duvelisib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1m</u>	Patient Entry into Study by Month for galcanezumab-gnlm in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1n</u>	Patient Entry into Study by Month for dacomitinib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1o</u>	Patient Entry into Study by Month for cemiplimab-rwlc in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1p</u>	Patient Entry into Study by Month for sarecycline in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1q</u>	Patient Entry into Study by Month for omadacycline in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1r</u>	Patient Entry into Study by Month for elapegadomase-lvlr in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1s</u>	Patient Entry into Study by Month for inotersen in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1t</u>	Patient Entry into Study by Month for talazoparib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1u</u>	Patient Entry into Study by Month for baloxavir marboxil in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1v</u>	Patient Entry into Study by Month for lorlatinib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1w</u>	Patient Entry into Study by Month for revefenacin in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1x</u>	Patient Entry into Study by Month for rifamycin in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1y</u>	Patient Entry into Study by Month for emapalumab-lzsg in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1z</u>	Patient Entry into Study by Month for glasdegib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1aa</u>	Patient Entry into Study by Month for larotrectinib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1ab</u>	Patient Entry into Study by Month for amifampridine in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Table of Contents

<u>Figure 1ac</u>	Patient Entry into Study by Month for gilteritinib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1ad</u>	Patient Entry into Study by Month for prucalopride in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1ae</u>	Patient Entry into Study by Month for calaspargase pegol-mknl in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1af</u>	Patient Entry into Study by Month for tagraxofusp-erzs in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1ag</u>	Patient Entry into Study by Month for ravulizumab in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Appendix A</u>	Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date
<u>Appendix B</u>	List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exposures in this Request
<u>Appendix C</u>	List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS), and National Drug Code (NDC) Codes Used to Define Exposures in this Request
<u>Appendix D</u>	List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request
<u>Appendix E</u>	List of Nonproprietary and Brand Proprietary of Medical Products Used to Define Covariates in this Request
<u>Appendix F</u>	Specifications Used in this Request
<u>Appendix G</u>	Baseline Characteristics Used in this Request
<u>Appendix H</u>	Design Diagram Used to Identify First Valid Index Exposure Meeting Incidence Washout Criteria and All Subsequent Exposure Episodes in this Request

**Glossary of Terms for Analyses Using
Cohort Identification and Descriptive Analysis (CIDA) Module***

Amount Supplied - number of units (pills, tablets, vials) dispensed. Net amount per National Drug Code (NDC) per

Blackout Period - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.

Care Setting - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Charlson/Elixhauser Combined Comorbidity Score - calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (e.g., in the 183 days prior to index).

Code Days - the minimum number of times the diagnosis must be found during the evaluation period in order to fulfill the algorithm to identify the corresponding patient characteristic.

Cohort Definition (drug/exposure) - indicates how the cohort will be defined: 01: Cohort includes only the first valid treatment episode during the query period; 02: Cohort includes all valid treatment episodes during the query period; 03: Cohort includes all valid treatment episodes during the query period until an event occurs.

Computed Start Marketing Date - represents the first observed dispensing date among all valid users within a GROUP (scenario) within each Data Partner site.

Days Supplied - number of days supplied for all dispensings in qualifying treatment episodes.

Eligible Members - number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.

Enrollment Gap - number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled" sequence.

Episodes - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.

Episode Gap - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.

Event Deduplication - specifies how events are counted by the Modular Program (MP) algorithm: 0: Counts all occurrences of a health outcome of interest (HOI) during an exposure episode; 1: de-duplicates occurrences of the same HOI code and code type on the same day; 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).

Exposure Episode Length - number of days after exposure initiation that is considered "exposed time."

Exposure Extension Period - number of days post treatment period in which the outcomes/events are counted for a treatment episode. Extensions are added after any episode gaps have been bridged.

Lookback Period - number of days wherein a member is required to have evidence of pre-existing condition

Maximum Episode Duration - truncates exposure episodes after a requester-specified number of exposed days. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

**Glossary of Terms for Analyses Using
Cohort Identification and Descriptive Analysis (CIDA) Module***

Member-Years - sum of all days of enrollment with medical and drug coverage in the query period preceded by an exposure washout period all divided by 365.25.

Minimum Days Supplied - specifies a minimum number of days in length of the days supplied for the episode to be considered.

Minimum Episode Duration - specifies a minimum number of days in length of the episode for it to be considered. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Monitoring Period - used to define time periods of interest for both sequential analysis and simple cohort characterization requests.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Caresetting/PDX parameter.

Query Period - period in which the modular program looks for exposures and outcomes of interest.

Switch Evaluation Step Value - value used to differentiate evaluation step. Each switch pattern can support up to 2 evaluation steps (0 = switch pattern evaluation start; 1 = first evaluation; 2 = second evaluation).

Switch Gap Inclusion Indicator - indicator for whether gaps in treatment episodes that are included in a switch episode will be counted as part of the switch episode duration.

Switch Pattern Cohort Inclusion Date - indicates which date to use for inclusion into the switch pattern cohort of interest as well as optionally as the index date of the treatment episode initiating the switch pattern. Valid options are the product approval date, product marketing date, other requester defined date, or computed start marketing date.

Switch Pattern Cohort Inclusion Strategy - indicates how the switch pattern cohort inclusion date will be used: 01: used only as a switch cohort entry date. First treatment episode dispensing date is used as index for computing time to first switch; 02: used as switch cohort entry date and as initial switch step index date for computing time to first switch.

Treatment Episode Truncation Indicator - indicates whether the exposure episode will be truncated at the occurrence of a requester-specified code.

Washout Period (drug/exposure) - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.

Washout Period (event/outcome) - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.

Years at Risk - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

*all terms may not be used in this report

Table 1a. Aggregated Characteristics of mogamulizumab-kpkc in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

mogamulizumab-kpkc		
Patient Characteristics	Number	Percent
Unique patients	1,147	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	70.1	10.8
Age	Number	Percent
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	252	22.0%
≥ 65 years	861	75.1%
Sex		
Female	495	43.2%
Male	652	56.8%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	192	16.7%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	150	13.1%
White	780	68.0%
Hispanic origin		
Yes	24	2.1%
No	891	77.7%
Unknown	232	20.2%
Year		
2018	*****	*****
2019	279	24.3%
2020	183	16.0%
2021	184	16.0%
2022	171	14.9%
2023	188	16.4%
2024	*****	*****
Health Characteristics		
Acute Myocardial Infarction	14	1.2%
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	46	4.0%
Atrial Fibrillation	140	12.2%

Table 1a. Aggregated Characteristics of mogamulizumab-kpkc in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

mogamulizumab-kpkc		
Health Characteristics	Number	Percent
Diabetes Mellitus	280	24.4%
Heart Failure	171	14.9%
Hyperlipidemia	540	47.1%
Hypertension	625	54.5%
Depression	243	21.2%
Ischemic Heart Disease	253	22.1%
Rheumatoid Arthritis/Osteoarthritis	155	13.5%
Stroke/TIA ³	29	2.5%
Breast Cancer	40	3.5%
Colorectal Cancer	19	1.7%
Prostate Cancer	67	5.8%
Lung Cancer	13	1.1%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	277	24.1%
Anemia	446	38.9%
Asthma	61	5.3%
Benign Prostatic Hyperplasia	100	8.7%
Chronic Kidney Disease	172	15.0%
COPD ⁴ and Bronchiectasis	109	9.5%
Glaucoma	100	8.7%
Osteoporosis	48	4.2%
Obesity: diagnosed or identified by weight management procedures	198	17.3%
Obesity: identified by weight management-related dispensings	15	1.3%
Overweight	132	11.5%
Smoking: diagnosed or identified by smoking cessation procedures	352	30.7%
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	22	1.9%
Drug Abuse or Dependence	43	3.7%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	86	7.5%
Liver Disease Based on CCW ⁵ Definition	59	5.1%
Liver Disease Extended Definition (CCW + Additional Codes)	60	5.2%
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	29.2	17.1
Mean number of emergency room encounters	0.5	1.1
Mean number of inpatient hospital encounters	0.5	1.1
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	8.2	12.8

Table 1a. Aggregated Characteristics of mogamulizumab-kpkc in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

mogamulizumab-kpkc		
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of filled prescriptions	28.0	19.3
Mean number of generics dispensed	12.3	6.6
Mean number of unique drug classes dispensed	11.1	5.8

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*******Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.**

Table 1b. Aggregated Characteristics of patisiran in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

patisiran		
Patient Characteristics	Number	Percent
Unique patients	625	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	68.6	9.3
Age	Number	Percent
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	139	22.2%
≥ 65 years	471	75.4%
Sex		
Female	227	36.3%
Male	398	63.7%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	213	34.1%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	82	13.1%
White	310	49.6%
Hispanic origin		
Yes	*****	*****
No	493	78.9%
Unknown	*****	*****
Year		
2018	*****	*****
2019	187	29.9%
2020	109	17.4%
2021	147	23.5%
2022	120	19.2%
2023	41	6.6%
2024	*****	*****
Health Characteristics		
Acute Myocardial Infarction	14	2.2%
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	*****	*****
Atrial Fibrillation	151	24.2%

Table 1b. Aggregated Characteristics of patisiran in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

patisiran		
Health Characteristics	Number	Percent
Diabetes Mellitus	125	20.0%
Heart Failure	411	65.8%
Hyperlipidemia	240	38.4%
Hypertension	325	52.0%
Depression	108	17.3%
Ischemic Heart Disease	178	28.5%
Rheumatoid Arthritis/Osteoarthritis	126	20.2%
Stroke/TIA ³	34	5.4%
Breast Cancer	13	2.1%
Colorectal Cancer	*****	*****
Prostate Cancer	38	6.1%
Lung Cancer	*****	*****
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	75	12.0%
Anemia	168	26.9%
Asthma	30	4.8%
Benign Prostatic Hyperplasia	61	9.8%
Chronic Kidney Disease	160	25.6%
COPD ⁴ and Bronchiectasis	50	8.0%
Glaucoma	81	13.0%
Osteoporosis	25	4.0%
Obesity: diagnosed or identified by weight management	80	12.8%
Obesity: identified by weight management-related dispensings	*****	*****
Overweight	47	7.5%
Smoking: diagnosed or identified by smoking cessation	150	24.0%
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	26	4.2%
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	44	7.0%
Liver Disease Based on CCW ⁵ Definition	60	9.6%
Liver Disease Extended Definition (CCW + Additional Codes)	60	9.6%
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	19.9	13.7
Mean number of emergency room encounters	0.5	1.2
Mean number of inpatient hospital encounters	0.3	0.8
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	6.6	12.1

Table 1c. Aggregated Characteristics of segesterone acetate and ethinyl estradiol vaginal system in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

segesterone acetate and ethinyl estradiol vaginal system		
Patient Characteristics	Number	Percent
Unique patients	19,514	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	29.2	7.9
Age	Number	Percent
0-17 years	*****	*****
18-24 years	6,100	31.3%
25-40 years	10,830	55.5%
41-64 years	1,724	8.8%
≥ 65 years	*****	*****
Sex		
Female	19,473	99.8%
Male	41	0.2%
Race ²		
American Indian or Alaska Native	82	0.4%
Asian	587	3.0%
Black or African American	1,342	6.9%
Multi-racial	658	3.4%
Native Hawaiian or Other Pacific Islander	15	0.1%
Unknown	9,524	48.8%
White	7,306	37.4%
Hispanic origin		
Yes	1,771	9.1%
No	7,149	36.6%
Unknown	10,594	54.3%
Year		
2018	0	0.0%
2019	186	1.0%
2020	3,618	18.5%
2021	6,797	34.8%
2022	4,112	21.1%
2023	2,687	13.8%
2024	2,114	10.8%
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease	0	0.0%
Non-Alzheimer's Dementia	*****	*****
Atrial Fibrillation	*****	*****

Table 1c. Aggregated Characteristics of segesterone acetate and ethinyl estradiol vaginal system in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

segesterone acetate and ethinyl estradiol vaginal system		
Health Characteristics	Number	Percent
Diabetes Mellitus	181	0.9%
Heart Failure	15	0.1%
Hyperlipidemia	303	1.6%
Hypertension	256	1.3%
Depression	3,631	18.6%
Ischemic Heart Disease	*****	*****
Rheumatoid Arthritis/Osteoarthritis	215	1.1%
Stroke/TIA ³	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	364	1.9%
Anemia	937	4.8%
Asthma	390	2.0%
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	18	0.1%
COPD ⁴ and Bronchiectasis	21	0.1%
Glaucoma	89	0.5%
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management	1,883	9.6%
Obesity: identified by weight management-related dispensings	277	1.4%
Overweight	717	3.7%
Smoking: diagnosed or identified by smoking cessation	681	3.5%
Smoking: identified by smoking-related dispensings	56	0.3%
Alcohol Abuse or Dependence	153	0.8%
Drug Abuse or Dependence	380	1.9%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	*****	*****
Liver Disease Based on CCW ⁵ Definition	76	0.4%
Liver Disease Extended Definition (CCW + Additional Codes)	78	0.4%
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	6.4	8.1
Mean number of emergency room encounters	0.2	0.7
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.0

Table 1c. Aggregated Characteristics of segesterone acetate and ethinyl estradiol vaginal system in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

segesterone acetate and ethinyl estradiol vaginal system		
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of other ambulatory encounters	2.0	4.8
Mean number of filled prescriptions	7.2	9.2
Mean number of generics dispensed	3.7	3.5
Mean number of unique drug classes dispensed	3.5	3.3

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*******Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.**

Table 1d. Aggregated Characteristics of migalastat in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

migalastat		
Patient Characteristics	Number	Percent
Unique patients	261	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	49.7	14.2
Age	Number	Percent
0-17 years	0	0.0%
18-24 years	20	7.7%
25-40 years	66	25.3%
41-64 years	106	40.6%
≥ 65 years	69	26.4%
Sex		
Female	126	48.3%
Male	135	51.7%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	73	28.0%
White	170	65.1%
Hispanic origin		
Yes	*****	*****
No	162	62.1%
Unknown	*****	*****
Year		
2018	26	10.0%
2019	49	18.8%
2020	43	16.5%
2021	34	13.0%
2022	25	9.6%
2023	40	15.3%
2024	44	16.9%
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease	0	0.0%
Non-Alzheimer's Dementia	*****	*****
Atrial Fibrillation	24	9.2%

Table 1d. Aggregated Characteristics of migalastat in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

migalastat		
Health Characteristics	Number	Percent
Diabetes Mellitus	25	9.6%
Heart Failure	43	16.5%
Hyperlipidemia	48	18.4%
Hypertension	74	28.4%
Depression	59	22.6%
Ischemic Heart Disease	35	13.4%
Rheumatoid Arthritis/Osteoarthritis	17	6.5%
Stroke/TIA ³	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	0	0.0%
Lung Cancer	*****	*****
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	16	6.1%
Anemia	27	10.3%
Asthma	14	5.4%
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	43	16.5%
COPD ⁴ and Bronchiectasis	*****	*****
Glaucoma	11	4.2%
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	49	18.8%
Obesity: identified by weight management-related dispensings	*****	*****
Overweight	19	7.3%
Smoking: diagnosed or identified by smoking cessation procedures	30	11.5%
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	*****	*****
Liver Disease Based on CCW ⁵ Definition	*****	*****
Liver Disease Extended Definition (CCW + Additional Codes)	*****	*****
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	13.8	12.7
Mean number of emergency room encounters	0.4	0.9
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	5.5	13.1

Table 1d. Aggregated Characteristics of migalastat in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

migalastat		
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of filled prescriptions	18.0	16.9
Mean number of generics dispensed	6.9	5.4
Mean number of unique drug classes dispensed	6.5	4.9

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*******Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.**

Table 1e. Aggregated Characteristics of stiripentol in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

stiripentol		
Patient Characteristics	Number	Percent
Unique patients	531	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	12.7	7.1
Age	Number	Percent
0-17 years	399	75.1%
18-24 years	99	18.6%
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	0	0.0%
Sex		
Female	263	49.5%
Male	268	50.5%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	31	5.8%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	209	39.4%
White	267	50.3%
Hispanic origin		
Yes	60	11.3%
No	322	60.6%
Unknown	149	28.1%
Year		
2018	0	0.0%
2019	201	37.9%
2020	166	31.3%
2021	98	18.5%
2022	24	4.5%
2023	21	4.0%
2024	21	4.0%
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease	0	0.0%
Non-Alzheimer's Dementia	*****	*****
Atrial Fibrillation	0	0.0%

Table 1e. Aggregated Characteristics of stiripentol in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

stiripentol		
Health Characteristics	Number	Percent
Diabetes Mellitus	*****	*****
Heart Failure	*****	*****
Hyperlipidemia	*****	*****
Hypertension	*****	*****
Depression	*****	*****
Ischemic Heart Disease	0	0.0%
Rheumatoid Arthritis/Osteoarthritis	0	0.0%
Stroke/TIA ³	*****	*****
Breast Cancer	0	0.0%
Colorectal Cancer	*****	*****
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	*****	*****
Anemia	26	4.9%
Asthma	20	3.8%
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	*****	*****
COPD ⁴ and Bronchiectasis	*****	*****
Glaucoma	0	0.0%
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	*****	*****
Obesity: identified by weight management-related dispensings	*****	*****
Overweight	*****	*****
Smoking: diagnosed or identified by smoking cessation procedures	0	0.0%
Smoking: identified by smoking-related dispensings	0	0.0%
Alcohol Abuse or Dependence	0	0.0%
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	0	0.0%
Liver Disease Based on CCW ⁵ Definition	*****	*****
Liver Disease Extended Definition (CCW + Additional Codes)	*****	*****
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	14.1	20.2
Mean number of emergency room encounters	0.8	1.7
Mean number of inpatient hospital encounters	0.3	0.7
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	50.8	56.6

Table 1e. Aggregated Characteristics of stiripentol in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

stiripentol		
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of filled prescriptions	25.6	18.1
Mean number of generics dispensed	7.2	4.7
Mean number of unique drug classes dispensed	6.6	4.2

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*******Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.**

Table 1f. Aggregated Characteristics of cenegermin-bkbj in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

cenegermin-bkbj		
Patient Characteristics	Number	Percent
Unique patients	9,413	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	71.1	12.5
Age	Number	Percent
0-17 years	69	0.7%
18-24 years	47	0.5%
25-40 years	335	3.6%
41-64 years	1,702	18.1%
≥ 65 years	7,260	77.1%
Sex		
Female	6,152	65.4%
Male	3,261	34.6%
Race ²		
American Indian or Alaska Native	43	0.5%
Asian	289	3.1%
Black or African American	427	4.5%
Multi-racial	34	0.4%
Native Hawaiian or Other Pacific Islander	17	0.2%
Unknown	1,140	12.1%
White	7,463	79.3%
Hispanic origin		
Yes	258	2.7%
No	7,504	79.7%
Unknown	1,651	17.5%
Year		
2018	0	0.0%
2019	997	10.6%
2020	1,375	14.6%
2021	1,593	16.9%
2022	1,704	18.1%
2023	2,065	21.9%
2024	1,679	17.8%
Health Characteristics	Number	Percent
Acute Myocardial Infarction	61	0.6%
Alzheimer's Disease	104	1.1%
Non-Alzheimer's Dementia	366	3.9%
Atrial Fibrillation	1,112	11.8%

Table 1f. Aggregated Characteristics of cenegermin-bkbj in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

cenegermin-bkbj		
Health Characteristics	Number	Percent
Diabetes Mellitus	2,625	27.9%
Heart Failure	1,343	14.3%
Hyperlipidemia	3,687	39.2%
Hypertension	4,771	50.7%
Depression	2,001	21.3%
Ischemic Heart Disease	2,017	21.4%
Rheumatoid Arthritis/Osteoarthritis	2,259	24.0%
Stroke/TIA ³	418	4.4%
Breast Cancer	324	3.4%
Colorectal Cancer	95	1.0%
Prostate Cancer	194	2.1%
Lung Cancer	101	1.1%
Endometrial Cancer	26	0.3%
Acquired Hypothyroidism	1,579	16.8%
Anemia	2,310	24.5%
Asthma	431	4.6%
Benign Prostatic Hyperplasia	420	4.5%
Chronic Kidney Disease	1,664	17.7%
COPD ⁴ and Bronchiectasis	839	8.9%
Glaucoma	3,108	33.0%
Osteoporosis	788	8.4%
Obesity: diagnosed or identified by weight management	1,627	17.3%
Obesity: identified by weight management-related dispensings	263	2.8%
Overweight	878	9.3%
Smoking: diagnosed or identified by smoking cessation procedures	1,639	17.4%
Smoking: identified by smoking-related dispensings	142	1.5%
Alcohol Abuse or Dependence	158	1.7%
Drug Abuse or Dependence	324	3.4%
History of Cardiac Arrest	37	0.4%
History of Coronary Angioplasty or Bypass	628	6.7%
Liver Disease Based on CCW ⁵ Definition	349	3.7%
Liver Disease Extended Definition (CCW + Additional Codes)	361	3.8%
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	22.1	17.7
Mean number of emergency room encounters	0.4	1.1
Mean number of inpatient hospital encounters	0.2	0.6
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	5.8	12.6

Table 1f. Aggregated Characteristics of cenegermin-bkbj in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

cenegermin-bkbj		
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of filled prescriptions	27.7	21.5
Mean number of generics dispensed	11.8	6.3
Mean number of unique drug classes dispensed	10.7	5.5

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

Table 1g. Aggregated Characteristics of lanadelumab in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

lanadelumab		
Patient Characteristics	Number	Percent
Unique patients	1,451	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	44.2	15.0
Age	Number	Percent
0-17 years	125	8.6%
18-24 years	137	9.4%
25-40 years	399	27.5%
41-64 years	535	36.9%
≥ 65 years	255	17.6%
Sex		
Female	989	68.2%
Male	462	31.8%
Race ²		
American Indian or Alaska Native	16	1.1%
Asian	18	1.2%
Black or African American	118	8.1%
Multi-racial	20	1.4%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	488	33.6%
White	791	54.5%
Hispanic origin		
Yes	95	6.5%
No	843	58.1%
Unknown	513	35.4%
Year		
2018	178	12.3%
2019	387	26.7%
2020	243	16.7%
2021	198	13.6%
2022	155	10.7%
2023	167	11.5%
2024	123	8.5%
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	*****	*****
Atrial Fibrillation	29	2.0%

Table 1g. Aggregated Characteristics of Ixarelumab in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Ixarelumab		
Health Characteristics	Number	Percent
Diabetes Mellitus	129	8.9%
Heart Failure	48	3.3%
Hyperlipidemia	207	14.3%
Hypertension	301	20.7%
Depression	312	21.5%
Ischemic Heart Disease	87	6.0%
Rheumatoid Arthritis/Osteoarthritis	153	10.5%
Stroke/TIA ³	12	0.8%
Breast Cancer	15	1.0%
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	118	8.1%
Anemia	153	10.5%
Asthma	161	11.1%
Benign Prostatic Hyperplasia	16	1.1%
Chronic Kidney Disease	54	3.7%
COPD ⁴ and Bronchiectasis	68	4.7%
Glaucoma	33	2.3%
Osteoporosis	34	2.3%
Obesity: diagnosed or identified by weight management procedures	265	18.3%
Obesity: identified by weight management-related dispensings	34	2.3%
Overweight	83	5.7%
Smoking: diagnosed or identified by smoking cessation procedures	214	14.7%
Smoking: identified by smoking-related dispensings	11	0.8%
Alcohol Abuse or Dependence	14	1.0%
Drug Abuse or Dependence	70	4.8%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	18	1.2%
Liver Disease Based on CCW ⁵ Definition	47	3.2%
Liver Disease Extended Definition (CCW + Additional Codes)	49	3.4%
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	11.9	13.2
Mean number of emergency room encounters	1.1	3.1
Mean number of inpatient hospital encounters	0.3	1.2
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	5.1	13.6

Table 1g. Aggregated Characteristics of lanadelumab in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

lanadelumab		
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of filled prescriptions	18.7	20.1
Mean number of generics dispensed	7.2	6.2
Mean number of unique drug classes dispensed	6.7	5.6

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

******Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.**

Table 1h. Aggregated Characteristics of eravacycline in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

eravacycline		
Patient Characteristics	Number	Percent
Unique patients	1,111	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	62.8	13.3
Age	Number	Percent
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	103	9.3%
41-64 years	419	37.7%
≥ 65 years	572	51.5%
Sex		
Female	566	50.9%
Male	545	49.1%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	20	1.8%
Black or African American	125	11.3%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	195	17.6%
White	758	68.2%
Hispanic origin		
Yes	45	4.1%
No	838	75.4%
Unknown	228	20.5%
Year		
2018	*****	*****
2019	*****	*****
2020	165	14.9%
2021	260	23.4%
2022	246	22.1%
2023	214	19.3%
2024	131	11.8%
Health Characteristics	Number	Percent
Acute Myocardial Infarction	42	3.8%
Alzheimer's Disease	16	1.4%
Non-Alzheimer's Dementia	101	9.1%
Atrial Fibrillation	229	20.6%

Table 1h. Aggregated Characteristics of eravacycline in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

eravacycline		
Health Characteristics	Number	Percent
Diabetes Mellitus	499	44.9%
Heart Failure	320	28.8%
Hyperlipidemia	600	54.0%
Hypertension	833	75.0%
Depression	398	35.8%
Ischemic Heart Disease	356	32.0%
Rheumatoid Arthritis/Osteoarthritis	316	28.4%
Stroke/TIA ³	90	8.1%
Breast Cancer	40	3.6%
Colorectal Cancer	45	4.1%
Prostate Cancer	40	3.6%
Lung Cancer	23	2.1%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	253	22.8%
Anemia	669	60.2%
Asthma	134	12.1%
Benign Prostatic Hyperplasia	115	10.4%
Chronic Kidney Disease	382	34.4%
COPD ⁴ and Bronchiectasis	304	27.4%
Glaucoma	63	5.7%
Osteoporosis	77	6.9%
Obesity: diagnosed or identified by weight management procedures	424	38.2%
Obesity: identified by weight management-related dispensings	41	3.7%
Overweight	141	12.7%
Smoking: diagnosed or identified by smoking cessation procedures	448	40.3%
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	71	6.4%
Drug Abuse or Dependence	107	9.6%
History of Cardiac Arrest	45	4.1%
History of Coronary Angioplasty or Bypass	132	11.9%
Liver Disease Based on CCW ⁵ Definition	229	20.6%
Liver Disease Extended Definition (CCW + Additional Codes)	230	20.7%
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	31.0	28.6
Mean number of emergency room encounters	1.6	3.2
Mean number of inpatient hospital encounters	1.8	1.8
Mean number of non-acute institutional encounters	0.4	0.9
Mean number of other ambulatory encounters	34.0	39.4

Table 1h. Aggregated Characteristics of eravacycline in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

eravacycline		
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of filled prescriptions	33.4	28.1
Mean number of generics dispensed	14.1	7.6
Mean number of unique drug classes dispensed	12.8	6.6

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*******Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.**

Table 1i. Aggregated Characteristics of doravirine in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

doravirine		
Patient Characteristics	Number	Percent
Unique patients	8,215	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	54.3	11.4
Age	Number	Percent
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	1,331	16.2%
41-64 years	5,059	61.6%
≥ 65 years	1,720	20.9%
Sex		
Female	2,181	26.5%
Male	6,034	73.5%
Race ²		
American Indian or Alaska Native	52	0.6%
Asian	107	1.3%
Black or African American	2,989	36.4%
Multi-racial	49	0.6%
Native Hawaiian or Other Pacific Islander	12	0.1%
Unknown	1,764	21.5%
White	3,242	39.5%
Hispanic origin		
Yes	718	8.7%
No	6,014	73.2%
Unknown	1,483	18.1%
Year		
2018	231	2.8%
2019	1,967	23.9%
2020	1,762	21.4%
2021	1,879	22.9%
2022	850	10.3%
2023	881	10.7%
2024	645	7.9%
Health Characteristics		
Acute Myocardial Infarction	124	1.5%
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	161	2.0%
Atrial Fibrillation	250	3.0%

Table 1i. Aggregated Characteristics of doravirine in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

doravirine		
Health Characteristics	Number	Percent
Diabetes Mellitus	1,522	18.5%
Heart Failure	792	9.6%
Hyperlipidemia	2,278	27.7%
Hypertension	3,055	37.2%
Depression	2,375	28.9%
Ischemic Heart Disease	1,114	13.6%
Rheumatoid Arthritis/Osteoarthritis	803	9.8%
Stroke/TIA ³	212	2.6%
Breast Cancer	31	0.4%
Colorectal Cancer	112	1.4%
Prostate Cancer	125	1.5%
Lung Cancer	44	0.5%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	387	4.7%
Anemia	1,767	21.5%
Asthma	499	6.1%
Benign Prostatic Hyperplasia	398	4.8%
Chronic Kidney Disease	1,610	19.6%
COPD ⁴ and Bronchiectasis	731	8.9%
Glaucoma	346	4.2%
Osteoporosis	178	2.2%
Obesity: diagnosed or identified by weight management procedures	1,227	14.9%
Obesity: identified by weight management-related dispensings	169	2.1%
Overweight	547	6.7%
Smoking: diagnosed or identified by smoking cessation procedures	2,077	25.3%
Smoking: identified by smoking-related dispensings	250	3.0%
Alcohol Abuse or Dependence	419	5.1%
Drug Abuse or Dependence	1,040	12.7%
History of Cardiac Arrest	29	0.4%
History of Coronary Angioplasty or Bypass	397	4.8%
Liver Disease Based on CCW ⁵ Definition	521	6.3%
Liver Disease Extended Definition (CCW + Additional Codes)	533	6.5%
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	14.9	22.2
Mean number of emergency room encounters	0.7	2.1
Mean number of inpatient hospital encounters	0.3	0.9
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	9.1	20.5

Table 1i. Aggregated Characteristics of doravirine in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

doravirine		
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of filled prescriptions	35.2	27.3
Mean number of generics dispensed	10.9	6.7
Mean number of unique drug classes dispensed	9.2	5.8

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*******Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.**

Table 1j. Aggregated Characteristics of moxetumomab pasudotox-tdfk in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

moxetumomab pasudotox-tdfk		
Patient Characteristics	Number	Percent
Unique patients	50	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	69.4	10.5
Age	Number	Percent
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	*****	*****
Sex		
Female	*****	*****
Male	*****	*****
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	*****	*****
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	*****	*****
Hispanic origin		
Yes	*****	*****
No	*****	*****
Unknown	*****	*****
Year		
2018	0	0.0%
2019	20	40.0%
2020	11	22.0%
2021	*****	*****
2022	*****	*****
2023	*****	*****
2024	*****	*****
Health Characteristics	Number	Percent
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease	0	0.0%
Non-Alzheimer's Dementia	0	0.0%
Atrial Fibrillation	*****	*****

Table 1j. Aggregated Characteristics of moxetumomab pasudotox-tdfk in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

moxetumomab pasudotox-tdfk		
Health Characteristics	Number	Percent
Diabetes Mellitus	*****	*****
Heart Failure	*****	*****
Hyperlipidemia	17	34.0%
Hypertension	21	42.0%
Depression	*****	*****
Ischemic Heart Disease	12	24.0%
Rheumatoid Arthritis/Osteoarthritis	*****	*****
Stroke/TIA ³	0	0.0%
Breast Cancer	*****	*****
Colorectal Cancer	0	0.0%
Prostate Cancer	*****	*****
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	*****	*****
Anemia	33	66.0%
Asthma	*****	*****
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	*****	*****
COPD ⁴ and Bronchiectasis	*****	*****
Glaucoma	*****	*****
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management	*****	*****
Obesity: identified by weight management-related dispensings	0	0.0%
Overweight	12	24.0%
Smoking: diagnosed or identified by smoking cessation	18	36.0%
Smoking: identified by smoking-related dispensings	0	0.0%
Alcohol Abuse or Dependence	0	0.0%
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****
Liver Disease Based on CCW ⁵ Definition	*****	*****
Liver Disease Extended Definition (CCW + Additional Codes)	*****	*****
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	23.6	16.8
Mean number of emergency room encounters	0.6	1.3
Mean number of inpatient hospital encounters	0.5	1.1
Mean number of non-acute institutional encounters	0.0	NaN ⁶
Mean number of other ambulatory encounters	8.0	10.3

Table 1j. Aggregated Characteristics of moxetumomab pasudotox-tdfk in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

moxetumomab pasudotox-tdfk		
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of filled prescriptions	16.6	12.5
Mean number of generics dispensed	8.3	5.3
Mean number of unique drug classes dispensed	7.6	4.6

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

⁶Data represented by NaN (Not a Number) is due to their inability to be calculated.

*******Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated**

Table 1k. Aggregated Characteristics of fremanezumab-vfrm in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

fremanezumab-vfrm		
Patient Characteristics	Number	Percent
Unique patients	93,384	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	46.7	13.0
Age	Number	Percent
0-17 years	630	0.7%
18-24 years	6,139	6.6%
25-40 years	26,916	28.8%
41-64 years	48,473	51.9%
≥ 65 years	11,226	12.0%
Sex		
Female	80,681	86.4%
Male	12,703	13.6%
Race ²		
American Indian or Alaska Native	460	0.5%
Asian	1,275	1.4%
Black or African American	5,872	6.3%
Multi-racial	2,365	2.5%
Native Hawaiian or Other Pacific Islander	131	0.1%
Unknown	22,154	23.7%
White	61,127	65.5%
Hispanic origin		
Yes	4,769	5.1%
No	58,002	62.1%
Unknown	30,613	32.8%
Year		
2018	2,498	2.7%
2019	15,522	16.6%
2020	14,297	15.3%
2021	21,792	23.3%
2022	14,634	15.7%
2023	12,506	13.4%
2024	12,135	13.0%
Health Characteristics		
Acute Myocardial Infarction	99	0.1%
Alzheimer's Disease	194	0.2%
Non-Alzheimer's Dementia	819	0.9%
Atrial Fibrillation	1,391	1.5%
Diabetes Mellitus	8,969	9.6%

Table 1k. Aggregated Characteristics of fremanezumab-vfrm in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

fremanezumab-vfrm		
Health Characteristics	Number	Percent
Heart Failure	2,309	2.5%
Hyperlipidemia	14,499	15.5%
Hypertension	18,512	19.8%
Depression	34,916	37.4%
Ischemic Heart Disease	4,408	4.7%
Rheumatoid Arthritis/Osteoarthritis	15,909	17.0%
Stroke/TIA ³	1,959	2.1%
Breast Cancer	1,161	1.2%
Colorectal Cancer	143	0.2%
Prostate Cancer	184	0.2%
Lung Cancer	132	0.1%
Endometrial Cancer	65	0.1%
Acquired Hypothyroidism	8,607	9.2%
Anemia	10,514	11.3%
Asthma	6,985	7.5%
Benign Prostatic Hyperplasia	594	0.6%
Chronic Kidney Disease	3,029	3.2%
COPD ⁴ and Bronchiectasis	3,582	3.8%
Glaucoma	3,152	3.4%
Osteoporosis	2,183	2.3%
Obesity: diagnosed or identified by weight management procedures	20,746	22.2%
Obesity: identified by weight management-related dispensings	3,927	4.2%
Overweight	7,000	7.5%
Smoking: diagnosed or identified by smoking cessation procedures	11,929	12.8%
Smoking: identified by smoking-related dispensings	1,335	1.4%
Alcohol Abuse or Dependence	1,341	1.4%
Drug Abuse or Dependence	4,514	4.8%
History of Cardiac Arrest	73	0.1%
History of Coronary Angioplasty or Bypass	850	0.9%
Liver Disease Based on CCW ⁵ Definition	2,129	2.3%
Liver Disease Extended Definition (CCW + Additional Codes)	2,173	2.3%
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	14.7	13.1
Mean number of emergency room encounters	0.6	1.7
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	5.1	12.2
Mean number of filled prescriptions	30.2	24.5

Table 1k. Aggregated Characteristics of fremanezumab-vfrm in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

fremanezumab-vfrm		
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of generics dispensed	11.3	7.0
Mean number of unique drug classes dispensed	10.5	6.2

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

Table 11. Aggregated Characteristics of duvelisib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

duvelisib		
Patient Characteristics	Number	Percent
Unique patients	623	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	70.5	9.7
Age	Number	Percent
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	129	20.7%
≥ 65 years	479	76.9%
Sex		
Female	273	43.8%
Male	350	56.2%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	69	11.1%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	93	14.9%
White	442	70.9%
Hispanic origin		
Yes	20	3.2%
No	490	78.7%
Unknown	113	18.1%
Year		
2018	26	4.2%
2019	125	20.1%
2020	124	19.9%
2021	109	17.5%
2022	111	17.8%
2023	68	10.9%
2024	60	9.6%
Health Characteristics		
Acute Myocardial Infarction	11	1.8%
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	22	3.5%
Atrial Fibrillation	108	17.3%

Table 11. Aggregated Characteristics of duvelisib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

duvelisib		
Health Characteristics	Number	Percent
Diabetes Mellitus	144	23.1%
Heart Failure	119	19.1%
Hyperlipidemia	241	38.7%
Hypertension	322	51.7%
Depression	119	19.1%
Ischemic Heart Disease	144	23.1%
Rheumatoid Arthritis/Osteoarthritis	82	13.2%
Stroke/TIA ³	37	5.9%
Breast Cancer	13	2.1%
Colorectal Cancer	12	1.9%
Prostate Cancer	28	4.5%
Lung Cancer	*****	*****
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	102	16.4%
Anemia	412	66.1%
Asthma	30	4.8%
Benign Prostatic Hyperplasia	79	12.7%
Chronic Kidney Disease	114	18.3%
COPD ⁴ and Bronchiectasis	77	12.4%
Glaucoma	55	8.8%
Osteoporosis	29	4.7%
Obesity: diagnosed or identified by weight management procedures	100	16.1%
Obesity: identified by weight management-related dispensings	*****	*****
Overweight	78	12.5%
Smoking: diagnosed or identified by smoking cessation procedures	196	31.5%
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	27	4.3%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	45	7.2%
Liver Disease Based on CCW ⁵ Definition	66	10.6%
Liver Disease Extended Definition (CCW + Additional Codes)	66	10.6%
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	28.9	16.5
Mean number of emergency room encounters	0.6	1.2
Mean number of inpatient hospital encounters	1.0	1.6
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	13.2	19.3

Table 1I. Aggregated Characteristics of duvelisib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

duvelisib		
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of filled prescriptions	26.5	17.8
Mean number of generics dispensed	12.2	6.6
Mean number of unique drug classes dispensed	11.3	5.8

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*******Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.**

Table 1m. Aggregated Characteristics of galcanezumab-gnlm in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

galcanezumab-gnlm		
Patient Characteristics	Number	Percent
Unique patients	212,175	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	46.9	12.8
Age	Number	Percent
0-17 years	1,184	0.6%
18-24 years	13,165	6.2%
25-40 years	62,239	29.3%
41-64 years	108,086	50.9%
≥ 65 years	27,501	13.0%
Sex		
Female	180,088	84.9%
Male	32,087	15.1%
Race ²		
American Indian or Alaska Native	1,127	0.5%
Asian	2,132	1.0%
Black or African American	13,152	6.2%
Multi-racial	3,268	1.5%
Native Hawaiian or Other Pacific Islander	198	0.1%
Unknown	63,397	29.9%
White	128,901	60.8%
Hispanic origin		
Yes	9,768	4.6%
No	129,498	61.0%
Unknown	72,909	34.4%
Year		
2018	1,560	0.7%
2019	38,183	18.0%
2020	51,174	24.1%
2021	44,576	21.0%
2022	27,998	13.2%
2023	27,213	12.8%
2024	21,471	10.1%
Health Characteristics	Number	Percent
Acute Myocardial Infarction	270	0.1%
Alzheimer's Disease	454	0.2%
Non-Alzheimer's Dementia	1,939	0.9%
Atrial Fibrillation	3,411	1.6%

Table 1m. Aggregated Characteristics of galcanezumab-gnlm in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

galcanezumab-gnlm		
Health Characteristics	Number	Percent
Diabetes Mellitus	21,583	10.2%
Heart Failure	5,993	2.8%
Hyperlipidemia	34,276	16.2%
Hypertension	44,548	21.0%
Depression	80,050	37.7%
Ischemic Heart Disease	11,289	5.3%
Rheumatoid Arthritis/Osteoarthritis	36,092	17.0%
Stroke/TIA ³	4,664	2.2%
Breast Cancer	2,597	1.2%
Colorectal Cancer	384	0.2%
Prostate Cancer	527	0.2%
Lung Cancer	341	0.2%
Endometrial Cancer	167	0.1%
Acquired Hypothyroidism	20,042	9.4%
Anemia	24,070	11.3%
Asthma	15,598	7.4%
Benign Prostatic Hyperplasia	1,650	0.8%
Chronic Kidney Disease	7,615	3.6%
COPD ⁴ and Bronchiectasis	9,418	4.4%
Glaucoma	7,138	3.4%
Osteoporosis	4,822	2.3%
Obesity: diagnosed or identified by weight management	47,701	22.5%
Obesity: identified by weight management-related dispensings	8,047	3.8%
Overweight	16,082	7.6%
Smoking: diagnosed or identified by smoking cessation procedures	30,271	14.3%
Smoking: identified by smoking-related dispensings	3,417	1.6%
Alcohol Abuse or Dependence	3,290	1.6%
Drug Abuse or Dependence	11,166	5.3%
History of Cardiac Arrest	200	0.1%
History of Coronary Angioplasty or Bypass	2,343	1.1%
Liver Disease Based on CCW ⁵ Definition	4,738	2.2%
Liver Disease Extended Definition (CCW + Additional Codes)	4,829	2.3%
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	14.5	12.9
Mean number of emergency room encounters	0.6	1.8
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	4.7	13.1

Table 1m. Aggregated Characteristics of galcanezumab-gnlm in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

galcanezumab-gnlm		
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of filled prescriptions	30.2	24.8
Mean number of generics dispensed	11.3	6.9
Mean number of unique drug classes dispensed	10.4	6.1

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

Table 1n. Aggregated Characteristics of dacomitinib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

dacomitinib		
Patient Characteristics	Number	Percent
Unique patients	95	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	70.3	7.8
Age	Number	Percent
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	0	0.0%
41-64 years	26	27.4%
≥ 65 years	69	72.6%
Sex		
Female	60	63.2%
Male	35	36.8%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	22	23.2%
White	49	51.6%
Hispanic origin		
Yes	*****	*****
No	67	70.5%
Unknown	*****	*****
Year		
2018	0	0.0%
2019	24	25.3%
2020	17	17.9%
2021	23	24.2%
2022	*****	*****
2023	14	14.7%
2024	*****	*****
Health Characteristics	Number	Percent
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease	0	0.0%
Non-Alzheimer's Dementia	*****	*****
Atrial Fibrillation	12	12.6%

Table 1n. Aggregated Characteristics of dacomitinib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

dacomitinib		
Health Characteristics	Number	Percent
Diabetes Mellitus	20	21.1%
Heart Failure	16	16.8%
Hyperlipidemia	41	43.2%
Hypertension	50	52.6%
Depression	13	13.7%
Ischemic Heart Disease	21	22.1%
Rheumatoid Arthritis/Osteoarthritis	11	11.6%
Stroke/TIA ³	*****	*****
Breast Cancer	11	11.6%
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	94	98.9%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	17	17.9%
Anemia	35	36.8%
Asthma	*****	*****
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	12	12.6%
COPD ⁵ and Bronchiectasis	18	18.9%
Glaucoma	*****	*****
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	*****	*****
Obesity: identified by weight management-related dispensings	*****	*****
Overweight	*****	*****
Smoking: diagnosed or identified by smoking cessation procedures	26	27.4%
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****
Liver Disease Based on CCW ⁵ Definition	*****	*****
Liver Disease Extended Definition (CCW + Additional Codes)	*****	*****
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	28.3	17.4
Mean number of emergency room encounters	0.4	0.8
Mean number of inpatient hospital encounters	0.6	0.9
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	11.0	12.8

Table 1n. Aggregated Characteristics of dacomitinib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

dacomitinib		
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of filled prescriptions	26.7	19.4
Mean number of generics dispensed	11.7	7.3
Mean number of unique drug classes dispensed	10.5	6.3

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*******Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.**

Table 1o. Aggregated Characteristics of cemiplimab-rwlc in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

cemiplimab-rwlc		
Patient Characteristics	Number	Percent
Unique patients	12,307	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	77.3	9.6
Age	Number	Percent
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	1,105	9.0%
≥ 65 years	11,147	90.6%
Sex		
Female	3,645	29.6%
Male	8,662	70.4%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	60	0.5%
Black or African American	286	2.3%
Multi-racial	23	0.2%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	889	7.2%
White	11,016	89.5%
Hispanic origin		
Yes	82	0.7%
No	10,250	83.3%
Unknown	1,975	16.0%
Year		
2018	23	0.2%
2019	1,310	10.6%
2020	1,550	12.6%
2021	1,714	13.9%
2022	2,023	16.4%
2023	3,058	24.8%
2024	2,629	21.4%
Health Characteristics	Number	Percent
Acute Myocardial Infarction	154	1.3%
Alzheimer's Disease	249	2.0%
Non-Alzheimer's Dementia	868	7.1%
Atrial Fibrillation	2,511	20.4%

Table 1o. Aggregated Characteristics of cemiplimab-rwlc in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

cemiplimab-rwlc		
Health Characteristics	Number	Percent
Diabetes Mellitus	3,265	26.5%
Heart Failure	2,393	19.4%
Hyperlipidemia	5,949	48.3%
Hypertension	8,160	66.3%
Depression	2,229	18.1%
Ischemic Heart Disease	4,362	35.4%
Rheumatoid Arthritis/Osteoarthritis	2,244	18.2%
Stroke/TIA ³	547	4.4%
Breast Cancer	429	3.5%
Colorectal Cancer	342	2.8%
Prostate Cancer	870	7.1%
Lung Cancer	2,341	19.0%
Endometrial Cancer	48	0.4%
Acquired Hypothyroidism	1,905	15.5%
Anemia	4,732	38.4%
Asthma	433	3.5%
Benign Prostatic Hyperplasia	1,536	12.5%
Chronic Kidney Disease	2,752	22.4%
COPD ⁴ and Bronchiectasis	2,480	20.2%
Glaucoma	1,145	9.3%
Osteoporosis	518	4.2%
Obesity: diagnosed or identified by weight management procedures	1,904	15.5%
Obesity: identified by weight management-related dispensings	160	1.3%
Overweight	1,450	11.8%
Smoking: diagnosed or identified by smoking cessation procedures	5,387	43.8%
Smoking: identified by smoking-related dispensings	71	0.6%
Alcohol Abuse or Dependence	401	3.3%
Drug Abuse or Dependence	438	3.6%
History of Cardiac Arrest	57	0.5%
History of Coronary Angioplasty or Bypass	1,570	12.8%
Liver Disease Based on CCW ⁵ Definition	646	5.2%
Liver Disease Extended Definition (CCW + Additional Codes)	653	5.3%
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	26.9	18.5
Mean number of emergency room encounters	0.6	1.2
Mean number of inpatient hospital encounters	0.4	0.8
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	8.5	13.3

Table 1o. Aggregated Characteristics of cemiplimab-rwlc in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

cemiplimab-rwlc		
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of filled prescriptions	21.4	17.8
Mean number of generics dispensed	9.9	5.6
Mean number of unique drug classes dispensed	9.1	5.0

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*******Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.**

Table 1p. Aggregated Characteristics of sarecycline in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

sarecycline		
Patient Characteristics	Number	Percent
Unique patients	17,939	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	23.6	11.1
Age	Number	Percent
0-17 years	7,791	43.4%
18-24 years	4,928	27.5%
25-40 years	3,486	19.4%
41-64 years	1,568	8.7%
≥ 65 years	166	0.9%
Sex		
Female	11,119	62.0%
Male	6,820	38.0%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	712	4.0%
Black or African American	683	3.8%
Multi-racial	515	2.9%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	8,932	49.8%
White	7,066	39.4%
Hispanic origin		
Yes	645	3.6%
No	6,590	36.7%
Unknown	10,704	59.7%
Year		
2018	0	0.0%
2019	3,559	19.8%
2020	3,193	17.8%
2021	3,611	20.1%
2022	3,581	20.0%
2023	2,416	13.5%
2024	1,579	8.8%
Health Characteristics	Number	Percent
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	*****	*****
Atrial Fibrillation	21	0.1%

Table 1p. Aggregated Characteristics of sarecycline in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

sarecycline		
Health Characteristics	Number	Percent
Diabetes Mellitus	189	1.1%
Heart Failure	31	0.2%
Hyperlipidemia	352	2.0%
Hypertension	373	2.1%
Depression	1,985	11.1%
Ischemic Heart Disease	56	0.3%
Rheumatoid Arthritis/Osteoarthritis	231	1.3%
Stroke/TIA ³	13	0.1%
Breast Cancer	30	0.2%
Colorectal Cancer	0	0.0%
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	257	1.4%
Anemia	505	2.8%
Asthma	279	1.6%
Benign Prostatic Hyperplasia	22	0.1%
Chronic Kidney Disease	52	0.3%
COPD ⁴ and Bronchiectasis	26	0.1%
Glaucoma	147	0.8%
Osteoporosis	27	0.2%
Obesity: diagnosed or identified by weight management procedures	655	3.7%
Obesity: identified by weight management-related dispensings	137	0.8%
Overweight	426	2.4%
Smoking: diagnosed or identified by smoking cessation procedures	242	1.3%
Smoking: identified by smoking-related dispensings	23	0.1%
Alcohol Abuse or Dependence	110	0.6%
Drug Abuse or Dependence	136	0.8%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****
Liver Disease Based on CCW ⁵ Definition	51	0.3%
Liver Disease Extended Definition (CCW + Additional Codes)	52	0.3%
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	6.8	8.2
Mean number of emergency room encounters	0.1	0.4
Mean number of inpatient hospital encounters	0.0	0.1
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	1.2	3.0

Table 1p. Aggregated Characteristics of sarecycline in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

sarecycline		
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of filled prescriptions	7.2	8.6
Mean number of generics dispensed	3.8	3.4
Mean number of unique drug classes dispensed	3.4	3.1

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*******Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.**

Table 1q. Aggregated Characteristics of omadacycline in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

omadacycline		
Patient Characteristics	Number	Percent
Unique patients	8,563	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	62.7	13.8
Age	Number	Percent
0-17 years	51	0.6%
18-24 years	144	1.7%
25-40 years	674	7.9%
41-64 years	3,412	39.8%
≥ 65 years	4,282	50.0%
Sex		
Female	4,263	49.8%
Male	4,300	50.2%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	158	1.8%
Black or African American	970	11.3%
Multi-racial	77	0.9%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	1,818	21.2%
White	5,510	64.3%
Hispanic origin		
Yes	321	3.7%
No	5,817	67.9%
Unknown	2,425	28.3%
Year		
2018	0	0.0%
2019	225	2.6%
2020	779	9.1%
2021	1,354	15.8%
2022	1,725	20.1%
2023	2,537	29.6%
2024	1,943	22.7%
Health Characteristics	Number	Percent
Acute Myocardial Infarction	142	1.7%
Alzheimer's Disease	76	0.9%
Non-Alzheimer's Dementia	378	4.4%
Atrial Fibrillation	1,279	14.9%

Table 1q. Aggregated Characteristics of omadacycline in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

omadacycline		
Health Characteristics	Number	Percent
Diabetes Mellitus	4,207	49.1%
Heart Failure	1,963	22.9%
Hyperlipidemia	4,188	48.9%
Hypertension	5,509	64.3%
Depression	2,277	26.6%
Ischemic Heart Disease	2,406	28.1%
Rheumatoid Arthritis/Osteoarthritis	2,351	27.5%
Stroke/TIA ³	337	3.9%
Breast Cancer	254	3.0%
Colorectal Cancer	102	1.2%
Prostate Cancer	184	2.1%
Lung Cancer	127	1.5%
Endometrial Cancer	32	0.4%
Acquired Hypothyroidism	1,384	16.2%
Anemia	3,368	39.3%
Asthma	802	9.4%
Benign Prostatic Hyperplasia	605	7.1%
Chronic Kidney Disease	2,300	26.9%
COPD ⁴ and Bronchiectasis	1,988	23.2%
Glaucoma	705	8.2%
Osteoporosis	485	5.7%
Obesity: diagnosed or identified by weight management procedures	3,171	37.0%
Obesity: identified by weight management-related dispensings	784	9.2%
Overweight	971	11.3%
Smoking: diagnosed or identified by smoking cessation procedures	2,698	31.5%
Smoking: identified by smoking-related dispensings	76	0.9%
Alcohol Abuse or Dependence	258	3.0%
Drug Abuse or Dependence	644	7.5%
History of Cardiac Arrest	61	0.7%
History of Coronary Angioplasty or Bypass	858	10.0%
Liver Disease Based on CCW ⁵ Definition	609	7.1%
Liver Disease Extended Definition (CCW + Additional Codes)	615	7.2%
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	26.3	24.0
Mean number of emergency room encounters	0.9	1.8
Mean number of inpatient hospital encounters	0.7	1.1
Mean number of non-acute institutional encounters	0.1	0.4

Table 1q. Aggregated Characteristics of omadacycline in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Health Service Utilization Intensity Metrics	omadacycline	
	Mean	Standard Deviation
Mean number of other ambulatory encounters	13.9	21.5
Mean number of filled prescriptions	32.4	24.4
Mean number of generics dispensed	13.4	7.0
Mean number of unique drug classes dispensed	12.1	6.1

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*******Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.**

Table 1r. Aggregated Characteristics of elapegademase-lvlr in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

elapegademase-lvlr		
Patient Characteristics	Number	Percent
Unique patients	42	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	18.2	10.3
Age	Number	Percent
0-17 years	19	45.2%
18-24 years	12	28.6%
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	0	0.0%
Sex		
Female	19	45.2%
Male	23	54.8%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	15	35.7%
White	14	33.3%
Hispanic origin		
Yes	*****	*****
No	26	61.9%
Unknown	*****	*****
Year		
2018	*****	*****
2019	21	50.0%
2020	*****	*****
2021	*****	*****
2022	*****	*****
2023	*****	*****
2024	*****	*****
Health Characteristics	Number	Percent
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease	0	0.0%
Non-Alzheimer's Dementia	0	0.0%
Atrial Fibrillation	0	0.0%

Table 1r. Aggregated Characteristics of elapegademase-lvlr in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

elapegademase-lvlr		
Health Characteristics	Number	Percent
Diabetes Mellitus	*****	*****
Heart Failure	0	0.0%
Hyperlipidemia	0	0.0%
Hypertension	*****	*****
Depression	*****	*****
Ischemic Heart Disease	0	0.0%
Rheumatoid Arthritis/Osteoarthritis	0	0.0%
Stroke/TIA ³	0	0.0%
Breast Cancer	0	0.0%
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	*****	*****
Anemia	*****	*****
Asthma	*****	*****
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	0	0.0%
COPD ⁴ and Bronchiectasis	*****	*****
Glaucoma	0	0.0%
Osteoporosis	0	0.0%
Obesity: diagnosed or identified by weight management procedures	*****	*****
Obesity: identified by weight management-related dispensings	0	0.0%
Overweight	0	0.0%
Smoking: diagnosed or identified by smoking cessation procedures	*****	*****
Smoking: identified by smoking-related dispensings	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	0	0.0%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	0	0.0%
Liver Disease Based on CCW ⁵ Definition	*****	*****
Liver Disease Extended Definition (CCW + Additional Codes)	*****	*****
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	11.4	7.2
Mean number of emergency room encounters	0.3	0.6
Mean number of inpatient hospital encounters	0.2	0.6
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	8.8	9.6

Table 1r. Aggregated Characteristics of elapegademase-lvlr in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

elapegademase-lvlr		
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of filled prescriptions	16.8	16.2
Mean number of generics dispensed	6.1	4.9
Mean number of unique drug classes dispensed	5.9	4.6

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*******Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.**

Table 1s. Aggregated Characteristics of inotersen in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

inotersen		
Patient Characteristics	Number	Percent
Unique patients	119	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	68.5	8.6
Age	Number	Percent
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	90	75.6%
Sex		
Female	52	43.7%
Male	67	56.3%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	44	37.0%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	64	53.8%
Hispanic origin		
Yes	*****	*****
No	100	84.0%
Unknown	*****	*****
Year		
2018	*****	*****
2019	70	58.8%
2020	15	12.6%
2021	16	13.4%
2022	*****	*****
2023	*****	*****
2024	0	0.0%
Health Characteristics	Number	Percent
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease	0	0.0%
Non-Alzheimer's Dementia	*****	*****
Atrial Fibrillation	27	22.7%

Table 1s. Aggregated Characteristics of inotersen in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

inotersen		
Health Characteristics	Number	Percent
Diabetes Mellitus	24	20.2%
Heart Failure	79	66.4%
Hyperlipidemia	50	42.0%
Hypertension	71	59.7%
Depression	17	14.3%
Ischemic Heart Disease	35	29.4%
Rheumatoid Arthritis/Osteoarthritis	24	20.2%
Stroke/TIA ³	11	9.2%
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	18	15.1%
Anemia	35	29.4%
Asthma	*****	*****
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	29	24.4%
COPD ⁴ and Bronchiectasis	*****	*****
Glaucoma	16	13.4%
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	19	16.0%
Obesity: identified by weight management-related dispensings	*****	*****
Overweight	13	10.9%
Smoking: diagnosed or identified by smoking cessation procedures	26	21.8%
Smoking: identified by smoking-related dispensings	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	*****	*****
Liver Disease Based on CCW ⁵ Definition	*****	*****
Liver Disease Extended Definition (CCW + Additional Codes)	*****	*****
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	19.0	13.8
Mean number of emergency room encounters	0.4	0.7
Mean number of inpatient hospital encounters	0.5	1.1
Mean number of non-acute institutional encounters	0.1	0.6
Mean number of other ambulatory encounters	8.7	14.3

Table 1s. Aggregated Characteristics of inotersen in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

inotersen		
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of filled prescriptions	21.2	15.4
Mean number of generics dispensed	8.9	5.6
Mean number of unique drug classes dispensed	8.4	5.0

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*******Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.**

Table 1t. Aggregated Characteristics of talazoparib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

talazoparib		
Patient Characteristics	Number	Percent
Unique patients	810	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	65.0	12.1
Age	Number	Percent
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	269	33.2%
≥ 65 years	479	59.1%
Sex		
Female	452	55.8%
Male		
Race ²		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	106	13.1%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	183	22.6%
White	494	61.0%
Hispanic origin		
Yes	36	4.4%
No	570	70.4%
Unknown	204	25.2%
Year		
2018	11	1.4%
2019	137	16.9%
2020	136	16.8%
2021	77	9.5%
2022	35	4.3%
2023	148	18.3%
2024	266	32.8%
Health Characteristics	Number	Percent
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	16	2.0%
Atrial Fibrillation	76	9.4%

Table 1t. Aggregated Characteristics of talazoparib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

talazoparib		
Health Characteristics	Number	Percent
Diabetes Mellitus	186	23.0%
Heart Failure	99	12.2%
Hyperlipidemia	245	30.2%
Hypertension	350	43.2%
Depression	180	22.2%
Ischemic Heart Disease	151	18.6%
Rheumatoid Arthritis/Osteoarthritis	112	13.8%
Stroke/TIA ³	21	2.6%
Breast Cancer	508	62.7%
Colorectal Cancer	21	2.6%
Prostate Cancer	329	40.6%
Lung Cancer	30	3.7%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	109	13.5%
Anemia	340	42.0%
Asthma	27	3.3%
Benign Prostatic Hyperplasia	52	6.4%
Chronic Kidney Disease	109	13.5%
COPD ⁴ and Bronchiectasis	56	6.9%
Glaucoma	40	4.9%
Osteoporosis	35	4.3%
Obesity: diagnosed or identified by weight management	159	19.6%
Obesity: identified by weight management-related dispensings	21	2.6%
Overweight	71	8.8%
Smoking: diagnosed or identified by smoking cessation	208	25.7%
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	13	1.6%
Drug Abuse or Dependence	25	3.1%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	44	5.4%
Liver Disease Based on CCW ⁵ Definition	73	9.0%
Liver Disease Extended Definition (CCW + Additional Codes)	74	9.1%
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	26.5	15.7
Mean number of emergency room encounters	0.6	1.4
Mean number of inpatient hospital encounters	0.4	0.8
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	8.4	13.2

Table 1t. Aggregated Characteristics of talazoparib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

talazoparib		
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of filled prescriptions	23.7	17.7
Mean number of generics dispensed	10.2	6.1
Mean number of unique drug classes dispensed	9.3	5.3

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

******Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.**

Table 1u. Aggregated Characteristics of baloxavir marboxil in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

baloxavir marboxil		
Patient Characteristics	Number	Percent
Unique patients	130,098	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	41.6	16.3
Age	Number	Percent
0-17 years	24,111	18.5%
18-24 years	13,123	10.1%
25-40 years	29,702	22.8%
41-64 years	39,798	30.6%
≥ 65 years	23,364	18.0%
Sex		
Female	70,809	54.4%
Male	59,289	45.6%
Race ²		
American Indian or Alaska Native	367	0.3%
Asian	1,904	1.5%
Black or African American	3,587	2.8%
Multi-racial	906	0.7%
Native Hawaiian or Other Pacific Islander	77	0.1%
Unknown	73,257	56.3%
White	50,000	38.4%
Hispanic origin		
Yes	3,617	2.8%
No	51,997	40.0%
Unknown	74,484	57.3%
Year		
2018	803	0.6%
2019	24,969	19.2%
2020	43,968	33.8%
2021	9,088	7.0%
2022	31,467	24.2%
2023	10,684	8.2%
2024	9,119	7.0%
Health Characteristics	Number	Percent
Acute Myocardial Infarction	151	0.1%
Alzheimer's Disease	539	0.4%
Non-Alzheimer's Dementia	1,602	1.2%
Atrial Fibrillation	2,966	2.3%

Table 1u. Aggregated Characteristics of baloxavir marboxil in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

baloxavir marboxil		
Health Characteristics	Number	Percent
Diabetes Mellitus	9,233	7.1%
Heart Failure	3,219	2.5%
Hyperlipidemia	16,037	12.3%
Hypertension	19,935	15.3%
Depression	14,390	11.1%
Ischemic Heart Disease	7,415	5.7%
Rheumatoid Arthritis/Osteoarthritis	9,021	6.9%
Stroke/TIA ³	847	0.7%
Breast Cancer	1,192	0.9%
Colorectal Cancer	279	0.2%
Prostate Cancer	762	0.6%
Lung Cancer	247	0.2%
Endometrial Cancer	68	0.1%
Acquired Hypothyroidism	6,413	4.9%
Anemia	8,557	6.6%
Asthma	3,567	2.7%
Benign Prostatic Hyperplasia	1,786	1.4%
Chronic Kidney Disease	3,254	2.5%
COPD ⁴ and Bronchiectasis	3,233	2.5%
Glaucoma	3,537	2.7%
Osteoporosis	1,705	1.3%
Obesity: diagnosed or identified by weight management	15,452	11.9%
Obesity: identified by weight management-related dispensings	2,615	2.0%
Overweight	7,557	5.8%
Smoking: diagnosed or identified by smoking cessation procedures	7,995	6.1%
Smoking: identified by smoking-related dispensings	444	0.3%
Alcohol Abuse or Dependence	925	0.7%
Drug Abuse or Dependence	1,531	1.2%
History of Cardiac Arrest	69	0.1%
History of Coronary Angioplasty or Bypass	2,022	1.6%
Liver Disease Based on CCW ⁵ Definition	1,327	1.0%
Liver Disease Extended Definition (CCW + Additional Codes)	1,355	1.0%
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	6.7	8.7
Mean number of emergency room encounters	0.2	0.7
Mean number of inpatient hospital encounters	0.0	0.2
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	1.8	6.7

Table 1u. Aggregated Characteristics of baloxavir marboxil in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

baloxavir marboxil		
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of filled prescriptions	10.8	13.5
Mean number of generics dispensed	4.9	4.5
Mean number of unique drug classes dispensed	4.6	4.2

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

Table 1v. Aggregated Characteristics of lorlatinib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

lorlatinib		
Patient Characteristics	Number	Percent
Unique patients	1,620	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	59.3	15.0
Age	Number	Percent
0-17 years	76	4.7%
18-24 years	11	0.7%
25-40 years	127	7.8%
41-64 years	666	41.1%
≥ 65 years	740	45.7%
Sex		
Female	891	55.0%
Male	729	45.0%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	154	9.5%
Black or African American	124	7.7%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	412	25.4%
White	907	56.0%
Hispanic origin		
Yes	82	5.1%
No	1,085	67.0%
Unknown	453	28.0%
Year		
2018	55	3.4%
2019	283	17.5%
2020	280	17.3%
2021	277	17.1%
2022	242	14.9%
2023	256	15.8%
2024	227	14.0%
Health Characteristics	Number	Percent
Acute Myocardial Infarction	25	1.5%
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	40	2.5%
Atrial Fibrillation	113	7.0%

Table 1v. Aggregated Characteristics of Irlatinib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Irlatinib		
Health Characteristics	Number	Percent
Diabetes Mellitus	245	15.1%
Heart Failure	152	9.4%
Hyperlipidemia	497	30.7%
Hypertension	599	37.0%
Depression	298	18.4%
Ischemic Heart Disease	219	13.5%
Rheumatoid Arthritis/Osteoarthritis	164	10.1%
Stroke/TIA ³	104	6.4%
Breast Cancer	59	3.6%
Colorectal Cancer	16	1.0%
Prostate Cancer	44	2.7%
Lung Cancer	1,498	92.5%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	210	13.0%
Anemia	625	38.6%
Asthma	103	6.4%
Benign Prostatic Hyperplasia	99	6.1%
Chronic Kidney Disease	203	12.5%
COPD ⁴ and Bronchiectasis	158	9.8%
Glaucoma	87	5.4%
Osteoporosis	49	3.0%
Obesity: diagnosed or identified by weight management	221	13.6%
Obesity: identified by weight management-related dispensings	21	1.3%
Overweight	139	8.6%
Smoking: diagnosed or identified by smoking cessation	405	25.0%
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	24	1.5%
Drug Abuse or Dependence	53	3.3%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	54	3.3%
Liver Disease Based on CCW ⁵ Definition	158	9.8%
Liver Disease Extended Definition (CCW + Additional Codes)	160	9.9%
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	22.3	13.4
Mean number of emergency room encounters	0.7	1.4
Mean number of inpatient hospital encounters	0.7	1.2
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	10.7	16.9

Table 1v. Aggregated Characteristics of lorlatinib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

lorlatinib		
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of filled prescriptions	22.1	16.6
Mean number of generics dispensed	9.2	5.6
Mean number of unique drug classes dispensed	8.5	4.9

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*******Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.**

Table 1w. Aggregated Characteristics of revefenacin in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

revefenacin		
Patient Characteristics	Number	Percent
Unique patients	15,603	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	70.7	10.6
Age	Number	Percent
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	206	1.3%
41-64 years	4,494	28.8%
≥ 65 years	10,869	69.7%
Sex		
Female	9,132	58.5%
Male	6,471	41.5%
Race ²		
American Indian or Alaska Native	84	0.5%
Asian	132	0.8%
Black or African American	1,650	10.6%
Multi-racial	73	0.5%
Native Hawaiian or Other Pacific Islander	37	0.2%
Unknown	1,972	12.6%
White	11,655	74.7%
Hispanic origin		
Yes	264	1.7%
No	10,862	69.6%
Unknown	4,477	28.7%
Year		
2018	*****	*****
2019	*****	*****
2020	2,068	13.3%
2021	2,636	16.9%
2022	2,457	15.7%
2023	3,537	22.7%
2024	3,437	22.0%
Health Characteristics	Number	Percent
Acute Myocardial Infarction	462	3.0%
Alzheimer's Disease	380	2.4%
Non-Alzheimer's Dementia	1,462	9.4%
Atrial Fibrillation	3,059	19.6%

Table 1w. Aggregated Characteristics of revefenacin in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

revefenacin		
Health Characteristics	Number	Percent
Diabetes Mellitus	4,665	29.9%
Heart Failure	5,687	36.4%
Hyperlipidemia	7,446	47.7%
Hypertension	10,505	67.3%
Depression	5,675	36.4%
Ischemic Heart Disease	5,967	38.2%
Rheumatoid Arthritis/Osteoarthritis	3,970	25.4%
Stroke/TIA ³	735	4.7%
Breast Cancer	454	2.9%
Colorectal Cancer	183	1.2%
Prostate Cancer	342	2.2%
Lung Cancer	1,130	7.2%
Endometrial Cancer	39	0.2%
Acquired Hypothyroidism	2,593	16.6%
Anemia	5,053	32.4%
Asthma	2,694	17.3%
Benign Prostatic Hyperplasia	1,254	8.0%
Chronic Kidney Disease	3,224	20.7%
COPD ⁴ and Bronchiectasis	13,538	86.8%
Glaucoma	1,084	6.9%
Osteoporosis	1,283	8.2%
Obesity: diagnosed or identified by weight	4,433	28.4%
Obesity: identified by weight management-related	428	2.7%
Overweight	1,471	9.4%
Smoking: diagnosed or identified by smoking cessation	9,590	61.5%
Smoking: identified by smoking-related dispensings	606	3.9%
Alcohol Abuse or Dependence	825	5.3%
Drug Abuse or Dependence	1,169	7.5%
History of Cardiac Arrest	168	1.1%
History of Coronary Angioplasty or Bypass	1,694	10.9%
Liver Disease Based on CCW ⁵ Definition	843	5.4%
Liver Disease Extended Definition (CCW + Additional	853	5.5%
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	17.5	15.8
Mean number of emergency room encounters	1.4	2.7
Mean number of inpatient hospital encounters	0.7	1.1
Mean number of non-acute institutional encounters	0.2	0.6
Mean number of other ambulatory encounters	15.6	22.6

Table 1w. Aggregated Characteristics of revefenacin in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

revefenacin		
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of filled prescriptions	39.6	29.6
Mean number of generics dispensed	14.3	7.3
Mean number of unique drug classes dispensed	13.0	6.4

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*******Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.**

Table 1x. Aggregated Characteristics of rifamycin in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

rifamycin		
Patient Characteristics	Number	Percent
Unique patients	110	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	51.8	13.1
Age	Number	Percent
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	50	45.5%
≥ 65 years	30	27.3%
Sex		
Female	66	60.0%
Male	44	40.0%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	50	45.5%
Hispanic origin		
Yes	*****	*****
No	*****	*****
Unknown	60	54.5%
Year		
2018	0	0.0%
2019	*****	*****
2020	41	37.3%
2021	15	13.6%
2022	11	10.0%
2023	30	27.3%
2024	*****	*****
Health Characteristics	Number	Percent
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease	0	0.0%
Non-Alzheimer's Dementia	0	0.0%
Atrial Fibrillation	12	10.9%

Table 1x. Aggregated Characteristics of rifamycin in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

rifamycin		
Health Characteristics	Number	Percent
Diabetes Mellitus	*****	*****
Heart Failure	*****	*****
Hyperlipidemia	19	17.3%
Hypertension	19	17.3%
Depression	17	15.5%
Ischemic Heart Disease	*****	*****
Rheumatoid Arthritis/Osteoarthritis	13	11.8%
Stroke/TIA ³	0	0.0%
Breast Cancer	*****	*****
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	*****	*****
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	*****	*****
Anemia	16	14.5%
Asthma	*****	*****
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	*****	*****
COPD ⁴ and Bronchiectasis	*****	*****
Glaucoma	*****	*****
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	15	13.6%
Obesity: identified by weight management-related dispensings	*****	*****
Overweight	12	10.9%
Smoking: diagnosed or identified by smoking cessation procedures	*****	*****
Smoking: identified by smoking-related dispensings	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	0	0.0%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	0	0.0%
Liver Disease Based on CCW ⁵ Definition	*****	*****
Liver Disease Extended Definition (CCW + Additional Codes)	*****	*****
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	11.0	12.7
Mean number of emergency room encounters	0.4	2.2
Mean number of inpatient hospital encounters	0.0	0.1
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	2.7	4.2

Table 1x. Aggregated Characteristics of rifamycin in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

rifamycin		
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of filled prescriptions	17.4	23.8
Mean number of generics dispensed	7.2	5.7
Mean number of unique drug classes dispensed	6.8	5.2

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

******Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.**

Table 1y. Aggregated Characteristics of emapalumab-lzsg in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

emapalumab-lzsg		
Patient Characteristics	Number	Percent
Unique patients	72	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	25.4	19.0
Age	Number	Percent
0-17 years	36	50.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	14	19.4%
≥ 65 years	*****	*****
Sex		
Female	34	47.2%
Male	38	52.8%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	35	48.6%
White	*****	*****
Hispanic origin		
Yes	14	19.4%
No	30	41.7%
Unknown	28	38.9%
Year		
2018	*****	*****
2019	11	15.3%
2020	19	26.4%
2021	20	27.8%
2022	*****	*****
2023	*****	*****
2024	*****	*****
Health Characteristics	Number	Percent
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease	0	0.0%
Non-Alzheimer's Dementia	*****	*****
Atrial Fibrillation	*****	*****

Table 1y. Aggregated Characteristics of emapalumab-lzsg in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

emapalumab-lzsg		
Health Characteristics	Number	Percent
Diabetes Mellitus	*****	*****
Heart Failure	*****	*****
Hyperlipidemia	17	23.6%
Hypertension	37	51.4%
Depression	12	16.7%
Ischemic Heart Disease	*****	*****
Rheumatoid Arthritis/Osteoarthritis	18	25.0%
Stroke/TIA ³	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	*****	*****
Anemia	56	77.8%
Asthma	*****	*****
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	11	15.3%
COPD ⁴ and Bronchiectasis	*****	*****
Glaucoma	0	0.0%
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	*****	*****
Obesity: identified by weight management-related dispensings	0	0.0%
Overweight	*****	*****
Smoking: diagnosed or identified by smoking cessation procedures	11	15.3%
Smoking: identified by smoking-related dispensings	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****
Liver Disease Based on CCW ⁵ Definition	38	52.8%
Liver Disease Extended Definition (CCW + Additional Codes)	38	52.8%
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	21.5	12.9
Mean number of emergency room encounters	1.7	1.7
Mean number of inpatient hospital encounters	2.1	1.6
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	29.5	23.3

Table 1y. Aggregated Characteristics of emapalumab-lzsg in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

emapalumab-lzsg		
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of filled prescriptions	25.9	21.6
Mean number of generics dispensed	11.8	6.6
Mean number of unique drug classes dispensed	10.7	5.6

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*******Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.**

Table 1z. Aggregated Characteristics of glasdegib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

glasdegib		
Patient Characteristics	Number	Percent
Unique patients	393	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	73.9	8.9
Age	Number	Percent
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	340	86.5%
Sex		
Female	161	41.0%
Male	232	59.0%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	32	8.1%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	49	12.5%
White	297	75.6%
Hispanic origin		
Yes	*****	*****
No	320	81.4%
Unknown	*****	*****
Year		
2018	*****	*****
2019	102	26.0%
2020	102	26.0%
2021	70	17.8%
2022	60	15.3%
2023	33	8.4%
2024	*****	*****
Health Characteristics	Number	Percent
Acute Myocardial Infarction	13	3.3%
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	17	4.3%
Atrial Fibrillation	81	20.6%

Table 1z. Aggregated Characteristics of glasdegib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

glasdegib		
Health Characteristics	Number	Percent
Diabetes Mellitus	113	28.8%
Heart Failure	101	25.7%
Hyperlipidemia	201	51.1%
Hypertension	259	65.9%
Depression	94	23.9%
Ischemic Heart Disease	124	31.6%
Rheumatoid Arthritis/Osteoarthritis	74	18.8%
Stroke/TIA ³	40	10.2%
Breast Cancer	22	5.6%
Colorectal Cancer	*****	*****
Prostate Cancer	32	8.1%
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	62	15.8%
Anemia	388	98.7%
Asthma	16	4.1%
Benign Prostatic Hyperplasia	59	15.0%
Chronic Kidney Disease	98	24.9%
COPD ⁴ and Bronchiectasis	62	15.8%
Glaucoma	40	10.2%
Osteoporosis	22	5.6%
Obesity: diagnosed or identified by weight management procedures	69	17.6%
Obesity: identified by weight management-related dispensings	*****	*****
Overweight	52	13.2%
Smoking: diagnosed or identified by smoking cessation procedures	165	42.0%
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	50	12.7%
Liver Disease Based on CCW ⁵ Definition	43	10.9%
Liver Disease Extended Definition (CCW + Additional Codes)	44	11.2%
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	55.2	20.3
Mean number of emergency room encounters	0.9	1.4
Mean number of inpatient hospital encounters	1.6	1.5
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	23.4	23.3

Table 1z. Aggregated Characteristics of glasdegib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

glasdegib		
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of filled prescriptions	31.7	24.2
Mean number of generics dispensed	13.4	6.1
Mean number of unique drug classes dispensed	12.4	5.3

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*******Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.**

Table 1aa. Aggregated Characteristics of larotrectinib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

larotrectinib		
Patient Characteristics	Number	Percent
Unique patients	517	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	55.7	18.7
Age	Number	Percent
0-17 years	73	14.1%
18-24 years	11	2.1%
25-40 years	35	6.8%
41-64 years	153	29.6%
≥ 65 years	245	47.4%
Sex		
Female	298	57.6%
Male	219	42.4%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	49	9.5%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	145	28.0%
White	292	56.5%
Hispanic origin		
Yes	37	7.2%
No	340	65.8%
Unknown	140	27.1%
Year		
2018	*****	*****
2019	108	20.9%
2020	90	17.4%
2021	111	21.5%
2022	67	13.0%
2023	93	18.0%
2024	*****	*****
Health Characteristics	Number	Percent
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	16	3.1%
Atrial Fibrillation	56	10.8%

Table 1aa. Aggregated Characteristics of larotrectinib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

larotrectinib		
Health Characteristics	Number	Percent
Diabetes Mellitus	90	17.4%
Heart Failure	48	9.3%
Hyperlipidemia	139	26.9%
Hypertension	219	42.4%
Depression	103	19.9%
Ischemic Heart Disease	77	14.9%
Rheumatoid Arthritis/Osteoarthritis	60	11.6%
Stroke/TIA ³	26	5.0%
Breast Cancer	62	12.0%
Colorectal Cancer	56	10.8%
Prostate Cancer	23	4.4%
Lung Cancer	118	22.8%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	101	19.5%
Anemia	217	42.0%
Asthma	36	7.0%
Benign Prostatic Hyperplasia	33	6.4%
Chronic Kidney Disease	47	9.1%
COPD ⁴ and Bronchiectasis	59	11.4%
Glaucoma	18	3.5%
Osteoporosis	17	3.3%
Obesity: diagnosed or identified by weight management	81	15.7%
Obesity: identified by weight management-related	*****	*****
Overweight	35	6.8%
Smoking: diagnosed or identified by smoking cessation	146	28.2%
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	15	2.9%
Drug Abuse or Dependence	26	5.0%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	20	3.9%
Liver Disease Based on CCW ⁵ Definition	75	14.5%
Liver Disease Extended Definition (CCW + Additional Codes)	77	14.9%
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	26.5	15.3
Mean number of emergency room encounters	0.7	1.1
Mean number of inpatient hospital encounters	0.8	1.4
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	12.8	20.6

Table 1aa. Aggregated Characteristics of larotrectinib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

larotrectinib		
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of filled prescriptions	20.7	16.5
Mean number of generics dispensed	9.5	6.0
Mean number of unique drug classes dispensed	8.7	5.3

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*******Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.**

Table 1ab. Aggregated Characteristics of amifampridine in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

amifampridine		
Patient Characteristics	Number	Percent
Unique patients	540	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	61.3	14.0
Age	Number	Percent
0-17 years	21	3.9%
18-24 years	15	2.8%
25-40 years	39	7.2%
41-64 years	168	31.1%
≥ 65 years	297	55.0%
Sex		
Female	305	56.5%
Male	235	43.5%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	39	7.2%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	91	16.9%
White	390	72.2%
Hispanic origin		
Yes	28	5.2%
No	410	75.9%
Unknown	102	18.9%
Year		
2018	0	0.0%
2019	210	38.9%
2020	69	12.8%
2021	94	17.4%
2022	59	10.9%
2023	60	11.1%
2024	48	8.9%
Health Characteristics	Number	Percent
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	11	2.0%
Atrial Fibrillation	45	8.3%

Table 1ab. Aggregated Characteristics of amifampridine in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

amifampridine		
Health Characteristics	Number	Percent
Diabetes Mellitus	99	18.3%
Heart Failure	57	10.6%
Hyperlipidemia	152	28.1%
Hypertension	212	39.3%
Depression	125	23.1%
Ischemic Heart Disease	105	19.4%
Rheumatoid Arthritis/Osteoarthritis	105	19.4%
Stroke/TIA ³	25	4.6%
Breast Cancer	20	3.7%
Colorectal Cancer	*****	*****
Prostate Cancer	16	3.0%
Lung Cancer	73	13.5%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	81	15.0%
Anemia	129	23.9%
Asthma	28	5.2%
Benign Prostatic Hyperplasia	27	5.0%
Chronic Kidney Disease	39	7.2%
COPD ⁴ and Bronchiectasis	98	18.1%
Glaucoma	35	6.5%
Osteoporosis	30	5.6%
Obesity: diagnosed or identified by weight management	93	17.2%
Obesity: identified by weight management-related dispensings	*****	*****
Overweight	59	10.9%
Smoking: diagnosed or identified by smoking cessation	163	30.2%
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	20	3.7%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	28	5.2%
Liver Disease Based on CCW ⁵ Definition	30	5.6%
Liver Disease Extended Definition (CCW + Additional Codes)	32	5.9%
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	18.0	13.4
Mean number of emergency room encounters	0.4	0.9
Mean number of inpatient hospital encounters	0.4	0.8
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	11.5	22.7

Table 1ab. Aggregated Characteristics of amifampridine in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

amifampridine		
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of filled prescriptions	21.6	18.2
Mean number of generics dispensed	8.6	5.8
Mean number of unique drug classes dispensed	8.1	5.4

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*******Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.**

Table 1ac. Aggregated Characteristics of gilteritinib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

gilteritinib		
Patient Characteristics	Number	Percent
Unique patients	2,670	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	65.3	12.4
Age	Number	Percent
0-17 years	47	1.8%
18-24 years	44	1.6%
25-40 years	181	6.8%
41-64 years	661	24.8%
≥ 65 years	1,737	65.1%
Sex		
Female	1,294	48.5%
Male	1,376	51.5%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	77	2.9%
Black or African American	177	6.6%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	497	18.6%
White	1,891	70.8%
Hispanic origin		
Yes	96	3.6%
No	1,978	74.1%
Unknown	596	22.3%
Year		
2018	35	1.3%
2019	418	15.7%
2020	524	19.6%
2021	540	20.2%
2022	415	15.5%
2023	430	16.1%
2024	308	11.5%
Health Characteristics	Number	Percent
Acute Myocardial Infarction	87	3.3%
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	107	4.0%
Atrial Fibrillation	432	16.2%

Table 1ac. Aggregated Characteristics of gilteritinib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

gilteritinib		
Health Characteristics	Number	Percent
Diabetes Mellitus	619	23.2%
Heart Failure	574	21.5%
Hyperlipidemia	1,136	42.5%
Hypertension	1,599	59.9%
Depression	665	24.9%
Ischemic Heart Disease	678	25.4%
Rheumatoid Arthritis/Osteoarthritis	480	18.0%
Stroke/TIA ³	218	8.2%
Breast Cancer	112	4.2%
Colorectal Cancer	31	1.2%
Prostate Cancer	123	4.6%
Lung Cancer	49	1.8%
Endometrial Cancer	19	0.7%
Acquired Hypothyroidism	408	15.3%
Anemia	2,398	89.8%
Asthma	215	8.1%
Benign Prostatic Hyperplasia	310	11.6%
Chronic Kidney Disease	443	16.6%
COPD ⁴ and Bronchiectasis	352	13.2%
Glaucoma	178	6.7%
Osteoporosis	134	5.0%
Obesity: diagnosed or identified by weight management	611	22.9%
Obesity: identified by weight management-related dispensings	22	0.8%
Overweight	342	12.8%
Smoking: diagnosed or identified by smoking cessation	1,020	38.2%
Smoking: identified by smoking-related dispensings	25	0.9%
Alcohol Abuse or Dependence	76	2.8%
Drug Abuse or Dependence	111	4.2%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	220	8.2%
Liver Disease Based on CCW ⁵ Definition	426	16.0%
Liver Disease Extended Definition (CCW + Additional Codes)	431	16.1%
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	36.0	22.0
Mean number of emergency room encounters	0.9	1.5
Mean number of inpatient hospital encounters	1.7	1.6
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	24.8	24.3

Table 1ac. Aggregated Characteristics of gilteritinib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

gilteritinib		
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of filled prescriptions	27.8	19.7
Mean number of generics dispensed	13.1	6.8
Mean number of unique drug classes dispensed	12.1	6.0

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*******Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.**

Table 1ad. Aggregated Characteristics of prucalopride in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

prucalopride		
Patient Characteristics	Number	Percent
Unique patients	49,006	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	55.1	15.3
Age	Number	Percent
0-17 years	788	1.6%
18-24 years	2,672	5.5%
25-40 years	8,060	16.4%
41-64 years	20,175	41.2%
≥ 65 years	17,311	35.3%
Sex		
Female	38,640	78.8%
Male	10,366	21.2%
Race ²		
American Indian or Alaska Native	181	0.4%
Asian	973	2.0%
Black or African American	3,836	7.8%
Multi-racial	468	1.0%
Native Hawaiian or Other Pacific Islander	40	0.1%
Unknown	10,923	22.3%
White	32,585	66.5%
Hispanic origin		
Yes	1,786	3.6%
No	33,986	69.4%
Unknown	13,234	27.0%
Year		
2018	0	0.0%
2019	6,217	12.7%
2020	10,224	20.9%
2021	10,431	21.3%
2022	8,724	17.8%
2023	7,991	16.3%
2024	5,419	11.1%
Health Characteristics	Number	Percent
Acute Myocardial Infarction	194	0.4%
Alzheimer's Disease	256	0.5%
Non-Alzheimer's Dementia	1,137	2.3%
Atrial Fibrillation	2,380	4.9%

Table 1ad. Aggregated Characteristics of prucalopride in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

prucalopride		
Health Characteristics	Number	Percent
Diabetes Mellitus	10,159	20.7%
Heart Failure	3,691	7.5%
Hyperlipidemia	14,386	29.4%
Hypertension	16,613	33.9%
Depression	18,555	37.9%
Ischemic Heart Disease	6,671	13.6%
Rheumatoid Arthritis/Osteoarthritis	11,443	23.4%
Stroke/TIA ³	1,140	2.3%
Breast Cancer	1,260	2.6%
Colorectal Cancer	320	0.7%
Prostate Cancer	503	1.0%
Lung Cancer	329	0.7%
Endometrial Cancer	125	0.3%
Acquired Hypothyroidism	7,866	16.1%
Anemia	11,393	23.2%
Asthma	4,724	9.6%
Benign Prostatic Hyperplasia	1,798	3.7%
Chronic Kidney Disease	4,191	8.6%
COPD ⁴ and Bronchiectasis	4,039	8.2%
Glaucoma	3,317	6.8%
Osteoporosis	3,473	7.1%
Obesity: diagnosed or identified by weight management procedures	9,263	18.9%
Obesity: identified by weight management-related dispensings	2,337	4.8%
Overweight	4,481	9.1%
Smoking: diagnosed or identified by smoking cessation procedures	9,180	18.7%
Smoking: identified by smoking-related dispensings	580	1.2%
Alcohol Abuse or Dependence	970	2.0%
Drug Abuse or Dependence	3,315	6.8%
History of Cardiac Arrest	109	0.2%
History of Coronary Angioplasty or Bypass	1,759	3.6%
Liver Disease Based on CCW ⁵ Definition	3,002	6.1%
Liver Disease Extended Definition (CCW + Additional Codes)	3,053	6.2%
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	20.5	16.9
Mean number of emergency room encounters	0.8	2.1
Mean number of inpatient hospital encounters	0.2	0.8
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	8.4	19.3

Table 1ad. Aggregated Characteristics of prucalopride in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

prucalopride		
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of filled prescriptions	33.9	27.9
Mean number of generics dispensed	12.9	7.6
Mean number of unique drug classes dispensed	12.0	6.7

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

Table 1ae. Aggregated Characteristics of calaspargase pegol-mknl in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

calaspargase pegol-mknl		
Patient Characteristics	Number	Percent
Unique patients	389	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	8.7	6.1
Age	Number	Percent
0-17 years	352	90.5%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	*****	*****
Sex		
Female	154	39.6%
Male	235	60.4%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	13	3.3%
Black or African American	14	3.6%
Multi-racial	17	4.4%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	222	57.1%
White	123	31.6%
Hispanic origin		
Yes	15	3.9%
No	117	30.1%
Unknown	257	66.1%
Year		
2018	0	0.0%
2019	*****	*****
2020	0	0.0%
2021	*****	*****
2022	*****	*****
2023	201	51.7%
2024	175	45.0%
Health Characteristics	Number	Percent
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease	0	0.0%
Non-Alzheimer's Dementia	*****	*****
Atrial Fibrillation	0	0.0%

Table 1ae. Aggregated Characteristics of calaspargase pegol-mknl in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

calaspargase pegol-mknl		
Health Characteristics	Number	Percent
Diabetes Mellitus	24	6.2%
Heart Failure	*****	*****
Hyperlipidemia	19	4.9%
Hypertension	107	27.5%
Depression	23	5.9%
Ischemic Heart Disease	*****	*****
Rheumatoid Arthritis/Osteoarthritis	*****	*****
Stroke/TIA ³	11	2.8%
Breast Cancer	0	0.0%
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	*****	*****
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	*****	*****
Anemia	359	92.3%
Asthma	33	8.5%
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	*****	*****
COPD ⁴ and Bronchiectasis	*****	*****
Glaucoma	*****	*****
Osteoporosis	0	0.0%
Obesity: diagnosed or identified by weight management procedures	16	4.1%
Obesity: identified by weight management-related dispensings	*****	*****
Overweight	*****	*****
Smoking: diagnosed or identified by smoking cessation procedures	*****	*****
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	*****	*****
Liver Disease Based on CCW ⁵ Definition	79	20.3%
Liver Disease Extended Definition (CCW + Additional Codes)	80	20.6%
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	22.8	12.1
Mean number of emergency room encounters	1.8	1.8
Mean number of inpatient hospital encounters	2.2	1.8
Mean number of non-acute institutional encounters	0.0	0.1

Table 1ae. Aggregated Characteristics of calaspargase pegol-mknl in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

calaspargase pegol-mknl		
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of other ambulatory encounters	6.6	8.1
Mean number of filled prescriptions	18.9	10.6
Mean number of generics dispensed	10.9	4.7
Mean number of unique drug classes dispensed	10.2	4.3

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

******Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.**

Table 1af. Aggregated Characteristics of tagraxofusp-erzs in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

tagraxofusp-erzs		
Patient Characteristics	Number	Percent
Unique patients	135	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	66.3	13.2
Age	Number	Percent
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	17	12.6%
≥ 65 years	100	74.1%
Sex		
Female	29	21.5%
Male	106	78.5%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	29	21.5%
White	95	70.4%
Hispanic origin		
Yes	*****	*****
No	94	69.6%
Unknown	*****	*****
Year		
2018	0	0.0%
2019	20	14.8%
2020	27	20.0%
2021	27	20.0%
2022	18	13.3%
2023	16	11.9%
2024	27	20.0%
Health Characteristics	Number	Percent
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease	0	0.0%
Non-Alzheimer's Dementia	*****	*****
Atrial Fibrillation	19	14.1%

Table 1af. Aggregated Characteristics of tagraxofusp-erzs in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

tagraxofusp-erzs		
Health Characteristics	Number	Percent
Diabetes Mellitus	20	14.8%
Heart Failure	16	11.9%
Hyperlipidemia	52	38.5%
Hypertension	70	51.9%
Depression	14	10.4%
Ischemic Heart Disease	23	17.0%
Rheumatoid Arthritis/Osteoarthritis	19	14.1%
Stroke/TIA ³	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	*****	*****
Anemia	92	68.1%
Asthma	*****	*****
Benign Prostatic Hyperplasia	19	14.1%
Chronic Kidney Disease	24	17.8%
COPD ⁴ and Bronchiectasis	11	8.1%
Glaucoma	11	8.1%
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	21	15.6%
Obesity: identified by weight management-related dispensings	0	0.0%
Overweight	19	14.1%
Smoking: diagnosed or identified by smoking cessation procedures	56	41.5%
Smoking: identified by smoking-related dispensings	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	*****	*****
Liver Disease Based on CCW ⁵ Definition	*****	*****
Liver Disease Extended Definition (CCW + Additional Codes)	*****	*****
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	22.5	16.5
Mean number of emergency room encounters	0.7	1.3
Mean number of inpatient hospital encounters	0.8	1.1
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	11.6	14.8

Table 1af. Aggregated Characteristics of tagraxofusp-erzs in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

tagraxofusp-erzs		
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of filled prescriptions	14.4	12.8
Mean number of generics dispensed	7.7	5.1
Mean number of unique drug classes dispensed	7.2	4.7

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

******Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.**

Table 1ag. Aggregated Characteristics of ravulizumab in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

ravulizumab		
Patient Characteristics	Number	Percent
Unique patients	3,694	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	57.2	17.0
Age	Number	Percent
0-17 years	214	5.8%
18-24 years	146	4.0%
25-40 years	556	15.1%
41-64 years	943	25.5%
≥ 65 years	1,835	49.7%
Sex		
Female	1,918	51.9%
Male	1,776	48.1%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	112	3.0%
Black or African American	418	11.3%
Multi-racial	28	0.8%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	806	21.8%
White	2,301	62.3%
Hispanic origin		
Yes	181	4.9%
No	2,616	70.8%
Unknown	897	24.3%
Year		
2018	0	0.0%
2019	313	8.5%
2020	524	14.2%
2021	425	11.5%
2022	728	19.7%
2023	998	27.0%
2024	706	19.1%
Health Characteristics	Number	Percent
Acute Myocardial Infarction	58	1.6%
Alzheimer's Disease	18	0.5%
Non-Alzheimer's Dementia	75	2.0%
Atrial Fibrillation	319	8.6%

Table 1ag. Aggregated Characteristics of ravulizumab in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

ravulizumab		
Health Characteristics	Number	Percent
Diabetes Mellitus	853	23.1%
Heart Failure	525	14.2%
Hyperlipidemia	1,207	32.7%
Hypertension	1,966	53.2%
Depression	728	19.7%
Ischemic Heart Disease	642	17.4%
Rheumatoid Arthritis/Osteoarthritis	538	14.6%
Stroke/TIA ³	160	4.3%
Breast Cancer	74	2.0%
Colorectal Cancer	38	1.0%
Prostate Cancer	108	2.9%
Lung Cancer	30	0.8%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	499	13.5%
Anemia	2,400	65.0%
Asthma	202	5.5%
Benign Prostatic Hyperplasia	241	6.5%
Chronic Kidney Disease	1,090	29.5%
COPD ⁴ and Bronchiectasis	258	7.0%
Glaucoma	252	6.8%
Osteoporosis	202	5.5%
Obesity: diagnosed or identified by weight management	919	24.9%
Obesity: identified by weight management-related	111	3.0%
Overweight	380	10.3%
Smoking: diagnosed or identified by smoking cessation	767	20.8%
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	56	1.5%
Drug Abuse or Dependence	138	3.7%
History of Cardiac Arrest	23	0.6%
History of Coronary Angioplasty or Bypass	204	5.5%
Liver Disease Based on CCW ⁵ Definition	245	6.6%
Liver Disease Extended Definition (CCW + Additional Codes)	248	6.7%
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	25.2	23.9
Mean number of emergency room encounters	0.6	1.4
Mean number of inpatient hospital encounters	0.5	1.0
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	9.3	16.0

Table 1ag. Aggregated Characteristics of ravulizumab in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

ravulizumab		
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of filled prescriptions	22.7	18.5
Mean number of generics dispensed	9.5	6.2
Mean number of unique drug classes dispensed	8.8	5.6

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*******Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.**

Table 2a. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
<i>mogamulizumab-kpkc</i>	18,766	18,766	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>patisiran</i>	15,474	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>segesterone acetate and ethinyl estradiol vaginal system</i>	27,215	12,263	45.1%	1,527	5.6%	3,602	13.2%	9,823	36.1%
<i>migalastat</i>	4,951	4,902	99.0%	*****	*****	35	0.7%	*****	*****
<i>stiripentol</i>	8,078	7,420	91.9%	494	6.1%	143	1.8%	21	0.3%
<i>cenegermin-bkbj</i>	44,936	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>lanadelumab</i>	27,529	27,347	99.3%	111	0.4%	71	0.3%	0	0.0%
<i>eravacycline</i>	10,640	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>doravirine</i>	126,327	122,684	97.1%	550	0.4%	3,067	2.4%	26	0.0%
<i>moxetumomab pasudotox-tdfk</i>	444	444	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>fremanezumab-vfrm</i>	752,054	674,993	89.8%	9,567	1.3%	67,199	8.9%	295	0.0%
<i>duvelisib</i>	3,922	3,899	99.4%	*****	*****	*****	*****	0	0.0%
<i>galcanezumab-gnlm</i>	2,001,899	1,900,448	94.9%	16,090	0.8%	85,114	4.3%	247	0.0%
<i>dacomitinib</i>	621	*****	*****	*****	*****	*****	*****	0	0.0%
<i>cemiplimab-rwlc</i>	115,988	*****	*****	0	0.0%	0	0.0%	*****	*****
<i>sarecycline</i>	59,994	59,411	99.0%	*****	*****	438	0.7%	*****	*****
<i>omadacycline</i>	44,006	43,695	99.3%	121	0.3%	190	0.4%	0	0.0%
<i>elapegademase-lvlr</i>	984	970	98.6%	14	1.4%	0	0.0%	0	0.0%
<i>inotersen</i>	1,709	1,709	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>talazoparib</i>	4,576	4,556	99.6%	*****	*****	*****	*****	0	0.0%
<i>baloxavir marboxil</i>	140,317	140,200	99.9%	86	0.1%	*****	*****	*****	*****
<i>lorlatinib</i>	15,731	15,579	99.0%	98	0.6%	*****	*****	*****	*****
<i>revefenacin</i>	76,191	74,192	97.4%	*****	*****	1,739	2.3%	*****	*****

Table 2a. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
<i>rifamycin</i>	186	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>emapalumab-lzsg</i>	1,055	1,055	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>glasdegib</i>	917	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>larotrectinib</i>	3,723	3,607	96.9%	*****	*****	*****	*****	0	0.0%
<i>amifampridine</i>	11,661	11,328	97.1%	54	0.5%	279	2.4%	0	0.0%
<i>gilteritinib</i>	15,650	15,407	98.4%	204	1.3%	*****	*****	*****	*****
<i>prucalopride</i>	309,149	257,917	83.4%	5,696	1.8%	45,453	14.7%	83	0.0%
<i>calaspargase pegol-mknl</i>	895	895	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>tagraxofusp-erzs</i>	1,588	1,588	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>ravulizumab</i>	31,190	29,119	93.4%	1,924	6.2%	35	0.1%	112	0.4%

¹For drugs requiring clinical administration and identified by procedure codes (rather than pharmacy claims with NDCs), days supplied are not recorded. A default of 1 day supplied was assigned per administration for summary purposes.

*******Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.**

Table 2b. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>mogamulizumab-kpkc</i>	18,766	1	1	1	1	30	1.2	2.3
<i>patisiran</i>	15,474	1	1	1	1	42	2.2	4.7
<i>segesterone acetate and ethinyl estradiol vaginal system</i>	27,215	1	28	55	198	638	123.4	129.9
<i>migalastat</i>	4,951	1	28	28	28	168	28.1	6.5
<i>stiripentol</i>	8,078	1	24	30	30	180	29.8	12.4
<i>cenegermin-bkbj</i>	44,936	1	14	14	14	34	13.1	2.7
<i>lanadelumab</i>	27,529	1	28	28	28	84	27.2	5.4
<i>eravacycline</i>	10,640	1	1	1	1	41	1.8	2.0
<i>doravirine</i>	126,327	1	30	30	30	210	30.7	10.4
<i>moxetumomab pasudotox-tdfk</i>	444	1	1	1	1	28	1.1	1.8
<i>fremanezumab-vfrm</i>	752,054	1	30	30	30	360	34.4	17.8
<i>duvelisib</i>	3,922	1	28	28	28	84	27.5	4.0
<i>galcanezumab-gnlm</i>	2,001,899	1	28	30	30	651	31.4	12.8
<i>dacomitinib</i>	621	1	30	30	30	90	29.3	4.7
<i>cemiplimab-rwlc</i>	115,988	1	1	1	1	148	1.2	2.0
<i>sarecycline</i>	59,994	1	30	30	30	180	30.1	6.1
<i>omadacycline</i>	44,006	1	1	1	14	90	8.6	11.7
<i>elapegademase-lvlr</i>	984	1	28	28	28	56	26.3	7.3
<i>inotersen</i>	1,709	2	28	28	28	30	27.8	1.9
<i>talazoparib</i>	4,576	1	30	30	30	90	28.1	5.7
<i>baloxavir marboxil</i>	140,317	1	1	1	1	180	2.2	5.8
<i>lorlatinib</i>	15,731	1	30	30	30	300	28.6	7.2
<i>revefenacin</i>	76,191	1	1	30	30	120	21.1	17.1
<i>rifamycin</i>	186	2	3	3	6	36	6.2	7.0
<i>emapalumab-lzsg</i>	1,055	1	1	1	1	7	1.2	0.9

Table 2b. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>glasdegib</i>	917	1	28	30	30	32	27.3	5.9
<i>larotrectinib</i>	3,723	1	30	30	30	90	28.3	6.1
<i>amifampridine</i>	11,661	1	30	30	30	90	31.0	9.9
<i>gilteritinib</i>	15,650	1	30	30	30	300	27.6	8.8
<i>prucalopride</i>	309,149	1	30	30	30	180	38.1	22.0
<i>calaspargase pegol-mknl</i>	895	1	1	1	1	30	1.1	1.4
<i>tagraxofusp-erzs</i>	1,588	1	1	1	1	21	1.0	0.5
<i>ravulizumab</i>	31,190	1	1	1	1	112	5.5	15.1

¹For drugs requiring clinical administration and identified by procedure codes (rather than pharmacy claims with NDCs), days supplied are not recorded. A default of 1 day supplied was assigned per administration for summary purposes.

Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
mogamulizumab-kpkc	18,766	18,766	100.0%	0	NaN	0	NaN	0	NaN
Female	8,419	8,419	44.9%	0	NaN	0	NaN	0	NaN
Male	10,347	10,347	55.1%	0	NaN	0	NaN	0	NaN
patisiran	15,474	*****	*****	*****	*****	0	NaN	0	NaN
Female	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	*****	*****	*****	0	0.0%	0	NaN	0	NaN
segesterone acetate and ethinyl estradiol vaginal system	27,215	12,263	100.0%	1,527	100.0%	3,602	100.0%	9,823	100.0%
Female	27,164	12,249	99.9%	*****	*****	*****	*****	9,795	99.7%
Male	51	14	0.1%	*****	*****	*****	*****	28	0.3%
migalastat	4,951	4,902	100.0%	*****	*****	35	100.0%	*****	*****
Female	2,421	2,400	49.0%	0	0.0%	21	60.0%	0	0.0%
Male	2,530	2,502	51.0%	*****	*****	14	40.0%	*****	*****
stiripentol	8,078	7,420	100.0%	494	100.0%	143	100.0%	21	100.0%
Female	4,416	4,068	54.8%	268	54.3%	*****	*****	*****	*****
Male	3,662	3,352	45.2%	226	45.7%	*****	*****	*****	*****
cenegermin-bkbj	44,936	*****	*****	*****	*****	0	NaN	0	NaN
Female	*****	*****	*****	0	0.0%	0	NaN	0	NaN
Male	*****	*****	*****	*****	*****	0	NaN	0	NaN
lanadelumab	27,529	27,347	100.0%	111	100.0%	71	100.0%	0	NaN
Female	18,565	18,482	67.6%	58	52.3%	25	35.2%	0	NaN
Male	8,964	8,865	32.4%	53	47.7%	46	64.8%	0	NaN
eravacycline	10,640	*****	*****	*****	*****	0	NaN	0	NaN
Female	*****	*****	*****	*****	*****	0	NaN	0	NaN

Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
Male	*****	*****	*****	0	0.0%	0	NaN	0	NaN
doravirine	126,327	122,684	100.0%	550	100.0%	3,067	100.0%	26	100.0%
Female	29,034	28,415	23.2%	*****	*****	470	15.3%	*****	*****
Male	97,293	94,269	76.8%	*****	*****	2,597	84.7%	*****	*****
moxetumomab pasudotox-tdfk	444	444	100.0%	0	NaN	0	NaN	0	NaN
Female	67	67	15.1%	0	NaN	0	NaN	0	NaN
Male	377	377	84.9%	0	NaN	0	NaN	0	NaN
fremanezumab-vfrm	752,054	674,993	100.0%	9,567	100.0%	67,199	100.0%	295	100.0%
Female	649,686	583,337	86.4%	8,294	86.7%	57,785	86.0%	270	91.5%
Male	102,368	91,656	13.6%	1,273	13.3%	9,414	14.0%	25	8.5%
duvelisib	3,922	3,899	100.0%	*****	*****	*****	*****	0	NaN
Female	1,750	*****	*****	*****	*****	*****	*****	0	NaN
Male	2,172	*****	*****	*****	*****	0	0.0%	0	NaN
galcanezumab-gnlm	2,001,899	1,900,448	100.0%	16,090	100.0%	85,114	100.0%	247	100.0%
Female	1,706,077	1,620,127	85.2%	13,697	85.1%	72,048	84.6%	205	83.0%
Male	295,822	280,321	14.8%	2,393	14.9%	13,066	15.4%	42	17.0%
dacomitinib	621	*****	*****	*****	*****	*****	*****	0	NaN
Female	356	*****	*****	0	0.0%	0	0.0%	0	NaN
Male	265	*****	*****	*****	*****	*****	*****	0	NaN
cemiplimab-rwlc	115,988	*****	*****	0	NaN	0	NaN	*****	*****
Female	*****	*****	*****	0	NaN	0	NaN	*****	*****
Male	*****	*****	*****	0	NaN	0	NaN	0	0.0%
sarecycline	59,994	59,411	100.0%	*****	*****	438	100.0%	*****	*****

Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
Female	36,002	35,688	60.1%	*****	*****	225	51.4%	*****	*****
Male	23,992	23,723	39.9%	*****	*****	213	48.6%	*****	*****
omadacycline	44,006	43,695	100.0%	121	100.0%	190	100.0%	0	NaN
Female	22,712	22,537	51.6%	62	51.2%	113	59.5%	0	NaN
Male	21,294	21,158	48.4%	59	48.8%	77	40.5%	0	NaN
elapegademase-lvlr	984	970	100.0%	14	100.0%	0	NaN	0	NaN
Female	441	*****	*****	*****	*****	0	NaN	0	NaN
Male	543	*****	*****	*****	*****	0	NaN	0	NaN
inotersen	1,709	1,709	100.0%	0	NaN	0	NaN	0	NaN
Female	909	909	53.2%	0	NaN	0	NaN	0	NaN
Male	800	800	46.8%	0	NaN	0	NaN	0	NaN
talazoparib	4,576	4,556	100.0%	*****	*****	*****	*****	0	NaN
Female	3,140	*****	*****	*****	*****	*****	*****	0	NaN
Male	1,436	*****	*****	*****	*****	0	0.0%	0	NaN
baloxavir marboxil	140,317	140,200	100.0%	86	100.0%	*****	*****	*****	*****
Female	76,356	76,299	54.4%	40	46.5%	*****	*****	*****	*****
Male	63,961	63,901	45.6%	46	53.5%	*****	*****	*****	*****
lorlatinib	15,731	15,579	100.0%	98	100.0%	*****	*****	*****	*****
Female	8,660	8,591	55.1%	*****	*****	*****	*****	0	0.0%
Male	7,071	6,988	44.9%	*****	*****	*****	*****	*****	*****
revefenacin	76,191	74,192	100.0%	*****	*****	1,739	100.0%	*****	*****
Female	44,542	43,340	58.4%	*****	*****	1,054	60.6%	*****	*****
Male	31,649	30,852	41.6%	*****	*****	685	39.4%	*****	*****
rifamycin	186	*****	*****	*****	*****	0	NaN	0	NaN

Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
Female	101	*****	*****	*****	*****	0	NaN	0	NaN
Male	85	*****	*****	*****	*****	0	NaN	0	NaN
emapalumab-lzsg	1,055	1,055	100.0%	0	NaN	0	NaN	0	NaN
Female	760	760	72.0%	0	NaN	0	NaN	0	NaN
Male	295	295	28.0%	0	NaN	0	NaN	0	NaN
glasdegib	917	*****	*****	*****	*****	0	NaN	0	NaN
Female	374	*****	*****	0	0.0%	0	NaN	0	NaN
Male	543	*****	*****	*****	*****	0	NaN	0	NaN
larotrectinib	3,723	3,607	100.0%	*****	*****	*****	*****	0	NaN
Female	1,943	1,875	52.0%	*****	*****	*****	*****	0	NaN
Male	1,780	1,732	48.0%	*****	*****	*****	*****	0	NaN
amifampridine	11,661	11,328	100.0%	54	100.0%	279	100.0%	0	NaN
Female	6,994	6,810	60.1%	26	48.1%	158	56.6%	0	NaN
Male	4,667	4,518	39.9%	28	51.9%	121	43.4%	0	NaN
gilteritinib	15,650	15,407	100.0%	204	100.0%	*****	*****	*****	*****
Female	7,913	7,758	50.4%	*****	*****	*****	*****	0	0.0%
Male	7,737	7,649	49.6%	*****	*****	*****	*****	*****	*****
prucalopride	309,149	257,917	100.0%	5,696	100.0%	45,453	100.0%	83	100.0%
Female	241,878	201,191	78.0%	4,231	74.3%	36,388	80.1%	68	81.9%
Male	67,271	56,726	22.0%	1,465	25.7%	9,065	19.9%	15	18.1%
calaspargase pegol-mknl	895	895	100.0%	0	NaN	0	NaN	0	NaN
Female	357	357	39.9%	0	NaN	0	NaN	0	NaN
Male	538	538	60.1%	0	NaN	0	NaN	0	NaN
tagraxofusp-erzs	1,588	1,588	100.0%	0	NaN	0	NaN	0	NaN

Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
Female	344	344	21.7%	0	NaN	0	NaN	0	NaN
Male	1,244	1,244	78.3%	0	NaN	0	NaN	0	NaN
ravulizumab	31,190	29,119	100.0%	1,924	100.0%	35	100.0%	112	100.0%
Female	16,647	15,523	53.3%	1,068	55.5%	20	57.1%	36	32.1%
Male	14,543	13,596	46.7%	856	44.5%	15	42.9%	76	67.9%

¹For drugs requiring clinical administration and identified by procedure codes (rather than pharmacy claims with NDCs), days supplied are not recorded. A default of 1 day supplied was assigned per administration for summary purposes.

*NaN: Not a number

******Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.**

Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
mogamulizumab-kpkc	18,766	1	1	1	1	30	1.2	2.3
Female	8,419	1	1	1	1	30	1.3	2.9
Male	10,347	1	1	1	1	28	1.2	1.8
patisiran	15,474	1	1	1	1	42	2.2	4.7
Female	5,568	1	1	1	1	42	2.8	5.7
Male	9,906	1	1	1	1	28	1.8	4.0
segesterone acetate and ethinyl estradiol vaginal system	27,215	1	28	55	198	638	123.4	129.9
Female	27,164	1	28	55	198	638	123.3	129.9
Male	51	1	30	115	336	365	169.1	139.1
migalastat	4,951	1	28	28	28	168	28.1	6.5
Female	2,421	1	28	28	28	84	28.0	5.9
Male	2,530	1	28	28	28	168	28.1	7.0
stiripentol	8,078	1	24	30	30	180	29.8	12.4
Female	4,416	1	24	30	30	144	29.5	11.3
Male	3,662	1	26	30	30	180	30.2	13.6
cenegermin-bkbj	44,936	1	14	14	14	34	13.1	2.7
Female	29,421	1	14	14	14	30	13.1	2.7
Male	15,515	1	14	14	14	34	13.0	2.7
lanadelumab	27,529	1	28	28	28	84	27.2	5.4
Female	18,565	1	28	28	28	84	27.2	4.9
Male	8,964	1	28	28	28	84	27.3	6.3
eravacycline	10,640	1	1	1	1	41	1.8	2.0
Female	5,417	1	1	1	1	41	1.7	1.9
Male	5,223	1	1	1	1	30	1.9	2.1
doravirine	126,327	1	30	30	30	210	30.7	10.4

Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Female	29,034	1	30	30	30	180	30.1	9.2
Male	97,293	1	30	30	30	210	30.9	10.7
moxetumomab pasudotox-tdfk	444	1	1	1	1	28	1.1	1.8
Female	67	1	1	1	1	1	1.0	0.0
Male	377	1	1	1	1	28	1.1	2.0
fremanezumab-vfrm	752,054	1	30	30	30	360	34.4	17.8
Female	649,686	1	30	30	30	360	34.4	17.7
Male	102,368	1	30	30	30	180	34.5	17.9
duvelisib	3,922	1	28	28	28	84	27.5	4.0
Female	1,750	1	28	28	28	84	27.7	4.3
Male	2,172	1	28	28	28	56	27.3	3.8
galcanezumab-gnlm	2,001,899	1	28	30	30	651	31.4	12.8
Female	1,706,077	1	28	30	30	651	31.4	12.8
Male	295,822	1	28	30	30	360	31.5	13.0
dacomitinib	621	1	30	30	30	90	29.3	4.7
Female	356	1	30	30	30	30	29.3	3.4
Male	265	13	30	30	30	90	29.3	6.1
cemiplimab-rwlc	115,988	1	1	1	1	148	1.2	2.0
Female	30,727	1	1	1	1	148	1.2	2.3
Male	85,261	1	1	1	1	21	1.2	1.9
sarecycline	59,994	1	30	30	30	180	30.1	6.1
Female	36,002	1	30	30	30	150	30.0	5.8
Male	23,992	1	30	30	30	180	30.1	6.5
omadacycline	44,006	1	1	1	14	90	8.6	11.7
Female	22,712	1	1	1	14	90	9.2	12.2
Male	21,294	1	1	1	14	90	8.0	11.1

Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
elapegademase-lvlr	984	1	28	28	28	56	26.3	7.3
Female	441	1	28	28	28	56	25.3	8.1
Male	543	1	28	28	28	56	27.1	6.5
inotersen	1,709	2	28	28	28	30	27.8	1.9
Female	909	4	28	28	28	30	27.9	1.7
Male	800	2	28	28	28	30	27.8	2.2
talazoparib	4,576	1	30	30	30	90	28.1	5.7
Female	3,140	1	30	30	30	90	28.3	5.5
Male	1,436	1	30	30	30	60	27.8	6.2
baloxavir marboxil	140,317	1	1	1	1	180	2.2	5.8
Female	76,356	1	1	1	1	120	2.3	5.9
Male	63,961	1	1	1	1	180	2.1	5.7
lorlatinib	15,731	1	30	30	30	300	28.6	7.2
Female	8,660	1	30	30	30	90	28.6	6.6
Male	7,071	1	30	30	30	300	28.6	8.0
revefenacin	76,191	1	1	30	30	120	21.1	17.1
Female	44,542	1	1	30	30	120	21.6	17.1
Male	31,649	1	1	30	30	120	20.4	17.2
rifamycin	186	2	3	3	6	36	6.2	7.0
Female	101	2	3	3	9	36	6.8	7.4
Male	85	2	3	3	6	31	5.5	6.6
emapalumab-lzsg	1,055	1	1	1	1	7	1.2	0.9
Female	760	1	1	1	1	7	1.1	0.6
Male	295	1	1	1	1	7	1.4	1.3

Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
glasdegib	917	1	28	30	30	32	27.3	5.9
Female	374	4	28	30	30	30	27.4	5.8
Male	543	1	28	30	30	32	27.3	5.9
larotrectinib	3,723	1	30	30	30	90	28.3	6.1
Female	1,943	1	30	30	30	90	28.7	6.7
Male	1,780	1	30	30	30	78	28.0	5.4
amifampridine	11,661	1	30	30	30	90	31.0	9.9
Female	6,994	1	30	30	30	90	30.9	9.5
Male	4,667	1	30	30	30	90	31.1	10.3
gilteritinib	15,650	1	30	30	30	300	27.6	8.8
Female	7,913	1	30	30	30	90	27.8	8.5
Male	7,737	1	30	30	30	300	27.4	9.1
prucalopride	309,149	1	30	30	30	180	38.1	22.0
Female	241,878	1	30	30	30	180	38.4	22.2
Male	67,271	1	30	30	30	180	37.2	21.5
calaspargase pegol-mknl	895	1	1	1	1	30	1.1	1.4
Female	357	1	1	1	1	30	1.2	2.1
Male	538	1	1	1	1	1	1.0	0.0
tagraxofusp-erzs	1,588	1	1	1	1	21	1.0	0.5
Female	344	1	1	1	1	1	1.0	0.0
Male	1,244	1	1	1	1	21	1.0	0.6
ravulizumab	31,190	1	1	1	1	112	5.5	15.1
Female	16,647	1	1	1	1	112	5.5	14.8
Male	14,543	1	1	1	1	112	5.5	15.4

¹For drugs requiring clinical administration and identified by procedure codes (rather than pharmacy claims with NDCs), days supplied are not recorded. A default of 1 day supplied was assigned per administration for summary purposes.

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
mogamulizumab-kpkc	18,766	18,766	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	20	20	0.1%	0	NaN	0	NaN	0	NaN
18-24 years	18	18	0.1%	0	NaN	0	NaN	0	NaN
25-40 years	370	370	2.0%	0	NaN	0	NaN	0	NaN
41-64 years	3,404	3,404	18.1%	0	NaN	0	NaN	0	NaN
≥ 65 years	14,954	14,954	79.7%	0	NaN	0	NaN	0	NaN
patisiran	15,474	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	2,734	2,734	17.7%	0	0.0%	0	NaN	0	NaN
≥ 65 years	12,534	*****	*****	*****	*****	0	NaN	0	NaN
segesterone acetate and ethinyl estradiol vaginal system	27,215	12,263	100.0%	1,527	100.0%	3,602	100.0%	9,823	100.0%
0-17 years	*****	*****	*****	70	4.6%	195	5.4%	*****	*****
18-24 years	8,463	3,602	29.4%	498	32.6%	1,093	30.3%	3,270	33.3%
25-40 years	14,990	6,961	56.8%	863	56.5%	1,990	55.2%	5,176	52.7%
41-64 years	2,561	1,157	9.4%	96	6.3%	324	9.0%	984	10.0%
≥ 65 years	*****	*****	*****	0	0.0%	0	0.0%	*****	*****
migalastat	4,951	4,902	100.0%	*****	*****	35	100.0%	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	281	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	1,028	1,016	20.7%	0	0.0%	12	34.3%	0	0.0%
41-64 years	2,136	2,125	43.3%	0	0.0%	*****	*****	*****	*****

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
≥ 65 years	1,506	*****	*****	*****	*****	*****	*****	0	0.0%
stiripentol	8,078	7,420	100.0%	494	100.0%	143	100.0%	21	100.0%
0-17 years	5,904	5,472	73.7%	334	67.6%	*****	*****	*****	*****
18-24 years	1,655	1,503	20.3%	112	22.7%	*****	*****	*****	*****
25-40 years	*****	445	6.0%	48	9.7%	*****	*****	*****	*****
41-64 years	*****	0	0.0%	0	0.0%	*****	*****	0	0.0%
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
cenegermin-bkbj	44,936	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	349	349	0.8%	0	0.0%	0	NaN	0	NaN
18-24 years	221	221	0.5%	0	0.0%	0	NaN	0	NaN
25-40 years	1,815	1,815	4.0%	0	0.0%	0	NaN	0	NaN
41-64 years	8,788	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	33,763	33,763	75.1%	0	0.0%	0	NaN	0	NaN
lanadelumab	27,529	27,347	100.0%	111	100.0%	71	100.0%	0	NaN
0-17 years	2,151	2,150	7.9%	*****	*****	0	0.0%	0	NaN
18-24 years	1,905	1,904	7.0%	*****	*****	0	0.0%	0	NaN
25-40 years	6,085	6,050	22.1%	*****	*****	*****	*****	0	NaN
41-64 years	10,823	10,788	39.4%	*****	*****	*****	*****	0	NaN
≥ 65 years	6,565	6,455	23.6%	56	50.5%	54	76.1%	0	NaN
eravacycline	10,640	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	23	23	0.2%	0	0.0%	0	NaN	0	NaN
18-24 years	97	97	0.9%	0	0.0%	0	NaN	0	NaN
25-40 years	732	732	6.9%	0	0.0%	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
≥ 65 years	*****	*****	*****	*****	*****	0	NaN	0	NaN
doravirine	126,327	122,684	100.0%	550	100.0%	3,067	100.0%	26	100.0%
0-17 years	83	*****	*****	0	0.0%	*****	*****	0	0.0%
18-24 years	903	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	13,187	12,661	10.3%	134	24.4%	*****	*****	*****	*****
41-64 years	80,672	78,569	64.0%	322	58.5%	*****	*****	*****	*****
≥ 65 years	31,482	30,483	24.8%	*****	*****	*****	*****	*****	*****
moxetumomab pasudotox-tdfk	444	444	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	322	322	72.5%	0	NaN	0	NaN	0	NaN
fremanezumab-vfrm	752,054	674,993	100.0%	9,567	100.0%	67,199	100.0%	295	100.0%
0-17 years	4,149	3,787	0.6%	*****	*****	285	0.4%	*****	*****
18-24 years	40,092	36,210	5.4%	*****	*****	3,337	5.0%	*****	*****
25-40 years	199,644	182,379	27.0%	2,305	24.1%	14,892	22.2%	68	23.1%
41-64 years	414,147	371,323	55.0%	5,472	57.2%	37,176	55.3%	176	59.7%
≥ 65 years	94,022	81,294	12.0%	1,205	12.6%	11,509	17.1%	14	4.7%
duvelisib	3,922	3,899	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
25-40 years	38	38	1.0%	0	0.0%	0	0.0%	0	NaN

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
41-64 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	3,294	*****	*****	*****	*****	*****	*****	0	NaN
galcanezumab-gnlm	2,001,899	1,900,448	100.0%	16,090	100.0%	85,114	100.0%	247	100.0%
0-17 years	9,725	9,264	0.5%	*****	*****	352	0.4%	*****	*****
18-24 years	106,546	103,085	5.4%	*****	*****	2,718	3.2%	*****	*****
25-40 years	545,144	525,380	27.6%	4,014	24.9%	15,697	18.4%	53	21.5%
41-64 years	1,088,142	1,032,358	54.3%	8,547	53.1%	47,109	55.3%	128	51.8%
≥ 65 years	252,342	230,361	12.1%	2,692	16.7%	19,238	22.6%	51	20.6%
dacomitinib	621	*****	*****	*****	*****	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN
41-64 years	155	155	25.1%	0	0.0%	0	0.0%	0	NaN
≥ 65 years	466	*****	*****	*****	*****	*****	*****	0	NaN
cemiplimab-rwlc	115,988	*****	*****	0	NaN	0	NaN	*****	*****
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	0.0%
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	0.0%
25-40 years	352	352	0.3%	0	NaN	0	NaN	0	0.0%
41-64 years	10,066	*****	*****	0	NaN	0	NaN	*****	*****
≥ 65 years	105,557	105,557	91.0%	0	NaN	0	NaN	0	0.0%
sarecycline	59,994	59,411	100.0%	*****	*****	438	100.0%	*****	*****
0-17 years	27,761	27,575	46.4%	58	41.7%	*****	*****	*****	*****
18-24 years	15,546	15,373	25.9%	*****	*****	132	30.1%	*****	*****
25-40 years	10,332	10,238	17.2%	24	17.3%	70	16.0%	0	0.0%

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
41-64 years	5,723	5,614	9.4%	17	12.2%	92	21.0%	0	0.0%
≥ 65 years	632	611	1.0%	*****	*****	*****	*****	0	0.0%
omadacycline	44,006	43,695	100.0%	121	100.0%	190	100.0%	0	NaN
0-17 years	321	*****	*****	0	0.0%	*****	*****	0	NaN
18-24 years	910	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	2,613	2,595	5.9%	*****	*****	*****	*****	0	NaN
41-64 years	14,462	14,365	32.9%	*****	*****	*****	*****	0	NaN
≥ 65 years	25,700	25,507	58.4%	71	58.7%	122	64.2%	0	NaN
elapegademase-lvlr	984	970	100.0%	14	100.0%	0	NaN	0	NaN
0-17 years	377	*****	*****	*****	*****	0	NaN	0	NaN
18-24 years	297	297	30.6%	0	0.0%	0	NaN	0	NaN
25-40 years	294	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	16	16	1.6%	0	0.0%	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN
inotersen	1,709	1,709	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	42	42	2.5%	0	NaN	0	NaN	0	NaN
41-64 years	306	306	17.9%	0	NaN	0	NaN	0	NaN
≥ 65 years	1,361	1,361	79.6%	0	NaN	0	NaN	0	NaN
talazoparib	4,576	4,556	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
25-40 years	382	*****	*****	*****	*****	*****	*****	0	NaN

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
41-64 years	1,822	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	2,338	*****	*****	*****	*****	0	0.0%	0	NaN
baloxavir marboxil	140,317	140,200	100.0%	86	100.0%	*****	*****	*****	*****
0-17 years	26,270	*****	*****	*****	*****	*****	*****	0	0.0%
18-24 years	13,954	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	31,854	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	43,243	43,222	30.8%	*****	*****	*****	*****	*****	*****
≥ 65 years	24,996	24,910	17.8%	67	77.9%	*****	*****	*****	*****
lorlatinib	15,731	15,579	100.0%	98	100.0%	*****	*****	*****	*****
0-17 years	631	584	3.7%	*****	*****	*****	*****	0	0.0%
18-24 years	110	106	0.7%	*****	*****	*****	*****	0	0.0%
25-40 years	1,183	1,164	7.5%	*****	*****	*****	*****	*****	*****
41-64 years	7,153	7,112	45.7%	18	18.4%	23	44.2%	0	0.0%
≥ 65 years	6,654	6,613	42.4%	23	23.5%	18	34.6%	0	0.0%
revefenacin	76,191	74,192	100.0%	*****	*****	1,739	100.0%	*****	*****
0-17 years	15	15	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	161	*****	*****	0	0.0%	*****	*****	0	0.0%
25-40 years	929	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	20,599	19,829	26.7%	*****	*****	666	38.3%	*****	*****
≥ 65 years	54,487	53,325	71.9%	*****	*****	1,015	58.4%	*****	*****
rifamycin	186	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	14	14	7.7%	0	0.0%	0	NaN	0	NaN
25-40 years	32	*****	*****	*****	*****	0	NaN	0	NaN

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
41-64 years	100	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	40	40	21.9%	0	0.0%	0	NaN	0	NaN
emapalumab-lzsg	1,055	1,055	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	660	660	62.6%	0	NaN	0	NaN	0	NaN
18-24 years	112	112	10.6%	0	NaN	0	NaN	0	NaN
25-40 years	151	151	14.3%	0	NaN	0	NaN	0	NaN
41-64 years	113	113	10.7%	0	NaN	0	NaN	0	NaN
≥ 65 years	19	19	1.8%	0	NaN	0	NaN	0	NaN
glasdegib	917	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	107	107	11.7%	0	0.0%	0	NaN	0	NaN
≥ 65 years	794	*****	*****	*****	*****	0	NaN	0	NaN
larotrectinib	3,723	3,607	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	861	772	21.4%	*****	*****	*****	*****	0	NaN
18-24 years	107	107	3.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	255	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	1,141	1,124	31.2%	17	15.6%	0	0.0%	0	NaN
≥ 65 years	1,359	*****	*****	*****	*****	*****	*****	0	NaN
amifampridine	11,661	11,328	100.0%	54	100.0%	279	100.0%	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	*****	*****	0	NaN
25-40 years	742	727	6.4%	*****	*****	*****	*****	0	NaN

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
41-64 years	3,335	3,236	28.6%	*****	*****	*****	*****	0	NaN
≥ 65 years	7,159	6,943	61.3%	*****	*****	*****	*****	0	NaN
gilteritinib	15,650	15,407	100.0%	204	100.0%	*****	*****	*****	*****
0-17 years	267	*****	*****	*****	*****	*****	*****	0	0.0%
18-24 years	293	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	1,023	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	4,105	4,048	26.3%	*****	*****	*****	*****	0	0.0%
≥ 65 years	9,962	9,794	63.6%	143	70.1%	25	65.8%	0	0.0%
prucalopride	309,149	257,917	100.0%	5,696	100.0%	45,453	100.0%	83	100.0%
0-17 years	5,307	4,961	1.9%	97	1.7%	*****	*****	*****	*****
18-24 years	16,760	14,592	5.7%	280	4.9%	*****	*****	*****	*****
25-40 years	51,801	44,840	17.4%	938	16.5%	6,007	13.2%	16	19.3%
41-64 years	132,260	110,232	42.7%	2,367	41.6%	19,635	43.2%	26	31.3%
≥ 65 years	103,021	83,292	32.3%	2,014	35.4%	17,686	38.9%	29	34.9%
calaspargase pegol-mknl	895	895	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	822	822	91.8%	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
tagraxofusp-erzs	1,588	1,588	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
25-40 years	43	43	2.7%	0	NaN	0	NaN	0	NaN

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
41-64 years	72	72	4.5%	0	NaN	0	NaN	0	NaN
≥ 65 years	1,428	1,428	89.9%	0	NaN	0	NaN	0	NaN
ravulizumab	31,190	29,119	100.0%	1,924	100.0%	35	100.0%	112	100.0%
0-17 years	1,906	1,838	6.3%	*****	*****	*****	*****	0	0.0%
18-24 years	1,129	1,080	3.7%	49	2.5%	0	0.0%	0	0.0%
25-40 years	4,843	4,560	15.7%	*****	*****	*****	*****	*****	*****
41-64 years	8,283	7,761	26.7%	482	25.1%	*****	*****	*****	*****
≥ 65 years	15,029	13,880	47.7%	1,053	54.7%	*****	*****	*****	*****

¹For drugs requiring clinical administration and identified by procedure codes (rather than pharmacy claims with NDCs), days supplied are not recorded. A default of 1 day supplied was assigned per administration for summary purposes.

*NaN: Not a number

*******Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.**

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
mogamulizumab-kpkc	18,766	1	1	1	1	30	1.2	2.3
0-17 years	20	1	1	1	1	1	1.0	0.0
18-24 years	18	1	1	1	1	1	1.0	0.0
25-40 years	370	1	1	1	1	28	1.4	3.1
41-64 years	3,404	1	1	1	1	30	1.4	3.2
≥ 65 years	14,954	1	1	1	1	30	1.2	2.1
patisiran	15,474	1	1	1	1	42	2.2	4.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	21	21	6.8	9.1
41-64 years	2,734	1	1	1	1	28	3.5	6.6
≥ 65 years	12,534	1	1	1	1	42	1.8	3.9
segesterone acetate and ethinyl estradiol vaginal system	27,215	1	28	55	198	638	123.4	129.9
0-17 years	*****	1	28	50	168	615	119.1	127.6
18-24 years	8,463	1	28	77	247	515	131.4	134.1
25-40 years	14,990	1	28	43	175	638	117.9	126.8
41-64 years	2,561	1	28	72	250	368	130.9	133.3
≥ 65 years	*****	27	95	190	279	340	186.8	129.7
migalastat	4,951	1	28	28	28	168	28.1	6.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	281	1	28	28	28	40	27.4	3.3
25-40 years	1,028	2	28	28	28	84	28.2	6.6
41-64 years	2,136	2	28	28	28	168	27.9	6.5
≥ 65 years	1,506	1	28	28	28	84	28.4	6.9

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
stiripentol	8,078	1	24	30	30	180	29.8	12.4
0-17 years	5,904	1	25	30	30	180	29.5	11.0
18-24 years	1,655	1	24	30	30	136	29.8	12.3
25-40 years	*****	2	20	30	30	180	33.5	22.8
41-64 years	*****	63	63	63	63	63	63.0	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
cenegermin-bkbj	44,936	1	14	14	14	34	13.1	2.7
0-17 years	349	2	14	14	14	21	12.5	3.0
18-24 years	221	1	7	14	14	28	12.4	4.2
25-40 years	1,815	1	8	14	14	30	12.2	3.2
41-64 years	8,788	1	14	14	14	34	12.8	3.0
≥ 65 years	33,763	1	14	14	14	30	13.2	2.6
lanadelumab	27,529	1	28	28	28	84	27.2	5.4
0-17 years	2,151	1	28	28	28	56	26.8	4.4
18-24 years	1,905	1	28	28	28	56	26.6	5.0
25-40 years	6,085	1	28	28	28	84	26.8	5.7
41-64 years	10,823	1	28	28	28	84	27.0	5.0
≥ 65 years	6,565	1	28	28	28	84	28.2	6.0
eravacycline	10,640	1	1	1	1	41	1.8	2.0
0-17 years	23	1	1	1	1	1	1.0	0.0
18-24 years	97	1	1	1	1	8	1.8	1.9
25-40 years	732	1	1	1	1	10	1.7	1.8
41-64 years	3,970	1	1	1	1	30	1.7	2.0
≥ 65 years	5,818	1	1	1	1	41	1.9	2.1

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	
doravirine	126,327	1	30	30	30	210	30.7	10.4
0-17 years	83	6	30	30	30	90	31.1	10.6
18-24 years	903	1	30	30	30	90	29.7	7.5
25-40 years	13,187	1	30	30	30	180	31.1	11.6
41-64 years	80,672	1	30	30	30	210	30.6	9.9
≥ 65 years	31,482	1	30	30	30	120	30.7	11.1
moxetumomab pasudotox-tdfk	444	1	1	1	1	28	1.1	1.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	1	28	1.2	2.6
≥ 65 years	322	1	1	1	1	28	1.1	1.5
fremanezumab-vfrm	752,054	1	30	30	30	360	34.4	17.8
0-17 years	4,149	1	28	30	30	180	33.1	16.2
18-24 years	40,092	1	30	30	30	360	34.0	17.7
25-40 years	199,644	1	30	30	30	360	33.4	16.5
41-64 years	414,147	1	30	30	30	270	34.5	17.8
≥ 65 years	94,022	1	30	30	30	270	36.5	20.1
duvelisib	3,922	1	28	28	28	84	27.5	4.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	25	25	25	25	25	25.0	NaN
25-40 years	*****	4	28	28	28	28	26.6	4.9
41-64 years	589	2	28	28	28	60	27.1	4.6
≥ 65 years	3,294	1	28	28	28	84	27.5	3.9

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
galcanezumab-gnlm	2,001,899	1	28	30	30	651	31.4	12.8
0-17 years	9,725	1	28	30	30	180	30.8	12.4
18-24 years	106,546	1	28	30	30	180	30.2	10.5
25-40 years	545,144	1	28	30	30	365	30.5	11.0
41-64 years	1,088,142	1	28	30	30	651	31.5	12.9
≥ 65 years	252,342	1	28	30	30	301	33.7	16.4
dacomitinib	621	1	30	30	30	90	29.3	4.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	155	1	30	30	30	30	28.1	5.2
≥ 65 years	466	7	30	30	30	90	29.7	4.5
cemiplimab-rwlc	115,988	1	1	1	1	148	1.2	2.0
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	352	1	1	1	1	21	1.1	1.5
41-64 years	10,066	1	1	1	1	148	1.3	2.8
≥ 65 years	105,557	1	1	1	1	21	1.2	1.9
sarecycline	59,994	1	30	30	30	180	30.1	6.1
0-17 years	27,761	1	30	30	30	150	29.9	5.1
18-24 years	15,546	1	30	30	30	180	30.2	6.6
25-40 years	10,332	1	30	30	30	90	29.9	6.1
41-64 years	5,723	1	30	30	30	90	30.5	8.2
≥ 65 years	632	4	30	30	30	90	31.2	10.3

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
omadacycline	44,006	1	1	1	14	90	8.6	11.7
0-17 years	321	1	6	30	30	83	20.6	13.6
18-24 years	910	1	1	1	15	32	9.3	10.9
25-40 years	2,613	1	1	12	16	90	12.6	12.0
41-64 years	14,462	1	1	5	14	90	9.5	11.3
≥ 65 years	25,700	1	1	1	12	90	7.5	11.6
elapegademase-lvlr	984	1	28	28	28	56	26.3	7.3
0-17 years	377	1	28	28	28	56	27.8	6.0
18-24 years	297	2	28	28	28	28	26.1	5.4
25-40 years	294	1	28	28	28	56	24.5	9.7
41-64 years	16	3	28	28	30	30	27.1	6.5
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
inotersen	1,709	2	28	28	28	30	27.8	1.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	42	26	28	28	28	28	28.0	0.3
41-64 years	306	2	28	28	28	30	27.6	3.1
≥ 65 years	1,361	4	28	28	28	30	27.9	1.6
talazoparib	4,576	1	30	30	30	90	28.1	5.7
0-17 years	*****	11	30	30	42	42	30.7	9.2
18-24 years	*****	15	15	15	15	15	15.0	0.0
25-40 years	382	2	30	30	30	90	27.4	7.1
41-64 years	1,822	2	30	30	30	90	27.6	6.0
≥ 65 years	2,338	1	30	30	30	60	28.6	5.1

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
baloxavir marboxil	140,317	1	1	1	1	180	2.2	5.8
0-17 years	26,270	1	1	1	1	90	1.2	2.0
18-24 years	13,954	1	1	1	1	60	1.2	2.3
25-40 years	31,854	1	1	1	1	90	1.2	2.6
41-64 years	43,243	1	1	1	1	100	1.5	3.8
≥ 65 years	24,996	1	1	1	1	180	6.3	11.2
lorlatinib	15,731	1	30	30	30	300	28.6	7.2
0-17 years	631	1	30	30	30	90	29.9	10.2
18-24 years	110	2	30	30	30	90	29.9	8.6
25-40 years	1,183	1	30	30	30	300	28.5	13.6
41-64 years	7,153	1	30	30	30	90	28.0	6.8
≥ 65 years	6,654	1	30	30	30	90	29.2	5.4
revefenacin	76,191	1	1	30	30	120	21.1	17.1
0-17 years	15	1	16	30	30	30	23.3	12.1
18-24 years	161	1	30	30	30	90	29.2	12.1
25-40 years	929	1	30	30	30	90	29.3	18.0
41-64 years	20,599	1	20	30	30	120	25.1	16.9
≥ 65 years	54,487	1	1	30	30	120	19.4	16.9
rifamycin	186	2	3	3	6	36	6.2	7.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	14	3	3	3	3	7	3.6	1.5
25-40 years	32	2	3	3	13	36	8.0	8.2
41-64 years	100	2	3	3	6	34	6.2	7.0
≥ 65 years	40	3	3	3	3	30	5.8	7.1

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
emapalumab-lzsg	1,055	1	1	1	1	7	1.2	0.9
0-17 years	660	1	1	1	1	7	1.2	1.0
18-24 years	112	1	1	1	1	7	1.2	0.9
25-40 years	151	1	1	1	1	1	1.0	0.0
41-64 years	113	1	1	1	1	7	1.1	0.8
≥ 65 years	19	1	1	1	1	1	1.0	0.0
glasdegib	917	1	28	30	30	32	27.3	5.9
0-17 years	*****	30	30	30	30	30	30.0	0.0
18-24 years	*****	30	30	30	30	30	30.0	NaN
25-40 years	*****	15	28	28	28	28	26.0	4.2
41-64 years	107	9	18	30	30	30	25.3	6.9
≥ 65 years	794	1	28	30	30	32	27.6	5.7
larotrectinib	3,723	1	30	30	30	90	28.3	6.1
0-17 years	861	1	22	29	30	78	26.2	6.6
18-24 years	107	1	30	30	30	30	29.4	3.6
25-40 years	255	1	30	30	30	60	28.9	5.5
41-64 years	1,141	1	30	30	30	60	28.5	6.2
≥ 65 years	1,359	1	30	30	30	90	29.4	5.7
amifampridine	11,661	1	30	30	30	90	31.0	9.9
0-17 years	174	1	30	30	30	30	28.8	4.8
18-24 years	251	3	30	30	30	90	30.2	7.3
25-40 years	742	2	30	30	30	90	30.4	8.7
41-64 years	3,335	1	30	30	30	90	31.1	10.4
≥ 65 years	7,159	1	30	30	30	90	31.1	9.9

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
gilteritinib	15,650	1	30	30	30	300	27.6	8.8
0-17 years	267	1	21	30	30	90	24.2	13.3
18-24 years	293	1	30	30	30	60	28.6	5.6
25-40 years	1,023	1	30	30	30	300	28.0	11.4
41-64 years	4,105	1	30	30	30	90	28.1	7.9
≥ 65 years	9,962	1	30	30	30	90	27.4	8.8
prucalopride	309,149	1	30	30	30	180	38.1	22.0
0-17 years	5,307	1	30	30	30	180	31.7	14.5
18-24 years	16,760	1	30	30	30	180	35.9	19.9
25-40 years	51,801	1	30	30	30	180	36.2	20.0
41-64 years	132,260	1	30	30	30	180	38.2	22.0
≥ 65 years	103,021	1	30	30	30	180	39.6	23.4
calaspargase pegol-mknl	895	1	1	1	1	30	1.1	1.4
0-17 years	822	1	1	1	1	30	1.1	1.4
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	1	1.0	NaN
41-64 years	*****	1	1	1	1	1	1.0	NaN
≥ 65 years	*****	1	1	1	1	1	1.0	0.0
tagraxofusp-erzs	1,588	1	1	1	1	21	1.0	0.5
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	43	1	1	1	1	1	1.0	0.0
41-64 years	72	1	1	1	1	1	1.0	0.0
≥ 65 years	1,428	1	1	1	1	21	1.0	0.5

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
ravulizumab	31,190	1	1	1	1	112	5.5	15.1
0-17 years	1,906	1	1	1	1	70	3.8	10.2
18-24 years	1,129	1	1	1	1	56	3.7	11.4
25-40 years	4,843	1	1	1	1	112	4.7	13.5
41-64 years	8,283	1	1	1	1	112	5.2	14.9
≥ 65 years	15,029	1	1	1	1	112	6.3	16.3

¹For drugs requiring clinical administration and identified by procedure codes (rather than pharmacy claims with NDCs), days supplied are not recorded. A default of 1 day supplied was assigned per administration for summary purposes.

*NaN: Not a number

******Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.**

Table 3a. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<i>mogamulizumab-kpkc</i>	1,147	987	86.1%	140	12.2%	*****	*****	*****	*****	*****	*****
<i>patisiran</i>	625	385	61.6%	191	30.6%	31	5.0%	*****	*****	*****	*****
<i>segesterone acetate and ethinyl estradiol vaginal</i>	19,514	6,600	33.8%	4,224	21.6%	6,636	34.0%	1,659	8.5%	395	2.0%
<i>migalastat</i>	261	19	7.3%	35	13.4%	79	30.3%	59	22.6%	69	26.4%
<i>stiripentol</i>	531	46	8.7%	65	12.2%	163	30.7%	132	24.9%	125	23.5%
<i>cenegermin-bkbj</i>	9,413	873	9.3%	7,319	77.8%	1,207	12.8%	*****	*****	*****	*****
<i>lanadelumab</i>	1,451	125	8.6%	151	10.4%	482	33.2%	325	22.4%	368	25.4%
<i>eravacycline</i>	1,111	940	84.6%	155	14.0%	16	1.4%	0	0.0%	0	0.0%
<i>doravirine</i>	8,215	779	9.5%	1,104	13.4%	2,624	31.9%	1,811	22.0%	1,897	23.1%
<i>moxetumomab pasudotox- tdfk</i>	50	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
<i>fremanezumab-vfrm</i>	93,384	13,797	14.8%	20,308	21.7%	36,884	39.5%	13,763	14.7%	8,632	9.2%
<i>duvelisib</i>	623	125	20.1%	200	32.1%	222	35.6%	54	8.7%	22	3.5%
<i>galcanezumab-gnlm</i>	212,175	30,725	14.5%	41,828	19.7%	82,192	38.7%	35,714	16.8%	21,716	10.2%
<i>dacomitinib</i>	95	25	26.3%	26	27.4%	32	33.7%	*****	*****	*****	*****
<i>cemiplimab-rwlc</i>	12,307	11,557	93.9%	662	5.4%	77	0.6%	*****	*****	*****	*****
<i>sarecycline</i>	17,939	5,653	31.5%	6,965	38.8%	4,844	27.0%	398	2.2%	79	0.4%
<i>omadacycline</i>	8,563	6,605	77.1%	1,086	12.7%	691	8.1%	154	1.8%	27	0.3%
<i>elapegadomase-lvlr</i>	42	*****	*****	0	0.0%	*****	*****	*****	*****	15	35.7%
<i>inotersen</i>	119	*****	*****	*****	*****	42	35.3%	26	21.8%	22	18.5%
<i>talazoparib</i>	810	140	17.3%	256	31.6%	357	44.1%	36	4.4%	21	2.6%
<i>baloxavir marboxil</i>	130,098	129,618	99.6%	434	0.3%	*****	*****	*****	*****	0	0.0%
<i>lorlatinib</i>	1,620	264	16.3%	359	22.2%	604	37.3%	237	14.6%	156	9.6%

Table 3a. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<i>revefenacin</i>	15,603	8,630	55.3%	2,920	18.7%	2,939	18.8%	812	5.2%	302	1.9%
<i>rifamycin</i>	110	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
<i>emapalumab-lzsg</i>	72	58	80.6%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>glasdegib</i>	393	177	45.0%	148	37.7%	*****	*****	*****	*****	0	0.0%
<i>larotrectinib</i>	517	103	19.9%	156	30.2%	172	33.3%	58	11.2%	28	5.4%
<i>amifampridine</i>	540	44	8.1%	50	9.3%	156	28.9%	91	16.9%	199	36.9%
<i>gilteritinib</i>	2,670	643	24.1%	766	28.7%	964	36.1%	228	8.5%	69	2.6%
<i>prucalopride</i>	49,006	13,353	27.2%	10,807	22.1%	14,645	29.9%	6,143	12.5%	4,058	8.3%
<i>calaspargase pegol-mknl</i>	389	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
<i>tagraxofusp-erzs</i>	135	120	88.9%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>ravulizumab</i>	3,694	3,200	86.6%	128	3.5%	211	5.7%	121	3.3%	34	0.9%

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 3b. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>mogamulizumab-kpkc</i>	1,147	1	5	10	21	1,504	20.0	55.4
<i>patisiran</i>	625	1	8	22	46	1,386	53.2	130.0
<i>segesterone acetate and ethinyl estradiol vaginal system</i>	19,514	1	30	90	289	1,655	172.1	201.0
<i>migalastat</i>	261	3	112	353	780	2,320	532.3	530.3
<i>stiripentol</i>	531	3	120	342	693	1,939	453.9	413.3
<i>cenegermin-bkbj</i>	9,413	1	56	56	56	1,246	62.4	38.9
<i>lanadelumab</i>	1,451	1	136	336	746	2,287	516.4	498.5
<i>eravacycline</i>	1,111	1	5	10	22	354	17.2	24.3
<i>doravirine</i>	8,215	1	113	314	690	2,313	471.7	464.7
<i>moxetumomab pasudotox-tdfk</i>	50	1	3	9	17	43	9.9	8.6
<i>fremanezumab-vfrm</i>	93,384	1	60	154	360	2,206	277.1	320.6
<i>duvelisib</i>	623	3	56	84	196	1,751	172.9	230.9
<i>galcanezumab-gnlm</i>	212,175	1	64	173	392	2,239	296.3	333.1
<i>dacomitinib</i>	95	1	30	90	240	1,783	191.6	274.9
<i>cemiplimab-rwlc</i>	12,307	1	3	6	13	861	11.2	25.2
<i>sarecycline</i>	17,939	1	30	60	120	1,547	100.5	108.9
<i>omadacycline</i>	8,563	1	10	14	30	1,870	44.1	100.1
<i>elapegademase-lvlr</i>	42	2	234	526	976	1,781	615.9	449.9
<i>inotersen</i>	119	28	112	280	588	1,680	399.7	388.4
<i>talazoparib</i>	810	1	60	101	191	1,815	158.9	191.2
<i>baloxavir marboxil</i>	130,098	1	1	1	1	645	2.4	7.2
<i>lorlatinib</i>	1,620	1	60	150	360	2,010	278.1	342.0
<i>revefenacin</i>	15,603	1	5	30	105	1,917	102.8	186.2
<i>rifamycin</i>	110	2	3	3	9	86	10.5	15.9
<i>emapalumab-lzsg</i>	72	1	2	7	24	91	17.4	22.4

Table 3b. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>glasdegib</i>	393	1	28	47	88	420	63.8	60.0
<i>larotrectinib</i>	517	1	58	90	240	1,862	204.1	260.2
<i>amifampridine</i>	540	2	121	411	1,094	2,033	666.7	628.9
<i>gilteritinib</i>	2,670	1	31	90	205	2,066	161.5	206.3
<i>prucalopride</i>	49,006	1	30	101	301	2,112	240.4	313.3
<i>calaspargase pegol-mknl</i>	389	1	1	2	3	72	2.5	3.9
<i>tagraxofusp-erzs</i>	135	1	1	4	16	155	11.9	20.3
<i>ravulizumab</i>	3,694	1	3	7	15	1,699	46.2	136.7

Table 3c. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
mogamulizumab-kpkc	1,147	987	100.0%	140	100.0%	*****	*****	*****	*****	*****	*****
Female	495	425	43.1%	*****	*****	*****	*****	*****	*****	*****	*****
Male	652	562	56.9%	*****	*****	*****	*****	*****	*****	0	0.0%
patisiran	625	385	100.0%	191	100.0%	31	100.0%	*****	*****	*****	*****
Female	227	135	35.1%	69	36.1%	*****	*****	*****	*****	*****	*****
Male	398	250	64.9%	122	63.9%	*****	*****	*****	*****	*****	*****
segesterone acetate and ethinyl estradiol vaginal system	19,514	6,600	100.0%	4,224	100.0%	6,636	100.0%	1,659	100.0%	395	100.0%
Female	19,473	*****	*****	*****	*****	6,615	99.7%	*****	*****	*****	*****
Male	41	*****	*****	*****	*****	21	0.3%	*****	*****	*****	*****
migalastat	261	19	100.0%	35	100.0%	79	100.0%	59	100.0%	69	100.0%
Female	126	*****	*****	*****	*****	37	46.8%	29	49.2%	36	52.2%
Male	135	*****	*****	*****	*****	42	53.2%	30	50.8%	33	47.8%
stiripentol	531	46	100.0%	65	100.0%	163	100.0%	132	100.0%	125	100.0%
Female	263	20	43.5%	29	44.6%	74	45.4%	67	50.8%	73	58.4%
Male	268	26	56.5%	36	55.4%	89	54.6%	65	49.2%	52	41.6%
cenegermin-bkbj	9,413	873	100.0%	7,319	100.0%	1,207	100.0%	*****	*****	*****	*****
Female	6,152	604	69.2%	4,721	64.5%	*****	*****	*****	*****	*****	*****
Male	3,261	269	30.8%	2,598	35.5%	*****	*****	*****	*****	0	0.0%
lanadelumab	1,451	125	100.0%	151	100.0%	482	100.0%	325	100.0%	368	100.0%
Female	989	89	71.2%	100	66.2%	331	68.7%	225	69.2%	244	66.3%
Male	462	36	28.8%	51	33.8%	151	31.3%	100	30.8%	124	33.7%

Table 3c. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
eravacycline	1,111	940	100.0%	155	100.0%	16	100.0%	0	NaN	0	NaN
Female	566	499	53.1%	*****	*****	*****	*****	0	NaN	0	NaN
Male	545	441	46.9%	*****	*****	*****	*****	0	NaN	0	NaN
doravirine	8,215	779	100.0%	1,104	100.0%	2,624	100.0%	1,811	100.0%	1,897	100.0%
Female	2,181	254	32.6%	332	30.1%	724	27.6%	466	25.7%	405	21.3%
Male	6,034	525	67.4%	772	69.9%	1,900	72.4%	1,345	74.3%	1,492	78.7%
moxetumomab pasudotox-tdfk	50	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
fremanezumab-vfrm	93,384	13,797	100.0%	20,308	100.0%	36,884	100.0%	13,763	100.0%	8,632	100.0%
Female	80,681	11,829	85.7%	17,568	86.5%	31,938	86.6%	11,913	86.6%	7,433	86.1%
Male	12,703	1,968	14.3%	2,740	13.5%	4,946	13.4%	1,850	13.4%	1,199	13.9%
duvelisib	623	125	100.0%	200	100.0%	222	100.0%	54	100.0%	22	100.0%
Female	273	50	40.0%	89	44.5%	105	47.3%	*****	*****	*****	*****
Male	350	75	60.0%	111	55.5%	117	52.7%	*****	*****	*****	*****
galcanezumab-gnlm	212,175	30,725	100.0%	41,828	100.0%	82,192	100.0%	35,714	100.0%	21,716	100.0%
Female	180,088	25,630	83.4%	35,306	84.4%	70,285	85.5%	30,395	85.1%	18,472	85.1%
Male	32,087	5,095	16.6%	6,522	15.6%	11,907	14.5%	5,319	14.9%	3,244	14.9%
dacomitinib	95	25	100.0%	26	100.0%	32	100.0%	*****	*****	*****	*****
Female	60	*****	*****	*****	*****	18	56.3%	*****	*****	*****	*****
Male	35	*****	*****	*****	*****	14	43.8%	*****	*****	*****	*****
cemiplimab-rwlc	12,307	11,557	100.0%	662	100.0%	77	100.0%	*****	*****	*****	*****
Female	3,645	3,465	30.0%	153	23.1%	*****	*****	*****	*****	*****	*****
Male	8,662	8,092	70.0%	509	76.9%	*****	*****	*****	*****	0	0.0%

Table 3c. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
sarecycline	17,939	5,653	100.0%	6,965	100.0%	4,844	100.0%	398	100.0%	79	100.0%
Female	11,119	3,693	65.3%	4,309	61.9%	2,838	58.6%	234	58.8%	45	57.0%
Male	6,820	1,960	34.7%	2,656	38.1%	2,006	41.4%	164	41.2%	34	43.0%
omadacycline	8,563	6,605	100.0%	1,086	100.0%	691	100.0%	154	100.0%	27	100.0%
Female	4,263	3,201	48.5%	551	50.7%	399	57.7%	98	63.6%	14	51.9%
Male	4,300	3,404	51.5%	535	49.3%	292	42.3%	56	36.4%	13	48.1%
elapegademase-lvlr	42	*****	*****	0	NaN	*****	*****	*****	*****	15	100.0%
Female	19	*****	*****	0	NaN	*****	*****	*****	*****	*****	*****
Male	23	*****	*****	0	NaN	*****	*****	*****	*****	*****	*****
inotersen	119	*****	*****	*****	*****	42	100.0%	26	100.0%	22	100.0%
Female	52	*****	*****	*****	*****	17	40.5%	13	50.0%	*****	*****
Male	67	*****	*****	*****	*****	25	59.5%	13	50.0%	*****	*****
talazoparib	810	140	100.0%	256	100.0%	357	100.0%	36	100.0%	21	100.0%
Female	452	*****	*****	126	49.2%	200	56.0%	*****	*****	21	100.0%
Male	358	*****	*****	130	50.8%	157	44.0%	*****	*****	0	0.0%
baloxavir marboxil	130,098	129,618	100.0%	434	100.0%	*****	*****	*****	*****	0	NaN
Female	70,809	70,560	54.4%	228	52.5%	*****	*****	*****	*****	0	NaN
Male	59,289	59,058	45.6%	206	47.5%	*****	*****	*****	*****	0	NaN
lorlatinib	1,620	264	100.0%	359	100.0%	604	100.0%	237	100.0%	156	100.0%
Female	891	149	56.4%	193	53.8%	339	56.1%	122	51.5%	88	56.4%
Male	729	115	43.6%	166	46.2%	265	43.9%	115	48.5%	68	43.6%
revefenacin	15,603	8,630	100.0%	2,920	100.0%	2,939	100.0%	812	100.0%	302	100.0%
Female	9,132	4,977	57.7%	1,748	59.9%	1,735	59.0%	484	59.6%	188	62.3%
Male	6,471	3,653	42.3%	1,172	40.1%	1,204	41.0%	328	40.4%	114	37.7%

Table 3c. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
rifamycin	110	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Female	66	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	44	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
emapalumab-lzsg	72	58	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
Female	34	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	38	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
glasdegib	393	177	100.0%	148	100.0%	*****	*****	*****	*****	0	NaN
Female	161	72	40.7%	61	41.2%	*****	*****	*****	*****	0	NaN
Male	232	105	59.3%	87	58.8%	*****	*****	*****	*****	0	NaN
larotrectinib	517	103	100.0%	156	100.0%	172	100.0%	58	100.0%	28	100.0%
Female	298	54	52.4%	99	63.5%	100	58.1%	*****	*****	*****	*****
Male	219	49	47.6%	57	36.5%	72	41.9%	*****	*****	*****	*****
amifampridine	540	44	100.0%	50	100.0%	156	100.0%	91	100.0%	199	100.0%
Female	305	24	54.5%	26	52.0%	80	51.3%	50	54.9%	125	62.8%
Male	235	20	45.5%	24	48.0%	76	48.7%	41	45.1%	74	37.2%
gilteritinib	2,670	643	100.0%	766	100.0%	964	100.0%	228	100.0%	69	100.0%
Female	1,294	293	45.6%	382	49.9%	463	48.0%	117	51.3%	39	56.5%
Male	1,376	350	54.4%	384	50.1%	501	52.0%	111	48.7%	30	43.5%
prucalopride	49,006	13,353	100.0%	10,807	100.0%	14,645	100.0%	6,143	100.0%	4,058	100.0%
Female	38,640	10,426	78.1%	8,555	79.2%	11,616	79.3%	4,862	79.1%	3,181	78.4%
Male	10,366	2,927	21.9%	2,252	20.8%	3,029	20.7%	1,281	20.9%	877	21.6%
calaspargase pegol-mknl	389	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN

Table 3c. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
tagraxofusp-erzs	135	120	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
Female	29	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	106	*****	*****	11	84.6%	*****	*****	0	NaN	0	NaN
ravulizumab	3,694	3,200	100.0%	128	100.0%	211	100.0%	121	100.0%	34	100.0%
Female	1,918	1,657	51.8%	73	57.0%	110	52.1%	60	49.6%	18	52.9%
Male	1,776	1,543	48.2%	55	43.0%	101	47.9%	61	50.4%	16	47.1%

*NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
mogamulizumab-kpkc	1,147	1	5	10	21	1,504	20.0	55.4
Female	495	1	5	11	23	1,504	22.2	75.5
Male	652	1	6	10	20	608	18.2	32.6
patisiran	625	1	8	22	46	1,386	53.2	130.0
Female	227	1	8	24	50	1,386	67.4	169.3
Male	398	1	8	22	43	976	45.2	100.3
segesterone acetate and ethinyl estradiol vaginal system	19,514	1	30	90	289	1,655	172.1	201.0
Female	19,473	1	30	90	289	1,655	172.0	201.0
Male	41	1	42	123	364	962	210.3	203.1
migalastat	261	3	112	353	780	2,320	532.3	530.3
Female	126	4	123	390	840	1,989	538.2	497.8
Male	135	3	112	334	699	2,320	526.8	560.7
stiripentol	531	3	120	342	693	1,939	453.9	413.3
Female	263	3	153	406	825	1,895	495.5	429.9
Male	268	3	104	300	607	1,939	413.1	392.9
cenegermin-bkbj	9,413	1	56	56	56	1,246	62.4	38.9
Female	6,152	1	56	56	56	1,246	62.7	41.3
Male	3,261	1	56	56	56	658	61.8	34.0
lanadelumab	1,451	1	136	336	746	2,287	516.4	498.5
Female	989	1	132	336	728	2,287	510.0	497.5
Male	462	1	140	355	784	2,108	530.1	501.0
eravacycline	1,111	1	5	10	22	354	17.2	24.3
Female	566	1	5	10	20	354	16.1	26.0
Male	545	1	5	11	25	226	18.4	22.3

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
doravirine	8,215	1	113	314	690	2,313	471.7	464.7
Female	2,181	1	90	263	576	2,080	401.0	402.7
Male	6,034	1	120	332	722	2,313	497.2	482.7
moxetumomab pasudotox-tdfk	50	1	3	9	17	43	9.9	8.6
Female	*****	1	1	9	15	18	9.6	6.7
Male	*****	1	3	7	18	43	10.0	8.9
fremanezumab-vfrm	93,384	1	60	154	360	2,206	277.1	320.6
Female	80,681	1	60	154	360	2,206	276.9	320.1
Male	12,703	1	60	154	360	2,164	278.2	323.8
duvelisib	623	3	56	84	196	1,751	172.9	230.9
Female	273	3	56	84	189	1,751	177.8	258.2
Male	350	3	47	84	196	1,512	169.1	207.4
galcanezumab-gnlm	212,175	1	64	173	392	2,239	296.3	333.1
Female	180,088	1	67	175	394	2,239	297.3	333.1
Male	32,087	1	60	162	390	2,215	290.7	333.4
dacomitinib	95	1	30	90	240	1,783	191.6	274.9
Female	60	1	30	90	210	1,161	174.1	220.7
Male	35	17	30	112	270	1,783	221.6	350.6
cemiplimab-rwlc	12,307	1	3	6	13	861	11.2	25.2
Female	3,645	1	3	5	11	861	10.4	27.6
Male	8,662	1	3	6	13	716	11.6	24.1
sarecycline	17,939	1	30	60	120	1,547	100.5	108.9
Female	11,119	1	30	60	120	1,521	97.2	105.4
Male	6,820	1	30	71	120	1,547	106.1	114.0

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
omadacycline	8,563	1	10	14	30	1,870	44.1	100.1
Female	4,263	1	10	14	30	1,870	48.8	106.0
Male	4,300	1	10	14	28	1,705	39.5	93.8
elapegademase-lvlr	42	2	234	526	976	1,781	615.9	449.9
Female	19	11	150	560	925	1,634	587.5	435.6
Male	23	2	234	492	1,082	1,781	639.3	469.8
inotersen	119	28	112	280	588	1,680	399.7	388.4
Female	52	28	128	392	741	1,526	486.8	428.7
Male	67	28	84	196	476	1,680	332.0	342.1
talazoparib	810	1	60	101	191	1,815	158.9	191.2
Female	452	3	60	120	240	1,815	196.6	238.3
Male	358	1	48	90	150	431	111.4	83.8
baloxavir marboxil	130,098	1	1	1	1	645	2.4	7.2
Female	70,809	1	1	1	1	504	2.4	7.0
Male	59,289	1	1	1	1	645	2.3	7.5
lorlatinib	1,620	1	60	150	360	2,010	278.1	342.0
Female	891	1	60	150	356	2,010	278.4	340.9
Male	729	1	60	138	370	1,960	277.7	343.6
revefenacin	15,603	1	5	30	105	1,917	102.8	186.2
Female	9,132	1	5	30	113	1,845	105.1	188.3
Male	6,471	1	4	30	96	1,917	99.6	183.3
rifamycin	110	2	3	3	9	86	10.5	15.9
Female	66	2	3	3	9	86	10.5	16.1
Male	44	2	3	3	11	81	10.6	15.8

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
emapalumab-lzsg	72	1	2	7	24	91	17.4	22.4
Female	34	1	2	16	36	91	24.9	27.5
Male	38	1	2	6	14	72	10.6	13.8
glasdegib	393	1	28	47	88	420	63.8	60.0
Female	161	4	30	48	88	420	63.7	57.7
Male	232	1	28	47	86	390	63.8	61.6
larotrectinib	517	1	58	90	240	1,862	204.1	260.2
Female	298	1	60	90	235	1,411	186.9	225.2
Male	219	5	51	104	240	1,862	227.4	300.4
amifampridine	540	2	121	411	1,094	2,033	666.7	628.9
Female	305	2	139	496	1,191	1,995	705.4	630.9
Male	235	12	120	330	986	2,033	616.5	624.1
gilteritinib	2,670	1	31	90	205	2,066	161.5	206.3
Female	1,294	1	35	90	210	2,066	169.7	218.6
Male	1,376	1	30	90	186	1,689	153.8	193.8
prucalopride	49,006	1	30	101	301	2,112	240.4	313.3
Female	38,640	1	30	104	302	2,112	240.2	312.0
Male	10,366	1	30	91	300	1,982	241.2	318.2
calaspargase pegol-mknl	389	1	1	2	3	72	2.5	3.9
Female	154	1	1	1	3	72	2.8	5.9
Male	235	1	1	2	3	10	2.3	1.7
tagraxofusp-erzs	135	1	1	4	16	155	11.9	20.3
Female	29	1	1	2	6	155	11.9	30.5
Male	106	1	1	5	16	111	11.9	16.6

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
ravulizumab	3,694	1	3	7	15	1,699	46.2	136.7
Female	1,918	1	3	7	16	1,699	47.5	143.8
Male	1,776	1	3	7	14	1,369	44.8	128.6

*NaN: Not a number

****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
mogamulizumab-kpkc	1,147	987	100.0%	140	100.0%	*****	*****	*****	*****	*****	*****
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	252	218	22.1%	*****	*****	*****	*****	*****	*****	0	0.0%
≥ 65 years	861	737	74.7%	110	78.6%	*****	*****	*****	*****	*****	*****
patisiran	625	385	100.0%	191	100.0%	31	100.0%	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****
41-64 years	139	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	471	281	73.0%	162	84.8%	18	58.1%	*****	*****	*****	*****
segesterone acetate and ethinyl estradiol vaginal system	19,514	6,600	100.0%	4,224	100.0%	6,636	100.0%	1,659	100.0%	395	100.0%
0-17 years	*****	*****	*****	177	4.2%	*****	*****	62	3.7%	19	4.8%
18-24 years	6,100	1,965	29.8%	1,293	30.6%	2,143	32.3%	565	34.1%	134	33.9%
25-40 years	10,830	3,771	57.1%	2,406	57.0%	3,612	54.4%	851	51.3%	190	48.1%
41-64 years	1,724	563	8.5%	348	8.2%	580	8.7%	181	10.9%	52	13.2%
≥ 65 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%
migalastat	261	19	100.0%	35	100.0%	79	100.0%	59	100.0%	69	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	20	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	66	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
41-64 years	106	*****	*****	*****	*****	36	45.6%	18	30.5%	31	44.9%
≥ 65 years	69	*****	*****	*****	*****	*****	*****	20	33.9%	23	33.3%
stiripentol	531	46	100.0%	65	100.0%	163	100.0%	132	100.0%	125	100.0%
0-17 years	399	*****	*****	*****	*****	122	74.8%	95	72.0%	91	72.8%
18-24 years	99	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	0.0%
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
cenegermin-bkbj	9,413	873	100.0%	7,319	100.0%	1,207	100.0%	*****	*****	*****	*****
0-17 years	69	*****	*****	45	0.6%	*****	*****	0	0.0%	0	0.0%
18-24 years	47	*****	*****	36	0.5%	*****	*****	0	0.0%	0	0.0%
25-40 years	335	33	3.8%	241	3.3%	61	5.1%	0	0.0%	0	0.0%
41-64 years	1,702	200	22.9%	1,193	16.3%	*****	*****	*****	*****	0	0.0%
≥ 65 years	7,260	624	71.5%	5,804	79.3%	820	67.9%	*****	*****	*****	*****
lanadelumab	1,451	125	100.0%	151	100.0%	482	100.0%	325	100.0%	368	100.0%
0-17 years	125	*****	*****	*****	*****	42	8.7%	36	11.1%	27	7.3%
18-24 years	137	*****	*****	*****	*****	50	10.4%	37	11.4%	15	4.1%
25-40 years	399	37	29.6%	48	31.8%	161	33.4%	82	25.2%	71	19.3%
41-64 years	535	42	33.6%	54	35.8%	173	35.9%	121	37.2%	145	39.4%
≥ 65 years	255	22	17.6%	18	11.9%	56	11.6%	49	15.1%	110	29.9%
eravacycline	1,111	940	100.0%	155	100.0%	16	100.0%	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
25-40 years	103	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
41-64 years	419	363	38.6%	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	572	467	49.7%	*****	*****	*****	*****	0	NaN	0	NaN
doravirine	8,215	779	100.0%	1,104	100.0%	2,624	100.0%	1,811	100.0%	1,897	100.0%
0-17 years	*****	*****	*****	0	0.0%	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	19	1.7%	*****	*****	*****	*****	*****	*****
25-40 years	1,331	168	21.6%	233	21.1%	521	19.9%	*****	*****	*****	*****
41-64 years	5,059	455	58.4%	651	59.0%	1,571	59.9%	1,153	63.7%	1,229	64.8%
≥ 65 years	1,720	139	17.8%	201	18.2%	499	19.0%	349	19.3%	532	28.0%
moxetumomab pasudotox-tdfk	50	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	39	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
fremanezumab-vfrm	93,384	13,797	100.0%	20,308	100.0%	36,884	100.0%	13,763	100.0%	8,632	100.0%
0-17 years	630	81	0.6%	182	0.9%	262	0.7%	73	0.5%	32	0.4%
18-24 years	6,139	973	7.1%	1,552	7.6%	2,487	6.7%	812	5.9%	315	3.6%
25-40 years	26,916	4,139	30.0%	6,271	30.9%	10,956	29.7%	3,628	26.4%	1,922	22.3%
41-64 years	48,473	6,679	48.4%	10,065	49.6%	19,120	51.8%	7,555	54.9%	5,054	58.5%
≥ 65 years	11,226	1,925	14.0%	2,238	11.0%	4,059	11.0%	1,695	12.3%	1,309	15.2%
duvelisib	623	125	100.0%	200	100.0%	222	100.0%	54	100.0%	22	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	129	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
≥ 65 years	479	95	76.0%	139	69.5%	*****	*****	*****	*****	22	100.0%
galcanezumab-gnlm	212,175	30,725	100.0%	41,828	100.0%	82,192	100.0%	35,714	100.0%	21,716	100.0%
0-17 years	1,184	172	0.6%	281	0.7%	469	0.6%	183	0.5%	79	0.4%
18-24 years	13,165	2,059	6.7%	2,914	7.0%	5,353	6.5%	2,020	5.7%	819	3.8%
25-40 years	62,239	9,123	29.7%	12,978	31.0%	25,288	30.8%	9,973	27.9%	4,877	22.5%
41-64 years	108,086	14,866	48.4%	20,177	48.2%	41,085	50.0%	19,375	54.3%	12,583	57.9%
≥ 65 years	27,501	4,505	14.7%	5,478	13.1%	9,997	12.2%	4,163	11.7%	3,358	15.5%
dacomitinib	95	25	100.0%	26	100.0%	32	100.0%	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
41-64 years	26	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	69	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
cemiplimab-rwlc	12,307	11,557	100.0%	662	100.0%	77	100.0%	*****	*****	*****	*****
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
41-64 years	1,105	1,042	9.0%	*****	*****	*****	*****	*****	*****	0	0.0%
≥ 65 years	11,147	10,463	90.5%	608	91.8%	*****	*****	*****	*****	*****	*****
sarecycline	17,939	5,653	100.0%	6,965	100.0%	4,844	100.0%	398	100.0%	79	100.0%
0-17 years	7,791	2,039	36.1%	3,178	45.6%	2,355	48.6%	199	50.0%	20	25.3%
18-24 years	4,928	1,651	29.2%	1,883	27.0%	1,284	26.5%	91	22.9%	19	24.1%

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
25-40 years	3,486	1,311	23.2%	1,328	19.1%	777	16.0%	56	14.1%	14	17.7%
41-64 years	1,568	577	10.2%	530	7.6%	*****	*****	*****	*****	*****	*****
≥ 65 years	166	75	1.3%	46	0.7%	*****	*****	*****	*****	*****	*****
omadacycline	8,563	6,605	100.0%	1,086	100.0%	691	100.0%	154	100.0%	27	100.0%
0-17 years	51	26	0.4%	*****	*****	*****	*****	*****	*****	0	0.0%
18-24 years	144	107	1.6%	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	674	499	7.6%	96	8.8%	63	9.1%	*****	*****	*****	*****
41-64 years	3,412	2,686	40.7%	429	39.5%	245	35.5%	*****	*****	*****	*****
≥ 65 years	4,282	3,287	49.8%	536	49.4%	358	51.8%	90	58.4%	11	40.7%
elapegademase-lvlr	42	*****	*****	0	NaN	*****	*****	15	100.0%	15	100.0%
0-17 years	19	*****	*****	0	NaN	*****	*****	*****	*****	*****	*****
18-24 years	12	*****	*****	0	NaN	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	0	NaN	*****	*****	*****	*****	*****	*****
41-64 years	*****	0	0.0%	0	NaN	0	0.0%	*****	*****	0	0.0%
≥ 65 years	0	0	0.0%	0	NaN	0	0.0%	0	0.0%	0	0.0%
inotersen	119	*****	*****	*****	*****	42	100.0%	26	100.0%	22	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	0	0.0%	0	0.0%	0	0.0%	*****	*****	*****	*****
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	90	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
talazoparib	810	140	100.0%	256	100.0%	357	100.0%	36	100.0%	21	100.0%
0-17 years	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%	*****	*****
18-24 years	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	0.0%

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
25-40 years	*****	*****	*****	*****	*****	32	9.0%	*****	*****	*****	*****
41-64 years	269	*****	*****	71	27.7%	129	36.1%	*****	*****	*****	*****
≥ 65 years	479	91	65.0%	168	65.6%	196	54.9%	*****	*****	*****	*****
baloxavir marboxil	130,098	129,618	100.0%	434	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	24,111	24,093	18.6%	18	4.1%	0	0.0%	0	0.0%	0	NaN
18-24 years	13,123	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	29,702	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	39,798	39,705	30.6%	82	18.9%	11	25.6%	0	0.0%	0	NaN
≥ 65 years	23,364	23,026	17.8%	305	70.3%	*****	*****	*****	*****	0	NaN
lorlatinib	1,620	264	100.0%	359	100.0%	604	100.0%	237	100.0%	156	100.0%
0-17 years	76	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	11	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	127	*****	*****	*****	*****	43	7.1%	24	10.1%	*****	*****
41-64 years	666	82	31.1%	142	39.6%	262	43.4%	111	46.8%	69	44.2%
≥ 65 years	740	155	58.7%	170	47.4%	255	42.2%	91	38.4%	69	44.2%
revefenacin	15,603	8,630	100.0%	2,920	100.0%	2,939	100.0%	812	100.0%	302	100.0%
0-17 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	206	97	1.1%	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	4,494	2,251	26.1%	888	30.4%	985	33.5%	*****	*****	*****	*****
≥ 65 years	10,869	6,268	72.6%	1,982	67.9%	1,900	64.6%	525	64.7%	194	64.2%
rifamycin	110	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
25-40 years	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
41-64 years	50	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	30	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
emapalumab-lzsg	72	58	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	36	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	14	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
glasdegib	393	177	100.0%	148	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	340	150	84.7%	132	89.2%	*****	*****	*****	*****	0	NaN
larotrectinib	517	103	100.0%	156	100.0%	172	100.0%	58	100.0%	28	100.0%
0-17 years	73	*****	*****	12	7.7%	31	18.0%	16	27.6%	*****	*****
18-24 years	11	0	0.0%	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	35	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	153	*****	*****	41	26.3%	52	30.2%	18	31.0%	*****	*****
≥ 65 years	245	55	53.4%	90	57.7%	74	43.0%	*****	*****	*****	*****
amifampridine	540	44	100.0%	50	100.0%	156	100.0%	91	100.0%	199	100.0%
0-17 years	21	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	15	0	0.0%	*****	*****	*****	*****	*****	*****	*****	*****

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
25-40 years	39	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	168	*****	*****	*****	*****	58	37.2%	29	31.9%	56	28.1%
≥ 65 years	297	23	52.3%	26	52.0%	76	48.7%	46	50.5%	126	63.3%
gilteritinib	2,670	643	100.0%	766	100.0%	964	100.0%	228	100.0%	69	100.0%
0-17 years	47	*****	*****	12	1.6%	17	1.8%	*****	*****	*****	*****
18-24 years	44	*****	*****	12	1.6%	15	1.6%	*****	*****	*****	*****
25-40 years	181	40	6.2%	49	6.4%	75	7.8%	*****	*****	*****	*****
41-64 years	661	147	22.9%	195	25.5%	231	24.0%	*****	*****	*****	*****
≥ 65 years	1,737	432	67.2%	498	65.0%	626	64.9%	140	61.4%	41	59.4%
prucalopride	49,006	13,353	100.0%	10,807	100.0%	14,645	100.0%	6,143	100.0%	4,058	100.0%
0-17 years	788	200	1.5%	191	1.8%	248	1.7%	105	1.7%	44	1.1%
18-24 years	2,672	740	5.5%	591	5.5%	799	5.5%	354	5.8%	188	4.6%
25-40 years	8,060	2,121	15.9%	1,758	16.3%	2,578	17.6%	1,008	16.4%	595	14.7%
41-64 years	20,175	4,909	36.8%	4,511	41.7%	6,386	43.6%	2,623	42.7%	1,746	43.0%
≥ 65 years	17,311	5,383	40.3%	3,756	34.8%	4,634	31.6%	2,053	33.4%	1,485	36.6%
calaspargase pegol-mknl	389	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	352	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
tagraxofusp-erzs	135	120	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	17	17	14.2%	0	0.0%	0	0.0%	0	NaN	0	NaN
≥ 65 years	100	86	71.7%	*****	*****	*****	*****	0	NaN	0	NaN
ravulizumab	3,694	3,200	100.0%	128	100.0%	211	100.0%	121	100.0%	34	100.0%
0-17 years	214	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	146	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	556	501	15.7%	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	943	833	26.0%	32	25.0%	37	17.5%	*****	*****	*****	*****
≥ 65 years	1,835	1,534	47.9%	71	55.5%	145	68.7%	73	60.3%	12	35.3%

*NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
mogamulizumab-kpkc	1,147	1	5	10	21	1,504	20.0	55.4
0-17 years	*****	1	1	5	14	14	6.7	6.7
18-24 years	*****	8	8	9	10	10	9.0	1.4
25-40 years	*****	1	5	8	16	223	17.4	40.3
41-64 years	252	1	4	9	17	628	19.0	47.5
≥ 65 years	861	1	6	11	23	1,504	20.4	58.1
patisiran	625	1	8	22	46	1,386	53.2	130.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	4	4	4	4	4	4.0	NaN
25-40 years	*****	1	3	15	35	840	98.1	225.5
41-64 years	139	1	5	17	42	1,386	67.6	177.4
≥ 65 years	471	1	10	23	47	1,056	47.8	107.8
segesterone acetate and ethinyl estradiol vaginal system	19,514	1	30	90	289	1,655	172.1	201.0
0-17 years	*****	1	30	86	270	1,123	166.6	194.8
18-24 years	6,100	1	30	90	350	1,633	182.3	204.5
25-40 years	10,830	1	30	86	257	1,655	163.2	194.8
41-64 years	1,724	1	30	90	350	1,561	194.5	224.8
≥ 65 years	*****	27	95	190	279	340	186.8	129.7
migalastat	261	3	112	353	780	2,320	532.3	530.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	20	28	71	317	570	1,597	384.5	376.0
25-40 years	66	16	89	280	596	1,929	438.5	480.4
41-64 years	106	4	119	310	862	2,047	562.0	561.3
≥ 65 years	69	3	188	447	888	2,320	619.4	551.8

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
stiripentol	531	3	120	342	693	1,939	453.9	413.3
0-17 years	399	3	105	320	689	1,939	436.6	407.9
18-24 years	99	3	165	412	770	1,895	498.9	410.5
25-40 years	*****	15	166	439	821	1,769	542.5	477.8
41-64 years	*****	63	63	63	63	63	63.0	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
cenegermin-bkbj	9,413	1	56	56	56	1,246	62.4	38.9
0-17 years	69	2	56	56	57	154	63.2	33.4
18-24 years	47	7	43	56	56	240	58.4	35.4
25-40 years	335	1	56	56	63	308	66.3	38.3
41-64 years	1,702	1	56	56	56	658	65.9	42.7
≥ 65 years	7,260	1	56	56	56	1,246	61.4	38.0
lanadelumab	1,451	1	136	336	746	2,287	516.4	498.5
0-17 years	125	2	154	392	658	2,050	461.8	391.6
18-24 years	137	1	87	266	504	1,949	370.5	366.9
25-40 years	399	1	112	271	588	2,108	408.9	410.2
41-64 years	535	1	140	361	788	2,287	546.8	524.7
≥ 65 years	255	1	196	598	1,163	2,072	726.0	593.5
eravacycline	1,111	1	5	10	22	354	17.2	24.3
0-17 years	*****	1	1	2	20	20	7.7	10.7
18-24 years	*****	1	1	7	19	58	12.7	16.2
25-40 years	103	1	5	8	17	47	12.1	10.6
41-64 years	419	1	5	10	21	226	16.5	22.2
≥ 65 years	572	1	5	12	25	354	18.8	27.4

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
doravirine	8,215	1	113	314	690	2,313	471.7	464.7
0-17 years	*****	30	110	421	647	955	430.7	360.0
18-24 years	*****	12	60	193	432	1,051	270.7	244.3
25-40 years	1,331	2	85	210	434	2,043	308.1	313.2
41-64 years	5,059	1	120	333	720	2,313	488.1	471.1
≥ 65 years	1,720	3	130	387	884	2,115	561.6	517.1
moxetumomab pasudotox-tdfk	50	1	3	9	17	43	9.9	8.6
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	5	9	9	5.0	5.7
41-64 years	*****	1	9	18	18	30	15.4	8.7
≥ 65 years	*****	1	3	6	15	43	8.9	8.3
fremanezumab-vfrm	93,384	1	60	154	360	2,206	277.1	320.6
0-17 years	630	1	60	120	270	1,548	217.8	243.0
18-24 years	6,139	1	60	135	296	1,983	222.1	241.0
25-40 years	26,916	1	60	148	323	2,206	247.6	286.6
41-64 years	48,473	1	74	173	388	2,191	294.6	334.7
≥ 65 years	11,226	1	60	168	392	2,164	305.6	364.7
duvelisib	623	3	56	84	196	1,751	172.9	230.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	25	25	25	25	25	25.0	NaN
25-40 years	*****	4	28	56	84	224	72.2	57.2
41-64 years	129	3	56	84	168	728	123.7	126.0
≥ 65 years	479	3	56	104	224	1,751	189.4	252.5

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
galcanezumab-gnlm	212,175	1	64	173	392	2,239	296.3	333.1
0-17 years	1,184	1	60	150	334	2,115	253.0	290.1
18-24 years	13,165	1	60	148	330	2,081	244.7	268.1
25-40 years	62,239	1	60	158	360	2,239	266.9	298.2
41-64 years	108,086	1	78	180	428	2,195	316.8	349.6
≥ 65 years	27,501	1	60	163	407	2,118	308.9	362.4
dacomitinib	95	1	30	90	240	1,783	191.6	274.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	26	1	30	75	150	1,783	167.7	346.1
≥ 65 years	69	7	46	90	270	1,161	200.6	245.1
cemiplimab-rwlc	12,307	1	3	6	13	861	11.2	25.2
0-17 years	*****	3	3	3	3	3	3.0	NaN
18-24 years	*****	1	1	3	6	6	3.3	2.5
25-40 years	51	1	2	4	8	42	7.7	9.5
41-64 years	1,105	1	3	6	12	716	12.0	33.4
≥ 65 years	11,147	1	3	6	13	861	11.2	24.3
sarecycline	17,939	1	30	60	120	1,547	100.5	108.9
0-17 years	7,791	1	30	90	120	1,521	106.7	104.1
18-24 years	4,928	1	30	60	120	1,470	95.3	101.4
25-40 years	3,486	1	30	60	90	1,320	88.5	100.2
41-64 years	1,568	2	30	60	120	1,297	111.4	147.5
≥ 65 years	166	7	30	60	120	1,547	118.8	209.6

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
omadacycline	8,563	1	10	14	30	1,870	44.1	100.1
0-17 years	51	1	10	30	210	672	129.9	180.0
18-24 years	144	1	10	14	38	739	58.5	115.0
25-40 years	674	1	10	14	34	1,166	48.9	102.8
41-64 years	3,412	1	10	14	28	1,870	40.2	101.5
≥ 65 years	4,282	1	10	14	30	1,264	45.0	96.2
elapegademase-lvlr	42	2	234	526	976	1,781	615.9	449.9
0-17 years	19	2	234	476	925	1,111	552.4	357.2
18-24 years	12	28	269	579	978	1,375	645.3	452.3
25-40 years	*****	11	200	560	1,027	1,781	719.4	625.9
41-64 years	*****	433	433	433	433	433	433.0	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
inotersen	119	28	112	280	588	1,680	399.7	388.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	420	420	587	754	754	587.0	236.2
41-64 years	*****	28	56	161	396	1,526	312.8	388.3
≥ 65 years	90	28	112	280	593	1,680	421.6	389.6
talazoparib	810	1	60	101	191	1,815	158.9	191.2
0-17 years	*****	56	56	60	804	804	306.7	430.7
18-24 years	*****	60	60	60	60	60	60.0	NaN
25-40 years	*****	10	60	120	210	1,539	180.7	256.6
41-64 years	269	3	60	120	236	1,230	187.1	203.8
≥ 65 years	479	1	60	90	180	1,815	139.7	170.1

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
baloxavir marboxil	130,098	1	1	1	1	645	2.4	7.2
0-17 years	24,111	1	1	1	1	90	1.3	2.3
18-24 years	13,123	1	1	1	1	91	1.3	2.6
25-40 years	29,702	1	1	1	1	120	1.3	2.8
41-64 years	39,798	1	1	1	1	270	1.6	4.7
≥ 65 years	23,364	1	1	1	1	645	6.8	14.5
lorlatinib	1,620	1	60	150	360	2,010	278.1	342.0
0-17 years	76	9	89	153	309	1,622	248.1	266.3
18-24 years	11	2	60	143	450	908	299.1	321.8
25-40 years	127	1	60	150	390	1,230	265.8	274.9
41-64 years	666	1	75	168	390	1,913	300.3	351.0
≥ 65 years	740	4	51	120	316	2,010	263.0	350.9
revefenacin	15,603	1	5	30	105	1,917	102.8	186.2
0-17 years	*****	1	1	1	60	286	69.8	123.5
18-24 years	*****	1	1	60	210	832	161.9	237.1
25-40 years	206	1	4	49	150	1,544	131.9	230.1
41-64 years	4,494	1	6	30	122	1,845	115.2	193.4
≥ 65 years	10,869	1	5	30	90	1,917	97.0	181.8
rifamycin	110	2	3	3	9	86	10.5	15.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	3	3	3	6	14	5.0	3.5
25-40 years	*****	2	3	3	6	86	12.9	23.6
41-64 years	50	2	3	6	12	81	12.4	16.3
≥ 65 years	30	3	3	3	6	39	7.8	10.1

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
emapalumab-lzsg	72	1	2	7	24	91	17.4	22.4
0-17 years	36	1	6	15	35	91	22.7	23.8
18-24 years	*****	2	6	7	30	37	15.4	14.5
25-40 years	*****	3	5	15	28	85	25.2	30.7
41-64 years	14	1	1	2	4	78	8.9	20.4
≥ 65 years	*****	1	1	2	4	7	2.7	2.2
glasdegib	393	1	28	47	88	420	63.8	60.0
0-17 years	*****	60	60	60	60	60	60.0	NaN
18-24 years	*****	30	30	30	30	30	30.0	NaN
25-40 years	*****	19	24	28	43	196	56.3	68.9
41-64 years	*****	10	28	39	84	210	60.1	51.9
≥ 65 years	340	1	28	52	89	420	64.5	61.1
larotrectinib	517	1	58	90	240	1,862	204.1	260.2
0-17 years	73	9	114	254	450	1,046	308.9	253.6
18-24 years	11	90	135	210	420	630	286.0	183.1
25-40 years	35	10	30	90	150	1,862	210.6	354.7
41-64 years	153	1	47	103	240	1,551	212.3	288.6
≥ 65 years	245	5	47	90	179	1,411	163.1	219.3
amifampridine	540	2	121	411	1,094	2,033	666.7	628.9
0-17 years	21	25	38	95	201	1,886	237.4	411.1
18-24 years	15	90	284	375	739	1,648	504.9	417.0
25-40 years	39	15	107	403	945	1,933	577.8	585.4
41-64 years	168	2	145	369	974	1,995	612.5	583.0
≥ 65 years	297	12	146	515	1,343	2,033	747.5	664.2

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
gilteritinib	2,670	1	31	90	205	2,066	161.5	206.3
0-17 years	47	1	30	90	200	1,110	137.2	187.7
18-24 years	44	12	37	84	225	855	190.2	234.7
25-40 years	181	1	60	102	189	1,050	158.3	174.2
41-64 years	661	1	38	90	210	2,066	174.4	224.7
≥ 65 years	1,737	1	31	90	197	1,689	156.9	201.7
prucalopride	49,006	1	30	101	301	2,112	240.4	313.3
0-17 years	788	1	30	92	270	1,736	213.5	271.3
18-24 years	2,672	1	30	92	300	1,895	225.1	281.3
25-40 years	8,060	1	30	114	300	1,982	232.6	302.1
41-64 years	20,175	1	38	120	330	2,086	250.6	318.8
≥ 65 years	17,311	1	30	90	300	2,112	235.9	318.0
calaspargase pegol-mknl	389	1	1	2	3	72	2.5	3.9
0-17 years	352	1	1	2	3	72	2.5	4.1
18-24 years	*****	1	1	2	3	6	2.0	1.3
25-40 years	*****	1	1	1	1	1	1.0	NaN
41-64 years	*****	1	1	1	1	1	1.0	NaN
≥ 65 years	*****	2	2	2	2	2	2.0	NaN
tagraxofusp-erzs	135	1	1	4	16	155	11.9	20.3
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	2	6	20	31	10.8	13.8
25-40 years	*****	1	1	1	4	21	3.6	5.7
41-64 years	17	1	1	2	3	24	4.2	6.3
≥ 65 years	100	1	1	6	20	155	14.5	22.7

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
ravulizumab	3,694	1	3	7	15	1,699	46.2	136.7
0-17 years	214	1	3	7	13	1,274	33.3	121.4
18-24 years	146	1	2	6	12	1,066	28.8	118.7
25-40 years	556	1	3	7	15	1,424	40.7	142.7
41-64 years	943	1	3	7	15	1,369	45.5	147.5
≥ 65 years	1,835	1	4	8	15	1,699	51.1	131.8

*NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 4a. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>mogamulizumab-kpkc</i>	18,570	18,536	99.8%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>patisiran</i>	14,710	14,585	99.2%	*****	*****	63	0.4%	*****	*****	0	0.0%
<i>segesterone acetate and ethinyl estradiol vaginal system</i>	23,401	9,751	41.7%	4,823	20.6%	7,540	32.2%	1,088	4.6%	199	0.9%
<i>migalastat</i>	1,130	499	44.2%	299	26.5%	253	22.4%	48	4.2%	31	2.7%
<i>stiripentol</i>	1,841	808	43.9%	528	28.7%	343	18.6%	93	5.1%	69	3.7%
<i>cenegermin-bkbj</i>	14,360	5,695	39.7%	8,373	58.3%	*****	*****	*****	*****	0	0.0%
<i>lanadelumab</i>	9,281	5,503	59.3%	2,075	22.4%	1,393	15.0%	205	2.2%	105	1.1%
<i>eravacycline</i>	2,579	2,461	95.4%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>doravirine</i>	32,989	16,545	50.2%	8,351	25.3%	5,814	17.6%	1,409	4.3%	870	2.6%
<i>moxetumomab pasudotox- tdfk</i>	441	441	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>fremanezumab-vfrm</i>	321,795	168,955	52.5%	93,436	29.0%	51,253	15.9%	6,253	1.9%	1,898	0.6%
<i>duvelisib</i>	1,596	867	54.3%	455	28.5%	250	15.7%	*****	*****	*****	*****
<i>galcanezumab-gnlm</i>	806,021	453,016	56.2%	210,920	26.2%	120,041	14.9%	16,522	2.0%	5,522	0.7%
<i>dacomitinib</i>	208	116	55.8%	47	22.6%	*****	*****	*****	*****	*****	*****
<i>cemiplimab-rwlc</i>	114,854	114,633	99.8%	162	0.1%	*****	*****	*****	*****	0	0.0%
<i>sarecycline</i>	40,752	30,933	75.9%	7,781	19.1%	1,947	4.8%	79	0.2%	12	0.0%
<i>omadacycline</i>	14,819	12,907	87.1%	1,288	8.7%	559	3.8%	*****	*****	*****	*****
<i>elapegademase-lvlr</i>	395	265	67.1%	82	20.8%	37	9.4%	*****	*****	*****	*****
<i>inotersen</i>	519	269	51.8%	124	23.9%	106	20.4%	*****	*****	*****	*****
<i>talazoparib</i>	1,844	985	53.4%	519	28.1%	320	17.4%	*****	*****	*****	*****
<i>baloxavir marboxil</i>	137,426	137,222	99.9%	190	0.1%	14	0.0%	0	0.0%	0	0.0%
<i>lorlatinib</i>	4,362	2,140	49.1%	1,141	26.2%	851	19.5%	162	3.7%	68	1.6%

Table 4a. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>revefenacin</i>	49,257	40,567	82.4%	5,775	11.7%	2,522	5.1%	301	0.6%	92	0.2%
<i>rifamycin</i>	144	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
<i>emapalumab-lzsg</i>	1,028	1,028	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>glasdegib</i>	576	383	66.5%	157	27.3%	36	6.3%	0	0.0%	0	0.0%
<i>larotrectinib</i>	1,175	616	52.4%	312	26.6%	199	16.9%	35	3.0%	13	1.1%
<i>amifampridine</i>	2,346	1,038	44.2%	611	26.0%	454	19.4%	131	5.6%	112	4.8%
<i>gilteritinib</i>	6,675	3,912	58.6%	1,733	26.0%	937	14.0%	75	1.1%	18	0.3%
<i>prucalopride</i>	140,131	77,220	55.1%	38,244	27.3%	20,044	14.3%	3,447	2.5%	1,176	0.8%
<i>calaspargase pegol-mknl</i>	894	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
<i>tagraxofusp-erzs</i>	567	567	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>ravulizumab</i>	29,128	28,344	97.3%	366	1.3%	326	1.1%	*****	*****	*****	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 4b. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>mogamulizumab-kpkc</i>	18,570	1	1	1	1	323	1.2	5.2
<i>patisiran</i>	14,710	1	1	1	1	672	2.3	16.6
<i>segesterone acetate and ethinyl estradiol vaginal system</i>	23,401	1	28	66	232	1,633	143.5	171.0
<i>migalastat</i>	1,130	3	28	56	112	2,320	123.0	210.2
<i>stiripentol</i>	1,841	2	30	48	120	1,871	130.9	224.0
<i>cenegermin-bkbj</i>	14,360	1	14	42	56	413	40.9	23.6
<i>lanadelumab</i>	9,281	1	28	28	78	2,071	80.7	151.6
<i>eravacycline</i>	2,579	1	1	2	9	337	7.4	13.0
<i>doravirine</i>	32,989	1	30	30	90	2,313	117.5	210.7
<i>moxetumomab pasudotox-tdfk</i>	441	1	1	1	1	28	1.1	1.8
<i>fremanezumab-vfrm</i>	321,795	1	30	30	90	2,206	80.4	114.9
<i>duvelisib</i>	1,596	1	28	28	81	1,269	67.5	86.5
<i>galcanezumab-gnlm</i>	806,021	1	30	30	84	2,144	78.0	121.2
<i>dacomitinib</i>	208	1	30	30	90	1,161	87.5	138.5
<i>cemiplimab-rwlc</i>	114,854	1	1	1	1	420	1.2	4.7
<i>sarecycline</i>	40,752	1	30	30	30	1,230	44.3	41.3
<i>omadacycline</i>	14,819	1	7	14	28	1,705	25.5	54.5
<i>elapegademase-lvlr</i>	395	1	28	28	56	1,232	65.5	139.0
<i>inotersen</i>	519	5	28	28	84	1,526	91.6	143.7
<i>talazoparib</i>	1,844	1	30	30	90	1,539	69.8	87.3
<i>baloxavir marboxil</i>	137,426	1	1	1	1	270	2.3	6.0
<i>lorlatinib</i>	4,362	1	30	40	90	1,920	103.3	172.8
<i>revefenacin</i>	49,257	1	1	20	30	1,887	32.6	72.2
<i>rifamycin</i>	144	2	3	3	6	72	8.0	10.8
<i>emapalumab-lzsg</i>	1,028	1	1	1	1	28	1.2	1.6

Table 4b. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>glasdegib</i>	576	1	28	30	60	240	43.5	32.9
<i>larotrectinib</i>	1,175	1	30	30	90	1,862	89.8	148.9
<i>amifampridine</i>	2,346	1	30	60	120	1,973	153.5	275.2
<i>gilteritinib</i>	6,675	1	30	30	60	1,946	64.6	93.9
<i>prucalopride</i>	140,131	1	30	30	90	2,112	84.1	129.4
<i>calaspargase pegol-mknl</i>	894	1	1	1	1	42	1.1	1.7
<i>tagraxofusp-erzs</i>	567	1	1	2	5	21	2.8	2.0
<i>ravulizumab</i>	29,128	1	1	1	1	952	5.9	37.8

Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
mogamulizumab-kpkc	18,570	18,536	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
Female	8,342	8,321	44.9%	*****	*****	*****	*****	0	NaN	0	NaN
Male	10,228	10,215	55.1%	*****	*****	*****	*****	0	NaN	0	NaN
patisiran	14,710	14,585	100.0%	*****	*****	63	100.0%	*****	*****	0	NaN
Female	5,130	5,066	34.7%	*****	*****	33	52.4%	*****	*****	0	NaN
Male	9,580	9,519	65.3%	*****	*****	30	47.6%	*****	*****	0	NaN
segesterone acetate and ethinyl estradiol vaginal system	23,401	9,751	100.0%	4,823	100.0%	7,540	100.0%	1,088	100.0%	199	100.0%
Female	23,352	9,737	99.9%	*****	*****	7,516	99.7%	*****	*****	199	100.0%
Male	49	14	0.1%	*****	*****	24	0.3%	*****	*****	0	0.0%
migalastat	1,130	499	100.0%	299	100.0%	253	100.0%	48	100.0%	31	100.0%
Female	565	251	50.3%	153	51.2%	124	49.0%	23	47.9%	14	45.2%
Male	565	248	49.7%	146	48.8%	129	51.0%	25	52.1%	17	54.8%
stiripentol	1,841	808	100.0%	528	100.0%	343	100.0%	93	100.0%	69	100.0%
Female	1,034	475	58.8%	282	53.4%	197	57.4%	41	44.1%	39	56.5%
Male	807	333	41.2%	246	46.6%	146	42.6%	52	55.9%	30	43.5%
cenegermin-bkbj	14,360	5,695	100.0%	8,373	100.0%	*****	*****	*****	*****	0	NaN
Female	9,478	3,824	67.1%	5,455	65.1%	199	68.4%	0	0.0%	0	NaN
Male	4,882	1,871	32.9%	2,918	34.9%	*****	*****	*****	*****	0	NaN
lanadelumab	9,281	5,503	100.0%	2,075	100.0%	1,393	100.0%	205	100.0%	105	100.0%
Female	6,034	3,516	63.9%	1,372	66.1%	925	66.4%	149	72.7%	72	68.6%
Male	3,247	1,987	36.1%	703	33.9%	468	33.6%	56	27.3%	33	31.4%

Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
eravacycline	2,579	2,461	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
Female	1,467	1,425	57.9%	*****	*****	*****	*****	0	NaN	0	NaN
Male	1,112	1,036	42.1%	*****	*****	*****	*****	0	NaN	0	NaN
doravirine	32,989	16,545	100.0%	8,351	100.0%	5,814	100.0%	1,409	100.0%	870	100.0%
Female	8,634	4,573	27.6%	2,162	25.9%	1,446	24.9%	284	20.2%	169	19.4%
Male	24,355	11,972	72.4%	6,189	74.1%	4,368	75.1%	1,125	79.8%	701	80.6%
moxetumomab pasudotox- tadfl	441	441	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	67	67	15.2%	0	NaN	0	NaN	0	NaN	0	NaN
Male	374	374	84.8%	0	NaN	0	NaN	0	NaN	0	NaN
fremanezumab-vfrm	321,795	168,955	100.0%	93,436	100.0%	51,253	100.0%	6,253	100.0%	1,898	100.0%
Female	278,995	146,887	86.9%	80,945	86.6%	44,163	86.2%	5,377	86.0%	1,623	85.5%
Male	42,800	22,068	13.1%	12,491	13.4%	7,090	13.8%	876	14.0%	275	14.5%
duvelisib	1,596	867	100.0%	455	100.0%	250	100.0%	*****	*****	*****	*****
Female	687	370	42.7%	195	42.9%	*****	*****	*****	*****	*****	*****
Male	909	497	57.3%	260	57.1%	*****	*****	*****	*****	0	0.0%
galcanezumab-gnlm	806,021	453,016	100.0%	210,920	100.0%	120,041	100.0%	16,522	100.0%	5,522	100.0%
Female	687,755	386,639	85.3%	180,036	85.4%	102,442	85.3%	13,964	84.5%	4,674	84.6%
Male	118,266	66,377	14.7%	30,884	14.6%	17,599	14.7%	2,558	15.5%	848	15.4%
dacomitinib	208	116	100.0%	47	100.0%	*****	*****	*****	*****	*****	*****
Female	118	66	56.9%	25	53.2%	*****	*****	*****	*****	*****	*****
Male	90	50	43.1%	22	46.8%	*****	*****	*****	*****	*****	*****

Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
cemiplimab-rwlc	114,854	114,633	100.0%	162	100.0%	*****	*****	*****	*****	0	NaN
Female	30,393	30,316	26.4%	*****	*****	*****	*****	0	0.0%	0	NaN
Male	84,461	84,317	73.6%	*****	*****	*****	*****	*****	*****	0	NaN
sarecycline	40,752	30,933	100.0%	7,781	100.0%	1,947	100.0%	79	100.0%	12	100.0%
Female	24,654	18,765	60.7%	4,734	60.8%	1,100	56.5%	*****	*****	*****	*****
Male	16,098	12,168	39.3%	3,047	39.2%	847	43.5%	*****	*****	*****	*****
omadacycline	14,819	12,907	100.0%	1,288	100.0%	559	100.0%	*****	*****	*****	*****
Female	7,631	6,545	50.7%	714	55.4%	337	60.3%	*****	*****	*****	*****
Male	7,188	6,362	49.3%	574	44.6%	222	39.7%	*****	*****	*****	*****
elapegademase-lvlr	395	265	100.0%	82	100.0%	37	100.0%	*****	*****	*****	*****
Female	221	159	60.0%	45	54.9%	*****	*****	*****	*****	*****	*****
Male	174	106	40.0%	37	45.1%	*****	*****	*****	*****	*****	*****
inotersen	519	269	100.0%	124	100.0%	106	100.0%	*****	*****	*****	*****
Female	287	151	56.1%	71	57.3%	*****	*****	*****	*****	*****	*****
Male	232	118	43.9%	53	42.7%	*****	*****	*****	*****	*****	*****
talazoparib	1,844	985	100.0%	519	100.0%	320	100.0%	*****	*****	*****	*****
Female	1,224	679	68.9%	321	61.8%	204	63.8%	*****	*****	*****	*****
Male	620	306	31.1%	198	38.2%	116	36.3%	0	0.0%	0	0.0%
baloxavir marboxil	137,426	137,222	100.0%	190	100.0%	14	100.0%	0	NaN	0	NaN
Female	74,781	74,677	54.4%	*****	*****	*****	*****	0	NaN	0	NaN
Male	62,645	62,545	45.6%	*****	*****	*****	*****	0	NaN	0	NaN
lorlatinib	4,362	2,140	100.0%	1,141	100.0%	851	100.0%	162	100.0%	68	100.0%
Female	2,378	1,203	56.2%	592	51.9%	451	53.0%	88	54.3%	44	64.7%
Male	1,984	937	43.8%	549	48.1%	400	47.0%	74	45.7%	24	35.3%

Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
revefenacin	49,257	40,567	100.0%	5,775	100.0%	2,522	100.0%	301	100.0%	92	100.0%
Female	28,417	23,162	57.1%	3,488	60.4%	1,535	60.9%	183	60.8%	49	53.3%
Male	20,840	17,405	42.9%	2,287	39.6%	987	39.1%	118	39.2%	43	46.7%
rifamycin	144	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Female	81	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	63	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
emapalumab-lzsg	1,028	1,028	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	742	742	72.2%	0	NaN	0	NaN	0	NaN	0	NaN
Male	286	286	27.8%	0	NaN	0	NaN	0	NaN	0	NaN
glasdegib	576	383	100.0%	157	100.0%	36	100.0%	0	NaN	0	NaN
Female	240	165	43.1%	61	38.9%	14	38.9%	0	NaN	0	NaN
Male	336	218	56.9%	96	61.1%	22	61.1%	0	NaN	0	NaN
larotrectinib	1,175	616	100.0%	312	100.0%	199	100.0%	35	100.0%	13	100.0%
Female	667	355	57.6%	183	58.7%	106	53.3%	*****	*****	*****	*****
Male	508	261	42.4%	129	41.3%	93	46.7%	*****	*****	*****	*****
amifampridine	2,346	1,038	100.0%	611	100.0%	454	100.0%	131	100.0%	112	100.0%
Female	1,423	670	64.5%	344	56.3%	261	57.5%	80	61.1%	68	60.7%
Male	923	368	35.5%	267	43.7%	193	42.5%	51	38.9%	44	39.3%
gilteritinib	6,675	3,912	100.0%	1,733	100.0%	937	100.0%	75	100.0%	18	100.0%
Female	3,328	1,948	49.8%	860	49.6%	474	50.6%	*****	*****	*****	*****
Male	3,347	1,964	50.2%	873	50.4%	463	49.4%	*****	*****	*****	*****
prucalopride	140,131	77,220	100.0%	38,244	100.0%	20,044	100.0%	3,447	100.0%	1,176	100.0%
Female	111,406	61,586	79.8%	30,475	79.7%	15,749	78.6%	2,711	78.6%	885	75.3%
Male	28,725	15,634	20.2%	7,769	20.3%	4,295	21.4%	736	21.4%	291	24.7%

Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
calaspargase pegol-mknl	894	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
tagraxofusp-erzs	567	567	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	120	120	21.2%	0	NaN	0	NaN	0	NaN	0	NaN
Male	447	447	78.8%	0	NaN	0	NaN	0	NaN	0	NaN
ravulizumab	29,128	28,344	100.0%	366	100.0%	326	100.0%	*****	*****	*****	*****
Female	15,477	15,053	53.1%	198	54.1%	179	54.9%	*****	*****	*****	*****
Male	13,651	13,291	46.9%	168	45.9%	147	45.1%	*****	*****	*****	*****

*NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
mogamulizumab-kpkc	18,570	1	1	1	1	323	1.2	5.2
Female	8,342	1	1	1	1	308	1.3	6.2
Male	10,228	1	1	1	1	323	1.2	4.3
patisiran	14,710	1	1	1	1	672	2.3	16.6
Female	5,130	1	1	1	1	672	3.0	22.5
Male	9,580	1	1	1	1	462	1.9	12.4
segesterone acetate and ethinyl estradiol vaginal system	23,401	1	28	66	232	1,633	143.5	171.0
Female	23,352	1	28	66	232	1,633	143.5	171.0
Male	49	1	30	112	336	662	176.0	164.2
migalastat	1,130	3	28	56	112	2,320	123.0	210.2
Female	565	3	28	56	112	1,568	120.0	197.4
Male	565	3	28	56	112	2,320	125.9	222.5
stiripentol	1,841	2	30	48	120	1,871	130.9	224.0
Female	1,034	2	30	40	120	1,678	126.0	219.7
Male	807	3	30	59	120	1,871	137.2	229.3
cenegermin-bkbj	14,360	1	14	42	56	413	40.9	23.6
Female	9,478	1	14	42	56	364	40.7	23.7
Male	4,882	1	21	42	56	413	41.3	23.3
lanadelumab	9,281	1	28	28	78	2,071	80.7	151.6
Female	6,034	1	28	28	84	2,071	83.6	156.8
Male	3,247	1	28	28	56	2,036	75.4	141.2
eravacycline	2,579	1	1	2	9	337	7.4	13.0
Female	1,467	1	1	1	7	337	6.2	12.5
Male	1,112	1	1	4	12	141	9.0	13.3

Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
doravirine	32,989	1	30	30	90	2,313	117.5	210.7
Female	8,634	1	30	30	90	2,005	101.3	175.3
Male	24,355	1	30	42	103	2,313	123.2	221.6
moxetumomab pasudotox-tdfk	441	1	1	1	1	28	1.1	1.8
Female	67	1	1	1	1	1	1.0	0.0
Male	374	1	1	1	1	28	1.1	2.0
fremanezumab-vfrm	321,795	1	30	30	90	2,206	80.4	114.9
Female	278,995	1	30	30	90	2,206	80.1	114.4
Male	42,800	1	30	30	90	2,032	82.6	118.5
duvelisib	1,596	1	28	28	81	1,269	67.5	86.5
Female	687	3	28	28	84	1,269	70.6	97.3
Male	909	1	28	28	56	644	65.1	77.3
galcanezumab-gnlm	806,021	1	30	30	84	2,144	78.0	121.2
Female	687,755	1	30	30	84	2,144	77.8	120.8
Male	118,266	1	30	30	84	1,985	78.9	123.1
dacomitinib	208	1	30	30	90	1,161	87.5	138.5
Female	118	1	30	30	90	1,161	88.5	135.5
Male	90	17	30	30	60	1,096	86.2	143.2
cemiplimab-rwlc	114,854	1	1	1	1	420	1.2	4.7
Female	30,393	1	1	1	1	315	1.3	5.1
Male	84,461	1	1	1	1	420	1.2	4.6
sarecycline	40,752	1	30	30	30	1,230	44.3	41.3
Female	24,654	1	30	30	30	916	43.8	39.6
Male	16,098	1	30	30	30	1,230	44.9	43.7

Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
omadacycline	14,819	1	7	14	28	1,705	25.5	54.5
Female	7,631	1	8	14	30	1,692	27.2	54.7
Male	7,188	1	7	14	20	1,705	23.6	54.2
elapegademase-lvlr	395	1	28	28	56	1,232	65.5	139.0
Female	221	1	28	28	56	1,111	50.5	104.9
Male	174	1	28	28	56	1,232	84.5	171.2
inotersen	519	5	28	28	84	1,526	91.6	143.7
Female	287	5	28	28	84	1,526	88.2	151.3
Male	232	28	28	28	112	819	95.9	134.0
talazoparib	1,844	1	30	30	90	1,539	69.8	87.3
Female	1,224	3	30	30	90	1,539	72.6	99.4
Male	620	1	30	34	90	360	64.3	56.1
baloxavir marboxil	137,426	1	1	1	1	270	2.3	6.0
Female	74,781	1	1	1	1	270	2.3	6.1
Male	62,645	1	1	1	1	180	2.2	5.9
lorlatinib	4,362	1	30	40	90	1,920	103.3	172.8
Female	2,378	1	30	30	90	1,920	104.3	175.5
Male	1,984	1	30	51	95	1,792	102.0	169.5
revefenacin	49,257	1	1	20	30	1,887	32.6	72.2
Female	28,417	1	1	30	30	1,755	33.8	72.3
Male	20,840	1	1	7	30	1,887	30.9	72.1
rifamycin	144	2	3	3	6	72	8.0	10.8
Female	81	2	3	3	6	72	8.5	12.0
Male	63	2	3	3	6	42	7.4	8.9

Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
emapalumab-lzsg	1,028	1	1	1	1	28	1.2	1.6
Female	742	1	1	1	1	24	1.1	1.3
Male	286	1	1	1	1	28	1.4	2.2
glasdegib	576	1	28	30	60	240	43.5	32.9
Female	240	4	28	30	58	210	42.8	30.8
Male	336	1	28	30	60	240	44.0	34.3
larotrectinib	1,175	1	30	30	90	1,862	89.8	148.9
Female	667	1	30	30	90	1,411	83.5	129.2
Male	508	3	30	30	90	1,862	98.0	171.2
amifampridine	2,346	1	30	60	120	1,973	153.5	275.2
Female	1,423	2	30	60	120	1,960	151.2	275.0
Male	923	1	30	60	148	1,973	157.0	275.6
gilteritinib	6,675	1	30	30	60	1,946	64.6	93.9
Female	3,328	1	30	30	60	1,946	66.0	101.3
Male	3,347	1	30	30	60	1,449	63.2	85.9
prucalopride	140,131	1	30	30	90	2,112	84.1	129.4
Female	111,406	1	30	30	90	2,112	83.3	127.6
Male	28,725	1	30	30	90	1,982	87.0	135.9
calaspargase pegol-mknl	894	1	1	1	1	42	1.1	1.7
Female	356	1	1	1	1	42	1.2	2.7
Male	538	1	1	1	1	1	1.0	0.0
tagraxofusp-erzs	567	1	1	2	5	21	2.8	2.0
Female	120	1	1	3	5	5	2.9	1.8
Male	447	1	1	2	5	21	2.8	2.0

Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
ravulizumab	29,128	1	1	1	1	952	5.9	37.8
Female	15,477	1	1	1	1	952	5.9	38.0
Male	13,651	1	1	1	1	908	5.8	37.4

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
mogamulizumab-kpkc	18,570	18,536	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	20	20	0.1%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	18	18	0.1%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	365	*****	*****	0	0.0%	*****	*****	0	NaN	0	NaN
41-64 years	3,362	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	14,805	14,783	79.8%	*****	*****	*****	*****	0	NaN	0	NaN
patisiran	14,710	14,585	100.0%	*****	*****	63	100.0%	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	2,428	2,382	16.3%	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	12,121	12,051	82.6%	33	58.9%	*****	*****	*****	*****	0	NaN
segesterone acetate and ethinyl estradiol vaginal system	23,401	9,751	100.0%	4,823	100.0%	7,540	100.0%	1,088	100.0%	199	100.0%
0-17 years	*****	*****	*****	260	5.4%	*****	*****	*****	*****	*****	*****
18-24 years	7,258	2,881	29.5%	1,462	30.3%	2,457	32.6%	*****	*****	*****	*****
25-40 years	12,940	5,543	56.8%	2,706	56.1%	4,060	53.8%	522	48.0%	109	54.8%
41-64 years	2,167	914	9.4%	395	8.2%	710	9.4%	125	11.5%	23	11.6%
≥ 65 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%
migalastat	1,130	499	100.0%	299	100.0%	253	100.0%	48	100.0%	31	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	88	45	9.0%	22	7.4%	*****	*****	*****	*****	0	0.0%
25-40 years	304	151	30.3%	89	29.8%	*****	*****	*****	*****	*****	*****

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
41-64 years	478	204	40.9%	133	44.5%	100	39.5%	*****	*****	*****	*****
≥ 65 years	260	99	19.8%	55	18.4%	80	31.6%	15	31.3%	11	35.5%
stiripentol	1,841	808	100.0%	528	100.0%	343	100.0%	93	100.0%	69	100.0%
0-17 years	1,356	588	72.8%	399	75.6%	254	74.1%	67	72.0%	48	69.6%
18-24 years	374	171	21.2%	96	18.2%	71	20.7%	*****	*****	*****	*****
25-40 years	*****	49	6.1%	*****	*****	18	5.2%	*****	*****	*****	*****
41-64 years	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	0.0%
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
cenegermin-bkbj	14,360	5,695	100.0%	8,373	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	108	50	0.9%	*****	*****	*****	*****	0	0.0%	0	NaN
18-24 years	78	39	0.7%	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	572	277	4.9%	271	3.2%	24	8.2%	0	0.0%	0	NaN
41-64 years	2,726	1,208	21.2%	1,386	16.6%	*****	*****	*****	*****	0	NaN
≥ 65 years	10,876	4,121	72.4%	6,626	79.1%	129	44.3%	0	0.0%	0	NaN
lanadelumab	9,281	5,503	100.0%	2,075	100.0%	1,393	100.0%	205	100.0%	105	100.0%
0-17 years	782	468	8.5%	175	8.4%	123	8.8%	*****	*****	*****	*****
18-24 years	898	603	11.0%	189	9.1%	91	6.5%	*****	*****	*****	*****
25-40 years	2,367	1,513	27.5%	490	23.6%	309	22.2%	*****	*****	*****	*****
41-64 years	3,407	1,988	36.1%	764	36.8%	521	37.4%	90	43.9%	44	41.9%
≥ 65 years	1,827	931	16.9%	457	22.0%	349	25.1%	55	26.8%	35	33.3%
eravacycline	2,579	2,461	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	20	20	0.8%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	69	69	2.8%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	309	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
41-64 years	947	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	1,234	1,164	47.3%	*****	*****	*****	*****	0	NaN	0	NaN
doravirine	32,989	16,545	100.0%	8,351	100.0%	5,814	100.0%	1,409	100.0%	870	100.0%
0-17 years	12	*****	*****	0	0.0%	*****	*****	*****	*****	*****	*****
18-24 years	366	*****	*****	93	1.1%	*****	*****	*****	*****	0	0.0%
25-40 years	4,863	2,794	16.9%	1,191	14.3%	691	11.9%	*****	*****	*****	*****
41-64 years	21,016	10,592	64.0%	5,290	63.3%	3,673	63.2%	902	64.0%	559	64.3%
≥ 65 years	6,732	2,946	17.8%	1,777	21.3%	1,389	23.9%	357	25.3%	263	30.2%
moxetumomab pasudotox- tdfk	441	441	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	319	319	72.3%	0	NaN	0	NaN	0	NaN	0	NaN
fremanezumab-vfrm	321,795	168,955	100.0%	93,436	100.0%	51,253	100.0%	6,253	100.0%	1,898	100.0%
0-17 years	1,959	1,076	0.6%	591	0.6%	249	0.5%	*****	*****	*****	*****
18-24 years	19,406	10,656	6.3%	5,792	6.2%	2,662	5.2%	*****	*****	*****	*****
25-40 years	89,667	48,902	28.9%	25,523	27.3%	13,459	26.3%	1,415	22.6%	368	19.4%
41-64 years	173,066	89,738	53.1%	50,464	54.0%	28,137	54.9%	3,599	57.6%	1,128	59.4%
≥ 65 years	37,697	18,583	11.0%	11,066	11.8%	6,746	13.2%	961	15.4%	341	18.0%
duvelisib	1,596	867	100.0%	455	100.0%	250	100.0%	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	278	157	18.1%	*****	*****	*****	*****	*****	*****	0	0.0%
≥ 65 years	1,299	699	80.6%	365	80.2%	213	85.2%	*****	*****	*****	*****
galcanezumab-gnlm	806,021	453,016	100.0%	210,920	100.0%	120,041	100.0%	16,522	100.0%	5,522	100.0%
0-17 years	3,752	2,143	0.5%	935	0.4%	554	0.5%	82	0.5%	38	0.7%
18-24 years	46,788	27,620	6.1%	12,134	5.8%	6,107	5.1%	723	4.4%	204	3.7%
25-40 years	228,568	132,108	29.2%	59,429	28.2%	31,843	26.5%	3,980	24.1%	1,208	21.9%
41-64 years	426,561	238,276	52.6%	110,768	52.5%	64,846	54.0%	9,393	56.9%	3,278	59.4%
≥ 65 years	100,352	52,869	11.7%	27,654	13.1%	16,691	13.9%	2,344	14.2%	794	14.4%
dacomitinib	208	116	100.0%	47	100.0%	*****	*****	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
41-64 years	48	26	22.4%	*****	*****	*****	*****	*****	*****	0	0.0%
≥ 65 years	160	90	77.6%	*****	*****	*****	*****	*****	*****	*****	*****
cemiplimab-rwlc	114,854	114,633	100.0%	162	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	351	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
41-64 years	9,873	9,844	8.6%	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	104,617	104,426	91.1%	142	87.7%	*****	*****	*****	*****	0	NaN
sarecycline	40,752	30,933	100.0%	7,781	100.0%	1,947	100.0%	79	100.0%	12	100.0%
0-17 years	19,001	14,466	46.8%	3,645	46.8%	854	43.9%	*****	*****	*****	*****
18-24 years	10,573	8,087	26.1%	1,937	24.9%	522	26.8%	*****	*****	*****	*****

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
25-40 years	7,090	5,372	17.4%	1,381	17.7%	324	16.6%	*****	*****	*****	*****
41-64 years	3,704	2,729	8.8%	744	9.6%	*****	*****	*****	*****	*****	*****
≥ 65 years	384	279	0.9%	74	1.0%	*****	*****	*****	*****	*****	*****
omadacycline	14,819	12,907	100.0%	1,288	100.0%	559	100.0%	*****	*****	*****	*****
0-17 years	181	143	1.1%	20	1.6%	*****	*****	*****	*****	0	0.0%
18-24 years	266	230	1.8%	23	1.8%	*****	*****	*****	*****	0	0.0%
25-40 years	1,215	1,059	8.2%	104	8.1%	*****	*****	*****	*****	*****	*****
41-64 years	5,804	5,161	40.0%	451	35.0%	169	30.2%	*****	*****	*****	*****
≥ 65 years	7,353	6,314	48.9%	690	53.6%	317	56.7%	*****	*****	*****	*****
elapegademase-lvlr	395	265	100.0%	82	100.0%	37	100.0%	*****	*****	*****	*****
0-17 years	149	102	38.5%	28	34.1%	*****	*****	*****	*****	*****	*****
18-24 years	122	80	30.2%	28	34.1%	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
inotersen	519	269	100.0%	124	100.0%	106	100.0%	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	23	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	81	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	415	208	77.3%	104	83.9%	88	83.0%	*****	*****	*****	*****
talazoparib	1,844	985	100.0%	519	100.0%	320	100.0%	*****	*****	*****	*****
0-17 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	*****	*****
18-24 years	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	0.0%

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
25-40 years	*****	*****	*****	*****	*****	19	5.9%	*****	*****	*****	*****
41-64 years	726	400	40.6%	*****	*****	126	39.4%	*****	*****	*****	*****
≥ 65 years	946	477	48.4%	*****	*****	175	54.7%	*****	*****	0	0.0%
baloxavir marboxil	137,426	137,222	100.0%	190	100.0%	14	100.0%	0	NaN	0	NaN
0-17 years	25,728	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
18-24 years	13,635	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
25-40 years	31,112	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	42,150	42,099	30.7%	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	24,801	24,670	18.0%	*****	*****	*****	*****	0	NaN	0	NaN
lorlatinib	4,362	2,140	100.0%	1,141	100.0%	851	100.0%	162	100.0%	68	100.0%
0-17 years	230	145	6.8%	42	3.7%	*****	*****	*****	*****	*****	*****
18-24 years	34	18	0.8%	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	341	161	7.5%	96	8.4%	60	7.1%	24	14.8%	0	0.0%
41-64 years	1,858	864	40.4%	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	1,899	952	44.5%	503	44.1%	349	41.0%	60	37.0%	35	51.5%
revefenacin	49,257	40,567	100.0%	5,775	100.0%	2,522	100.0%	301	100.0%	92	100.0%
0-17 years	14	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
18-24 years	55	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	470	330	0.8%	91	1.6%	*****	*****	*****	*****	*****	*****
41-64 years	11,685	8,848	21.8%	1,843	31.9%	858	34.0%	*****	*****	*****	*****
≥ 65 years	37,033	31,341	77.3%	3,828	66.3%	1,623	64.4%	190	63.1%	51	55.4%
rifamycin	144	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	12	12	8.6%	0	0.0%	0	NaN	0	NaN	0	NaN

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
25-40 years	23	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
41-64 years	71	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	38	38	27.3%	0	0.0%	0	NaN	0	NaN	0	NaN
emapalumab-lzsg	1,028	1,028	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	638	638	62.1%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	107	107	10.4%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	151	151	14.7%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	113	113	11.0%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	19	19	1.8%	0	NaN	0	NaN	0	NaN	0	NaN
glasdegib	576	383	100.0%	157	100.0%	36	100.0%	0	NaN	0	NaN
0-17 years	*****	0	0.0%	*****	*****	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	494	326	85.1%	*****	*****	*****	*****	0	NaN	0	NaN
larotrectinib	1,175	616	100.0%	312	100.0%	199	100.0%	35	100.0%	13	100.0%
0-17 years	287	148	24.0%	81	26.0%	*****	*****	*****	*****	*****	*****
18-24 years	32	15	2.4%	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	64	37	6.0%	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	311	165	26.8%	66	21.2%	62	31.2%	*****	*****	*****	*****
≥ 65 years	481	251	40.7%	136	43.6%	80	40.2%	*****	*****	*****	*****
amifampridine	2,346	1,038	100.0%	611	100.0%	454	100.0%	131	100.0%	112	100.0%
0-17 years	49	20	1.9%	19	3.1%	*****	*****	*****	*****	*****	*****
18-24 years	74	38	3.7%	20	3.3%	*****	*****	*****	*****	*****	*****

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
25-40 years	144	68	6.6%	39	6.4%	*****	*****	*****	*****	*****	*****
41-64 years	717	362	34.9%	164	26.8%	124	27.3%	36	27.5%	31	27.7%
≥ 65 years	1,362	550	53.0%	369	60.4%	291	64.1%	82	62.6%	70	62.5%
gilteritinib	6,675	3,912	100.0%	1,733	100.0%	937	100.0%	75	100.0%	18	100.0%
0-17 years	124	80	2.0%	25	1.4%	19	2.0%	0	0.0%	0	0.0%
18-24 years	124	80	2.0%	25	1.4%	*****	*****	*****	*****	0	0.0%
25-40 years	464	279	7.1%	115	6.6%	*****	*****	*****	*****	0	0.0%
41-64 years	1,730	1,013	25.9%	449	25.9%	250	26.7%	*****	*****	*****	*****
≥ 65 years	4,233	2,460	62.9%	1,119	64.6%	588	62.8%	*****	*****	*****	*****
prucalopride	140,131	77,220	100.0%	38,244	100.0%	20,044	100.0%	3,447	100.0%	1,176	100.0%
0-17 years	2,240	1,345	1.7%	531	1.4%	298	1.5%	51	1.5%	15	1.3%
18-24 years	7,596	4,352	5.6%	2,005	5.2%	1,010	5.0%	176	5.1%	53	4.5%
25-40 years	23,501	13,217	17.1%	6,391	16.7%	3,186	15.9%	533	15.5%	174	14.8%
41-64 years	59,244	32,051	41.5%	16,535	43.2%	8,706	43.4%	1,437	41.7%	515	43.8%
≥ 65 years	47,550	26,255	34.0%	12,782	33.4%	6,844	34.1%	1,250	36.3%	419	35.6%
calaspargase pegol-mknl	894	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	821	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
tagraxofusp-erzs	567	567	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
25-40 years	20	20	3.5%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	42	42	7.4%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	485	485	85.5%	0	NaN	0	NaN	0	NaN	0	NaN
ravulizumab	29,128	28,344	100.0%	366	100.0%	326	100.0%	*****	*****	*****	*****
0-17 years	1,818	1,766	6.2%	*****	*****	*****	*****	*****	*****	0	0.0%
18-24 years	1,078	1,063	3.8%	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	4,579	4,476	15.8%	52	14.2%	39	12.0%	*****	*****	*****	*****
41-64 years	7,786	7,599	26.8%	85	23.2%	77	23.6%	*****	*****	*****	*****
≥ 65 years	13,867	13,440	47.4%	185	50.5%	191	58.6%	*****	*****	*****	*****

*NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
mogamulizumab-kpkc	18,570	1	1	1	1	323	1.2	5.2
0-17 years	20	1	1	1	1	1	1.0	0.0
18-24 years	18	1	1	1	1	1	1.0	0.0
25-40 years	365	1	1	1	1	140	1.4	7.3
41-64 years	3,362	1	1	1	1	252	1.4	5.7
≥ 65 years	14,805	1	1	1	1	323	1.2	5.0
patisiran	14,710	1	1	1	1	672	2.3	16.6
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	273	8.7	34.5
41-64 years	2,428	1	1	1	1	672	3.9	25.9
≥ 65 years	12,121	1	1	1	1	651	1.9	13.6
segesterone acetate and ethinyl estradiol vaginal system	23,401	1	28	66	232	1,633	143.5	171.0
0-17 years	*****	1	30	69	196	1,123	138.2	164.3
18-24 years	7,258	1	30	84	269	1,633	153.2	174.7
25-40 years	12,940	1	28	60	197	1,578	136.6	166.9
41-64 years	2,167	1	29	80	250	1,272	154.7	183.0
≥ 65 years	*****	27	95	190	279	340	186.8	129.7
migalastat	1,130	3	28	56	112	2,320	123.0	210.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	88	11	28	28	84	696	87.4	107.9
25-40 years	304	9	28	36	84	1,929	95.2	171.5
41-64 years	478	3	28	56	112	1,680	124.6	204.0
≥ 65 years	260	3	28	56	168	2,320	164.4	273.2

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
stiripentol	1,841	2	30	48	120	1,871	130.9	224.0
0-17 years	1,356	2	30	48	120	1,871	128.5	218.7
18-24 years	374	3	30	40	120	1,630	132.1	217.6
25-40 years	*****	5	30	58	120	1,400	157.8	298.5
41-64 years	*****	63	63	63	63	63	63.0	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
cenegermin-bkbj	14,360	1	14	42	56	413	40.9	23.6
0-17 years	108	2	14	42	56	154	40.4	28.2
18-24 years	78	1	14	32	56	112	35.2	21.9
25-40 years	572	1	14	37	56	274	38.8	27.9
41-64 years	2,726	1	14	42	56	413	41.1	29.5
≥ 65 years	10,876	1	21	42	56	364	41.0	21.5
lanadelumab	9,281	1	28	28	78	2,071	80.7	151.6
0-17 years	782	1	28	28	60	2,050	73.8	137.2
18-24 years	898	1	28	28	56	1,025	56.5	82.1
25-40 years	2,367	1	28	28	56	2,024	68.9	134.4
41-64 years	3,407	1	28	28	84	2,071	85.9	163.8
≥ 65 years	1,827	1	28	28	84	2,036	101.3	176.0
eravacycline	2,579	1	1	2	9	337	7.4	13.0
0-17 years	20	1	1	1	1	2	1.2	0.4
18-24 years	69	1	1	1	1	30	2.6	4.6
25-40 years	309	1	1	1	5	39	4.0	6.3
41-64 years	947	1	1	2	8	93	7.3	11.5
≥ 65 years	1,234	1	1	4	12	337	8.7	15.3

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
doravirine	32,989	1	30	30	90	2,313	117.5	210.7
0-17 years	12	30	30	70	272	925	215.3	284.5
18-24 years	366	1	30	30	90	690	73.2	90.2
25-40 years	4,863	1	30	30	90	1,910	84.3	137.7
41-64 years	21,016	1	30	30	90	2,313	117.5	211.8
≥ 65 years	6,732	1	30	60	120	2,065	143.5	248.4
moxetumomab pasudotox-tdfk	441	1	1	1	1	28	1.1	1.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	1	28	1.2	2.6
≥ 65 years	319	1	1	1	1	28	1.1	1.5
fremanezumab-vfrm	321,795	1	30	30	90	2,206	80.4	114.9
0-17 years	1,959	1	30	30	84	1,346	70.0	95.3
18-24 years	19,406	1	30	30	89	1,334	70.3	88.8
25-40 years	89,667	1	30	30	90	2,206	74.3	102.5
41-64 years	173,066	1	30	30	90	2,191	82.5	118.9
≥ 65 years	37,697	1	30	44	90	2,035	91.0	134.2
duvelisib	1,596	1	28	28	81	1,269	67.5	86.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	25	25	25	25	25	25.0	NaN
25-40 years	*****	4	28	28	56	224	56.2	54.3
41-64 years	278	3	28	28	56	588	57.4	63.0
≥ 65 years	1,299	1	28	28	84	1,269	69.9	91.0

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
galcanezumab-gnlm	806,021	1	30	30	84	2,144	78.0	121.2
0-17 years	3,752	1	28	30	84	1,839	79.8	133.6
18-24 years	46,788	1	30	30	60	2,043	68.8	101.5
25-40 years	228,568	1	30	30	71	2,144	72.7	110.2
41-64 years	426,561	1	30	30	84	2,105	80.3	126.6
≥ 65 years	100,352	1	30	30	90	1,985	84.7	128.3
dacomitinib	208	1	30	30	90	1,161	87.5	138.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	48	1	30	30	116	690	90.8	127.0
≥ 65 years	160	7	30	30	90	1,161	86.5	142.2
cemiplimab-rwlc	114,854	1	1	1	1	420	1.2	4.7
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	351	1	1	1	1	42	1.1	2.2
41-64 years	9,873	1	1	1	1	357	1.3	6.5
≥ 65 years	104,617	1	1	1	1	420	1.2	4.5
sarecycline	40,752	1	30	30	30	1,230	44.3	41.3
0-17 years	19,001	1	30	30	30	755	43.7	38.9
18-24 years	10,573	1	30	30	30	1,230	44.4	43.0
25-40 years	7,090	1	30	30	30	905	43.5	38.9
41-64 years	3,704	1	30	30	60	880	47.2	49.1
≥ 65 years	384	5	30	30	60	861	51.4	63.7

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
omadacycline	14,819	1	7	14	28	1,705	25.5	54.5
0-17 years	181	1	1	14	30	420	36.6	66.4
18-24 years	266	1	8	14	30	720	31.7	66.1
25-40 years	1,215	1	10	14	30	1,166	27.1	58.6
41-64 years	5,804	1	8	14	20	1,705	23.6	55.0
≥ 65 years	7,353	1	7	14	28	1,249	26.2	52.5
elapegademase-lvlr	395	1	28	28	56	1,232	65.5	139.0
0-17 years	149	1	28	28	56	1,111	70.4	147.3
18-24 years	122	4	28	28	56	1,047	63.5	122.6
25-40 years	*****	1	1	28	56	1,232	61.5	148.6
41-64 years	*****	3	28	56	88	118	61.9	38.7
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
inotersen	519	5	28	28	84	1,526	91.6	143.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	23	26	28	28	56	252	51.0	49.7
41-64 years	81	28	28	28	112	1,526	104.3	206.2
≥ 65 years	415	5	28	28	84	1,260	91.4	131.8
talazoparib	1,844	1	30	30	90	1,539	69.8	87.3
0-17 years	*****	15	15	15	56	804	153.3	319.2
18-24 years	*****	60	60	60	60	60	60.0	NaN
25-40 years	*****	3	30	30	60	1,539	63.5	128.8
41-64 years	726	3	30	30	84	960	69.3	87.6
≥ 65 years	946	1	30	30	90	720	70.8	74.2

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
baloxavir marboxil	137,426	1	1	1	1	270	2.3	6.0
0-17 years	25,728	1	1	1	1	90	1.2	2.2
18-24 years	13,635	1	1	1	1	90	1.2	2.5
25-40 years	31,112	1	1	1	1	120	1.3	2.7
41-64 years	42,150	1	1	1	1	270	1.5	4.1
≥ 65 years	24,801	1	1	1	1	214	6.4	11.6
lorlatinib	4,362	1	30	40	90	1,920	103.3	172.8
0-17 years	230	1	30	30	68	1,622	82.0	149.4
18-24 years	34	2	30	30	90	622	96.8	139.2
25-40 years	341	1	30	60	90	704	99.0	133.3
41-64 years	1,858	1	30	53	120	1,913	107.6	175.9
≥ 65 years	1,899	1	30	30	90	1,920	102.5	179.0
revefenacin	49,257	1	1	20	30	1,887	32.6	72.2
0-17 years	14	1	16	30	30	60	24.9	15.8
18-24 years	55	1	29	30	60	802	85.3	165.9
25-40 years	470	1	19	30	60	1,544	57.8	113.9
41-64 years	11,685	1	1	30	30	1,755	44.3	85.3
≥ 65 years	37,033	1	1	2	30	1,887	28.5	66.1
rifamycin	144	2	3	3	6	72	8.0	10.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	12	3	3	3	3	14	4.2	3.2
25-40 years	23	2	3	3	9	72	11.2	16.6
41-64 years	71	2	3	3	9	56	8.7	10.6
≥ 65 years	38	3	3	3	6	30	6.1	7.2

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
emapalumab-lzsg	1,028	1	1	1	1	28	1.2	1.6
0-17 years	638	1	1	1	1	28	1.3	1.9
18-24 years	107	1	1	1	1	13	1.3	1.4
25-40 years	151	1	1	1	1	1	1.0	0.0
41-64 years	113	1	1	1	1	7	1.1	0.8
≥ 65 years	19	1	1	1	1	1	1.0	0.0
glasdegib	576	1	28	30	60	240	43.5	32.9
0-17 years	*****	60	60	60	60	60	60.0	NaN
18-24 years	*****	30	30	30	30	30	30.0	NaN
25-40 years	*****	19	26	28	50	112	42.3	30.6
41-64 years	*****	10	27	30	56	120	37.6	24.3
≥ 65 years	494	1	28	30	60	240	44.4	34.0
larotrectinib	1,175	1	30	30	90	1,862	89.8	148.9
0-17 years	287	3	25	30	75	759	78.6	108.7
18-24 years	32	15	30	60	89	630	98.3	127.7
25-40 years	64	10	30	30	78	1,862	115.2	270.4
41-64 years	311	1	30	30	105	1,491	104.5	181.3
≥ 65 years	481	5	30	30	90	1,411	83.1	122.3
amifampridine	2,346	1	30	60	120	1,973	153.5	275.2
0-17 years	49	1	30	60	90	956	101.7	160.6
18-24 years	74	3	30	30	90	867	102.4	146.3
25-40 years	144	2	30	59	114	1,799	156.5	294.9
41-64 years	717	2	30	30	120	1,958	143.5	278.3
≥ 65 years	1,362	3	30	60	150	1,973	163.0	279.6

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
gilteritinib	6,675	1	30	30	60	1,946	64.6	93.9
0-17 years	124	1	28	30	60	300	52.0	56.3
18-24 years	124	1	30	30	60	690	67.5	101.7
25-40 years	464	1	30	30	60	720	61.8	75.8
41-64 years	1,730	1	30	30	60	1,946	66.6	104.6
≥ 65 years	4,233	1	30	30	60	1,530	64.4	91.7
prucalopride	140,131	1	30	30	90	2,112	84.1	129.4
0-17 years	2,240	1	30	30	65	1,411	75.1	120.5
18-24 years	7,596	1	30	30	90	1,507	79.2	117.5
25-40 years	23,501	1	30	30	90	1,982	79.8	122.9
41-64 years	59,244	1	30	30	90	1,955	85.3	131.3
≥ 65 years	47,550	1	30	30	90	2,112	85.9	132.3
calaspargase pegol-mknl	894	1	1	1	1	42	1.1	1.7
0-17 years	821	1	1	1	1	42	1.1	1.8
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	1	1.0	NaN
41-64 years	*****	1	1	1	1	1	1.0	NaN
≥ 65 years	*****	1	1	1	1	1	1.0	0.0
tagraxofusp-erzs	567	1	1	2	5	21	2.8	2.0
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	5	5	2.4	1.8
25-40 years	20	1	1	1	4	5	2.2	1.6
41-64 years	42	1	1	1	2	5	1.7	1.3
≥ 65 years	485	1	1	3	5	21	3.0	2.0

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
ravulizumab	29,128	1	1	1	1	952	5.9	37.8
0-17 years	1,818	1	1	1	1	534	3.9	22.7
18-24 years	1,078	1	1	1	1	616	3.9	30.3
25-40 years	4,579	1	1	1	1	952	4.9	35.9
41-64 years	7,786	1	1	1	1	897	5.5	38.0
≥ 65 years	13,867	1	1	1	1	787	6.8	40.2

*NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 5a. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<i>mogamulizumab-kpkc</i>	1,147	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>patisiran</i>	625	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>segesterone acetate and ethinyl estradiol vaginal system</i>	19,514	7,991	41.0%	4,050	20.8%	6,437	33.0%	857	4.4%	179	0.9%
<i>migalastat</i>	261	79	30.3%	59	22.6%	80	30.7%	24	9.2%	19	7.3%
<i>stiripentol</i>	531	200	37.7%	134	25.2%	107	20.2%	39	7.3%	51	9.6%
<i>cenegermin-bkbj</i>	9,413	2,699	28.7%	6,478	68.8%	236	2.5%	0	0.0%	0	0.0%
<i>lanadelumab</i>	1,451	735	50.7%	281	19.4%	324	22.3%	69	4.8%	42	2.9%
<i>eravacycline</i>	1,111	1,026	92.3%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>doravirine</i>	8,215	3,371	41.0%	1,815	22.1%	1,883	22.9%	629	7.7%	517	6.3%
<i>moxetumomab pasudotox- tdfk</i>	50	50	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>fremanezumab-vfrm</i>	93,384	46,255	49.5%	26,708	28.6%	17,071	18.3%	2,456	2.6%	894	1.0%
<i>duvelisib</i>	623	305	49.0%	199	31.9%	*****	*****	*****	*****	*****	*****
<i>galcanezumab-gnlm</i>	212,175	115,920	54.6%	51,592	24.3%	35,560	16.8%	6,424	3.0%	2,679	1.3%
<i>dacomitinib</i>	95	58	61.1%	19	20.0%	*****	*****	*****	*****	*****	*****
<i>cemiplimab-rwlc</i>	12,307	12,242	99.5%	47	0.4%	*****	*****	*****	*****	0	0.0%
<i>sarecycline</i>	17,939	13,084	72.9%	3,796	21.2%	1,000	5.6%	*****	*****	*****	*****
<i>omadacycline</i>	8,563	7,696	89.9%	557	6.5%	269	3.1%	*****	*****	*****	*****
<i>elapegademase-lvlr</i>	42	20	47.6%	*****	*****	*****	*****	*****	*****	*****	*****
<i>inotersen</i>	119	54	45.4%	26	21.8%	*****	*****	*****	*****	*****	*****
<i>talazoparib</i>	810	363	44.8%	268	33.1%	*****	*****	*****	*****	*****	*****
<i>baloxavir marboxil</i>	130,098	129,925	99.9%	161	0.1%	12	0.0%	0	0.0%	0	0.0%
<i>lorlatinib</i>	1,620	667	41.2%	424	26.2%	395	24.4%	93	5.7%	41	2.5%

Table 5a. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<i>revefenacin</i>	15,603	12,256	78.5%	2,165	13.9%	1,000	6.4%	136	0.9%	46	0.3%
<i>rifamycin</i>	110	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
<i>emapalumab-lzsg</i>	72	72	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>glasdegib</i>	393	260	66.2%	109	27.7%	24	6.1%	0	0.0%	0	0.0%
<i>larotrectinib</i>	517	238	46.0%	150	29.0%	103	19.9%	*****	*****	*****	*****
<i>amifampridine</i>	540	167	30.9%	118	21.9%	146	27.0%	55	10.2%	54	10.0%
<i>gilteritinib</i>	2,670	1,547	57.9%	695	26.0%	387	14.5%	*****	*****	*****	*****
<i>prucalopride</i>	49,006	27,819	56.8%	12,142	24.8%	6,849	14.0%	1,595	3.3%	601	1.2%
<i>calaspargase pegol-mknl</i>	389	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
<i>tagraxofusp-erzs</i>	135	135	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>ravulizumab</i>	3,694	3,480	94.2%	81	2.2%	89	2.4%	*****	*****	*****	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 5b. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<i>mogamulizumab-kpkc</i>	1,147	1	1	1	1	252	1.9	9.6
<i>patisiran</i>	625	1	1	1	1	231	5.3	21.1
<i>segesterone acetate and ethinyl estradiol vaginal system</i>	19,514	1	30	70	239	1,633	145.1	173.1
<i>migalastat</i>	261	3	28	84	280	2,320	225.8	343.2
<i>stiripentol</i>	531	3	30	60	210	1,871	203.5	315.7
<i>cenegermin-bkbj</i>	9,413	1	28	56	56	336	45.8	22.3
<i>lanadelumab</i>	1,451	1	28	28	117	2,071	129.6	244.4
<i>eravacycline</i>	1,111	1	2	7	14	337	11.1	15.9
<i>doravirine</i>	8,215	1	30	60	180	2,313	186.4	307.0
<i>moxetumomab pasudotox-tdfk</i>	50	1	1	1	1	28	2.1	5.3
<i>fremanezumab-vfrm</i>	93,384	1	30	37	90	2,206	91.8	135.9
<i>duvelisib</i>	623	3	28	39	84	1,048	71.7	85.0
<i>galcanezumab-gnlm</i>	212,175	1	30	30	90	2,144	91.5	153.4
<i>dacomitinib</i>	95	1	30	30	88	1,161	79.8	140.2
<i>cemiplimab-rwlc</i>	12,307	1	1	1	1	420	1.6	8.5
<i>sarecycline</i>	17,939	1	30	30	60	1,230	46.8	46.6
<i>omadacycline</i>	8,563	1	8	14	15	1,705	23.2	53.2
<i>elapegademase-lvlr</i>	42	1	28	56	150	1,111	135.4	242.3
<i>inotersen</i>	119	28	28	56	140	1,526	120.9	192.9
<i>talazoparib</i>	810	1	30	60	90	1,539	80.3	102.0
<i>baloxavir marboxil</i>	130,098	1	1	1	1	270	2.2	5.9
<i>lorlatinib</i>	1,620	1	30	60	140	1,913	132.6	210.1
<i>revefenacin</i>	15,603	1	1	30	30	1,557	41.3	84.1
<i>rifamycin</i>	110	2	3	3	6	72	7.7	11.0
<i>emapalumab-lzsg</i>	72	1	1	1	1	28	1.9	4.2

Table 5b. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<i>glasdegib</i>	393	1	28	30	60	240	43.0	33.0
<i>larotrectinib</i>	517	1	30	55	90	1,862	104.8	174.7
<i>amifampridine</i>	540	2	30	90	270	1,960	255.5	393.1
<i>gilteritinib</i>	2,670	1	30	30	60	1,727	63.7	95.1
<i>prucalopride</i>	49,006	1	30	30	90	2,112	91.0	152.3
<i>calaspargase pegol-mknl</i>	389	1	1	1	1	42	1.1	2.1
<i>tagraxofusp-erzs</i>	135	1	1	1	1	5	1.5	1.2
<i>ravulizumab</i>	3,694	1	1	1	1	872	14.0	67.9

Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
mogamulizumab-kpkc	1,147	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Female	495	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	652	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
patisiran	625	603	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
Female	227	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	398	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
segesterone acetate and ethinyl estradiol vaginal system	19,514	7,991	100.0%	4,050	100.0%	6,437	100.0%	857	100.0%	179	100.0%
Female	19,473	*****	*****	*****	*****	6,416	99.7%	*****	*****	179	100.0%
Male	41	*****	*****	*****	*****	21	0.3%	*****	*****	0	0.0%
migalastat	261	79	100.0%	59	100.0%	80	100.0%	24	100.0%	19	100.0%
Female	126	40	50.6%	28	47.5%	34	42.5%	*****	*****	*****	*****
Male	135	39	49.4%	31	52.5%	46	57.5%	*****	*****	*****	*****
stiripentol	531	200	100.0%	134	100.0%	107	100.0%	39	100.0%	51	100.0%
Female	263	98	49.0%	72	53.7%	49	45.8%	18	46.2%	26	51.0%
Male	268	102	51.0%	62	46.3%	58	54.2%	21	53.8%	25	49.0%
cenegermin-bkbj	9,413	2,699	100.0%	6,478	100.0%	236	100.0%	0	NaN	0	NaN
Female	6,152	1,818	67.4%	4,175	64.4%	159	67.4%	0	NaN	0	NaN
Male	3,261	881	32.6%	2,303	35.6%	77	32.6%	0	NaN	0	NaN
lanadelumab	1,451	735	100.0%	281	100.0%	324	100.0%	69	100.0%	42	100.0%
Female	989	493	67.1%	193	68.7%	218	67.3%	*****	*****	*****	*****
Male	462	242	32.9%	88	31.3%	106	32.7%	*****	*****	*****	*****

Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

eravacycline	1,111	1,026	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
Female	566	539	52.5%	*****	*****	*****	*****	0	NaN	0	NaN
Male	545	487	47.5%	58	69.9%	0	0.0%	0	NaN	0	NaN
doravirine	8,215	3,371	100.0%	1,815	100.0%	1,883	100.0%	629	100.0%	517	100.0%
Female	2,181	980	29.1%	511	28.2%	455	24.2%	132	21.0%	103	19.9%
Male	6,034	2,391	70.9%	1,304	71.8%	1,428	75.8%	497	79.0%	414	80.1%
moxetumomab pasudotox-tdfk	50	50	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
fremanezumab-vfrm	93,384	46,255	100.0%	26,708	100.0%	17,071	100.0%	2,456	100.0%	894	100.0%
Female	80,681	39,982	86.4%	23,071	86.4%	14,765	86.5%	2,110	85.9%	753	84.2%
Male	12,703	6,273	13.6%	3,637	13.6%	2,306	13.5%	346	14.1%	141	15.8%
duvelisib	623	305	100.0%	199	100.0%	*****	*****	*****	*****	*****	*****
Female	273	129	42.3%	93	46.7%	*****	*****	*****	*****	*****	*****
Male	350	176	57.7%	106	53.3%	*****	*****	*****	*****	0	0.0%
galcanezumab-gnlm	212,175	115,920	100.0%	51,592	100.0%	35,560	100.0%	6,424	100.0%	2,679	100.0%
Female	180,088	98,226	84.7%	43,875	85.0%	30,326	85.3%	5,394	84.0%	2,267	84.6%
Male	32,087	17,694	15.3%	7,717	15.0%	5,234	14.7%	1,030	16.0%	412	15.4%
dacomitinib	95	58	100.0%	19	100.0%	*****	*****	*****	*****	*****	*****
Female	60	37	63.8%	*****	*****	*****	*****	*****	*****	*****	*****
Male	35	21	36.2%	*****	*****	*****	*****	0	0.0%	0	0.0%
cemiplimab-rwlc	12,307	12,242	100.0%	47	100.0%	*****	*****	*****	*****	0	NaN
Female	3,645	3,619	29.6%	*****	*****	*****	*****	0	0.0%	0	NaN
Male	8,662	8,623	70.4%	*****	*****	*****	*****	*****	*****	0	NaN
sarecycline	17,939	13,084	100.0%	3,796	100.0%	1,000	100.0%	*****	*****	*****	*****
Female	11,119	8,167	62.4%	2,364	62.3%	552	55.2%	*****	*****	*****	*****
Male	6,820	4,917	37.6%	1,432	37.7%	448	44.8%	*****	*****	*****	*****

Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

omadacycline	8,563	7,696	100.0%	557	100.0%	269	100.0%	*****	*****	*****	*****
Female	4,263	3,795	49.3%	295	53.0%	153	56.9%	*****	*****	*****	*****
Male	4,300	3,901	50.7%	262	47.0%	116	43.1%	*****	*****	*****	*****
elapegademase-lvlr	42	20	100.0%	*****	*****	*****	*****	*****	*****	*****	*****
Female	19	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****
Male	23	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
inotersen	119	54	100.0%	26	100.0%	*****	*****	*****	*****	*****	*****
Female	52	24	44.4%	11	42.3%	*****	*****	*****	*****	*****	*****
Male	67	30	55.6%	15	57.7%	*****	*****	*****	*****	0	0.0%
talazoparib	810	363	100.0%	268	100.0%	166	100.0%	*****	*****	*****	*****
Female	452	217	59.8%	*****	*****	*****	*****	*****	*****	*****	*****
Male	358	146	40.2%	*****	*****	*****	*****	0	0.0%	0	0.0%
baloxavir marboxil	130,098	129,925	100.0%	161	100.0%	12	100.0%	0	NaN	0	NaN
Female	70,809	70,720	54.4%	*****	*****	*****	*****	0	NaN	0	NaN
Male	59,289	59,205	45.6%	*****	*****	*****	*****	0	NaN	0	NaN
lorlatinib	1,620	667	100.0%	424	100.0%	395	100.0%	93	100.0%	41	100.0%
Female	891	376	56.4%	227	53.5%	216	54.7%	47	50.5%	25	61.0%
Male	729	291	43.6%	197	46.5%	179	45.3%	46	49.5%	16	39.0%
revefenacin	15,603	12,256	100.0%	2,165	100.0%	1,000	100.0%	136	100.0%	46	100.0%
Female	9,132	7,131	58.2%	1,299	60.0%	598	59.8%	80	58.8%	24	52.2%
Male	6,471	5,125	41.8%	866	40.0%	402	40.2%	56	41.2%	22	47.8%
rifamycin	110	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Female	66	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	44	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
emapalumab-lzsg	72	72	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	34	34	47.2%	0	NaN	0	NaN	0	NaN	0	NaN
Male	38	38	52.8%	0	NaN	0	NaN	0	NaN	0	NaN

Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

glasdegib	393	260	100.0%	109	100.0%	24	100.0%	0	NaN	0	NaN
Female	161	108	41.5%	*****	*****	*****	*****	0	NaN	0	NaN
Male	232	152	58.5%	*****	*****	*****	*****	0	NaN	0	NaN
larotrectinib	517	238	100.0%	150	100.0%	103	100.0%	*****	*****	*****	*****
Female	298	133	55.9%	93	62.0%	*****	*****	*****	*****	*****	*****
Male	219	105	44.1%	57	38.0%	*****	*****	*****	*****	*****	*****
amifampridine	540	167	100.0%	118	100.0%	146	100.0%	55	100.0%	54	100.0%
Female	305	94	56.3%	65	55.1%	83	56.8%	31	56.4%	32	59.3%
Male	235	73	43.7%	53	44.9%	63	43.2%	24	43.6%	22	40.7%
gilteritinib	2,670	1,547	100.0%	695	100.0%	387	100.0%	*****	*****	*****	*****
Female	1,294	762	49.3%	334	48.1%	178	46.0%	*****	*****	*****	*****
Male	1,376	785	50.7%	361	51.9%	209	54.0%	*****	*****	*****	*****
prucalopride	49,006	27,819	100.0%	12,142	100.0%	6,849	100.0%	1,595	100.0%	601	100.0%
Female	38,640	21,961	78.9%	9,601	79.1%	5,377	78.5%	1,255	78.7%	446	74.2%
Male	10,366	5,858	21.1%	2,541	20.9%	1,472	21.5%	340	21.3%	155	25.8%
calaspargase pegol-mknl	389	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Female	154	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	235	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
tagraxofusp-erzs	135	135	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	29	29	21.5%	0	NaN	0	NaN	0	NaN	0	NaN
Male	106	106	78.5%	0	NaN	0	NaN	0	NaN	0	NaN
ravulizumab	3,694	3,480	100.0%	81	100.0%	89	100.0%	*****	*****	*****	*****
Female	1,918	1,799	51.7%	49	60.5%	*****	*****	*****	*****	0	0.0%
Male	1,776	1,681	48.3%	32	39.5%	*****	*****	*****	*****	*****	*****

*NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
mogamulizumab-kpkc	1,147	1	1	1	1	252	1.9	9.6
Female	495	1	1	1	1	252	2.0	11.9
Male	652	1	1	1	1	140	1.8	7.3
patisiran	625	1	1	1	1	231	5.3	21.1
Female	227	1	1	1	1	231	6.1	22.0
Male	398	1	1	1	1	210	4.9	20.6
segesterone acetate and ethinyl estradiol vaginal system	19,514	1	30	70	239	1,633	145.1	173.1
Female	19,473	1	30	70	238	1,633	145.0	173.1
Male	41	1	30	112	336	662	171.3	158.4
migalastat	261	3	28	84	280	2,320	225.8	343.2
Female	126	4	28	84	336	1,568	229.5	315.2
Male	135	3	28	84	224	2,320	222.3	368.6
stiripentol	531	3	30	60	210	1,871	203.5	315.7
Female	263	3	30	60	210	1,678	206.3	318.4
Male	268	3	30	60	200	1,871	200.8	313.6
cenegermin-bkbj	9,413	1	28	56	56	336	45.8	22.3
Female	6,152	1	28	56	56	294	45.5	22.4
Male	3,261	1	28	56	56	336	46.3	22.2
lanadelumab	1,451	1	28	28	117	2,071	129.6	244.4
Female	989	1	28	35	137	2,071	136.8	257.2
Male	462	1	28	28	112	2,036	114.3	214.1
eravacycline	1,111	1	2	7	14	337	11.1	15.9
Female	566	1	2	7	14	337	10.3	17.5
Male	545	1	2	7	16	84	11.9	13.9
doravirine	8,215	1	30	60	180	2,313	186.4	307.0

Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Female	2,181	1	30	60	150	2,005	152.9	253.0
Male	6,034	1	30	60	193	2,313	198.5	323.5
moxetumomab pasudotox-tdfk	50	1	1	1	1	28	2.1	5.3
Female	*****	1	1	1	1	1	1.0	0.0
Male	*****	1	1	1	1	28	2.3	5.8
fremanezumab-vfrm	93,384	1	30	37	90	2,206	91.8	135.9
Female	80,681	1	30	36	90	2,206	91.6	134.8
Male	12,703	1	30	40	90	2,032	93.4	142.1
duvelisib	623	3	28	39	84	1,048	71.7	85.0
Female	273	3	28	56	84	1,048	74.9	95.6
Male	350	3	28	30	84	477	69.2	75.8
galcanezumab-gnlm	212,175	1	30	30	90	2,144	91.5	153.4
Female	180,088	1	30	30	90	2,144	91.5	153.1
Male	32,087	1	30	30	90	1,985	92.0	155.4
dacomitinib	95	1	30	30	88	1,161	79.8	140.2
Female	60	1	30	30	89	1,161	91.9	170.3
Male	35	17	30	30	60	330	59.2	57.5
cemiplimab-rwlc	12,307	1	1	1	1	420	1.6	8.5
Female	3,645	1	1	1	1	294	1.7	8.6
Male	8,662	1	1	1	1	420	1.5	8.4
sarecycline	17,939	1	30	30	60	1,230	46.8	46.6
Female	11,119	1	30	30	60	916	46.0	44.3
Male	6,820	1	30	30	60	1,230	48.1	50.1
omadacycline	8,563	1	8	14	15	1,705	23.2	53.2
Female	4,263	1	8	14	16	1,055	23.9	50.1
Male	4,300	1	9	14	15	1,705	22.5	56.1

Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
elapegademase-lvlr	42	1	28	56	150	1,111	135.4	242.3
Female	19	1	28	28	84	1,111	107.7	248.9
Male	23	1	28	56	168	1,111	158.2	240.0
inotersen	119	28	28	56	140	1,526	120.9	192.9
Female	52	28	28	56	151	1,526	137.3	251.8
Male	67	28	28	56	112	700	108.1	130.9
talazoparib	810	1	30	60	90	1,539	80.3	102.0
Female	452	3	30	53	90	1,539	86.6	125.4
Male	358	1	30	60	90	359	72.3	59.8
baloxavir marboxil	130,098	1	1	1	1	270	2.2	5.9
Female	70,809	1	1	1	1	270	2.3	6.1
Male	59,289	1	1	1	1	180	2.1	5.8
lorlatinib	1,620	1	30	60	140	1,913	132.6	210.1
Female	891	1	30	60	147	1,913	132.5	208.1
Male	729	1	30	60	120	1,792	132.8	212.6
revefenacin	15,603	1	1	30	30	1,557	41.3	84.1
Female	9,132	1	1	30	30	1,557	42.0	85.5
Male	6,471	1	1	30	30	1,380	40.4	82.0
rifamycin	110	2	3	3	6	72	7.7	11.0
Female	66	2	3	3	6	72	8.2	12.5
Male	44	2	3	3	6	31	7.0	8.3
emapalumab-lzsg	72	1	1	1	1	28	1.9	4.2
Female	34	1	1	1	1	24	1.8	4.0
Male	38	1	1	1	1	28	2.0	4.5

Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
glasdegib	393	1	28	30	60	240	43.0	33.0
Female	161	4	28	30	60	150	42.8	29.5
Male	232	1	28	30	60	240	43.2	35.3
larotrectinib	517	1	30	55	90	1,862	104.8	174.7
Female	298	1	30	59	90	1,411	102.6	158.0
Male	219	5	30	47	103	1,862	107.9	195.5
amifampridine	540	2	30	90	270	1,960	255.5	393.1
Female	305	2	30	90	300	1,960	260.1	388.4
Male	235	5	30	90	240	1,958	249.6	399.9
gilteritinib	2,670	1	30	30	60	1,727	63.7	95.1
Female	1,294	1	30	30	60	1,727	64.8	108.5
Male	1,376	1	30	30	74	774	62.6	80.5
prucalopride	49,006	1	30	30	90	2,112	91.0	152.3
Female	38,640	1	30	30	90	2,112	90.2	150.2
Male	10,366	1	30	30	90	1,982	94.1	159.7
calaspargase pegol-mknl	389	1	1	1	1	42	1.1	2.1
Female	154	1	1	1	1	42	1.3	3.3
Male	235	1	1	1	1	1	1.0	0.0
tagraxofusp-erzs	135	1	1	1	1	5	1.5	1.2
Female	29	1	1	1	1	5	1.3	1.0
Male	106	1	1	1	1	5	1.5	1.3
ravulizumab	3,694	1	1	1	1	872	14.0	67.9
Female	1,918	1	1	1	1	719	14.1	66.6
Male	1,776	1	1	1	1	872	13.9	69.4

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
mogamulizumab-kpkc	1,147	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	*****	*****	0	NaN	0	NaN
41-64 years	252	*****	*****	0	0.0%	*****	*****	0	NaN	0	NaN
≥ 65 years	861	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
patisiran	625	603	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	139	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	471	458	76.0%	*****	*****	*****	*****	0	NaN	0	NaN
segesterone acetate and ethinyl estradiol vaginal system	19,514	7,991	100.0%	4,050	100.0%	6,437	100.0%	857	100.0%	179	100.0%
0-17 years	*****	*****	*****	199	4.9%	*****	*****	*****	*****	*****	*****
18-24 years	6,100	2,391	29.9%	1,240	30.6%	2,101	32.6%	313	36.5%	55	30.7%
25-40 years	10,830	4,533	56.7%	2,286	56.4%	3,493	54.3%	423	49.4%	95	53.1%
41-64 years	1,724	716	9.0%	325	8.0%	575	8.9%	*****	*****	*****	*****
≥ 65 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%
migalastat	261	79	100.0%	59	100.0%	80	100.0%	24	100.0%	19	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	20	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	66	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	106	31	39.2%	23	39.0%	32	40.0%	*****	*****	*****	*****

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
≥ 65 years	69	15	19.0%	14	23.7%	24	30.0%	*****	*****	*****	*****
stiripentol	531	200	100.0%	134	100.0%	107	100.0%	39	100.0%	51	100.0%
0-17 years	399	148	74.0%	108	80.6%	80	74.8%	28	71.8%	35	68.6%
18-24 years	99	41	20.5%	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	11	5.5%	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	0.0%
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
cenegermin-bkbj	9,413	2,699	100.0%	6,478	100.0%	236	100.0%	0	NaN	0	NaN
0-17 years	69	*****	*****	39	0.6%	*****	*****	0	NaN	0	NaN
18-24 years	47	*****	*****	28	0.4%	*****	*****	0	NaN	0	NaN
25-40 years	335	*****	*****	194	3.0%	*****	*****	0	NaN	0	NaN
41-64 years	1,702	543	20.1%	1,044	16.1%	115	48.7%	0	NaN	0	NaN
≥ 65 years	7,260	1,993	73.8%	5,173	79.9%	94	39.8%	0	NaN	0	NaN
lanadelumab	1,451	735	100.0%	281	100.0%	324	100.0%	69	100.0%	42	100.0%
0-17 years	125	62	8.4%	31	11.0%	*****	*****	*****	*****	*****	*****
18-24 years	137	83	11.3%	24	8.5%	*****	*****	*****	*****	0	0.0%
25-40 years	399	224	30.5%	75	26.7%	78	24.1%	*****	*****	*****	*****
41-64 years	535	255	34.7%	105	37.4%	130	40.1%	28	40.6%	17	40.5%
≥ 65 years	255	111	15.1%	46	16.4%	66	20.4%	21	30.4%	11	26.2%
eravacycline	1,111	1,026	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	103	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	419	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
≥ 65 years	572	521	50.8%	*****	*****	*****	*****	0	NaN	0	NaN
doravirine	8,215	3,371	100.0%	1,815	100.0%	1,883	100.0%	629	100.0%	517	100.0%
0-17 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	19	1.0%	*****	*****	*****	*****	0	0.0%
25-40 years	1,331	626	18.6%	324	17.9%	*****	*****	*****	*****	29	5.6%
41-64 years	5,059	2,041	60.5%	1,102	60.7%	1,165	61.9%	406	64.5%	345	66.7%
≥ 65 years	1,720	646	19.2%	370	20.4%	421	22.4%	140	22.3%	143	27.7%
moxetumomab pasudotox-tdfk	50	50	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	39	39	78.0%	0	NaN	0	NaN	0	NaN	0	NaN
fremanezumab-vfrm	93,384	46,255	100.0%	26,708	100.0%	17,071	100.0%	2,456	100.0%	894	100.0%
0-17 years	630	314	0.7%	217	0.8%	82	0.5%	*****	*****	*****	*****
18-24 years	6,139	3,158	6.8%	1,863	7.0%	976	5.7%	*****	*****	*****	*****
25-40 years	26,916	13,756	29.7%	7,613	28.5%	4,783	28.0%	588	23.9%	176	19.7%
41-64 years	48,473	23,476	50.8%	13,942	52.2%	9,126	53.5%	1,385	56.4%	544	60.9%
≥ 65 years	11,226	5,551	12.0%	3,073	11.5%	2,104	12.3%	358	14.6%	140	15.7%
duvelisib	623	305	100.0%	199	100.0%	*****	*****	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
41-64 years	129	70	23.0%	42	21.1%	17	15.6%	0	0.0%	0	0.0%
≥ 65 years	479	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
galcanezumab-gnlm	212,175	115,920	100.0%	51,592	100.0%	35,560	100.0%	6,424	100.0%	2,679	100.0%
0-17 years	1,184	616	0.5%	298	0.6%	209	0.6%	41	0.6%	20	0.7%
18-24 years	13,165	7,530	6.5%	3,189	6.2%	2,009	5.6%	315	4.9%	122	4.6%
25-40 years	62,239	34,537	29.8%	15,246	29.6%	10,170	28.6%	1,672	26.0%	614	22.9%
41-64 years	108,086	58,430	50.4%	25,921	50.2%	18,564	52.2%	3,602	56.1%	1,569	58.6%
≥ 65 years	27,501	14,807	12.8%	6,938	13.4%	4,608	13.0%	794	12.4%	354	13.2%
dacomitinib	95	58	100.0%	19	100.0%	*****	*****	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
41-64 years	26	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
≥ 65 years	69	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
cemiplimab-rwlc	12,307	12,242	100.0%	47	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
41-64 years	1,105	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	11,147	11,092	90.6%	*****	*****	*****	*****	*****	*****	0	NaN
sarecycline	17,939	13,084	100.0%	3,796	100.0%	1,000	100.0%	*****	*****	*****	*****
0-17 years	7,791	5,635	43.1%	1,721	45.3%	413	41.3%	*****	*****	*****	*****
18-24 years	4,928	3,600	27.5%	1,014	26.7%	294	29.4%	*****	*****	*****	*****
25-40 years	3,486	2,591	19.8%	708	18.7%	*****	*****	*****	*****	*****	*****

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
41-64 years	1,568	1,131	8.6%	326	8.6%	*****	*****	*****	*****	*****	*****
≥ 65 years	166	127	1.0%	27	0.7%	*****	*****	*****	*****	*****	*****
omadacycline	8,563	7,696	100.0%	557	100.0%	269	100.0%	*****	*****	*****	*****
0-17 years	51	38	0.5%	*****	*****	*****	*****	*****	*****	0	0.0%
18-24 years	144	129	1.7%	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	674	605	7.9%	44	7.9%	*****	*****	*****	*****	*****	*****
41-64 years	3,412	3,120	40.5%	202	36.3%	77	28.6%	*****	*****	*****	*****
≥ 65 years	4,282	3,804	49.4%	295	53.0%	164	61.0%	*****	*****	*****	*****
elapegademase-lvlr	42	20	100.0%	*****	*****	*****	*****	*****	*****	*****	*****
0-17 years	19	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	12	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	0.0%
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
inotersen	119	54	100.0%	*****	*****	31	100.0%	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	90	40	74.1%	*****	*****	*****	*****	*****	*****	0	0.0%
talazoparib	810	363	100.0%	268	100.0%	166	100.0%	*****	*****	*****	*****
0-17 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	*****	*****
18-24 years	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
41-64 years	269	116	32.0%	85	31.7%	*****	*****	*****	*****	*****	*****
≥ 65 years	479	212	58.4%	168	62.7%	*****	*****	*****	*****	0	0.0%
baloxavir marboxil	130,098	129,925	100.0%	161	100.0%	12	100.0%	0	NaN	0	NaN
0-17 years	24,111	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
18-24 years	13,123	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
25-40 years	29,702	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	39,798	39,753	30.6%	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	23,364	23,256	17.9%	*****	*****	*****	*****	0	NaN	0	NaN
lorlatinib	1,620	667	100.0%	424	100.0%	395	100.0%	93	100.0%	41	100.0%
0-17 years	76	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	11	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	127	55	8.2%	28	6.6%	27	6.8%	17	18.3%	0	0.0%
41-64 years	666	246	36.9%	183	43.2%	180	45.6%	37	39.8%	20	48.8%
≥ 65 years	740	324	48.6%	193	45.5%	169	42.8%	*****	*****	*****	*****
revefenacin	15,603	12,256	100.0%	2,165	100.0%	1,000	100.0%	136	100.0%	46	100.0%
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	206	147	1.2%	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	4,494	3,330	27.2%	702	32.4%	391	39.1%	*****	*****	*****	*****
≥ 65 years	10,869	8,755	71.4%	1,418	65.5%	595	59.5%	76	55.9%	25	54.3%

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
rifamycin	110	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
41-64 years	50	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	30	30	28.3%	0	0.0%	0	NaN	0	NaN	0	NaN
emapalumab-lzsg	72	72	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	36	36	50.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
glasdegib	393	260	100.0%	109	100.0%	24	100.0%	0	NaN	0	NaN
0-17 years	*****	0	0.0%	*****	*****	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	340	225	86.5%	*****	*****	*****	*****	0	NaN	0	NaN
larotrectinib	517	238	100.0%	150	100.0%	103	100.0%	*****	*****	*****	*****
0-17 years	73	33	13.9%	20	13.3%	*****	*****	*****	*****	*****	*****
18-24 years	11	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	35	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	153	71	29.8%	38	25.3%	*****	*****	*****	*****	*****	*****
≥ 65 years	245	113	47.5%	77	51.3%	*****	*****	*****	*****	*****	*****

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
amifampridine	540	167	100.0%	118	100.0%	146	100.0%	55	100.0%	54	100.0%
0-17 years	21	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
18-24 years	15	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	39	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	168	55	32.9%	36	30.5%	42	28.8%	*****	*****	*****	*****
≥ 65 years	297	86	51.5%	62	52.5%	87	59.6%	28	50.9%	34	63.0%
gilteritinib	2,670	1,547	100.0%	695	100.0%	387	100.0%	*****	*****	*****	*****
0-17 years	47	30	1.9%	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	44	24	1.6%	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	181	104	6.7%	49	7.1%	28	7.2%	0	0.0%	0	0.0%
41-64 years	661	388	25.1%	175	25.2%	*****	*****	*****	*****	*****	*****
≥ 65 years	1,737	1,001	64.7%	450	64.7%	254	65.6%	*****	*****	*****	*****
prucalopride	49,006	27,819	100.0%	12,142	100.0%	6,849	100.0%	1,595	100.0%	601	100.0%
0-17 years	788	478	1.7%	171	1.4%	103	1.5%	*****	*****	*****	*****
18-24 years	2,672	1,576	5.7%	635	5.2%	341	5.0%	*****	*****	*****	*****
25-40 years	8,060	4,623	16.6%	1,978	16.3%	1,109	16.2%	264	16.6%	86	14.3%
41-64 years	20,175	10,927	39.3%	5,289	43.6%	3,020	44.1%	678	42.5%	261	43.4%
≥ 65 years	17,311	10,215	36.7%	4,069	33.5%	2,276	33.2%	534	33.5%	217	36.1%
calaspargase pegol-mknl	389	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	352	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
tagraxofusp-erzs	135	135	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	17	17	12.6%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	100	100	74.1%	0	NaN	0	NaN	0	NaN	0	NaN
ravulizumab	3,694	3,480	100.0%	81	100.0%	89	100.0%	*****	*****	*****	*****
0-17 years	214	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	146	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	556	529	15.2%	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	943	902	25.9%	13	16.0%	*****	*****	*****	*****	*****	*****
≥ 65 years	1,835	1,702	48.9%	48	59.3%	60	67.4%	*****	*****	*****	*****

*NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
mogamulizumab-kpkc	1,147	1	1	1	1	252	1.9	9.6
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	140	5.8	25.8
41-64 years	252	1	1	1	1	252	2.7	16.3
≥ 65 years	861	1	1	1	1	84	1.5	4.7
patisiran	625	1	1	1	1		5.3	21.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	NaN
25-40 years	*****	1	1	1	1	42	6.8	12.4
41-64 years	139	1	1	1	1	168	8.8	28.6
≥ 65 years	471	1	1	1	1	231	4.3	18.5
segesterone acetate and ethinyl estradiol vaginal system	19,514	1	30	70	239	1,633	145.1	173.1
0-17 years	*****	1	30	60	213	1,123	140.6	169.2
18-24 years	6,100	1	30	84	272	1,633	154.3	176.2
25-40 years	10,830	1	28	60	205	1,578	138.5	169.0
41-64 years	1,724	1	30	82	250	1,272	155.7	186.8
≥ 65 years	*****	27	95	190	279	340	186.8	129.7
migalastat	261	3	28	84	280	2,320	225.8	343.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	20	28	28	56	149	364	108.7	107.9
25-40 years	66	16	28	76	196	1,929	183.0	311.4
41-64 years	106	4	28	87	282	1,680	223.9	312.6
≥ 65 years	69	3	52	140	336	2,320	303.4	437.7

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
stiripentol	531	3	30	60	210	1,871	203.5	315.7
0-17 years	399	3	30	60	180	1,871	194.2	307.1
18-24 years	99	3	30	60	282	1,630	215.9	312.6
25-40 years	*****	15	30	90	235	1,306	285.8	418.7
41-64 years	*****	63	63	63	63	63	63.0	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
cenegermin-bkbj	9,413	1	28	56	56	336	45.8	22.3
0-17 years	69	2	14	56	56	154	45.6	30.7
18-24 years	47	7	28	42	56	112	42.1	22.0
25-40 years	335	1	21	56	56	274	45.4	30.9
41-64 years	1,702	1	28	56	56	294	47.8	30.1
≥ 65 years	7,260	1	28	56	56	336	45.3	19.4
lanadelumab	1,451	1	28	28	117	2,071	129.6	244.4
0-17 years	125	1	28	50	91	2,050	126.8	276.6
18-24 years	137	1	28	28	84	672	75.2	104.1
25-40 years	399	1	28	28	98	1,935	106.7	215.2
41-64 years	535	1	28	56	140	2,071	140.7	256.6
≥ 65 years	255	1	28	56	196	2,036	172.9	286.8
eravacycline	1,111	1	2	7	14	337	11.1	15.9
0-17 years	*****	1	1	1	2	2	1.3	0.6
18-24 years	*****	1	1	1	8	30	5.8	8.0
25-40 years	103	1	1	4	10	39	7.3	8.6
41-64 years	419	1	1	6	14	84	10.2	13.0
≥ 65 years	572	1	3	8	16	337	12.6	18.6

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
doravirine	8,215	1	30	60	180	2,313	186.4	307.0
0-17 years	*****	30	30	30	110	244	79.0	86.9
18-24 years	*****	12	30	30	120	690	95.5	123.1
25-40 years	1,331	2	30	56	120	1,910	122.4	192.1
41-64 years	5,059	1	30	60	184	2,313	193.7	315.6
≥ 65 years	1,720	3	30	60	216	2,065	220.1	350.4
moxetumomab pasudotox-tdfk	50	1	1	1	1	28	2.1	5.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	1	28	4.0	9.0
≥ 65 years	*****	1	1	1	1	28	1.7	4.3
fremanezumab-vfrm	93,384	1	30	37	90	2,206	91.8	135.9
0-17 years	630	1	30	37	90	1,346	76.3	100.6
18-24 years	6,139	1	30	30	90	1,334	79.3	105.5
25-40 years	26,916	1	30	30	90	2,206	84.7	120.0
41-64 years	48,473	1	30	52	90	2,191	95.9	143.6
≥ 65 years	11,226	1	30	44	90	1,992	98.9	151.6
duvelisib	623	3	28	39	84	1,048	71.7	85.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	25	25	25	25	25	25.0	NaN
25-40 years	*****	4	28	49	84	224	64.2	59.6
41-64 years	129	3	28	28	56	364	56.1	51.2
≥ 65 years	479	3	28	55	84	1,048	76.2	92.3

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
galcanezumab-gnlm	212,175	1	30	30	90	2,144	91.5	153.4
0-17 years	1,184	1	30	30	90	1,562	98.6	162.7
18-24 years	13,165	1	30	30	84	1,852	80.9	131.8
25-40 years	62,239	1	30	30	90	2,144	85.7	140.3
41-64 years	108,086	1	30	30	90	2,093	95.9	162.6
≥ 65 years	27,501	1	30	30	90	1,985	92.6	153.1
dacomitinib	95	1	30	30	88	1,161	79.8	140.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	26	1	30	30	90	510	72.2	100.1
≥ 65 years	69	7	30	30	60	1,161	82.7	153.1
cemiplimab-rwlc	12,307	1	1	1	1	420	1.6	8.5
0-17 years	*****	1	1	1	1	1	1.0	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	42	1.8	5.7
41-64 years	1,105	1	1	1	1	224	1.9	9.4
≥ 65 years	11,147	1	1	1	1	420	1.6	8.4
sarecycline	17,939	1	30	30	60	1,230	46.8	46.6
0-17 years	7,791	1	30	30	60	755	46.7	43.1
18-24 years	4,928	1	30	30	60	1,230	47.7	51.4
25-40 years	3,486	1	30	30	49	905	44.9	41.8
41-64 years	1,568	2	30	30	60	880	49.0	52.5
≥ 65 years	166	7	30	30	30	861	49.7	77.1

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
omadacycline	8,563	1	8	14	15	1,705	23.2	53.2
0-17 years	51	1	9	22	35	420	55.5	97.2
18-24 years	144	1	8	14	28	720	29.2	73.4
25-40 years	674	1	10	14	16	1,166	26.1	68.3
41-64 years	3,412	1	9	14	15	1,705	21.1	52.6
≥ 65 years	4,282	1	8	14	15	949	23.7	49.1
elapegademase-lvlr	42	1	28	56	150	1,111	135.4	242.3
0-17 years	19	1	28	112	224	1,111	224.7	334.9
18-24 years	12	14	28	28	70	280	64.2	76.6
25-40 years	*****	1	28	42	56	252	59.0	72.7
41-64 years	*****	56	56	56	56	56	56.0	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
inotersen	119	28	28	56	140	1,526	120.9	192.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	28	28	56	84	84	56.0	39.6
41-64 years	*****	28	28	44	161	1,526	183.4	333.3
≥ 65 years	90	28	28	56	140	700	103.5	123.5
talazoparib	810	1	30	60	90	1,539	80.3	102.0
0-17 years	*****	15	15	56	804	804	291.7	444.2
18-24 years	*****	60	60	60	60	60	60.0	NaN
25-40 years	*****	10	30	30	90	1,539	83.5	200.6
41-64 years	269	3	30	60	94	960	87.8	108.2
≥ 65 years	479	1	30	60	90	510	74.4	71.2

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
baloxavir marboxil	130,098	1	1	1	1	270	2.2	5.9
0-17 years	24,111	1	1	1	1	90	1.2	2.2
18-24 years	13,123	1	1	1	1	60	1.2	2.3
25-40 years	29,702	1	1	1	1	120	1.3	2.7
41-64 years	39,798	1	1	1	1	270	1.5	4.1
≥ 65 years	23,364	1	1	1	1	214	6.3	11.4
lorlatinib	1,620	1	30	60	140	1,913	132.6	210.1
0-17 years	76	9	30	41	120	1,622	128.4	228.3
18-24 years	11	2	28	40	143	290	92.5	99.5
25-40 years	127	1	30	60	188	699	133.8	165.0
41-64 years	666	1	30	60	150	1,913	142.2	224.7
≥ 65 years	740	2	30	60	120	1,789	124.8	202.5
revefenacin	15,603	1	1	30	30	1,557	41.3	84.1
0-17 years	*****	1	1	1	30	30	12.6	15.9
18-24 years	*****	1	1	30	60	772	86.2	178.4
25-40 years	206	1	2	30	60	1,544	61.0	138.0
41-64 years	4,494	1	2	30	44	1,557	49.8	95.9
≥ 65 years	10,869	1	1	30	30	1,470	37.3	76.4
rifamycin	110	2	3	3	6	72	7.7	11.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	3	3	3	3	14	4.4	3.5
25-40 years	*****	2	3	3	6	72	9.5	16.8
41-64 years	50	2	3	3	12	56	9.0	11.0
≥ 65 years	30	3	3	3	3	30	5.5	7.0

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
emapalumab-lzsg	72	1	1	1	1	28	1.9	4.2
0-17 years	36	1	1	1	1	28	2.6	5.9
18-24 years	*****	1	1	1	1	4	1.3	1.0
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	14	1	1	1	1	7	1.4	1.6
≥ 65 years	*****	1	1	1	1	1	1.0	0.0
glasdegib	393	1	28	30	60	240	43.0	33.0
0-17 years	*****	60	60	60	60	60	60.0	NaN
18-24 years	*****	30	30	30	30	30	30.0	NaN
25-40 years	*****	19	24	28	43	112	42.3	35.1
41-64 years	*****	10	26	30	60	120	40.7	27.9
≥ 65 years	340	1	28	30	60	240	43.3	33.7
larotrectinib	517	1	30	55	90	1,862	104.8	174.7
0-17 years	73	9	30	53	103	759	101.7	131.7
18-24 years	11	30	30	60	240	630	161.0	185.6
25-40 years	35	10	30	30	90	1,862	159.0	352.4
41-64 years	153	1	30	47	120	1,257	111.5	180.5
≥ 65 years	245	5	30	58	90	1,411	91.3	140.3
amifampridine	540	2	30	90	270	1,960	255.5	393.1
0-17 years	21	25	30	60	90	480	84.3	102.7
18-24 years	15	30	30	90	284	867	188.7	236.8
25-40 years	39	15	30	72	355	1,103	211.2	271.2
41-64 years	168	2	30	90	266	1,958	259.2	408.6
≥ 65 years	297	5	30	91	272	1,960	274.8	414.1

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
gilteritinib	2,670	1	30	30	60	1,727	63.7	95.1
0-17 years	47	1	14	30	60	226	43.8	49.7
18-24 years	44	1	30	30	67	360	64.9	66.0
25-40 years	181	1	30	30	68	359	59.8	61.7
41-64 years	661	1	30	30	60	1,727	65.2	106.0
≥ 65 years	1,737	1	30	30	60	1,380	64.0	95.1
prucalopride	49,006	1	30	30	90	2,112	91.0	152.3
0-17 years	788	1	30	30	82	1,411	86.2	153.8
18-24 years	2,672	1	30	30	90	1,469	85.6	133.3
25-40 years	8,060	1	30	30	90	1,982	87.8	146.0
41-64 years	20,175	1	30	30	90	1,955	94.6	156.7
≥ 65 years	17,311	1	30	30	90	2,112	89.4	152.4
calaspargase pegol-mknl	389	1	1	1	1	42	1.1	2.1
0-17 years	352	1	1	1	1	42	1.1	2.2
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	1	1.0	NaN
41-64 years	*****	1	1	1	1	1	1.0	NaN
≥ 65 years	*****	1	1	1	1	1	1.0	NaN
tagraxofusp-erzs	135	1	1	1	1	5	1.5	1.2
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	2	5	1.6	1.2
41-64 years	17	1	1	1	1	4	1.2	0.7
≥ 65 years	100	1	1	1	1	5	1.5	1.3

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
ravulizumab	3,694	1	1	1	1	872	14.0	67.9
0-17 years	214	1	1	1	1	280	6.2	29.7
18-24 years	146	1	1	1	1	616	8.6	57.8
25-40 years	556	1	1	1	1	719	10.6	56.7
41-64 years	943	1	1	1	1	872	13.3	72.4
≥ 65 years	1,835	1	1	1	1	787	16.7	72.4

*NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 6a. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>mogamulizumab-kpkc</i>	17,423	17,394	99.8%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>patisiran</i>	14,085	13,982	99.3%	*****	*****	53	0.4%	*****	*****	0	0.0%
<i>segesterone acetate and ethinyl estradiol vaginal system</i>	3,887	1,760	45.3%	773	19.9%	1,103	28.4%	231	5.9%	20	0.5%
<i>migalastat</i>	869	420	48.3%	240	27.6%	173	19.9%	24	2.8%	12	1.4%
<i>stiripentol</i>	1,310	608	46.4%	394	30.1%	236	18.0%	54	4.1%	18	1.4%
<i>cenegermin-bkbj</i>	4,947	2,996	60.6%	1,895	38.3%	*****	*****	*****	*****	0	0.0%
<i>lanadelumab</i>	7,830	4,768	60.9%	1,794	22.9%	1,069	13.7%	136	1.7%	63	0.8%
<i>eravacycline</i>	1,468	1,435	97.8%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>doravirine</i>	24,774	13,174	53.2%	6,536	26.4%	3,931	15.9%	780	3.1%	353	1.4%
<i>moxetumomab pasudotox-tdfk</i>	391	391	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>fremanezumab-vfrm</i>	228,411	122,700	53.7%	66,728	29.2%	34,182	15.0%	3,797	1.7%	1,004	0.4%
<i>duvelisib</i>	973	562	57.8%	256	26.3%	141	14.5%	*****	*****	*****	*****
<i>galcanezumab-gnlm</i>	593,846	337,096	56.8%	159,328	26.8%	84,481	14.2%	10,098	1.7%	2,843	0.5%
<i>dacomitinib</i>	113	58	51.3%	28	24.8%	*****	*****	*****	*****	*****	*****
<i>cemiplimab-rwlc</i>	102,547	102,391	99.8%	115	0.1%	41	0.0%	0	0.0%	0	0.0%
<i>sarecycline</i>	22,813	17,849	78.2%	3,985	17.5%	947	4.2%	*****	*****	*****	*****
<i>omadacycline</i>	6,256	5,211	83.3%	731	11.7%	290	4.6%	*****	*****	*****	*****
<i>elapegademase-lvlr</i>	353	245	69.4%	73	20.7%	*****	*****	*****	*****	*****	*****
<i>inotersen</i>	400	215	53.8%	98	24.5%	75	18.8%	*****	*****	*****	*****
<i>talazoparib</i>	1,034	622	60.2%	251	24.3%	*****	*****	*****	*****	*****	*****
<i>baloxavir marboxil</i>	7,328	7,297	99.6%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>lorlatinib</i>	2,742	1,473	53.7%	717	26.1%	456	16.6%	69	2.5%	27	1.0%
<i>revefenacin</i>	33,654	28,311	84.1%	3,610	10.7%	1,522	4.5%	165	0.5%	46	0.1%

Table 6a. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>rifamycin</i>	34	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
<i>emapalumab-lzsg</i>	956	956	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>glasdegib</i>	183	123	67.2%	48	26.2%	12	6.6%	0	0.0%	0	0.0%
<i>larotrectinib</i>	658	378	57.4%	162	24.6%	96	14.6%	*****	*****	*****	*****
<i>amifampridine</i>	1,806	871	48.2%	493	27.3%	308	17.1%	76	4.2%	58	3.2%
<i>gilteritinib</i>	4,005	2,365	59.1%	1,038	25.9%	550	13.7%	*****	*****	*****	*****
<i>prucalopride</i>	91,125	49,401	54.2%	26,102	28.6%	13,195	14.5%	1,852	2.0%	575	0.6%
<i>calaspargase pegol-mknl</i>	505	505	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>tagraxofusp-erzs</i>	432	432	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>ravulizumab</i>	25,434	24,864	97.8%	285	1.1%	237	0.9%	*****	*****	*****	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 6b. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>mogamulizumab-kpkc</i>	17,423	1	1	1	1	323	1.2	4.8
<i>patisiran</i>	14,085	1	1	1	1	672	2.1	16.4
<i>segesterone acetate and ethinyl estradiol vaginal system</i>	3,887	1	28	56	204	1,275	135.7	160.0
<i>migalastat</i>	869	3	28	56	84	1,204	92.1	134.4
<i>stiripentol</i>	1,310	2	30	40	90	1,489	101.5	164.7
<i>cenegermin-bkbj</i>	4,947	1	14	28	42	413	31.6	23.1
<i>lanadelumab</i>	7,830	1	28	28	56	2,044	71.7	125.1
<i>eravacycline</i>	1,468	1	1	1	5	141	4.6	9.3
<i>doravirine</i>	24,774	1	30	30	90	2,106	94.6	160.5
<i>moxetumomab pasudotox-tdfk</i>	391	1	1	1	1	2	1.0	0.1
<i>fremanezumab-vfrm</i>	228,411	1	30	30	90	2,040	75.7	104.8
<i>duvelisib</i>	973	1	28	28	56	1,269	64.8	87.3
<i>galcanezumab-gnlm</i>	593,846	1	30	30	84	2,105	73.2	106.9
<i>dacomitinib</i>	113	30	30	30	90	1,096	93.9	137.4
<i>cemiplimab-rwlc</i>	102,547	1	1	1	1	357	1.2	4.0
<i>sarecycline</i>	22,813	1	30	30	30	841	42.2	36.5
<i>omadacycline</i>	6,256	1	6	14	30	1,692	28.7	56.1
<i>elapegademase-lvlr</i>	353	1	28	28	56	1,232	57.2	118.8
<i>inotersen</i>	400	5	28	28	84	1,260	82.9	124.4
<i>talazoparib</i>	1,034	3	30	30	60	945	61.6	72.9
<i>baloxavir marboxil</i>	7,328	1	1	1	1	135	2.9	7.6
<i>lorlatinib</i>	2,742	1	30	30	90	1,920	85.9	143.6
<i>revefenacin</i>	33,654	1	1	1	30	1,887	28.5	65.6
<i>rifamycin</i>	34	3	3	6	9	42	9.1	10.0
<i>emapalumab-lzsg</i>	956	1	1	1	1	21	1.2	1.2

Table 6b. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>glasdegib</i>	183	5	28	30	58	210	44.5	32.6
<i>larotrectinib</i>	658	3	30	30	65	1,491	78.0	123.8
<i>amifampridine</i>	1,806	1	30	56	90	1,973	122.9	219.6
<i>gilteritinib</i>	4,005	1	30	30	60	1,946	65.2	93.1
<i>prucalopride</i>	91,125	1	30	30	90	1,831	80.4	115.1
<i>calaspargase pegol-mknl</i>	505	1	1	1	1	30	1.1	1.3
<i>tagraxofusp-erzs</i>	432	1	1	4	5	21	3.3	2.0
<i>ravulizumab</i>	25,434	1	1	1	1	952	4.7	30.8

Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
mogamulizumab-kpkc	17,423	17,394	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
Female	7,847	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	9,576	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
patisiran	14,085	13,982	100.0%	*****	*****	53	100.0%	*****	*****	0	NaN
Female	4,903	4,849	34.7%	*****	*****	30	56.6%	*****	*****	0	NaN
Male	9,182	9,133	65.3%	*****	*****	23	43.4%	*****	*****	0	NaN
segesterone acetate and ethinyl estradiol vaginal system	3,887	1,760	100.0%	773	100.0%	1,103	100.0%	231	100.0%	20	100.0%
Female	*****	*****	*****	*****	*****	*****	*****	*****	*****	20	100.0%
Male	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
migalastat	869	420	100.0%	240	100.0%	173	100.0%	24	100.0%	12	100.0%
Female	439	211	50.2%	125	52.1%	90	52.0%	*****	*****	*****	*****
Male	430	209	49.8%	115	47.9%	83	48.0%	*****	*****	*****	*****
stiripentol	1,310	608	100.0%	394	100.0%	236	100.0%	54	100.0%	18	100.0%
Female	771	377	62.0%	210	53.3%	148	62.7%	*****	*****	*****	*****
Male	539	231	38.0%	184	46.7%	88	37.3%	*****	*****	*****	*****
cenegermin-bkbj	4,947	2,996	100.0%	1,895	100.0%	*****	*****	*****	*****	0	NaN
Female	3,326	2,006	67.0%	*****	*****	*****	*****	0	0.0%	0	NaN
Male	1,621	990	33.0%	*****	*****	*****	*****	*****	*****	0	NaN
lanadelumab	7,830	4,768	100.0%	1,794	100.0%	1,069	100.0%	136	100.0%	63	100.0%
Female	5,045	3,023	63.4%	1,179	65.7%	707	66.1%	96	70.6%	40	63.5%
Male	2,785	1,745	36.6%	615	34.3%	362	33.9%	40	29.4%	23	36.5%

Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
eravacycline	1,468	1,435	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
Female	901	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
Male	567	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
doravirine	24,774	13,174	100.0%	6,536	100.0%	3,931	100.0%	780	100.0%	353	100.0%
Female	6,453	3,593	27.3%	1,651	25.3%	991	25.2%	152	19.5%	66	18.7%
Male	18,321	9,581	72.7%	4,885	74.7%	2,940	74.8%	628	80.5%	287	81.3%
moxetumomab pasudotox-tdfk	391	391	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	60	60	15.3%	0	NaN	0	NaN	0	NaN	0	NaN
Male	331	331	84.7%	0	NaN	0	NaN	0	NaN	0	NaN
fremanezumab-vfrm	228,411	122,700	100.0%	66,728	100.0%	34,182	100.0%	3,797	100.0%	1,004	100.0%
Female	198,314	106,905	87.1%	57,874	86.7%	29,398	86.0%	3,267	86.0%	870	86.7%
Male	30,097	15,795	12.9%	8,854	13.3%	4,784	14.0%	530	14.0%	134	13.3%
duvelisib	973	562	100.0%	256	100.0%	141	100.0%	*****	*****	*****	*****
Female	414	241	42.9%	102	39.8%	*****	*****	*****	*****	*****	*****
Male	559	321	57.1%	154	60.2%	*****	*****	*****	*****	0	0.0%
galcanezumab-gnlm	593,846	337,096	100.0%	159,328	100.0%	84,481	100.0%	10,098	100.0%	2,843	100.0%
Female	507,667	288,413	85.6%	136,161	85.5%	72,116	85.4%	8,570	84.9%	2,407	84.7%
Male	86,179	48,683	14.4%	23,167	14.5%	12,365	14.6%	1,528	15.1%	436	15.3%
dacomitinib	113	58	100.0%	28	100.0%	*****	*****	*****	*****	*****	*****
Female	58	29	50.0%	14	50.0%	*****	*****	*****	*****	0	0.0%
Male	55	29	50.0%	14	50.0%	*****	*****	*****	*****	*****	*****

Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
cemiplimab-rwlc	102,547	102,391	100.0%	115	100.0%	41	100.0%	0	NaN	0	NaN
Female	26,748	26,697	26.1%	37	32.2%	14	34.1%	0	NaN	0	NaN
Male	75,799	75,694	73.9%	78	67.8%	27	65.9%	0	NaN	0	NaN
sarecycline	22,813	17,849	100.0%	3,985	100.0%	947	100.0%	*****	*****	*****	*****
Female	13,535	10,598	59.4%	2,370	59.5%	548	57.9%	*****	*****	*****	*****
Male	9,278	7,251	40.6%	1,615	40.5%	399	42.1%	*****	*****	*****	*****
omadacycline	6,256	5,211	100.0%	731	100.0%	290	100.0%	*****	*****	*****	*****
Female	3,368	2,750	52.8%	419	57.3%	*****	*****	*****	*****	*****	*****
Male	2,888	2,461	47.2%	312	42.7%	*****	*****	*****	*****	*****	*****
elapegademase-lvlr	353	245	100.0%	73	100.0%	27	100.0%	*****	*****	*****	*****
Female	202	147	60.0%	41	56.2%	*****	*****	*****	*****	*****	*****
Male	151	98	40.0%	32	43.8%	*****	*****	*****	*****	*****	*****
inotersen	400	215	100.0%	98	100.0%	75	100.0%	*****	*****	*****	*****
Female	235	127	59.1%	60	61.2%	*****	*****	*****	*****	*****	*****
Male	165	88	40.9%	38	38.8%	*****	*****	*****	*****	*****	*****
talazoparib	1,034	622	100.0%	251	100.0%	*****	*****	*****	*****	*****	*****
Female	772	462	74.3%	*****	*****	*****	*****	*****	*****	*****	*****
Male	262	160	25.7%	*****	*****	*****	*****	0	0.0%	0	0.0%
baloxavir marboxil	7,328	7,297	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
Female	3,972	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
Male	3,356	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
lorlatinib	2,742	1,473	100.0%	717	100.0%	456	100.0%	69	100.0%	27	100.0%
Female	1,487	827	56.1%	365	50.9%	235	51.5%	*****	*****	*****	*****
Male	1,255	646	43.9%	352	49.1%	221	48.5%	*****	*****	*****	*****

Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
revefenacin	33,654	28,311	100.0%	3,610	100.0%	1,522	100.0%	165	100.0%	46	100.0%
Female	19,285	16,031	56.6%	2,189	60.6%	937	61.6%	103	62.4%	25	54.3%
Male	14,369	12,280	43.4%	1,421	39.4%	585	38.4%	62	37.6%	21	45.7%
rifamycin	34	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
emapalumab-lzsg	956	956	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	708	708	74.1%	0	NaN	0	NaN	0	NaN	0	NaN
Male	248	248	25.9%	0	NaN	0	NaN	0	NaN	0	NaN
glasdegib	183	123	100.0%	48	100.0%	12	100.0%	0	NaN	0	NaN
Female	79	57	46.3%	*****	*****	*****	*****	0	NaN	0	NaN
Male	104	66	53.7%	*****	*****	*****	*****	0	NaN	0	NaN
larotrectinib	658	378	100.0%	162	100.0%	96	100.0%	*****	*****	*****	*****
Female	369	222	58.7%	90	55.6%	*****	*****	*****	*****	*****	*****
Male	289	156	41.3%	72	44.4%	*****	*****	*****	*****	*****	*****
amifampridine	1,806	871	100.0%	493	100.0%	308	100.0%	76	100.0%	58	100.0%
Female	1,118	576	66.1%	279	56.6%	178	57.8%	49	64.5%	36	62.1%
Male	688	295	33.9%	214	43.4%	130	42.2%	27	35.5%	22	37.9%
gilteritinib	4,005	2,365	100.0%	1,038	100.0%	550	100.0%	*****	*****	*****	*****
Female	2,034	1,186	50.1%	526	50.7%	*****	*****	*****	*****	*****	*****
Male	1,971	1,179	49.9%	512	49.3%	*****	*****	*****	*****	*****	*****
prucalopride	91,125	49,401	100.0%	26,102	100.0%	13,195	100.0%	1,852	100.0%	575	100.0%
Female	72,766	39,625	80.2%	20,874	80.0%	10,372	78.6%	1,456	78.6%	439	76.3%
Male	18,359	9,776	19.8%	5,228	20.0%	2,823	21.4%	396	21.4%	136	23.7%

Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
calaspargase pegol-mknl	505	505	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	202	202	40.0%	0	NaN	0	NaN	0	NaN	0	NaN
Male	303	303	60.0%	0	NaN	0	NaN	0	NaN	0	NaN
tagraxofusp-erzs	432	432	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	91	91	21.1%	0	NaN	0	NaN	0	NaN	0	NaN
Male	341	341	78.9%	0	NaN	0	NaN	0	NaN	0	NaN
ravulizumab	25,434	24,864	100.0%	285	100.0%	237	100.0%	*****	*****	*****	*****
Female	13,559	13,254	53.3%	149	52.3%	130	54.9%	*****	*****	*****	*****
Male	11,875	11,610	46.7%	136	47.7%	107	45.1%	*****	*****	*****	*****

*NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
mogamulizumab-kpkc	17,423	1	1	1	1	323	1.2	4.8
Female	7,847	1	1	1	1	308	1.3	5.6
Male	9,576	1	1	1	1	323	1.1	4.0
patisiran	14,085	1	1	1	1	672	2.1	16.4
Female	4,903	1	1	1	1	672	2.8	22.5
Male	9,182	1	1	1	1	462	1.7	11.9
segesterone acetate and ethinyl estradiol vaginal system	3,887	1	28	56	204	1,275	135.7	160.0
Female	*****	1	28	56	203	1,275	135.6	159.9
Male	*****	21	60	103	328	598	199.9	201.9
migalastat	869	3	28	56	84	1,204	92.1	134.4
Female	439	3	28	56	84	1,204	88.6	131.8
Male	430	6	28	56	84	1,036	95.6	137.2
stiripentol	1,310	2	30	40	90	1,489	101.5	164.7
Female	771	2	30	40	90	1,482	98.7	165.1
Male	539	3	30	40	90	1,489	105.5	164.2
cenegermin-bkbj	4,947	1	14	28	42	413	31.6	23.1
Female	3,326	1	14	28	42	364	31.8	23.5
Male	1,621	1	14	28	42	413	31.2	22.1
lanadelumab	7,830	1	28	28	56	2,044	71.7	125.1
Female	5,045	1	28	28	56	2,044	73.2	125.7
Male	2,785	1	28	28	56	2,024	69.0	123.9
eravacycline	1,468	1	1	1	5	141	4.6	9.3
Female	901	1	1	1	2	78	3.6	6.8
Male	567	1	1	1	7	141	6.2	12.1

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
doravirine	24,774	1	30	30	90	2,106	94.6	160.5
Female	6,453	1	30	30	90	1,949	83.8	135.3
Male	18,321	1	30	30	90	2,106	98.4	168.4
moxetumomab pasudotox-tdfk	391	1	1	1	1	2	1.0	0.1
Female	60	1	1	1	1	1	1.0	0.0
Male	331	1	1	1	1	2	1.0	0.1
fremanezumab-vfrm	228,411	1	30	30	90	2,040	75.7	104.8
Female	198,314	1	30	30	90	2,040	75.4	104.5
Male	30,097	1	30	30	90	1,706	78.0	106.7
duvelisib	973	1	28	28	56	1,269	64.8	87.3
Female	414	8	28	28	84	1,269	67.9	98.4
Male	559	1	28	28	56	644	62.6	78.1
galcanezumab-gnlm	593,846	1	30	30	84	2,105	73.2	106.9
Female	507,667	1	30	30	84	2,105	73.0	106.7
Male	86,179	1	30	30	84	1,839	74.0	108.2
dacomitinib	113	30	30	30	90	1,096	93.9	137.4
Female	58	30	30	45	120	390	85.0	87.4
Male	55	30	30	30	75	1,096	103.3	175.9
cemiplimab-rwlc	102,547	1	1	1	1	357	1.2	4.0
Female	26,748	1	1	1	1	315	1.2	4.4
Male	75,799	1	1	1	1	357	1.1	3.9
sarecycline	22,813	1	30	30	30	841	42.2	36.5
Female	13,535	1	30	30	30	841	42.0	35.3
Male	9,278	1	30	30	30	780	42.6	38.2

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
omadacycline	6,256	1	6	14	30	1,692	28.7	56.1
Female	3,368	1	7	14	30	1,692	31.5	59.8
Male	2,888	1	5	14	30	1,249	25.4	51.1
elapegademase-lvlr	353	1	28	28	56	1,232	57.2	118.8
Female	202	1	28	28	56	868	45.1	78.6
Male	151	1	28	28	56	1,232	73.3	156.2
inotersen	400	5	28	28	84	1,260	82.9	124.4
Female	235	5	28	28	84	1,260	77.3	116.1
Male	165	28	28	28	84	819	90.9	135.3
talazoparib	1,034	3	30	30	60	945	61.6	72.9
Female	772	3	30	30	60	945	64.4	79.3
Male	262	3	30	30	60	360	53.4	48.5
baloxavir marboxil	7,328	1	1	1	1	135	2.9	7.6
Female	3,972	1	1	1	1	90	2.6	6.9
Male	3,356	1	1	1	1	135	3.1	8.3
lorlatinib	2,742	1	30	30	90	1,920	85.9	143.6
Female	1,487	1	30	30	90	1,920	87.4	150.3
Male	1,255	1	30	30	90	1,754	84.1	135.3
revefenacin	33,654	1	1	1	30	1,887	28.5	65.6
Female	19,285	1	1	4	30	1,755	29.9	64.8
Male	14,369	1	1	1	30	1,887	26.7	66.7
rifamycin	34	3	3	6	9	42	9.1	10.0
Female	15	3	3	6	12	30	9.9	10.0
Male	19	3	3	6	9	42	8.5	10.3

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
emapalumab-lzsg	956	1	1	1	1	21	1.2	1.2
Female	708	1	1	1	1	21	1.1	1.1
Male	248	1	1	1	1	15	1.3	1.5
glasdegib	183	5	28	30	58	210	44.5	32.6
Female	79	11	30	30	56	210	42.7	33.5
Male	104	5	28	30	60	180	45.9	32.0
larotrectinib	658	3	30	30	65	1,491	78.0	123.8
Female	369	7	30	30	60	837	68.1	97.5
Male	289	3	30	30	84	1,491	90.5	150.0
amifampridine	1,806	1	30	56	90	1,973	122.9	219.6
Female	1,118	2	30	30	90	1,956	121.5	226.0
Male	688	1	30	60	119	1,973	125.3	208.7
gilteritinib	4,005	1	30	30	60	1,946	65.2	93.1
Female	2,034	1	30	30	60	1,946	66.7	96.5
Male	1,971	1	30	30	60	1,449	63.6	89.4
prucalopride	91,125	1	30	30	90	1,831	80.4	115.1
Female	72,766	1	30	30	90	1,831	79.7	113.7
Male	18,359	1	30	30	90	1,680	83.0	120.3
calaspargase pegol-mknl	505	1	1	1	1	30	1.1	1.3
Female	202	1	1	1	1	30	1.1	2.0
Male	303	1	1	1	1	1	1.0	0.0
tagraxofusp-erzs	432	1	1	4	5	21	3.3	2.0
Female	91	1	1	4	5	5	3.4	1.7
Male	341	1	1	3	5	21	3.2	2.0

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
ravulizumab	25,434	1	1	1	1	952	4.7	30.8
Female	13,559	1	1	1	1	952	4.7	31.8
Male	11,875	1	1	1	1	908	4.6	29.7

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
mogamulizumab-kpkc	17,423	17,394	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	17	17	0.1%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	16	16	0.1%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	336	336	1.9%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	3,110	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
≥ 65 years	13,944	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
patisiran	14,085	13,982	100.0%	*****	*****	53	100.0%	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	2,289	2,251	16.1%	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	11,650	11,593	82.9%	*****	*****	28	52.8%	*****	*****	0	NaN
segesterone acetate and ethinyl estradiol vaginal system	3,887	1,760	100.0%	773	100.0%	1,103	100.0%	231	100.0%	20	100.0%
0-17 years	176	62	3.5%	61	7.9%	*****	*****	*****	*****	0	0.0%
18-24 years	1,158	490	27.8%	222	28.7%	356	32.3%	*****	*****	*****	*****
25-40 years	2,110	1,010	57.4%	420	54.3%	567	51.4%	*****	*****	*****	*****
41-64 years	443	198	11.3%	70	9.1%	*****	*****	*****	*****	*****	*****
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
migalastat	869	420	100.0%	240	100.0%	173	100.0%	24	100.0%	12	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	68	38	9.0%	16	6.7%	*****	*****	*****	*****	0	0.0%
25-40 years	238	125	29.8%	73	30.4%	*****	*****	*****	*****	*****	*****
41-64 years	372	173	41.2%	110	45.8%	68	39.3%	*****	*****	*****	*****
≥ 65 years	191	84	20.0%	41	17.1%	*****	*****	*****	*****	*****	*****
stiripentol	1,310	608	100.0%	394	100.0%	236	100.0%	54	100.0%	18	100.0%
0-17 years	957	440	72.4%	291	73.9%	174	73.7%	*****	*****	*****	*****
18-24 years	275	130	21.4%	77	19.5%	*****	*****	13	24.1%	*****	*****
25-40 years	78	38	6.3%	26	6.6%	*****	*****	*****	*****	*****	*****
41-64 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
cenegermin-bkbj	4,947	2,996	100.0%	1,895	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	39	25	0.8%	14	0.7%	0	0.0%	0	0.0%	0	NaN
18-24 years	31	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
25-40 years	237	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	1,024	665	22.2%	342	18.0%	*****	*****	*****	*****	0	NaN
≥ 65 years	3,616	2,128	71.0%	1,453	76.7%	35	63.6%	0	0.0%	0	NaN
lanadelumab	7,830	4,768	100.0%	1,794	100.0%	1,069	100.0%	136	100.0%	63	100.0%
0-17 years	657	406	8.5%	144	8.0%	98	9.2%	*****	*****	*****	*****
18-24 years	761	520	10.9%	165	9.2%	66	6.2%	*****	*****	*****	*****
25-40 years	1,968	1,289	27.0%	415	23.1%	231	21.6%	*****	*****	*****	*****
41-64 years	2,872	1,733	36.3%	659	36.7%	391	36.6%	62	45.6%	27	42.9%
≥ 65 years	1,572	820	17.2%	411	22.9%	283	26.5%	34	25.0%	24	38.1%

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
eravacycline	1,468	1,435	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	17	17	1.2%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	55	55	3.8%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	206	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	528	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	662	643	44.8%	*****	*****	*****	*****	0	NaN	0	NaN
doravirine	24,774	13,174	100.0%	6,536	100.0%	3,931	100.0%	780	100.0%	353	100.0%
0-17 years	*****	*****	*****	0	0.0%	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	74	1.1%	*****	*****	*****	*****	0	0.0%
25-40 years	3,532	2,168	16.5%	867	13.3%	417	10.6%	*****	*****	*****	*****
41-64 years	15,957	8,551	64.9%	4,188	64.1%	2,508	63.8%	496	63.6%	214	60.6%
≥ 65 years	5,012	2,300	17.5%	1,407	21.5%	968	24.6%	217	27.8%	120	34.0%
moxetumomab pasudotox-tdfk	391	391	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	280	280	71.6%	0	NaN	0	NaN	0	NaN	0	NaN
fremanezumab-vfrm	228,411	122,700	100.0%	66,728	100.0%	34,182	100.0%	3,797	100.0%	1,004	100.0%
0-17 years	1,329	762	0.6%	374	0.6%	167	0.5%	*****	*****	*****	*****
18-24 years	13,267	7,498	6.1%	3,929	5.9%	1,686	4.9%	*****	*****	*****	*****
25-40 years	62,751	35,146	28.6%	17,910	26.8%	8,676	25.4%	827	21.8%	192	19.1%
41-64 years	124,593	66,262	54.0%	36,522	54.7%	19,011	55.6%	2,214	58.3%	584	58.2%
≥ 65 years	26,471	13,032	10.6%	7,993	12.0%	4,642	13.6%	603	15.9%	201	20.0%

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
duvelisib	973	562	100.0%	256	100.0%	141	100.0%	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
41-64 years	*****	*****	*****	43	16.8%	*****	*****	*****	*****	0	0.0%
≥ 65 years	820	471	83.8%	213	83.2%	*****	*****	*****	*****	*****	*****
galcanezumab-gnlm	593,846	337,096	100.0%	159,328	100.0%	84,481	100.0%	10,098	100.0%	2,843	100.0%
0-17 years	2,568	1,527	0.5%	637	0.4%	345	0.4%	41	0.4%	18	0.6%
18-24 years	33,623	20,090	6.0%	8,945	5.6%	4,098	4.9%	408	4.0%	82	2.9%
25-40 years	166,329	97,571	28.9%	44,183	27.7%	21,673	25.7%	2,308	22.9%	594	20.9%
41-64 years	318,475	179,846	53.4%	84,847	53.3%	46,282	54.8%	5,791	57.3%	1,709	60.1%
≥ 65 years	72,851	38,062	11.3%	20,716	13.0%	12,083	14.3%	1,550	15.3%	440	15.5%
dacomitinib	113	58	100.0%	28	100.0%	*****	*****	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
41-64 years	22	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
≥ 65 years	91	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
cemiplimab-rwlc	102,547	102,391	100.0%	115	100.0%	41	100.0%	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	8,768	8,748	8.5%	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	93,470	93,334	91.2%	*****	*****	*****	*****	0	NaN	0	NaN

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
sarecycline	22,813	17,849	100.0%	3,985	100.0%	947	100.0%	*****	*****	*****	*****
0-17 years	11,210	8,831	49.5%	1,924	48.3%	441	46.6%	*****	*****	*****	*****
18-24 years	5,645	4,487	25.1%	923	23.2%	*****	*****	*****	*****	0	0.0%
25-40 years	3,604	2,781	15.6%	673	16.9%	*****	*****	*****	*****	0	0.0%
41-64 years	2,136	1,598	9.0%	418	10.5%	*****	*****	*****	*****	*****	*****
≥ 65 years	218	152	0.9%	47	1.2%	*****	*****	*****	*****	0	0.0%
omadacycline	6,256	5,211	100.0%	731	100.0%	290	100.0%	*****	*****	*****	*****
0-17 years	130	105	2.0%	14	1.9%	11	3.8%	0	0.0%	0	0.0%
18-24 years	122	101	1.9%	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	541	454	8.7%	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	2,392	2,041	39.2%	249	34.1%	*****	*****	*****	*****	*****	*****
≥ 65 years	3,071	2,510	48.2%	395	54.0%	*****	*****	*****	*****	*****	*****
elapegademase-lvlr	353	245	100.0%	73	100.0%	*****	*****	*****	*****	*****	*****
0-17 years	130	95	38.8%	*****	*****	*****	*****	*****	*****	0	0.0%
18-24 years	*****	*****	*****	26	35.6%	*****	*****	*****	*****	*****	*****
25-40 years	107	76	31.0%	18	24.7%	*****	*****	*****	*****	*****	*****
41-64 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
inotersen	400	215	100.0%	98	100.0%	75	100.0%	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	21	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	54	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
≥ 65 years	325	168	78.1%	*****	*****	62	82.7%	*****	*****	*****	*****

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
talazoparib	1,034	622	100.0%	251	100.0%	*****	*****	*****	*****	*****	*****
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	27	10.8%	*****	*****	*****	*****	0	0.0%
41-64 years	457	284	45.7%	106	42.2%	*****	*****	*****	*****	*****	*****
≥ 65 years	467	265	42.6%	118	47.0%	*****	*****	*****	*****	0	0.0%
baloxavir marboxil	7,328	7,297	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	1,617	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
18-24 years	512	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
25-40 years	1,410	1,410	19.3%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	2,352	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
≥ 65 years	1,437	1,414	19.4%	*****	*****	*****	*****	0	NaN	0	NaN
lorlatinib	2,742	1,473	100.0%	717	100.0%	456	100.0%	69	100.0%	27	100.0%
0-17 years	154	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
18-24 years	23	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	214	106	7.2%	68	9.5%	*****	*****	*****	*****	0	0.0%
41-64 years	1,192	618	42.0%	308	43.0%	*****	*****	*****	*****	12	44.4%
≥ 65 years	1,159	628	42.6%	310	43.2%	180	39.5%	26	37.7%	15	55.6%
revefenacin	33,654	28,311	100.0%	3,610	100.0%	1,522	100.0%	165	100.0%	46	100.0%
0-17 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****
25-40 years	264	183	0.6%	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	7,191	5,518	19.5%	1,141	31.6%	467	30.7%	*****	*****	*****	*****
≥ 65 years	26,164	22,586	79.8%	2,410	66.8%	1,028	67.5%	114	69.1%	26	56.5%

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
rifamycin	34	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	21	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
emapalumab-lzsg	956	956	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	602	602	63.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	98	98	10.3%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	145	145	15.2%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	99	99	10.4%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	12	12	1.3%	0	NaN	0	NaN	0	NaN	0	NaN
glasdegib	183	123	100.0%	48	100.0%	12	100.0%	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
≥ 65 years	154	*****	*****	*****	*****	12	100.0%	0	NaN	0	NaN
larotrectinib	658	378	100.0%	162	100.0%	96	100.0%	*****	*****	*****	*****
0-17 years	214	115	30.4%	61	37.7%	*****	*****	*****	*****	0	0.0%
18-24 years	21	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	29	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	158	94	24.9%	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	236	138	36.5%	59	36.4%	*****	*****	*****	*****	*****	*****

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
amifampridine	1,806	871	100.0%	493	100.0%	308	100.0%	76	100.0%	58	100.0%
0-17 years	28	13	1.5%	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	59	32	3.7%	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	105	55	6.3%	31	6.3%	*****	*****	*****	*****	*****	*****
41-64 years	549	307	35.2%	128	26.0%	82	26.6%	*****	*****	*****	*****
≥ 65 years	1,065	464	53.3%	307	62.3%	204	66.2%	54	71.1%	36	62.1%
gilteritinib	4,005	2,365	100.0%	1,038	100.0%	550	100.0%	*****	*****	*****	*****
0-17 years	77	50	2.1%	14	1.3%	13	2.4%	0	0.0%	0	0.0%
18-24 years	80	56	2.4%	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	283	175	7.4%	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	1,069	625	26.4%	274	26.4%	*****	*****	*****	*****	*****	*****
≥ 65 years	2,496	1,459	61.7%	669	64.5%	334	60.7%	*****	*****	*****	*****
prucalopride	91,125	49,401	100.0%	26,102	100.0%	13,195	100.0%	1,852	100.0%	575	100.0%
0-17 years	1,452	867	1.8%	360	1.4%	195	1.5%	*****	*****	*****	*****
18-24 years	4,924	2,776	5.6%	1,370	5.2%	669	5.1%	*****	*****	*****	*****
25-40 years	15,441	8,594	17.4%	4,413	16.9%	2,077	15.7%	269	14.5%	88	15.3%
41-64 years	39,069	21,124	42.8%	11,246	43.1%	5,686	43.1%	759	41.0%	254	44.2%
≥ 65 years	30,239	16,040	32.5%	8,713	33.4%	4,568	34.6%	716	38.7%	202	35.1%
calaspargase pegol-mknl	505	505	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	469	469	92.9%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
tagraxofusp-erzs	432	432	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	14	14	3.2%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	385	385	89.1%	0	NaN	0	NaN	0	NaN	0	NaN
ravulizumab	25,434	24,864	100.0%	285	100.0%	237	100.0%	*****	*****	*****	*****
0-17 years	1,604	1,561	6.3%	*****	*****	*****	*****	*****	*****	0	0.0%
18-24 years	932	921	3.7%	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	4,023	3,947	15.9%	39	13.7%	*****	*****	*****	*****	*****	*****
41-64 years	6,843	6,697	26.9%	72	25.3%	62	26.2%	*****	*****	*****	*****
≥ 65 years	12,032	11,738	47.2%	137	48.1%	131	55.3%	26	59.1%	0	0.0%

*NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
mogamulizumab-kpkc	17,423	1	1	1	1	323	1.2	4.8
0-17 years	17	1	1	1	1	1	1.0	0.0
18-24 years	16	1	1	1	1	1	1.0	0.0
25-40 years	336	1	1	1	1	1	1.0	0.0
41-64 years	3,110	1	1	1	1	84	1.3	3.7
≥ 65 years	13,944	1	1	1	1	323	1.2	5.1
patisiran	14,085	1	1	1	1	672	2.1	16.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	273	8.9	36.0
41-64 years	2,289	1	1	1	1	672	3.6	25.7
≥ 65 years	11,650	1	1	1	1	651	1.8	13.4
segesterone acetate and ethinyl estradiol vaginal system	3,887	1	28	56	204	1,275	135.7	160.0
0-17 years	176	1	30	90	151	730	126.6	138.1
18-24 years	1,158	1	28	68	247	1,030	147.4	166.8
25-40 years	2,110	1	28	42	178	1,275	126.9	155.7
41-64 years	443	1	28	60	250	741	150.8	167.4
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
migalastat	869	3	28	56	84	1,204	92.1	134.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	68	11	28	28	84	696	81.1	107.9
25-40 years	238	9	28	28	84	840	70.8	91.0
41-64 years	372	3	28	56	84	1,204	96.3	149.1
≥ 65 years	191	6	28	56	140	1,036	114.1	153.7

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
stiripentol	1,310	2	30	40	90	1,489	101.5	164.7
0-17 years	957	2	30	40	90	1,489	101.1	161.2
18-24 years	275	3	30	36	90	1,205	101.9	161.4
25-40 years	78	5	30	40	80	1,400	105.3	214.3
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
cenegermin-bkbj	4,947	1	14	28	42	413	31.6	23.1
0-17 years	39	3	14	28	42	84	31.2	20.3
18-24 years	31	1	14	14	42	56	24.7	17.4
25-40 years	237	4	14	28	42	133	29.6	19.7
41-64 years	1,024	1	14	28	42	413	30.0	24.6
≥ 65 years	3,616	1	14	28	42	364	32.2	22.9
lanadelumab	7,830	1	28	28	56	2,044	71.7	125.1
0-17 years	657	1	28	28	56	871	63.7	85.5
18-24 years	761	1	28	28	56	1,025	53.2	77.1
25-40 years	1,968	1	28	28	56	2,024	61.3	109.6
41-64 years	2,872	1	28	28	56	2,044	75.6	137.6
≥ 65 years	1,572	1	28	28	84	1,567	89.7	147.4
eravacycline	1,468	1	1	1	5	141	4.6	9.3
0-17 years	17	1	1	1	1	2	1.1	0.3
18-24 years	55	1	1	1	1	15	1.8	2.7
25-40 years	206	1	1	1	1	32	2.4	3.9
41-64 years	528	1	1	1	6	93	5.0	9.5
≥ 65 years	662	1	1	1	5	141	5.4	10.6

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
doravirine	24,774	1	30	30	90	2,106	94.6	160.5
0-17 years	*****	30	30	254	617	925	351.7	354.8
18-24 years	*****	1	30	30	63	593	64.9	73.0
25-40 years	3,532	1	30	30	60	1,590	70.0	107.1
41-64 years	15,957	1	30	30	90	2,106	93.3	158.3
≥ 65 years	5,012	1	30	60	112	2,055	117.2	195.1
moxetumomab pasudotox-tdfk	391	1	1	1	1	2	1.0	0.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	1	1	1.0	0.0
≥ 65 years	280	1	1	1	1	2	1.0	0.1
fremanezumab-vfrm	228,411	1	30	30	90	2,040	75.7	104.8
0-17 years	1,329	1	28	30	81	1,140	67.1	92.7
18-24 years	13,267	1	30	30	84	1,331	66.1	79.6
25-40 years	62,751	1	30	30	84	2,003	69.8	93.7
41-64 years	124,593	1	30	30	90	2,040	77.3	107.4
≥ 65 years	26,471	1	30	45	90	2,035	87.7	126.0
duvelisib	973	1	28	28	56	1,269	64.8	87.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	28	28	28	28	28	28.0	0.0
41-64 years	*****	5	28	28	56	588	58.5	71.8
≥ 65 years	820	1	28	28	63	1,269	66.1	90.0

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
galcanezumab-gnlm	593,846	1	30	30	84	2,105	73.2	106.9
0-17 years	2,568	1	28	30	60	1,839	71.2	116.8
18-24 years	33,623	1	28	30	60	2,043	64.1	86.3
25-40 years	166,329	1	30	30	60	1,948	67.8	96.1
41-64 years	318,475	1	30	30	84	2,105	75.0	111.3
≥ 65 years	72,851	1	30	30	90	1,834	81.7	117.5
dacomitinib	113	30	30	30	90	1,096	93.9	137.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	22	30	30	60	120	690	112.9	152.5
≥ 65 years	91	30	30	30	90	1,096	89.4	134.0
cemiplimab-rwlc	102,547	1	1	1	1	357	1.2	4.0
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	8,768	1	1	1	1	357	1.3	6.0
≥ 65 years	93,470	1	1	1	1	315	1.1	3.8
sarecycline	22,813	1	30	30	30	841	42.2	36.5
0-17 years	11,210	1	30	30	30	750	41.7	35.5
18-24 years	5,645	1	30	30	30	660	41.5	33.7
25-40 years	3,604	1	30	30	30	555	42.2	35.7
41-64 years	2,136	1	30	30	33	841	45.8	46.4
≥ 65 years	218	5	30	30	60	371	52.6	51.3

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days					
		Minimum	Q1	Median	Q3	Maximum	Mean Standard Deviation
omadacycline	6,256	1	6	14	30	1,692	28.7 56.1
0-17 years	130	1	1	1	30	240	29.2 48.0
18-24 years	122	1	10	24	30	360	34.6 56.3
25-40 years	541	1	11	15	30	540	28.4 43.6
41-64 years	2,392	1	7	14	30	1,692	27.2 58.2
≥ 65 years	3,071	1	5	14	30	1,249	29.7 56.7
elapegademase-lvlr	353	1	28	28	56	1,232	57.2 118.8
0-17 years	130	1	28	28	56	695	47.9 72.3
18-24 years	110	4	28	28	56	1,047	63.4 126.9
25-40 years	*****	1	1	28	56	1,232	61.7 154.0
41-64 years	*****	3	28	70	88	118	62.8 42.3
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN NaN
inotersen	400	5	28	28	84	1,260	82.9 124.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN NaN
25-40 years	21	26	28	28	56	252	50.6 51.4
41-64 years	54	28	28	28	56	420	64.7 69.7
≥ 65 years	325	5	28	28	84	1,260	88.1 134.0
talazoparib	1,034	3	30	30	60	945	61.6 72.9
0-17 years	*****	15	15	15	15	15	15.0 0.0
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN NaN
25-40 years	*****	3	30	30	60	450	52.7 60.7
41-64 years	457	4	30	30	60	945	58.5 70.8
≥ 65 years	467	3	30	30	71	720	67.0 77.1

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
baloxavir marboxil	7,328	1	1	1	1	135	2.9	7.6
0-17 years	1,617	1	1	1	1	60	1.2	2.3
18-24 years	512	1	1	1	1	90	1.6	4.8
25-40 years	1,410	1	1	1	1	30	1.2	2.1
41-64 years	2,352	1	1	1	1	60	1.9	4.9
≥ 65 years	1,437	1	1	1	7	135	8.4	14.0
lorlatinib	2,742	1	30	30	90	1,920	85.9	143.6
0-17 years	154	1	30	30	60	480	59.1	79.0
18-24 years	23	14	30	30	90	622	98.8	156.7
25-40 years	214	1	30	38	90	704	78.4	105.3
41-64 years	1,192	1	30	30	90	1,710	88.3	137.9
≥ 65 years	1,159	1	30	30	90	1,920	88.2	160.7
revefenacin	33,654	1	1	1	30	1,887	28.5	65.6
0-17 years	*****	16	30	30	30	60	31.8	11.6
18-24 years	*****	4	30	30	60	802	84.4	154.2
25-40 years	264	1	30	30	60	900	55.3	91.1
41-64 years	7,191	1	1	30	30	1,755	40.9	77.7
≥ 65 years	26,164	1	1	1	30	1,887	24.8	60.9
rifamycin	34	3	3	6	9	42	9.1	10.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	3	3	3	3	3	3.0	0.0
25-40 years	*****	9	9	28	30	30	22.3	11.6
41-64 years	*****	3	3	3	9	42	8.0	9.9
≥ 65 years	*****	3	3	6	11	27	8.6	8.1

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
emapalumab-lzsg	956	1	1	1	1	21	1.2	1.2
0-17 years	602	1	1	1	1	21	1.2	1.4
18-24 years	98	1	1	1	1	13	1.3	1.5
25-40 years	145	1	1	1	1	1	1.0	0.0
41-64 years	99	1	1	1	1	7	1.1	0.6
≥ 65 years	12	1	1	1	1	1	1.0	0.0
glasdegib	183	5	28	30	58	210	44.5	32.6
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	28	28	42	56	56	42.0	19.8
41-64 years	*****	10	28	30	30	60	32.4	15.8
≥ 65 years	154	5	30	30	60	210	46.7	34.5
larotrectinib	658	3	30	30	65	1,491	78.0	123.8
0-17 years	214	3	21	30	60	592	70.7	98.7
18-24 years	21	15	30	30	60	300	65.5	69.0
25-40 years	29	15	30	30	60	450	62.2	92.1
41-64 years	158	4	30	30	90	1,491	97.6	182.3
≥ 65 years	236	10	30	30	87	837	74.5	100.0
amifampridine	1,806	1	30	56	90	1,973	122.9	219.6
0-17 years	28	1	30	60	86	956	114.8	194.0
18-24 years	59	3	30	30	90	649	80.4	104.8
25-40 years	105	2	30	30	90	1,799	136.2	302.0
41-64 years	549	3	30	30	90	1,956	108.1	212.0
≥ 65 years	1,065	3	30	60	120	1,973	131.8	218.7

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
gilteritinib	4,005	1	30	30	60	1,946	65.2	93.1
0-17 years	77	1	30	30	60	300	57.0	59.7
18-24 years	80	1	30	30	59	690	68.9	117.2
25-40 years	283	1	30	30	60	720	63.0	83.7
41-64 years	1,069	1	30	30	60	1,946	67.5	103.7
≥ 65 years	2,496	1	30	30	60	1,530	64.6	89.2
prucalopride	91,125	1	30	30	90	1,831	80.4	115.1
0-17 years	1,452	1	30	30	60	1,085	69.1	97.3
18-24 years	4,924	1	30	30	90	1,507	75.7	107.9
25-40 years	15,441	1	30	30	90	1,637	75.6	108.6
41-64 years	39,069	1	30	30	90	1,831	80.5	115.7
≥ 65 years	30,239	1	30	30	90	1,806	83.9	119.2
calaspargase pegol-mknl	505	1	1	1	1	30	1.1	1.3
0-17 years	469	1	1	1	1	30	1.1	1.3
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	*****	1	1	1	1	1	1.0	NaN
tagraxofusp-erzs	432	1	1	4	5	21	3.3	2.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	3	5	5	2.8	1.8
25-40 years	*****	1	2	3	5	5	3.0	1.7
41-64 years	25	1	1	1	4	5	2.1	1.5
≥ 65 years	385	1	1	4	5	21	3.4	2.0

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
ravulizumab	25,434	1	1	1	1	952	4.7	30.8
0-17 years	1,604	1	1	1	1	534	3.6	21.6
18-24 years	932	1	1	1	1	448	3.2	23.2
25-40 years	4,023	1	1	1	1	952	4.2	31.9
41-64 years	6,843	1	1	1	1	897	4.4	30.2
≥ 65 years	12,032	1	1	1	1	721	5.3	32.4

*NaN: Not a number

****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 7a. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<i>mogamulizumab-kpkc</i>	17,423	1	13	13	13	1,672	17.4	48.6
<i>patisiran</i>	14,085	1	20	20	20	1,101	22.6	22.6
<i>segesterone acetate and ethinyl estradiol vaginal system</i>	3,887	1	97	283	341	1,375	251.0	171.5
<i>migalastat</i>	869	1	2	6	15	1,915	28.8	123.8
<i>stiripentol</i>	1,310	1	2	6	16	434	24.8	57.6
<i>cenegermin-bkbj</i>	4,947	1	2	6	28	1,712	71.1	188.5
<i>lanadelumab</i>	7,830	1	3	7	18	2,085	20.5	65.5
<i>eravacycline</i>	1,468	1	1	3	6	827	13.0	59.0
<i>doravirine</i>	24,774	1	3	7	18	1,935	23.7	72.4
<i>moxetumomab pasudotox-tdfk</i>	391	1	1	1	23	131	9.3	14.7
<i>fremanezumab-vfrm</i>	228,411	1	3	7	21	2,038	25.7	75.0
<i>duvelisib</i>	973	1	3	6	16	1,255	18.1	56.5
<i>galcanezumab-gnlm</i>	593,846	1	3	7	20	1,912	25.2	75.7
<i>dacomitinib</i>	113	1	3	6	16	112	16.3	22.8
<i>cemiplimab-rwlc</i>	102,547	1	20	20	20	1,616	23.8	29.0
<i>sarecycline</i>	22,813	1	4	12	32	1,960	38.2	92.2
<i>omadacycline</i>	6,256	1	2	6	28	1,399	44.3	111.9
<i>elapegademase-lvlr</i>	353	1	5	11	26	600	22.6	44.6
<i>inotersen</i>	400	1	3	7	18	381	19.3	43.4
<i>talazoparib</i>	1,034	1	3	6	15	1,085	15.6	46.1
<i>baloxavir marboxil</i>	7,328	1	31	202	421	2,109	316.7	369.6
<i>lorlatinib</i>	2,742	1	3	6	16	1,071	25.3	79.0
<i>revefenacin</i>	33,654	1	10	26	37	1,526	38.9	70.7
<i>rifamycin</i>	34	1	3	7	32	1,119	69.4	211.4
<i>emapalumab-lzsg</i>	956	1	2	4	6	1,579	8.7	52.3
<i>glasdegib</i>	183	1	3	6	12	108	9.9	14.2

Table 7a. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<i>larotrectinib</i>	658	1	2	6	14	875	17.4	49.0
<i>amifampridine</i>	1,806	1	3	6	15	1,127	16.5	53.3
<i>gilteritinib</i>	4,005	1	3	9	26	858	26.2	54.7
<i>prucalopride</i>	91,125	1	3	9	27	1,866	36.0	99.1
<i>calaspargase pegol-mknl</i>	505	1	24	35	55	387	49.4	38.5
<i>tagraxofusp-erzs</i>	432	1	13	20	25	416	24.5	37.9
<i>ravulizumab</i>	25,434	1	55	55	55	1,769	53.1	35.6

Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
mogamulizumab-kpkc	17,423	1	13	13	13	1,672	17.4	48.6
Female	7,847	1	13	13	13	1,638	17.9	49.3
Male	9,576	1	13	13	13	1,672	17.1	48.0
patisiran	14,085	1	20	20	20	1,101	22.6	22.6
Female	4,903	1	20	20	20	1,101	23.3	28.6
Male	9,182	1	20	20	20	460	22.3	18.6
segesterone acetate and ethinyl estradiol vaginal system	3,887	1	97	283	341	1,375	251.0	171.5
Female	*****	1	98	283	341	1,375	250.9	171.4
Male	*****	5	53	273	345	729	259.4	236.9
migalastat	869	1	2	6	15	1,915	28.8	123.8
Female	439	1	2	6	19	1,485	29.6	109.1
Male	430	1	3	6	14	1,915	28.1	137.4
stiripentol	1,310	1	2	6	16	434	24.8	57.6
Female	771	1	2	5	14	434	24.3	58.4
Male	539	1	2	7	18	348	25.6	56.5
cenegermin-bkbj	4,947	1	2	6	28	1,712	71.1	188.5
Female	3,326	1	2	6	29	1,712	71.7	187.1
Male	1,621	1	2	6	28	1,684	70.0	191.3
lanadelumab	7,830	1	3	7	18	2,085	20.5	65.5
Female	5,045	1	3	7	19	2,085	21.6	71.2
Male	2,785	1	3	7	18	1,490	18.5	53.6
eravacycline	1,468	1	1	3	6	827	13.0	59.0
Female	901	1	1	2	6	827	14.4	63.9
Male	567	1	1	5	6	743	10.8	50.4
doravirine	24,774	1	3	7	18	1,935	23.7	72.4

Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Female	6,453	1	3	7	20	1,935	24.8	69.7
Male	18,321	1	3	6	18	1,622	23.3	73.3
moxetumomab pasudotox-tdfk	391	1	1	1	23	131	9.3	14.7
Female	60	1	1	1	23	46	8.4	11.8
Male	331	1	1	1	23	131	9.5	15.1
fremanezumab-vfrm	228,411	1	3	7	21	2,038	25.7	75.0
Female	198,314	1	3	7	21	1,915	25.7	75.0
Male	30,097	1	3	7	21	2,038	25.5	75.0
duvelisib	973	1	3	6	16	1,255	18.1	56.5
Female	414	1	2	6	16	285	15.5	31.3
Male	559	1	3	6	16	1,255	20.1	69.4
galcanezumab-gnlm	593,846	1	3	7	20	1,912	25.2	75.7
Female	507,667	1	3	7	20	1,912	24.9	74.4
Male	86,179	1	3	7	21	1,876	27.2	82.7
dacomitinib	113	1	3	6	16	112	16.3	22.8
Female	58	1	2	6	14	112	14.2	22.6
Male	55	1	5	9	27	105	18.4	23.0
cemiplimab-rwlc	102,547	1	20	20	20	1,616	23.8	29.0
Female	26,748	1	20	20	20	1,315	24.0	25.8
Male	75,799	1	20	20	20	1,616	23.7	30.1
sarecycline	22,813	1	4	12	32	1,960	38.2	92.2
Female	13,535	1	4	11	31	1,960	38.6	95.0
Male	9,278	1	5	12	32	1,478	37.7	87.8
omadacycline	6,256	1	2	6	28	1,399	44.3	111.9
Female	3,368	1	2	6	28	1,399	44.6	116.9
Male	2,888	1	2	6	29	1,290	44.0	105.7

Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
elapegademase-lvlr	353	1	5	11	26	600	22.6	44.6
Female	202	1	5	13	27	600	23.6	53.2
Male	151	1	5	9	23	176	21.3	29.8
inotersen	400	1	3	7	18	381	19.3	43.4
Female	235	1	4	7	18	303	20.0	42.2
Male	165	1	3	7	17	381	18.3	45.2
talazoparib	1,034	1	3	6	15	1,085	15.6	46.1
Female	772	1	3	7	16	1,085	16.3	49.9
Male	262	1	2	5	11	330	13.7	32.5
baloxavir marboxil	7,328	1	31	202	421	2,109	316.7	369.6
Female	3,972	1	30	199	418	2,109	311.7	365.2
Male	3,356	1	32	203	427	1,852	322.6	374.6
lorlatinib	2,742	1	3	6	16	1,071	25.3	79.0
Female	1,487	1	3	6	16	1,071	28.9	92.6
Male	1,255	1	3	6	15	771	21.0	58.7
revefenacin	33,654	1	10	26	37	1,526	38.9	70.7
Female	19,285	1	9	26	37	1,526	38.6	70.7
Male	14,369	1	12	27	37	1,492	39.1	70.8
rifamycin	34	1	3	7	32	1,119	69.4	211.4
Female	15	1	4	6	29	88	19.1	24.7
Male	19	1	2	11	33	1,119	109.1	278.8
emapalumab-lzsg	956	1	2	4	6	1,579	8.7	52.3
Female	708	1	3	6	8	1,579	9.7	60.4
Male	248	1	2	3	6	139	6.0	10.5

Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
glasdegib	183	1	3	6	12	108	9.9	14.2
Female	79	1	2	5	11	108	9.3	15.7
Male	104	1	3	7	12	83	10.3	13.0
larotrectinib	658	1	2	6	14	875	17.4	49.0
Female	369	1	3	7	15	336	18.4	41.0
Male	289	1	2	5	13	875	16.1	57.6
amifampridine	1,806	1	3	6	15	1,127	16.5	53.3
Female	1,118	1	3	6	14	1,127	17.1	57.1
Male	688	1	3	5	16	943	15.5	46.5
gilteritinib	4,005	1	3	9	26	858	26.2	54.7
Female	2,034	1	3	10	26	719	26.0	49.4
Male	1,971	1	3	8	25	858	26.4	59.7
prucalopride	91,125	1	3	9	27	1,866	36.0	99.1
Female	72,766	1	3	9	27	1,866	36.4	100.0
Male	18,359	1	3	8	26	1,754	34.6	95.4
calaspargase pegol-mknl	505	1	24	35	55	387	49.4	38.5
Female	202	7	27	41	86	174	56.4	39.5
Male	303	1	23	34	50	387	44.7	37.1
tagraxofusp-erzs	432	1	13	20	25	416	24.5	37.9
Female	91	1	16	23	27	355	28.2	44.8
Male	341	1	13	19	25	416	23.5	35.9
ravulizumab	25,434	1	55	55	55	1,769	53.1	35.6
Female	13,559	1	54	55	55	1,070	53.4	37.1
Male	11,875	1	55	55	55	1,769	52.7	33.7

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024 , by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
mogamulizumab-kpkc	17,423	1	13	13	13	1,672	17.4	48.6
0-17 years	17	2	6	13	13	27	11.8	7.7
18-24 years	16	6	6	13	13	27	12.1	6.2
25-40 years	336	4	12	13	20	604	18.7	42.0
41-64 years	3,110	1	12	13	13	1,668	18.9	65.8
≥ 65 years	13,944	1	13	13	13	1,672	17.1	44.1
patisiran	14,085	1	20	20	20	1,101	22.6	22.6
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	20	20	20	33	33	24.3	7.5
25-40 years	*****	2	20	20	24	549	37.4	66.3
41-64 years	2,289	1	20	20	20	685	22.6	22.2
≥ 65 years	11,650	1	20	20	20	1,101	22.4	21.5
segesterone acetate and ethinyl estradiol vaginal system	3,887	1	97	283	341	1,375	251.0	171.5
0-17 years	176	1	54	273	337	1,124	232.8	170.0
18-24 years	1,158	1	105	283	339	1,224	251.1	169.4
25-40 years	2,110	1	97	286	341	1,375	252.9	172.1
41-64 years	443	1	92	280	343	1,068	248.7	174.6
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
migalastat	869	1	2	6	15	1,915	28.8	123.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	68	1	3	6	28	791	31.0	97.3
25-40 years	238	1	3	7	22	1,682	40.1	147.5
41-64 years	372	1	2	6	12	1,485	21.1	96.6
≥ 65 years	191	1	3	5	17	1,915	28.9	145.1

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
stiripentol	1,310	1	2	6	16	434	24.8	57.6
0-17 years	957	1	2	6	16	434	24.2	55.9
18-24 years	275	1	2	6	17	384	30.4	66.9
25-40 years	78	1	1	3	9	327	12.5	38.3
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
cenegermin-bkbj	4,947	1	2	6	28	1,712	71.1	188.5
0-17 years	39	1	1	5	24	389	39.6	92.2
18-24 years	31	1	2	6	15	360	32.5	79.4
25-40 years	237	1	1	6	28	1,502	63.0	176.8
41-64 years	1,024	1	2	7	35	1,684	66.1	179.2
≥ 65 years	3,616	1	2	5	28	1,712	73.8	193.1
lanadelumab	7,830	1	3	7	18	2,085	20.5	65.5
0-17 years	657	1	3	7	16	565	17.3	35.8
18-24 years	761	1	3	8	21	575	19.4	37.8
25-40 years	1,968	1	4	8	21	2,085	24.1	84.6
41-64 years	2,872	1	3	7	18	1,590	20.5	67.4
≥ 65 years	1,572	1	3	7	15	1,044	18.0	53.5
eravacycline	1,468	1	1	3	6	827	13.0	59.0
0-17 years	17	2	6	6	6	317	23.8	75.6
18-24 years	55	1	4	6	6	30	6.0	4.2
25-40 years	206	1	3	6	6	827	20.8	95.9
41-64 years	528	1	2	5	6	597	13.5	47.9
≥ 65 years	662	1	1	2	3	743	10.5	53.6

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
doravirine	24,774	1	3	7	18	1,935	23.7	72.4
0-17 years	*****	2	8	12	46	210	48.2	80.8
18-24 years	*****	1	4	9	28	495	29.5	63.8
25-40 years	3,532	1	4	10	26	1,622	29.0	71.7
41-64 years	15,957	1	3	7	18	1,935	23.9	74.6
≥ 65 years	5,012	1	2	5	13	1,570	18.8	65.5
moxetumomab pasudotox-tdfk	391	1	1	1	23	131	9.3	14.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	22	26	36	16.6	13.7
41-64 years	*****	1	1	1	23	131	9.6	17.3
≥ 65 years	280	1	1	1	23	119	9.0	13.6
fremanezumab-vfrm	228,411	1	3	7	21	2,038	25.7	75.0
0-17 years	1,329	1	3	6	19	1,798	21.9	73.1
18-24 years	13,267	1	3	7	22	1,490	25.0	65.9
25-40 years	62,751	1	3	7	20	1,907	25.0	73.2
41-64 years	124,593	1	3	7	21	2,038	26.1	75.7
≥ 65 years	26,471	1	3	6	20	1,752	25.9	80.2
duvelisib	973	1	3	6	16	1,255	18.1	56.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	5	6	22	38	39	22.0	18.5
41-64 years	*****	1	3	7	23	414	22.7	47.3
≥ 65 years	820	1	2	6	15	1,255	17.3	58.1

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
galcanezumab-gnlm	593,846	1	3	7	20	1,912	25.2	75.7
0-17 years	2,568	1	3	7	19	1,167	21.0	56.1
18-24 years	33,623	1	3	7	19	1,517	22.4	62.6
25-40 years	166,329	1	3	7	20	1,837	24.7	72.4
41-64 years	318,475	1	3	7	20	1,912	25.4	76.2
≥ 65 years	72,851	1	3	6	19	1,676	26.9	86.0
dacomitinib	113	1	3	6	16	112	16.3	22.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	22	1	3	9	45	112	26.7	33.5
≥ 65 years	91	1	3	6	16	105	13.7	18.7
cemiplimab-rwlc	102,547	1	20	20	20	1,616	23.8	29.0
0-17 years	*****	86	86	131	175	175	130.5	62.9
18-24 years	*****	19	20	20	20	20	19.9	0.4
25-40 years	*****	12	20	20	21	357	25.9	29.5
41-64 years	8,768	1	20	20	20	1,486	24.8	36.9
≥ 65 years	93,470	1	20	20	20	1,616	23.7	28.1
sarecycline	22,813	1	4	12	32	1,960	38.2	92.2
0-17 years	11,210	1	4	12	33	1,960	39.2	94.8
18-24 years	5,645	1	4	11	30	1,265	37.0	86.2
25-40 years	3,604	1	4	10	29	1,415	35.1	85.4
41-64 years	2,136	1	4	12	34	1,478	42.0	104.5
≥ 65 years	218	1	3	9	27	555	34.1	76.6

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
omadacycline	6,256	1	2	6	28	1,399	44.3	111.9
0-17 years	130	1	5	6	13	526	16.4	48.5
18-24 years	122	1	6	15	46	744	54.7	109.5
25-40 years	541	1	3	7	29	1,335	39.3	100.6
41-64 years	2,392	1	3	8	37	1,399	50.1	118.2
≥ 65 years	3,071	1	2	5	23	1,281	41.5	110.4
elapegademase-lvlr	353	1	5	11	26	600	22.6	44.6
0-17 years	130	1	4	8	17	106	14.8	20.0
18-24 years	110	1	6	10	21	391	22.7	45.7
25-40 years	*****	1	8	25	35	600	33.0	61.6
41-64 years	*****	2	3	8	13	14	8.0	5.1
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
inotersen	400	1	3	7	18	381	19.3	43.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	21	1	3	5	22	98	17.2	25.9
41-64 years	54	1	2	6	13	189	18.3	40.3
≥ 65 years	325	1	3	7	19	381	19.6	44.9
talazoparib	1,034	1	3	6	15	1,085	15.6	46.1
0-17 years	*****	6	6	7	11	11	8.0	2.6
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	5	10	22	341	20.2	38.0
41-64 years	457	1	3	6	14	347	14.0	31.7
≥ 65 years	467	1	2	5	14	1,085	16.2	58.3

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
baloxavir marboxil	7,328	1	31	202	421	2,109	316.7	369.6
0-17 years	1,617	1	44	270	445	2,109	346.7	374.6
18-24 years	512	1	17	191	443	1,489	305.4	343.9
25-40 years	1,410	1	22	187	438	1,798	334.8	406.4
41-64 years	2,352	1	22	154	400	1,832	295.6	364.8
≥ 65 years	1,437	1	48	206	387	1,836	303.8	338.7
lorlatinib	2,742	1	3	6	16	1,071	25.3	79.0
0-17 years	154	1	4	10	22	341	24.2	48.6
18-24 years	23	1	2	6	16	211	18.8	43.2
25-40 years	214	1	3	6	14	287	17.5	36.3
41-64 years	1,192	1	3	6	14	916	18.8	50.9
≥ 65 years	1,159	1	3	6	18	1,071	33.7	106.7
revefenacin	33,654	1	10	26	37	1,526	38.9	70.7
0-17 years	*****	3	12	19	38	56	23.2	17.9
18-24 years	*****	1	4	7	12	373	42.0	95.3
25-40 years	264	1	4	13	31	845	38.5	85.9
41-64 years	7,191	1	5	22	39	1,286	40.9	80.0
≥ 65 years	26,164	1	13	27	36	1,526	38.3	67.8
rifamycin	34	1	3	7	32	1,119	69.4	211.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	41	41	65	88	88	64.5	33.2
25-40 years	*****	3	3	4	33	33	13.3	17.0
41-64 years	*****	1	2	6	29	588	46.7	128.0
≥ 65 years	*****	1	4	7	35	1,119	151.3	391.4

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
emapalumab-lzsg	956	1	2	4	6	1,579	8.7	52.3
0-17 years	602	1	2	6	13	254	7.9	12.3
18-24 years	98	1	2	3	6	1,579	21.1	159.6
25-40 years	145	1	2	4	6	134	7.2	13.5
41-64 years	99	1	2	3	6	33	4.2	4.3
≥ 65 years	12	1	2	3	6	23	5.8	6.2
glasdegib	183	1	3	6	12	108	9.9	14.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	3	3	5	6	6	4.5	2.1
41-64 years	*****	1	2	4	10	86	8.7	16.2
≥ 65 years	154	1	3	6	12	108	10.2	14.0
larotrectinib	658	1	2	6	14	875	17.4	49.0
0-17 years	214	1	2	7	18	239	17.3	34.8
18-24 years	21	1	4	8	20	30	11.7	9.8
25-40 years	29	1	3	7	18	185	29.4	50.7
41-64 years	158	1	2	5	11	875	19.7	76.6
≥ 65 years	236	1	2	6	13	322	15.0	36.7
amifampridine	1,806	1	3	6	15	1,127	16.5	53.3
0-17 years	28	1	3	6	10	60	9.1	11.5
18-24 years	59	1	3	6	17	588	21.5	76.3
25-40 years	105	1	4	11	23	287	23.0	39.9
41-64 years	549	1	3	7	19	943	20.5	61.2
≥ 65 years	1,065	1	2	5	13	1,127	13.7	48.8

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
gilteritinib	4,005	1	3	9	26	858	26.2	54.7
0-17 years	77	1	4	12	48	591	48.0	99.1
18-24 years	80	1	3	9	35	286	28.6	48.8
25-40 years	283	1	4	12	35	363	30.2	47.5
41-64 years	1,069	1	3	9	25	858	25.7	58.3
≥ 65 years	2,496	1	3	9	25	784	25.3	52.0
prucalopride	91,125	1	3	9	27	1,866	36.0	99.1
0-17 years	1,452	1	3	9	26	1,173	33.6	87.8
18-24 years	4,924	1	3	8	25	1,617	33.3	98.7
25-40 years	15,441	1	3	8	24	1,714	32.6	92.7
41-64 years	39,069	1	3	9	26	1,866	35.7	99.6
≥ 65 years	30,239	1	3	9	29	1,754	38.7	101.9
calaspargase pegol-mknl	505	1	24	35	55	387	49.4	38.5
0-17 years	469	1	24	35	55	387	49.5	38.8
18-24 years	*****	4	27	38	57	156	49.1	33.8
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	*****	20	20	20	20	20	20.0	NaN
tagraxofusp-erzs	432	1	13	20	25	416	24.5	37.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	15	19	26	34	17.8	10.5
25-40 years	*****	1	9	28	43	62	27.8	21.2
41-64 years	25	2	4	20	29	75	21.1	16.6
≥ 65 years	385	1	13	19	25	416	24.9	39.8

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
ravulizumab	25,434	1	55	55	55	1,769	53.1	35.6
0-17 years	1,604	1	27	55	55	369	49.3	28.4
18-24 years	932	1	55	55	56	868	58.5	45.1
25-40 years	4,023	1	55	55	57	1,769	58.3	53.5
41-64 years	6,843	1	54	55	55	1,201	53.5	38.3
≥ 65 years	12,032	1	55	55	55	923	51.2	24.6

*NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 8a. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<i>mogamulizumab-kpkc</i>	1,075	1	6	6	8	560	12.0	35.3
<i>patisiran</i>	579	1	20	20	21	549	25.9	35.0
<i>segesterone acetate and ethinyl estradiol vaginal system</i>	2,925	1	105	281	340	1,375	255.0	174.1
<i>migalastat</i>	163	1	3	6	23	1,682	46.2	185.8
<i>stiripentol</i>	322	1	3	8	23	384	39.7	78.2
<i>cenegermin-bkbj</i>	3,212	1	1	5	22	1,712	66.8	184.8
<i>lanadelumab</i>	1,096	1	3	7	17	2,085	29.4	110.3
<i>eravacycline</i>	426	1	1	3	7	743	15.9	64.2
<i>doravirine</i>	5,229	1	3	7	20	1,935	32.5	106.9
<i>moxetumomab pasudotox-tdfk</i>	42	1	1	1	1	131	6.5	21.1
<i>fremanezumab-vfrm</i>	59,541	1	3	8	23	2,038	29.9	88.8
<i>duvelisib</i>	315	1	3	6	16	494	18.7	46.3
<i>galcanezumab-gnlm</i>	141,488	1	3	8	25	1,912	31.5	92.7
<i>dacomitinib</i>	41	1	4	6	34	112	22.3	29.2
<i>cemiplimab-rwlc</i>	10,771	1	20	20	20	1,486	22.8	21.8
<i>sarecycline</i>	9,557	1	4	11	30	1,403	37.8	92.0
<i>omadacycline</i>	2,409	1	3	10	48	1,399	57.3	126.5
<i>elapegademase-lvlr</i>	35	1	4	7	25	176	22.7	36.1
<i>inotersen</i>	85	1	2	6	13	381	18.0	52.5
<i>talazoparib</i>	390	1	3	5	14	341	16.1	37.5
<i>baloxavir marboxil</i>	5,836	1	30	236	449	2,109	339.7	387.4
<i>lorlatinib</i>	807	1	2	6	16	1,071	32.0	104.9
<i>revefenacin</i>	7,372	1	5	22	41	1,526	49.0	104.1
<i>rifamycin</i>	22	1	4	14	33	1,119	95.9	259.5
<i>emapalumab-lzsg</i>	60	1	2	3	6	139	9.0	24.4
<i>glasdegib</i>	121	1	3	7	12	108	11.2	16.2

Table 8a. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<i>larotrectinib</i>	235	1	3	6	17	875	21.6	69.3
<i>amifampridine</i>	317	1	3	6	18	1,127	27.7	104.4
<i>gilteritinib</i>	1,482	1	4	10	30	719	29.8	58.2
<i>prucalopride</i>	25,339	1	4	11	35	1,866	51.6	135.0
<i>calaspargase pegol-mknl</i>	196	1	27	35	51	158	46.3	31.7
<i>tagraxofusp-erzs</i>	83	1	20	25	33	156	28.1	20.2
<i>ravulizumab</i>	3,313	1	13	13	54	1,047	29.2	40.6

Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
mogamulizumab-kpkc	1,075	1	6	6	8	560	12.0	35.3
Female	467	3	6	6	10	496	12.1	32.6
Male	608	1	6	6	7	560	11.8	37.3
patisiran	579	1	20	20	21	549	25.9	35.0
Female	200	1	20	20	21	549	27.3	46.5
Male	379	1	20	20	21	285	25.1	27.1
segesterone acetate and ethinyl estradiol vaginal system	2,925	1	105	281	340	1,375	255.0	174.1
Female	*****	1	105	281	340	1,375	254.9	174.0
Male	*****	5	96	316	354	729	295.0	231.6
migalastat	163	1	3	6	23	1,682	46.2	185.8
Female	80	1	3	6	24	1,485	46.5	176.6
Male	83	1	3	5	21	1,682	45.9	195.2
stiripentol	322	1	3	8	23	384	39.7	78.2
Female	162	1	3	7	24	384	38.5	75.7
Male	160	1	3	9	23	348	40.9	80.9
cenegermin-bkbj	3,212	1	1	5	22	1,712	66.8	184.8
Female	2,134	1	1	5	22	1,712	67.3	183.3
Male	1,078	1	1	5	22	1,684	65.9	187.7
lanadelumab	1,096	1	3	7	17	2,085	29.4	110.3
Female	729	1	3	6	15	2,085	30.2	120.5
Male	367	1	3	7	20	1,044	27.7	86.9
eravacycline	426	1	1	3	7	743	15.9	64.2
Female	219	1	1	4	8	393	16.8	54.1
Male	207	1	1	3	6	743	15.0	73.5

Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
doravirine	5,229	1	3	7	20	1,935	32.5	106.9
Female	1,392	1	3	8	23	1,935	30.1	84.8
Male	3,837	1	3	6	19	1,622	33.4	113.8
moxetumomab pasudotox-tdfk	42	1	1	1	1	131	6.5	21.1
Female	*****	1	1	1	1	1	1.0	0.0
Male	*****	1	1	1	1	131	7.2	22.4
fremanezumab-vfrm	59,541	1	3	8	23	2,038	29.9	88.8
Female	51,594	1	3	8	23	1,915	29.8	88.1
Male	7,947	1	3	8	24	2,038	30.7	93.1
duvelisib	315	1	3	6	16	494	18.7	46.3
Female	141	1	3	6	16	281	16.0	30.4
Male	174	1	3	6	18	494	20.9	56.0
galcanezumab-gnlm	141,488	1	3	8	25	1,912	31.5	92.7
Female	120,683	1	3	8	25	1,912	30.8	90.0
Male	20,805	1	3	9	26	1,844	35.6	106.6
dacomitinib	41	1	4	6	34	112	22.3	29.2
Female	26	1	3	8	34	112	23.0	30.5
Male	15	1	6	6	39	105	21.1	27.7
cemiplimab-rwlc	10,771	1	20	20	20	1,486	22.8	21.8
Female	3,128	1	20	20	20	559	22.9	16.7
Male	7,643	1	20	20	20	1,486	22.8	23.6
sarecycline	9,557	1	4	11	30	1,403	37.8	92.0
Female	5,743	1	4	11	30	1,403	38.0	92.8
Male	3,814	1	4	12	30	1,282	37.4	90.8

Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
omadacycline	2,409	1	3	10	48	1,399	57.3	126.5
Female	1,252	1	3	10	45	1,399	58.7	135.8
Male	1,157	1	3	11	50	1,137	55.7	115.8
elapegademase-ivlr	35	1	4	7	25	176	22.7	36.1
Female	16	2	5	9	19	105	17.6	25.1
Male	19	1	4	7	28	176	27.1	43.5
inotersen	85	1	2	6	13	381	18.0	52.5
Female	40	1	2	5	10	303	14.7	47.3
Male	45	1	3	7	19	381	21.0	57.1
talazoparib	390	1	3	5	14	341	16.1	37.5
Female	245	1	2	6	14	341	15.6	35.0
Male	145	1	3	5	12	330	16.7	41.4
baloxavir marboxil	5,836	1	30	236	449	2,109	339.7	387.4
Female	3,193	1	30	222	439	2,109	332.2	382.6
Male	2,643	1	32	252	459	1,852	348.8	393.0
lorlatinib	807	1	2	6	16	1,071	32.0	104.9
Female	444	1	3	7	17	1,071	40.6	128.3
Male	363	1	2	6	15	771	21.5	64.5
revefenacin	7,372	1	5	22	41	1,526	49.0	104.1
Female	4,364	1	5	23	41	1,526	48.2	103.3
Male	3,008	1	5	22	42	1,410	50.1	105.3
rifamycin	22	1	4	14	33	1,119	95.9	259.5
Female	*****	1	4	5	24	88	20.6	28.6
Male	*****	1	6	14	33	1,119	148.1	331.9

Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
emapalumab-lzsg	60	1	2	3	6	139	9.0	24.4
Female	27	2	2	2	6	134	9.6	25.7
Male	33	1	3	3	6	139	8.5	23.6
glasdegib	121	1	3	7	12	108	11.2	16.2
Female	54	1	2	6	14	108	11.4	18.4
Male	67	1	4	8	12	83	10.9	14.3
larotrectinib	235	1	3	6	17	875	21.6	69.3
Female	136	1	3	8	17	336	21.4	48.6
Male	99	1	2	5	16	875	21.9	90.5
amifampridine	317	1	3	6	18	1,127	27.7	104.4
Female	185	1	3	6	19	1,127	29.7	113.4
Male	132	1	3	6	17	943	24.8	90.7
gilteritinib	1,482	1	4	10	30	719	29.8	58.2
Female	752	1	4	11	29	719	30.4	60.2
Male	730	1	4	10	30	546	29.1	56.2
prucalopride	25,339	1	4	11	35	1,866	51.6	135.0
Female	20,105	1	4	11	35	1,866	51.7	135.0
Male	5,234	1	3	10	33	1,754	51.3	134.8
calaspargase pegol-mknl	196	1	27	35	51	158	46.3	31.7
Female	76	7	33	41	66	156	54.7	35.9
Male	120	1	27	34	48	158	41.0	27.6
tagraxofusp-erzs	83	1	20	25	33	156	28.1	20.2
Female	14	2	26	34	41	69	33.7	15.2
Male	69	1	20	23	31	156	27.0	21.0

Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
ravulizumab	3,313	1	13	13	54	1,047	29.2	40.6
Female	1,712	1	13	13	55	1,047	30.7	46.7
Male	1,601	1	13	13	48	398	27.7	32.8

****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
mogamulizumab-	1,075	1	6	6	8	560	12.0	35.3
0-17 years	*****	3	3	8	13	13	8.0	7.1
18-24 years	*****	6	6	6	6	6	6.0	0.0
25-40 years	*****	4	6	7	13	288	23.8	56.7
41-64 years	226	1	6	6	13	146	11.4	15.6
≥ 65 years	819	4	6	6	7	560	11.7	38.4
patisiran	579	1	20	20	21	549	25.9	35.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	20	20	20	20	20	20.0	NaN
25-40 years	*****	2	11	20	68	549	100.5	181.2
41-64 years	125	1	20	20	22	165	25.2	23.9
≥ 65 years	442	1	20	20	20	285	24.2	23.6
segesterone acetate and ethinyl estradiol vaginal system	2,925	1	105	281	340	1,375	255.0	174.1
0-17 years	128	1	43	254	332	1,124	224.2	174.9
18-24 years	897	1	113	285	339	1,224	254.6	168.2
25-40 years	1,590	1	104	285	340	1,375	257.4	175.9
41-64 years	310	1	113	279	345	1,068	256.9	181.1
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
migalastat	163	1	3	6	23	1,682	46.2	185.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	13	1	3	4	11	111	22.0	36.3
25-40 years	42	1	3	12	47	1,682	76.9	263.8
41-64 years	64	1	3	7	21	1,485	43.7	194.9

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
≥ 65 years	44	1	1	4	16	473	27.5	78.4
stiripentol	322	1	3	8	23	384	39.7	78.2
0-17 years	235	1	3	8	25	349	36.5	69.9
18-24 years	66	1	3	8	20	384	54.9	103.7
25-40 years	21	1	2	5	17	327	27.0	71.2
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
cenegermin-bkbj	3,212	1	1	5	22	1,712	66.8	184.8
0-17 years	26	1	1	5	22	389	52.0	110.8
18-24 years	18	1	2	5	7	68	10.7	17.3
25-40 years	142	1	1	5	14	1,194	37.5	118.1
41-64 years	628	1	2	6	26	1,684	60.9	170.7
≥ 65 years	2,398	1	1	5	22	1,712	70.7	192.5
lanadelumab	1,096	1	3	7	17	2,085	29.4	110.3
0-17 years	101	1	3	7	14	221	17.5	35.7
18-24 years	114	1	3	7	21	202	18.9	31.1
25-40 years	302	1	3	7	16	2,085	39.1	153.5
41-64 years	395	1	3	7	19	917	26.6	92.2
≥ 65 years	184	1	3	6	14	1,044	32.4	119.0
eravacycline	426	1	1	3	7	743	15.9	64.2
0-17 years	*****	317	317	317	317	317	317.0	NaN
18-24 years	*****	1	1	4	7	30	7.8	11.1
25-40 years	*****	1	2	5	8	735	21.2	99.0
41-64 years	174	1	1	4	7	105	8.6	15.9
≥ 65 years	190	1	1	3	8	743	19.8	75.4

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
doravirine	5,229	1	3	7	20	1,935	32.5	106.9
0-17 years	*****	8	8	11	210	210	76.3	115.8
18-24 years	*****	1	3	12	46	490	41.9	78.2
25-40 years	849	1	3	10	28	1,622	37.7	102.5
41-64 years	3,216	1	3	7	20	1,935	33.0	108.8
≥ 65 years	1,099	1	2	5	14	1,570	26.5	105.9
moxetumomab	42	1	1	1	1	131	6.5	21.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	20	20	20	20	20	20.0	NaN
41-64 years	*****	1	1	1	1	131	17.3	46.0
≥ 65 years	*****	1	1	1	1	35	3.4	7.9
fremanezumab-	59,541	1	3	8	23	2,038	29.9	88.8
0-17 years	411	1	3	7	19	675	22.2	53.5
18-24 years	3,859	1	3	8	24	1,461	27.2	69.3
25-40 years	17,034	1	3	8	22	1,889	27.8	81.8
41-64 years	31,358	1	3	8	24	2,038	31.1	93.2
≥ 65 years	6,879	1	3	8	24	1,752	31.6	95.6
duvelisib	315	1	3	6	16	494	18.7	46.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	5	5	7	39	39	17.0	19.1
41-64 years	*****	1	3	6	15	414	17.1	51.2
≥ 65 years	246	1	3	6	18	494	19.1	45.3
galcanezumab-	141,488	1	3	8	25	1,912	31.5	92.7
0-17 years	732	1	3	8	24	756	27.8	68.4

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
18-24 years	8,618	1	3	8	24	1,426	27.0	73.9
25-40 years	41,518	1	3	8	24	1,837	30.0	86.5
41-64 years	72,841	1	3	9	25	1,912	32.0	94.1
≥ 65 years	17,779	1	3	8	26	1,676	35.6	108.2
dacomitinib	41	1	4	6	34	112	22.3	29.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	*****	1	6	39	62	112	42.0	41.1
≥ 65 years	*****	1	4	6	28	105	16.0	21.3
cemiplimab-rwlc	10,771	1	20	20	20	1,486	22.8	21.8
0-17 years	*****	86	86	86	86	86	86.0	NaN
18-24 years	*****	19	19	20	20	20	19.5	0.7
25-40 years	*****	13	20	20	24	357	30.2	51.4
41-64 years	947	1	20	20	21	1,486	25.1	49.6
≥ 65 years	9,778	1	20	20	20	679	22.6	16.5
sarecycline	9,557	1	4	11	30	1,403	37.8	92.0
0-17 years	4,612	1	4	12	30	1,403	38.0	97.1
18-24 years	2,499	1	4	11	27	977	36.5	84.5
25-40 years	1,623	1	4	10	28	1,282	34.1	79.1
41-64 years	758	1	5	12	35	873	46.1	105.7
≥ 65 years	65	1	6	14	86	555	64.0	115.2

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
omadacycline	2,409	1	3	10	48	1,399	57.3	126.5
0-17 years	21	1	4	10	22	138	22.0	35.3
18-24 years	41	1	4	14	46	744	68.7	139.4
25-40 years	185	1	4	11	45	390	45.1	77.6
41-64 years	953	1	4	14	62	1,399	68.1	142.5
≥ 65 years	1,209	1	2	8	39	1,137	50.8	119.0
elapegademase-	35	1	4	7	25	176	22.7	36.1
0-17 years	13	1	4	11	28	105	25.4	31.8
18-24 years	11	1	4	6	11	176	21.7	51.3
25-40 years	*****	4	7	13	29	86	22.0	24.6
41-64 years	*****	6	6	6	6	6	6.0	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
inotersen	85	1	2	6	13	381	18.0	52.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	4	4	20	36	36	20.0	22.6
41-64 years	*****	1	2	6	13	84	14.4	22.9
≥ 65 years	70	1	2	6	13	381	18.6	57.1
talazoparib	390	1	3	5	14	341	16.1	37.5
0-17 years	*****	11	11	11	11	11	11.0	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	3	8	22	341	29.8	61.2
41-64 years	143	1	2	5	11	287	14.3	31.3
≥ 65 years	209	1	3	5	12	330	14.8	35.7
baloxavir marboxil	5,836	1	30	236	449	2,109	339.7	387.4
0-17 years	1,375	1	45	288	461	2,109	363.3	386.4

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
18-24 years	444	1	15	163	461	1,489	307.7	349.4
25-40 years	1,204	1	21	206	460	1,798	348.8	420.8
41-64 years	1,829	1	19	199	437	1,832	323.8	387.9
≥ 65 years	984	1	52	274	432	1,836	339.7	358.8
lorlatinib	807	1	2	6	16	1,071	32.0	104.9
0-17 years	*****	1	4	9	20	341	25.9	67.1
18-24 years	*****	1	1	5	16	24	8.5	9.4
25-40 years	66	1	3	6	18	287	21.0	44.6
41-64 years	351	1	2	5	13	357	18.6	45.1
≥ 65 years	336	1	3	7	19	1,071	49.5	151.0
revefenacin	7,372	1	5	22	41	1,526	49.0	104.1
0-17 years	*****	19	19	38	56	56	37.5	26.2
18-24 years	*****	3	4	8	14	373	45.7	106.5
25-40 years	82	1	4	12	27	845	44.7	117.7
41-64 years	2,011	1	4	18	47	971	52.2	101.9
≥ 65 years	5,265	1	6	24	40	1,526	47.8	104.8
rifamycin	22	1	4	14	33	1,119	95.9	259.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	41	41	65	88	88	64.5	33.2
25-40 years	*****	4	4	19	33	33	18.5	20.5
41-64 years	*****	1	4	12	31	588	57.4	153.9
≥ 65 years	*****	1	3	11	568	1,119	285.3	555.9

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
emapalumab-lzsg	60	1	2	3	6	139	9.0	24.4
0-17 years	33	1	2	3	6	16	4.1	3.3
18-24 years	*****	2	3	6	6	139	19.4	44.9
25-40 years	*****	2	2	3	12	134	25.8	53.1
41-64 years	*****	1	2	3	10	33	7.9	10.9
≥ 65 years	*****	2	2	3	3	3	2.5	0.6
glasdegib	121	1	3	7	12	108	11.2	16.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	3	3	3	3	3	3.0	NaN
41-64 years	*****	1	2	7	14	86	13.0	21.7
≥ 65 years	106	1	3	7	12	108	11.0	15.5
larotrectinib	235	1	3	6	17	875	21.6	69.3
0-17 years	49	1	2	4	17	219	16.6	34.0
18-24 years	*****	1	3	12	28	30	15.1	11.9
25-40 years	*****	1	3	8	18	185	32.5	58.7
41-64 years	63	1	4	7	13	875	33.3	117.9
≥ 65 years	99	1	3	5	16	296	15.2	37.0
amifampridine	317	1	3	6	18	1,127	27.7	104.4
0-17 years	*****	1	5	6	9	22	8.2	7.2
18-24 years	*****	1	3	13	27	588	76.9	192.0
25-40 years	22	1	4	16	46	111	28.1	30.6
41-64 years	103	1	3	7	21	943	31.7	104.6
≥ 65 years	174	1	3	6	14	1,127	23.7	107.1
gilteritinib	1,482	1	4	10	30	719	29.8	58.2
0-17 years	28	1	5	18	47	508	49.4	97.8

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
18-24 years	24	1	3	10	58	286	36.9	61.7
25-40 years	113	1	6	18	44	248	40.0	54.7
41-64 years	374	1	4	9	29	719	31.9	68.0
≥ 65 years	943	1	4	10	27	510	26.9	52.3
prucalopride	25,339	1	4	11	35	1,866	51.6	135.0
0-17 years	421	1	4	10	31	1,173	43.9	113.7
18-24 years	1,416	1	4	11	34	1,617	49.8	133.4
25-40 years	4,331	1	4	10	31	1,620	45.1	118.6
41-64 years	10,716	1	3	10	34	1,866	50.1	135.9
≥ 65 years	8,455	1	4	11	39	1,754	57.5	142.5
calaspargase pegol-	196	1	27	35	51	158	46.3	31.7
0-17 years	177	1	27	35	50	158	46.2	31.7
18-24 years	*****	20	33	37	57	156	48.8	32.5
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	*****	20	20	20	20	20	20.0	NaN
tagraxofusp-erzs	83	1	20	25	33	156	28.1	20.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	20	20	26	34	34	26.7	7.0
25-40 years	*****	26	26	30	41	41	32.3	7.8
41-64 years	*****	2	20	21	34	40	24.2	11.6
≥ 65 years	68	1	20	25	33	156	28.5	21.9

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
ravulizumab	3,313	1	13	13	54	1,047	29.2	40.6
0-17 years	197	1	13	25	55	315	36.6	36.3
18-24 years	126	10	13	16	55	559	42.0	63.7
25-40 years	496	1	13	15	55	830	37.8	49.9
41-64 years	838	1	13	14	55	1,047	33.7	49.9
≥ 65 years	1,656	1	13	13	16	524	22.6	27.0

*NaN: Not a number

****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 9. Summary of Reasons Treatment Episodes Ended for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024^{1,2}

Censoring Reason									
		End of Exposure Episode ³		Occurrence of User-Defined Censoring Criteria ⁴		Disenrollment ⁵		End of Data ⁶	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>mogamulizumab-kpkc</i>	18,570	18,569	100.0%	0	0.0%	*****	*****	*****	*****
<i>patisiran</i>	14,710	14,707	100.0%	0	0.0%	18	0.1%	11	0.1%
<i>segesterone acetate and ethinyl estradiol vaginal system</i>	23,401	23,400	100.0%	0	0.0%	6,738	28.8%	2,915	12.5%
<i>migalastat</i>	1,130	1,126	99.6%	0	0.0%	190	16.8%	106	9.4%
<i>stiripentol</i>	1,841	1,839	99.9%	0	0.0%	308	16.7%	225	12.2%
<i>cenegermin-bkbj</i>	14,360	14,302	99.6%	0	0.0%	648	4.5%	501	3.5%
<i>lanadelumab</i>	9,281	9,263	99.8%	0	0.0%	844	9.1%	476	5.1%
<i>eravacycline</i>	2,579	2,566	99.5%	0	0.0%	*****	*****	*****	*****
<i>doravirine</i>	32,989	32,714	99.2%	0	0.0%	5,150	15.6%	3,282	9.9%
<i>moxetumomab pasudotox-tdfk</i>	441	441	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>fremanezumab-vfrm</i>	321,795	321,587	99.9%	0	0.0%	36,531	11.4%	20,354	6.3%
<i>duvelisib</i>	1,596	1,512	94.7%	0	0.0%	71	4.4%	43	2.7%
<i>galcanezumab-gnlm</i>	806,021	805,434	99.9%	0	0.0%	87,694	10.9%	48,380	6.0%
<i>dacomitinib</i>	208	195	93.8%	0	0.0%	*****	*****	*****	*****
<i>cemiplimab-rwlc</i>	114,854	114,844	100.0%	0	0.0%	109	0.1%	106	0.1%
<i>sarecycline</i>	40,752	40,751	100.0%	0	0.0%	1,678	4.1%	575	1.4%
<i>omadacycline</i>	14,819	14,758	99.6%	0	0.0%	567	3.8%	405	2.7%
<i>elapegademase-lvlr</i>	395	395	100.0%	0	0.0%	32	8.1%	28	7.1%
<i>inotersen</i>	519	514	99.0%	0	0.0%	*****	*****	*****	*****
<i>talazoparib</i>	1,844	1,809	98.1%	0	0.0%	248	13.4%	187	10.1%
<i>baloxavir marboxil</i>	137,426	137,388	100.0%	0	0.0%	254	0.2%	62	0.0%
<i>lorlatinib</i>	4,362	4,163	95.4%	0	0.0%	612	14.0%	365	8.4%

Table 9. Summary of Reasons Treatment Episodes Ended for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024^{1,2}

Censoring Reason									
	Total Number of Episodes	End of Exposure Episode ³		Occurrence of User-Defined Censoring Criteria ⁴		Disenrollment ⁵		End of Data ⁶	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>revefenacin</i>	49,257	48,710	98.9%	0	0.0%	2,584	5.2%	1,550	3.1%
<i>rifamycin</i>	144	*****	*****	0	0.0%	*****	*****	0	0.0%
<i>emapalumab-lzsg</i>	1,028	*****	*****	0	0.0%	*****	*****	*****	*****
<i>glasdegib</i>	576	447	77.6%	0	0.0%	*****	*****	*****	*****
<i>larotrectinib</i>	1,175	1,113	94.7%	0	0.0%	153	13.0%	91	7.7%
<i>amifampridine</i>	2,346	2,283	97.3%	0	0.0%	335	14.3%	239	10.2%
<i>gilteritinib</i>	6,675	6,171	92.4%	0	0.0%	498	7.5%	303	4.5%
<i>prucalopride</i>	140,131	139,711	99.7%	0	0.0%	14,712	10.5%	9,080	6.5%
<i>calaspargase pegol-mknl</i>	894	894	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>tagraxofusp-erzs</i>	567	567	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>ravulizumab</i>	29,128	29,116	100.0%	0	0.0%	310	1.1%	248	0.9%

¹An episode may be censored due to more than one reason if they occur on the same date. Therefore, the sum of the reasons for censoring may be greater than the total number of episodes.

²All reasons for censoring may not be displayed to prevent publication of small cells.

³Represents episodes censored due to end of the exposure episode. In as-treated analyses, exposure episodes are defined using days supplied as recorded in outpatient pharmacy dispensing records, and episodes end after days supplied are exhausted or a pre-determined maximum episode duration is met. In point exposure analyses, exposure episodes end when a pre-determined maximum episode duration is met.

⁴Represents episodes censored due to occurrence of additional user-defined criteria using drug, procedure, diagnosis, and/or laboratory codes.

⁵Represents episodes censored due to disenrollment from health plan. Data Partners often artificially assign a "disenrollment" date equal to data end date for members still enrolled on that date. Therefore, a patient may have dual reasons for censoring as "disenrollment" and "end of data" on the same day - this can be interpreted as right-censoring in most cases.

⁶Represents episodes censored due to Data Partner data end date. This end date represents the last day of the most recent year-month in which all of a Data Partner's data tables in the Sentinel Common Data Model have at least 80% of the record count relative to the prior month.

*******Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.**

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	mogamulizumab-kpkc		patisiran		segesterone acetate and ethinyl estradiol	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements						
Enrolled at any point during the query period	346,550,804	N/A	346,550,804	N/A	346,550,804	N/A
Had required coverage type (medical and/or drug coverage)	258,772,839	87,777,965	258,772,839	87,777,965	258,772,839	87,777,965
Enrolled during specified age range	258,766,609	6,230	258,766,609	6,230	258,766,609	6,230
Had requestable medical charts	258,766,609	0	258,766,609	0	258,766,609	0
Met demographic requirements (sex, race, and Hispanic origin)	258,674,002	92,607	258,674,002	92,607	258,674,002	92,607
Members with a valid index event						
Had any cohort-defining claim during the query period	1,251	258,672,751	672	258,673,330	24,101	258,649,901
Claim recorded during specified age range	1,251	0	672	0	24,101	0
Episode defining index claim recorded during the query period	1,251	0	672	0	24,101	0
Members with required pre-index history						
Had sufficient pre-index continuous enrollment	1,147	104	625	47	19,514	4,587
Met inclusion and exclusion criteria	1,147	0	625	0	19,514	0
Members with required post-index follow-up						
Had sufficient post-index continuous enrollment	1,147	0	625	0	19,514	0
Final cohort						
Number of members	1,147	N/A	625	N/A	19,514	N/A

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	migalastat		stiripentol		cenegermin-bkbj	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements						
Enrolled at any point during the query period	346,550,804	N/A	346,550,804	N/A	346,550,804	N/A
Had required coverage type (medical and/or drug coverage)	258,772,839	87,777,965	258,772,839	87,777,965	258,772,839	87,777,965
Enrolled during specified age range	258,766,609	6,230	258,766,609	6,230	258,766,609	6,230
Had requestable medical charts	258,766,609	0	258,766,609	0	258,766,609	0
Met demographic requirements (sex, race, and Hispanic origin)	258,674,002	92,607	258,674,002	92,607	258,674,002	92,607
Members with a valid index event						
Had any cohort-defining claim during the query period	327	258,673,675	588	258,673,414	10,071	258,663,931
Claim recorded during specified age range	327	0	588	0	10,071	0
Episode defining index claim recorded during the query period	327	0	588	0	10,071	0
Members with required pre-index history						
Had sufficient pre-index continuous enrollment	261	66	531	57	9,413	658
Met inclusion and exclusion criteria	261	0	531	0	9,413	0
Members with required post-index follow-up						
Had sufficient post-index continuous enrollment	261	0	531	0	9,413	0
Final cohort						
Number of members	261	N/A	531	N/A	9,413	N/A

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	lanadelumab		eravacycline		doravirine	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements						
Enrolled at any point during the query period	346,550,804	N/A	346,550,804	N/A	346,550,804	N/A
Had required coverage type (medical and/or drug coverage)	258,772,839	87,777,965	258,772,839	87,777,965	258,772,839	87,777,965
Enrolled during specified age range	258,766,609	6,230	258,766,609	6,230	258,766,609	6,230
Had requestable medical charts	258,766,609	0	258,766,609	0	258,766,609	0
Met demographic requirements (sex, race, and Hispanic origin)	258,674,002	92,607	258,674,002	92,607	258,674,002	92,607
Members with a valid index event						
Had any cohort-defining claim during the query period	1,671	258,672,331	1,271	258,672,731	10,036	258,663,966
Claim recorded during specified age range	1,671	0	1,271	0	10,036	0
Episode defining index claim recorded during the query period	1,671	0	1,271	0	10,036	0
Members with required pre-index history						
Had sufficient pre-index continuous enrollment	1,451	220	1,111	160	8,215	1,821
Met inclusion and exclusion criteria	1,451	0	1,111	0	8,215	0
Members with required post-index follow-up						
Had sufficient post-index continuous enrollment	1,451	0	1,111	0	8,215	0
Final cohort						
Number of members	1,451	N/A	1,111	N/A	8,215	N/A

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	moxetumomab pasudotox-tdfk		fremanezumab-vfrm		duvelisib	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements						
Enrolled at any point during the query period	346,550,804	N/A	346,550,804	N/A	346,550,804	N/A
Had required coverage type (medical and/or drug coverage)	258,772,839	87,777,965	258,772,839	87,777,965	258,772,839	87,777,965
Enrolled during specified age range	258,766,609	6,230	258,766,609	6,230	258,766,609	6,230
Had requestable medical charts	258,766,609	0	258,766,609	0	258,766,609	0
Met demographic requirements (sex, race, and Hispanic origin)	258,674,002	92,607	258,674,002	92,607	258,674,002	92,607
Members with a valid index event						
Had any cohort-defining claim during the query period	*****	*****	109,400	258,564,602	676	258,673,326
Claim recorded during specified age range	*****	0	109,400	0	676	0
Episode defining index claim recorded during the query period	*****	0	109,400	0	676	0
Members with required pre-index history						
Had sufficient pre-index continuous enrollment	50	*****	93,384	16,016	623	53
Met inclusion and exclusion criteria	50	0	93,384	0	623	0
Members with required post-index follow-up						
Had sufficient post-index continuous enrollment	50	0	93,384	0	623	0
Final cohort						
Number of members	50	N/A	93,384	N/A	623	N/A

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	galcanezumab-gnlm		dacomitinib		cemiplimab-rwlc	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements						
Enrolled at any point during the query period	346,550,804	N/A	346,550,804	N/A	346,550,804	N/A
Had required coverage type (medical and/or drug coverage)	258,772,839	87,777,965	258,772,839	87,777,965	258,772,839	87,777,965
Enrolled during specified age range	258,766,609	6,230	258,766,609	6,230	258,766,609	6,230
Had requestable medical charts	258,766,609	0	258,766,609	0	258,766,609	0
Met demographic requirements (sex, race, and Hispanic origin)	258,674,002	92,607	258,674,002	92,607	258,674,002	92,607
Members with a valid index event						
Had any cohort-defining claim during the query period	249,562	258,424,440	110	258,673,892	13,305	258,660,697
Claim recorded during specified age range	249,562	0	110	0	13,305	0
Episode defining index claim recorded during the query period	249,562	0	110	0	13,305	0
Members with required pre-index history						
Had sufficient pre-index continuous enrollment	212,175	37,387	95	15	12,307	998
Met inclusion and exclusion criteria	212,175	0	95	0	12,307	0
Members with required post-index follow-up						
Had sufficient post-index continuous enrollment	212,175	0	95	0	12,307	0
Final cohort						
Number of members	212,175	N/A	95	N/A	12,307	N/A

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	sarecycline		omadacycline		elapegademase-lvlr	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements						
Enrolled at any point during the query period	346,550,804	N/A	346,550,804	N/A	346,550,804	N/A
Had required coverage type (medical and/or drug coverage)	258,772,839	87,777,965	258,772,839	87,777,965	258,772,839	87,777,965
Enrolled during specified age range	258,766,609	6,230	258,766,609	6,230	258,766,609	6,230
Had requestable medical charts	258,766,609	0	258,766,609	0	258,766,609	0
Met demographic requirements (sex, race, and Hispanic origin)	258,674,002	92,607	258,674,002	92,607	258,674,002	92,607
Members with a valid index event						
Had any cohort-defining claim during the query period	19,963	258,654,039	9,695	258,664,307	*****	*****
Claim recorded during specified age range	19,963	0	9,695	0	*****	0
Episode defining index claim recorded during the query period	19,963	0	9,695	0	*****	0
Members with required pre-index history						
Had sufficient pre-index continuous enrollment	17,939	2,024	8,563	1,132	42	*****
Met inclusion and exclusion criteria	17,939	0	8,563	0	42	0
Members with required post-index follow-up						
Had sufficient post-index continuous enrollment	17,939	0	8,563	0	42	0
Final cohort						
Number of members	17,939	N/A	8,563	N/A	42	N/A

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	inotersen		talazoparib		baloxavir marboxil	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements						
Enrolled at any point during the query period	346,550,804	N/A	346,550,804	N/A	346,550,804	N/A
Had required coverage type (medical and/or drug coverage)	258,772,839	87,777,965	258,772,839	87,777,965	258,772,839	87,777,965
Enrolled during specified age range	258,766,609	6,230	258,766,609	6,230	258,766,609	6,230
Had requestable medical charts	258,766,609	0	258,766,609	0	258,766,609	0
Met demographic requirements (sex, race, and Hispanic origin)	258,674,002	92,607	258,674,002	92,607	258,674,002	92,607
Members with a valid index event						
Had any cohort-defining claim during the query period	*****	*****	937	258,673,065	150,478	258,523,524
Claim recorded during specified age range	*****	0	937	0	*****	*****
Episode defining index claim recorded during the query period	*****	0	937	0	*****	0
Members with required pre-index history						
Had sufficient pre-index continuous enrollment	119	*****	810	127	130,098	*****
Met inclusion and exclusion criteria	119	0	810	0	130,098	0
Members with required post-index follow-up						
Had sufficient post-index continuous enrollment	119	0	810	0	130,098	0
Final cohort						
Number of members	119	N/A	810	N/A	130,098	N/A

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	lorlatinib		revedfenacin		rifamycin	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements						
Enrolled at any point during the query period	346,550,804	N/A	346,550,804	N/A	346,550,804	N/A
Had required coverage type (medical and/or drug coverage)	258,772,839	87,777,965	258,772,839	87,777,965	258,772,839	87,777,965
Enrolled during specified age range	258,766,609	6,230	258,766,609	6,230	258,766,609	6,230
Had requestable medical charts	258,766,609	0	258,766,609	0	258,766,609	0
Met demographic requirements (sex, race, and Hispanic origin)	258,674,002	92,607	258,674,002	92,607	258,674,002	92,607
Members with a valid index event						
Had any cohort-defining claim during the query period	1,904	258,672,098	18,295	258,655,707	150	258,673,852
Claim recorded during specified age range	1,904	0	18,295	0	150	0
Episode defining index claim recorded during the query period	1,904	0	18,295	0	150	0
Members with required pre-index history						
Had sufficient pre-index continuous enrollment	1,620	284	15,603	2,692	110	40
Met inclusion and exclusion criteria	1,620	0	15,603	0	110	0
Members with required post-index follow-up						
Had sufficient post-index continuous enrollment	1,620	0	15,603	0	110	0
Final cohort						
Number of members	1,620	N/A	15,603	N/A	110	N/A

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	emapalumab-lzsg		glasdegib		larotrectinib	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements						
Enrolled at any point during the query period	346,550,804	N/A	346,550,804	N/A	346,550,804	N/A
Had required coverage type (medical and/or drug coverage)	258,772,839	87,777,965	258,772,839	87,777,965	258,772,839	87,777,965
Enrolled during specified age range	258,766,609	6,230	258,766,609	6,230	258,766,609	6,230
Had requestable medical charts	258,766,609	0	258,766,609	0	258,766,609	0
Met demographic requirements (sex, race, and Hispanic origin)	258,674,002	92,607	258,674,002	92,607	258,674,002	92,607
Members with a valid index event						
Had any cohort-defining claim during the query period	83	258,673,919	405	258,673,597	624	258,673,378
Claim recorded during specified age range	83	0	405	0	624	0
Episode defining index claim recorded during the query period	83	0	405	0	624	0
Members with required pre-index history						
Had sufficient pre-index continuous enrollment	72	11	393	12	517	107
Met inclusion and exclusion criteria	72	0	393	0	517	0
Members with required post-index follow-up						
Had sufficient post-index continuous enrollment	72	0	393	0	517	0
Final cohort						
Number of members	72	N/A	393	N/A	517	N/A

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	amifampridine		gilteritinib		prucalopride	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements						
Enrolled at any point during the query period	346,550,804	N/A	346,550,804	N/A	346,550,804	N/A
Had required coverage type (medical and/or drug coverage)	258,772,839	87,777,965	258,772,839	87,777,965	258,772,839	87,777,965
Enrolled during specified age range	258,766,609	6,230	258,766,609	6,230	258,766,609	6,230
Had requestable medical charts	258,766,609	0	258,766,609	0	258,766,609	0
Met demographic requirements (sex, race, and Hispanic origin)	258,674,002	92,607	258,674,002	92,607	258,674,002	92,607
Members with a valid index event						
Had any cohort-defining claim during the query period	633	258,673,369	3,042	258,670,960	55,465	258,618,537
Claim recorded during specified age range	633	0	3,042	0	55,465	0
Episode defining index claim recorded during the query period	633	0	3,042	0	55,465	0
Members with required pre-index history						
Had sufficient pre-index continuous enrollment	540	93	2,670	372	49,006	6,459
Met inclusion and exclusion criteria	540	0	2,670	0	49,006	0
Members with required post-index follow-up						
Had sufficient post-index continuous enrollment	540	0	2,670	0	49,006	0
Final cohort						
Number of members	540	N/A	2,670	N/A	49,006	N/A

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	calaspargase pegol-mknl		tagraxofusp-erzs		ravulizumab	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements						
Enrolled at any point during the query period	346,550,804	N/A	346,550,804	N/A	346,550,804	N/A
Had required coverage type (medical and/or drug coverage)	258,772,839	87,777,965	258,772,839	87,777,965	258,772,839	87,777,965
Enrolled during specified age range	258,766,609	6,230	258,766,609	6,230	258,766,609	6,230
Had requestable medical charts	258,766,609	0	258,766,609	0	258,766,609	0
Met demographic requirements (sex, race, and Hispanic origin)	258,674,002	92,607	258,674,002	92,607	258,674,002	92,607
Members with a valid index event						
Had any cohort-defining claim during the query period	455	258,673,547	156	258,673,846	4,043	258,669,959
Claim recorded during specified age range	455	0	156	0	4,043	0
Episode defining index claim recorded during the query period	455	0	156	0	4,043	0
Members with required pre-index history						
Had sufficient pre-index continuous enrollment	389	66	135	21	3,694	349
Met inclusion and exclusion criteria	389	0	135	0	3,694	0
Members with required post-index follow-up						
Had sufficient post-index continuous enrollment	389	0	135	0	3,694	0
Final cohort						
Number of members	389	N/A	135	N/A	3,694	N/A

N/A: Not Applicable

****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Figure 1a. Patient Entry into Study by Month for mogamulizumab-kpkc in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

*The FDA approval date for this drug was on August 8, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>


Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1b. Patient Entry into Study by Month for patisiran in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

*The FDA approval date for this drug was on August 10, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1c. Patient Entry into Study by Month for segesterone acetate and ethinyl estradiol vaginal system in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024



*The FDA approval date for this drug was on August 10, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

Figure 1d. Patient Entry into Study by Month for migalastat in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

*The FDA approval date for this drug was on August 10, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>


Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1e. Patient Entry into Study by Month for stiripentol in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

*The FDA approval date for this drug was on August 20, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1f. Patient Entry into Study by Month for cenegermin-bkbj in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024



*The FDA approval date for this drug was on August 22, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

Figure 1g. Patient Entry into Study by Month for lanadelumab in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

*The FDA approval date for this drug was on August 23, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>


Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1h. Patient Entry into Study by Month for eravacycline in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

*The FDA approval date for this drug was on August 27, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1i. Patient Entry into Study by Month for doravirine in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024




*The FDA approval date for this drug was on August 30, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

Figure 1j. Patient Entry into Study by Month for moxetumomab pasudotox-tdfk in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

*The FDA approval date for this drug was on September 13, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1k. Patient Entry into Study by Month for fremanezumab-vfrm in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024




*The FDA approval date for this drug was on September 14, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

Figure 1I. Patient Entry into Study by Month for duvelisib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

*The FDA approval date for this drug was on September 24, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1m. Patient Entry into Study by Month for galcanezumab-gnlm in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024



*The FDA approval date for this drug was on September 27, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

Figure 1n. Patient Entry into Study by Month for dacomitinib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

*The FDA approval date for this drug was on September 27, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>


Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1o. Patient Entry into Study by Month for cemiplimab-rwlc in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

*The FDA approval date for this drug was on September 28, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1p. Patient Entry into Study by Month for sarecycline in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024



*The FDA approval date for this drug was on October 1, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

Figure 1q. Patient Entry into Study by Month for omadacycline in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

*The FDA approval date for this drug was on October 2, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1r. Patient Entry into Study by Month for elapegademase-lvlr in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

*The FDA approval date for this drug was on October 5, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1s. Patient Entry into Study by Month for inotersen in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

*The FDA approval date for this drug was on October 5, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>


Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1t. Patient Entry into Study by Month for talazoparib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

*The FDA approval date for this drug was on October 16, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1u. Patient Entry into Study by Month for baloxavir marboxil in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024



*The FDA approval date for this drug was on October 24, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

Figure 1v. Patient Entry into Study by Month for lorlatinib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

*The FDA approval date for this drug was on November 2, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1w. Patient Entry into Study by Month for revefenacin in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

*The FDA approval date for this drug was on November 9, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1x. Patient Entry into Study by Month for rifamycin in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

*The FDA approval date for this drug was on November 16, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1y. Patient Entry into Study by Month for emapalumab-lzsg in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

*The FDA approval date for this drug was on November 20, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1z. Patient Entry into Study by Month for glasdegib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

*The FDA approval date for this drug was on November 21, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1aa. Patient Entry into Study by Month for larotrectinib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

*The FDA approval date for this drug was on November 26, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1ab. Patient Entry into Study by Month for amifampridine in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

*The FDA approval date for this drug was on November 28, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>


Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1ac. Patient Entry into Study by Month for gilteritinib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

*The FDA approval date for this drug was on November 28, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1ad. Patient Entry into Study by Month for prucalopride in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024



*The FDA approval date for this drug was on December 14, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

Figure 1ae. Patient Entry into Study by Month for calaspargase pegol-mknl in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

*The FDA approval date for this drug was on December 20, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1af. Patient Entry into Study by Month for tagraxofusp-erzs in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

*The FDA approval date for this drug was on December 21, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1ag. Patient Entry into Study by Month for ravulizumab in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

*The FDA approval date for this drug was on December 21, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Appendix A. Start and End Dates for Each Data Partner (DP) up to Request End Date (June 23, 2025)

DP ID	DP Start Date	DP End Date ¹
DP01	01/01/2000	01/31/2024
DP02	01/01/2000	01/31/2024
DP03	01/01/2008	08/31/2024
DP04	01/01/2006	10/31/2024
DP05	01/01/2005	07/31/2022
DP06	01/01/2000	04/30/2024
DP07	01/01/2004	03/31/2024
DP08	01/01/2000	04/30/2024
DP09	01/01/2007	10/31/2024
DP10	01/01/2000	04/30/2024
DP11	01/01/2014	12/31/2021
DP12	01/01/2008	12/31/2024
DP13	01/01/2010	06/30/2024

¹End Date represents the earliest of: (1) query end date, or (2) last day of the most recent month for which all of a Data Partner's data tables (enrollment, dispensing, etc.) have at least 80% of the record count relative to the prior month.

Appendix B. List of Generic and Brand Names of Medical Products Used to Define Exposures in this Request

Generic Name	Brand Name
Mogamulizumab-Kpkc	
mogamulizumab-kpkc	Poteligeo
Patisiran	
patisiran sodium, lipid complex	Onpattro
Segesterone Acetate and Ethinyl Estradiol Vaginal System	
segesterone acetate/ethinyl estradiol	Annovera
Migalastat	
migalastat HCl	Galafold
Stiripentol	
stiripentol	Diacomit
Cenegermin-Bkbj	
cenegermin-bkbj	OXERVATE
cenegermin-bkbj	Oxervate
Lanadelumab	
lanadelumab-flyo	Takhzyro
Eravacycline	
eravacycline di-hydrochloride	Xerava
Doravirine	
doravirine	Pifeltro
doravirine/lamivudine/tenofovir disoproxil fumarate	Delstrigo
Moxetumomab Pasudotox-Tdfk	
moxetumomab pasudotox-tdfk	Lumoxiti
Fremanezumab-Vfrm	
fremanezumab-vfrm	Ajovy Autoinjector
fremanezumab-vfrm	Ajovy Syringe
Duvelisib	
duvelisib	Copiktra
Galcanzumab-Gnlm	
galcanzumab-gnlm	Emgality Pen
galcanzumab-gnlm	Emgality Syringe
Dacomitinib	
dacomitinib	Vizimpro
Cemiplimab-Rwlc	
cemiplimab-rwlc	Libtayo
Sarecycline	
sarecycline HCl	Seysara
Omadacycline	
omadacycline tosylate	Nuzyra
omadacycline tosylate	Nuzyra (7 Day with Load Dose)
omadacycline tosylate	Nuzyra (7 Day)
Elapegademase-Lvlr	
elapegademase-lvlr	Revcovi
Inotersen	
inotersen sodium	Tegsedi
Talazoparib	
talazoparib	Talzenna
talazoparib tosylate	Talzenna
Baloxavir Marboxil	
BALOXAVIR MARBOXIL	Xofluza
baloxavir marboxil	Xofluza

Appendix B. List of Generic and Brand Names of Medical Products Used to Define Exposures in this Request

Generic Name	Brand Name
Lorlatinib	
lorlatinib	Lorbrena
Revefenacin	
revefenacin	Yupelri
Rifamycin	
Rifamycin	Aemcolo
rifamycin sodium	Aemcolo
Emapalumab-Lzsg	
emapalumab-lzsg	GAMIFANT
emapalumab-lzsg	Gamifant
Glasdegib	
glasdegib maleate	Daurismo
Larotrectinib	
larotrectinib sulfate	Vitrakvi
Amifampridine	
amifampridine	Ruzurgi
amifampridine phosphate	Firdapse
Gilteritinib	
gilteritinib	Xospata
gilteritinib fumarate	Xospata
Prucalopride	
PRUCALOPRIDE	MOTEGRITY
prucalopride succinate	Motegrity
prucalopride succinate	prucalopride
Calaspargase Pegol-Mknl	
calaspargase pegol-mknl	Asparlas
Tagraxofusp-Erzs	
tagraxofusp-erzs	Elzonris
Ravulizumab	
ravulizumab-cwvz	Ultomiris

Appendix C. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS), and National Drug Code (NDC) Codes Used to Define Exposures in this Request

Code	Description	Code Category	Code Type
Mogamulizumab-Kpkc			
42747076101	mogamulizumab-kpkc	Procedure	NDC
C9038	Injection, mogamulizumab-kpkc, 1 mg	Procedure	HCPCS
J9204	Injection, mogamulizumab-kpkc, 1 mg	Procedure	HCPCS
Patisiran			
71336100001	patisiran sodium, lipid complex	Procedure	NDC
C9036	Injection, patisiran, 0.1 mg	Procedure	HCPCS
J0222	Injection, patisiran, 0.1 mg	Procedure	HCPCS
Segesterone Acetate and Ethinyl Estradiol Vaginal System			
12822031301	segesterone acetate/ethinyl estradiol	Procedure	NDC
50261031301	segesterone acetate/ethinyl estradiol	Procedure	NDC
68308075201	segesterone acetate/ethinyl estradiol	Procedure	NDC
J7294	Segesterone acetate and ethinyl estradiol 0.15 mg, 0.013 mg per 24 hours; yearly vaginal system, ea	Procedure	HCPCS
Migalastat			
71904010001	migalastat HCl	Procedure	NDC
Stiripentol			
68418793906	stiripentol	Procedure	NDC
68418794001	stiripentol	Procedure	NDC
68418794006	stiripentol	Procedure	NDC
68418794101	stiripentol	Procedure	NDC
68418794106	stiripentol	Procedure	NDC
68418794201	stiripentol	Procedure	NDC
68418794206	stiripentol	Procedure	NDC
Cenegermin-Bkbj			
71981000101	cenegermin-bkbj	Procedure	NDC
71981002001	cenegermin-bkbj	Procedure	NDC
71981002007	cenegermin-bkbj	Procedure	NDC
Lanadelumab			
47783064401	lanadelumab-flyo	Procedure	NDC
47783064501	lanadelumab-flyo	Procedure	NDC
47783064601	lanadelumab-flyo	Procedure	NDC
J0593	Injection, lanadelumab-flyo, 1 mg (code may be used for Medicare when drug administered under direct supervision of a physician, not for use when drug is self-administered)	Procedure	HCPCS
Eravacycline			
71773005001	eravacycline di-hydrochloride	Procedure	NDC
71773005005	eravacycline di-hydrochloride	Procedure	NDC
71773005012	eravacycline di-hydrochloride	Procedure	NDC
71773010005	eravacycline di-hydrochloride	Procedure	NDC
71773010012	eravacycline di-hydrochloride	Procedure	NDC
J0122	Injection, eravacycline, 1 mg	Procedure	HCPCS
Doravirine			
00006306901	doravirine	Procedure	NDC
00006500701	doravirine/lamivudine/tenofovir disoproxil fumarate	Procedure	NDC
50090623700	doravirine	Procedure	NDC
50090626800	doravirine	Procedure	NDC

Appendix C. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS), and National Drug Code (NDC) Codes Used to Define Exposures in this Request

Code	Description	Code Category	Code Type
Moxetumomab Pasudotox-Tdfr			
00310470001	moxetumomab pasudotox-tdfr	Procedure	NDC
73380470001	moxetumomab pasudotox-tdfr	Procedure	NDC
C9045	Injection, moxetumomab pasudotox-tdfr, 0.01 mg	Procedure	HCPCS
J9313	Injection, moxetumomab pasudotox-tdfr, 0.01 mg	Procedure	HCPCS
Fremanezumab-Vfrm			
51759020210	fremanezumab-vfrm	Procedure	NDC
51759020211	fremanezumab-vfrm	Procedure	NDC
51759020222	fremanezumab-vfrm	Procedure	NDC
51759020410	fremanezumab-vfrm	Procedure	NDC
51759020411	fremanezumab-vfrm	Procedure	NDC
C9040	Injection, fremanezumab-vfrm, 1 mg	Procedure	HCPCS
J3031	Injection, fremanezumab-vfrm, 1 mg (code may be used for Medicare when drug administered under the direct supervision of a physician, not for use when drug is self-administered)	Procedure	HCPCS
Duvelisib			
71779011501	duvelisib	Procedure	NDC
71779011502	duvelisib	Procedure	NDC
71779011503	duvelisib	Procedure	NDC
71779012501	duvelisib	Procedure	NDC
71779012502	duvelisib	Procedure	NDC
71779012504	duvelisib	Procedure	NDC
73116011501	duvelisib	Procedure	NDC
73116011502	duvelisib	Procedure	NDC
73116011503	duvelisib	Procedure	NDC
73116012501	duvelisib	Procedure	NDC
73116012502	duvelisib	Procedure	NDC
73116012504	duvelisib	Procedure	NDC
73116021528	duvelisib	Procedure	NDC
73116021556	duvelisib	Procedure	NDC
73116022528	duvelisib	Procedure	NDC
73116022556	duvelisib	Procedure	NDC
Galcanzumab-Gnlm			
00002143601	galcanzumab-gnlm	Procedure	NDC
00002143611	galcanzumab-gnlm	Procedure	NDC
00002143661	galcanzumab-gnlm	Procedure	NDC
00002237701	galcanzumab-gnlm	Procedure	NDC
00002237711	galcanzumab-gnlm	Procedure	NDC
00002311501	galcanzumab-gnlm	Procedure	NDC
00002311509	galcanzumab-gnlm	Procedure	NDC
Dacomitinib			
00069019730	dacomitinib	Procedure	NDC
00069119830	dacomitinib	Procedure	NDC
00069229930	dacomitinib	Procedure	NDC
63539019790	dacomitinib	Procedure	NDC
Cemiplimab-Rwlc			
61755000801	cemiplimab-rwlc	Procedure	NDC

Appendix C. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS), and National Drug Code (NDC) Codes Used to Define Exposures in this Request

Code	Description	Code Category	Code Type
C9044	Injection, cemiplimab-rwlc, 1 mg	Procedure	HCPCS
J9119	Injection, cemiplimab-rwlc, 1 mg	Procedure	HCPCS
Sarecycline			
16110024530	sarecycline HCl	Procedure	NDC
16110024630	sarecycline HCl	Procedure	NDC
16110024730	sarecycline HCl	Procedure	NDC
Omadacycline			
71715000101	omadacycline tosylate	Procedure	NDC
71715000102	omadacycline tosylate	Procedure	NDC
71715000221	omadacycline tosylate	Procedure	NDC
71715000223	omadacycline tosylate	Procedure	NDC
71715000224	omadacycline tosylate	Procedure	NDC
71715000227	omadacycline tosylate	Procedure	NDC
71715000228	omadacycline tosylate	Procedure	NDC
C9051	Injection, omadacycline, 1 mg	Procedure	HCPCS
J0121	Injection, omadacycline, 1 mg	Procedure	HCPCS
XW033B6	Introduction of Omadacycline Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6	Procedure	ICD-10-PCS
XW043B6	Introduction of Omadacycline Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6	Procedure	ICD-10-PCS
Elapegademase-Lvlr			
10122050201	elapegademase-lvlr	Procedure	NDC
57665000201	elapegademase-lvlr	Procedure	NDC
Inotersen			
72126000701	inotersen sodium	Procedure	NDC
72126000702	inotersen sodium	Procedure	NDC
Talazoparib			
00069025230	talazoparib tosylate	Procedure	NDC
00069029630	talazoparib tosylate	Procedure	NDC
00069035330	talazoparib tosylate	Procedure	NDC
00069045430	talazoparib tosylate	Procedure	NDC
00069054630	talazoparib tosylate	Procedure	NDC
00069065530	talazoparib tosylate	Procedure	NDC
00069075730	talazoparib tosylate	Procedure	NDC
00069103130	talazoparib tosylate	Procedure	NDC
00069119530	talazoparib tosylate	Procedure	NDC
00069123530	talazoparib tosylate	Procedure	NDC
00069150130	talazoparib tosylate	Procedure	NDC
00069175130	talazoparib tosylate	Procedure	NDC
46014029601	talazoparib tosylate	Procedure	NDC
46014119503	talazoparib tosylate	Procedure	NDC
63539005130	talazoparib	Procedure	NDC
63539029530	talazoparib	Procedure	NDC
Baloxavir Marboxil			
50090410200	baloxavir marboxil	Procedure	NDC
50090410400	baloxavir marboxil	Procedure	NDC
50242058301	BALOXAVIR MARBOXIL	Procedure	NDC

Appendix C. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS), and National Drug Code (NDC) Codes Used to Define Exposures in this Request

Code	Description	Code Category	Code Type
50242082802	baloxavir marboxil	Procedure	NDC
50242082886	baloxavir marboxil	Procedure	NDC
50242086001	baloxavir marboxil	Procedure	NDC
50242086002	baloxavir marboxil	Procedure	NDC
50242086086	BALOXAVIR MARBOXIL	Procedure	NDC
50242086087	baloxavir marboxil	Procedure	NDC
50242087701	baloxavir marboxil	Procedure	NDC
50242087786	BALOXAVIR MARBOXIL	Procedure	NDC
Lorlatinib			
00069022701	lorlatinib	Procedure	NDC
00069022703	lorlatinib	Procedure	NDC
00069023101	lorlatinib	Procedure	NDC
63539092701	lorlatinib	Procedure	NDC
Revefenacin			
49502080632	revefenacin	Procedure	NDC
49502080633	revefenacin	Procedure	NDC
49502080677	revefenacin	Procedure	NDC
49502080687	revefenacin	Procedure	NDC
49502080693	revefenacin	Procedure	NDC
J7677	Revefenacin inhalation solution, FDA-approved final product, noncompounded, administered through DME, 1 mcg	Procedure	HCPCS
Rifamycin			
57841120000	rifamycin sodium	Procedure	NDC
57841120001	rifamycin sodium	Procedure	NDC
57841120002	Rifamycin	Procedure	NDC
57841120100	Rifamycin	Procedure	NDC
57841120101	Rifamycin	Procedure	NDC
71068000100	rifamycin sodium	Procedure	NDC
71068000110	rifamycin sodium	Procedure	NDC
71068000111	rifamycin sodium	Procedure	NDC
71068000188	rifamycin sodium	Procedure	NDC
71068000198	rifamycin sodium	Procedure	NDC
Emapalumab-Lzsg			
66658050101	emapalumab-lzsg	Procedure	NDC
66658050501	emapalumab-lzsg	Procedure	NDC
66658051001	emapalumab-lzsg	Procedure	NDC
66658052201	emapalumab-lzsg	Procedure	NDC
66658052301	emapalumab-lzsg	Procedure	NDC
66658052401	emapalumab-lzsg	Procedure	NDC
66658052501	emapalumab-lzsg	Procedure	NDC
72171050101	emapalumab-lzsg	Procedure	NDC
72171050501	emapalumab-lzsg	Procedure	NDC
C9050	Injection, emapalumab-lzsg, 1 mg	Procedure	HCPCS
J9210	Injection, emapalumab-lzsg, 1 mg	Procedure	HCPCS
Glasdegib			
00069029860	glasdegib maleate	Procedure	NDC
00069153130	glasdegib maleate	Procedure	NDC

Appendix C. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS), and National Drug Code (NDC) Codes Used to Define Exposures in this Request

Code	Description	Code Category	Code Type
Larotrectinib			
50419039001	larotrectinib sulfate	Procedure	NDC
50419039101	larotrectinib sulfate	Procedure	NDC
50419039201	larotrectinib sulfate	Procedure	NDC
50419039302	larotrectinib sulfate	Procedure	NDC
50419039303	larotrectinib sulfate	Procedure	NDC
71777039001	larotrectinib sulfate	Procedure	NDC
71777039101	larotrectinib sulfate	Procedure	NDC
71777039201	larotrectinib sulfate	Procedure	NDC
Amifampridine			
49938011001	amifampridine	Procedure	NDC
69616021103	amifampridine phosphate	Procedure	NDC
69616021104	amifampridine phosphate	Procedure	NDC
69616021106	amifampridine phosphate	Procedure	NDC
69616021108	amifampridine phosphate	Procedure	NDC
Gilteritinib			
00469142521	gilteritinib	Procedure	NDC
00469142590	gilteritinib fumarate	Procedure	NDC
XW0DXV5	Introduction of Gilteritinib Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 5	Procedure	ICD-10-PCS
Prucalopride			
54092054601	prucalopride succinate	Procedure	NDC
54092054701	prucalopride succinate	Procedure	NDC
54092054702	PRUCALOPRIDE	Procedure	NDC
70954059610	prucalopride succinate	Procedure	NDC
70954059710	prucalopride succinate	Procedure	NDC
Calaspargase Pegol-Mknl			
72694051501	calaspargase pegol-mknl	Procedure	NDC
J9118	Injection, calaspargase pegol-mknl, 10 units	Procedure	HCPCS
Tagraxofusp-Erzs			
72187040101	tagraxofusp-erzs	Procedure	NDC
C9049	Injection, tagraxofusp-erzs, 10 mcg	Procedure	HCPCS
J9269	Injection, tagraxofusp-erzs, 10 mcg	Procedure	HCPCS
XW033Q5	Introduction of Tagraxofusp-erzs Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 5	Procedure	ICD-10-PCS
XW043Q5	Introduction of Tagraxofusp-erzs Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5	Procedure	ICD-10-PCS
Ravulizumab			
25682002201	ravulizumab-cwvz	Procedure	NDC
25682002501	ravulizumab-cwvz	Procedure	NDC
25682002801	ravulizumab-cwvz	Procedure	NDC
25682003101	ravulizumab-cwvz	Procedure	NDC
C9052	Injection, ravulizumab-cwvz, 10 mg	Procedure	HCPCS
J1303	Injection, ravulizumab-cwvz, 10 mg	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
Acquired Hypothyroidism			
E00.0	Congenital iodine-deficiency syndrome, neurological type	Diagnosis	ICD-10-CM
E00.1	Congenital iodine-deficiency syndrome, myxedematous type	Diagnosis	ICD-10-CM
E00.2	Congenital iodine-deficiency syndrome, mixed type	Diagnosis	ICD-10-CM
E00.9	Congenital iodine-deficiency syndrome, unspecified	Diagnosis	ICD-10-CM
E01.8	Other iodine-deficiency related thyroid disorders and allied conditions	Diagnosis	ICD-10-CM
E02	Subclinical iodine-deficiency hypothyroidism	Diagnosis	ICD-10-CM
E03.0	Congenital hypothyroidism with diffuse goiter	Diagnosis	ICD-10-CM
E03.1	Congenital hypothyroidism without goiter	Diagnosis	ICD-10-CM
E03.2	Hypothyroidism due to medicaments and other exogenous substances	Diagnosis	ICD-10-CM
E03.3	Postinfectious hypothyroidism	Diagnosis	ICD-10-CM
E03.4	Atrophy of thyroid (acquired)	Diagnosis	ICD-10-CM
E03.8	Other specified hypothyroidism	Diagnosis	ICD-10-CM
E03.9	Hypothyroidism, unspecified	Diagnosis	ICD-10-CM
E89.0	Postprocedural hypothyroidism	Diagnosis	ICD-10-CM
Alcohol Abuse or Dependence			
F10.10	Alcohol abuse, uncomplicated	Diagnosis	ICD-10-CM
F10.11	Alcohol abuse, in remission	Diagnosis	ICD-10-CM
F10.120	Alcohol abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.121	Alcohol abuse with intoxication delirium	Diagnosis	ICD-10-CM
F10.129	Alcohol abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.130	Alcohol abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.131	Alcohol abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F10.132	Alcohol abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.139	Alcohol abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.14	Alcohol abuse with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.150	Alcohol abuse with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.151	Alcohol abuse with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.159	Alcohol abuse with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.180	Alcohol abuse with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.181	Alcohol abuse with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.182	Alcohol abuse with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.188	Alcohol abuse with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.19	Alcohol abuse with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.20	Alcohol dependence, uncomplicated	Diagnosis	ICD-10-CM
F10.21	Alcohol dependence, in remission	Diagnosis	ICD-10-CM
F10.220	Alcohol dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.221	Alcohol dependence with intoxication delirium	Diagnosis	ICD-10-CM
F10.229	Alcohol dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.230	Alcohol dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.231	Alcohol dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F10.232	Alcohol dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.239	Alcohol dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F10.24	Alcohol dependence with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.250	Alcohol dependence with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.251	Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.259	Alcohol dependence with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.26	Alcohol dependence with alcohol-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F10.27	Alcohol dependence with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.280	Alcohol dependence with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.281	Alcohol dependence with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.282	Alcohol dependence with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.288	Alcohol dependence with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.29	Alcohol dependence with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.920	Alcohol use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.921	Alcohol use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F10.929	Alcohol use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.930	Alcohol use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.931	Alcohol use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F10.932	Alcohol use, unspecified with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.939	Alcohol use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.94	Alcohol use, unspecified with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.950	Alcohol use, unspecified with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.951	Alcohol use, unspecified with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.959	Alcohol use, unspecified with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.96	Alcohol use, unspecified with alcohol-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F10.97	Alcohol use, unspecified with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.980	Alcohol use, unspecified with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.981	Alcohol use, unspecified with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.982	Alcohol use, unspecified with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.988	Alcohol use, unspecified with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.99	Alcohol use, unspecified with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
G62.1	Alcoholic polyneuropathy	Diagnosis	ICD-10-CM
HZ2ZZZZ	Detoxification Services for Substance Abuse Treatment	Procedure	ICD-10-PCS
HZ30ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ31ZZZ	Individual Counseling for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ32ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ33ZZZ	Individual Counseling for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ34ZZZ	Individual Counseling for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
HZ35ZZZ	Individual Counseling for Substance Abuse Treatment, Vocational	Procedure	ICD-10-PCS
HZ36ZZZ	Individual Counseling for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ37ZZZ	Individual Counseling for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ38ZZZ	Individual Counseling for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ39ZZZ	Individual Counseling for Substance Abuse Treatment, Continuing Care	Procedure	ICD-10-PCS
HZ3BZZZ	Individual Counseling for Substance Abuse Treatment, Spiritual	Procedure	ICD-10-PCS
HZ40ZZZ	Group Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ93ZZZ	Pharmacotherapy for Substance Abuse Treatment, Antabuse	Procedure	ICD-10-PCS
HZ96ZZZ	Pharmacotherapy for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
I42.6	Alcoholic cardiomyopathy	Diagnosis	ICD-10-CM
K29.20	Alcoholic gastritis without bleeding	Diagnosis	ICD-10-CM
K29.21	Alcoholic gastritis with bleeding	Diagnosis	ICD-10-CM
K70.0	Alcoholic fatty liver	Diagnosis	ICD-10-CM
K70.10	Alcoholic hepatitis without ascites	Diagnosis	ICD-10-CM
K70.11	Alcoholic hepatitis with ascites	Diagnosis	ICD-10-CM
K70.2	Alcoholic fibrosis and sclerosis of liver	Diagnosis	ICD-10-CM
K70.30	Alcoholic cirrhosis of liver without ascites	Diagnosis	ICD-10-CM
K70.31	Alcoholic cirrhosis of liver with ascites	Diagnosis	ICD-10-CM
K70.40	Alcoholic hepatic failure without coma	Diagnosis	ICD-10-CM
K70.41	Alcoholic hepatic failure with coma	Diagnosis	ICD-10-CM
K70.9	Alcoholic liver disease, unspecified	Diagnosis	ICD-10-CM
R78.0	Finding of alcohol in blood	Diagnosis	ICD-10-CM
T51.0X1A	Toxic effect of ethanol, accidental (unintentional), initial encounter	Procedure	ICD-10-PCS
T51.0X2A	Toxic effect of ethanol, intentional self-harm, initial encounter	Procedure	ICD-10-PCS
T51.0X3A	Toxic effect of ethanol, assault, initial encounter	Procedure	ICD-10-PCS
T51.0X4A	Toxic effect of ethanol, undetermined, initial encounter	Procedure	ICD-10-PCS
Z65.8	Other specified problems related to psychosocial circumstances	Diagnosis	ICD-10-CM
Z71.41	Alcohol abuse counseling and surveillance of alcoholic	Diagnosis	ICD-10-CM
Alzheimer's Disease			
G30.0	Alzheimer's disease with early onset	Diagnosis	ICD-10-CM
G30.1	Alzheimer's disease with late onset	Diagnosis	ICD-10-CM
G30.8	Other Alzheimer's disease	Diagnosis	ICD-10-CM
G30.9	Alzheimer's disease, unspecified	Diagnosis	ICD-10-CM
Acute Myocardial Infarction			
I21.01	ST elevation (STEMI) myocardial infarction involving left main coronary artery	Diagnosis	ICD-10-CM
I21.02	ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery	Diagnosis	ICD-10-CM
I21.09	ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall	Diagnosis	ICD-10-CM
I21.11	ST elevation (STEMI) myocardial infarction involving right coronary artery	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I21.19	ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall	Diagnosis	ICD-10-CM
I21.21	ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery	Diagnosis	ICD-10-CM
I21.29	ST elevation (STEMI) myocardial infarction involving other sites	Diagnosis	ICD-10-CM
I21.3	ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I21.4	Non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I21.9	Acute myocardial infarction, unspecified	Diagnosis	ICD-10-CM
I21.A1	Myocardial infarction type 2	Diagnosis	ICD-10-CM
I21.A9	Other myocardial infarction type	Diagnosis	ICD-10-CM
I21.B	Myocardial infarction with coronary microvascular dysfunction	Diagnosis	ICD-10-CM
I22.0	Subsequent ST elevation (STEMI) myocardial infarction of anterior wall	Diagnosis	ICD-10-CM
I22.1	Subsequent ST elevation (STEMI) myocardial infarction of inferior wall	Diagnosis	ICD-10-CM
I22.2	Subsequent non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I22.8	Subsequent ST elevation (STEMI) myocardial infarction of other sites	Diagnosis	ICD-10-CM
I22.9	Subsequent ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I23.0	Hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.1	Atrial septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.2	Ventricular septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.3	Rupture of cardiac wall without hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.4	Rupture of chordae tendineae as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.5	Rupture of papillary muscle as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.6	Thrombosis of atrium, auricular appendage, and ventricle as current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.7	Postinfarction angina	Diagnosis	ICD-10-CM
I23.8	Other current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
Anemia			
C94.6	Myelodysplastic disease, not elsewhere classified	Diagnosis	ICD-10-CM
D46.0	Refractory anemia without ring sideroblasts, so stated	Diagnosis	ICD-10-CM
D46.1	Refractory anemia with ring sideroblasts	Diagnosis	ICD-10-CM
D46.20	Refractory anemia with excess of blasts, unspecified	Diagnosis	ICD-10-CM
D46.21	Refractory anemia with excess of blasts 1	Diagnosis	ICD-10-CM
D46.22	Refractory anemia with excess of blasts 2	Diagnosis	ICD-10-CM
D46.4	Refractory anemia, unspecified	Diagnosis	ICD-10-CM
D46.9	Myelodysplastic syndrome, unspecified	Diagnosis	ICD-10-CM
D46.A	Refractory cytopenia with multilineage dysplasia	Diagnosis	ICD-10-CM
D46.B	Refractory cytopenia with multilineage dysplasia and ring sideroblasts	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
D46.C	Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality	Diagnosis	ICD-10-CM
D46.Z	Other myelodysplastic syndromes	Diagnosis	ICD-10-CM
D47.4	Osteomyelofibrosis	Diagnosis	ICD-10-CM
D50.0	Iron deficiency anemia secondary to blood loss (chronic)	Diagnosis	ICD-10-CM
D50.1	Sideropenic dysphagia	Diagnosis	ICD-10-CM
D50.8	Other iron deficiency anemias	Diagnosis	ICD-10-CM
D50.9	Iron deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D51.0	Vitamin B12 deficiency anemia due to intrinsic factor deficiency	Diagnosis	ICD-10-CM
D51.1	Vitamin B12 deficiency anemia due to selective vitamin B12 malabsorption with proteinuria	Diagnosis	ICD-10-CM
D51.2	Transcobalamin II deficiency	Diagnosis	ICD-10-CM
D51.3	Other dietary vitamin B12 deficiency anemia	Diagnosis	ICD-10-CM
D51.8	Other vitamin B12 deficiency anemias	Diagnosis	ICD-10-CM
D51.9	Vitamin B12 deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D52.0	Dietary folate deficiency anemia	Diagnosis	ICD-10-CM
D52.1	Drug-induced folate deficiency anemia	Diagnosis	ICD-10-CM
D52.8	Other folate deficiency anemias	Diagnosis	ICD-10-CM
D52.9	Folate deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D53.0	Protein deficiency anemia	Diagnosis	ICD-10-CM
D53.1	Other megaloblastic anemias, not elsewhere classified	Diagnosis	ICD-10-CM
D53.2	Scorbutic anemia	Diagnosis	ICD-10-CM
D53.8	Other specified nutritional anemias	Diagnosis	ICD-10-CM
D53.9	Nutritional anemia, unspecified	Diagnosis	ICD-10-CM
D55.0	Anemia due to glucose-6-phosphate dehydrogenase [G6PD] deficiency	Diagnosis	ICD-10-CM
D55.1	Anemia due to other disorders of glutathione metabolism	Diagnosis	ICD-10-CM
D55.2	Anemia due to disorders of glycolytic enzymes	Diagnosis	ICD-10-CM
D55.21	Anemia due to pyruvate kinase deficiency	Diagnosis	ICD-10-CM
D55.29	Anemia due to other disorders of glycolytic enzymes	Diagnosis	ICD-10-CM
D55.3	Anemia due to disorders of nucleotide metabolism	Diagnosis	ICD-10-CM
D55.8	Other anemias due to enzyme disorders	Diagnosis	ICD-10-CM
D55.9	Anemia due to enzyme disorder, unspecified	Diagnosis	ICD-10-CM
D56.0	Alpha thalassemia	Diagnosis	ICD-10-CM
D56.1	Beta thalassemia	Diagnosis	ICD-10-CM
D56.2	Delta-beta thalassemia	Diagnosis	ICD-10-CM
D56.3	Thalassemia minor	Diagnosis	ICD-10-CM
D56.4	Hereditary persistence of fetal hemoglobin [HPFH]	Diagnosis	ICD-10-CM
D56.5	Hemoglobin E-beta thalassemia	Diagnosis	ICD-10-CM
D56.8	Other thalassemias	Diagnosis	ICD-10-CM
D56.9	Thalassemia, unspecified	Diagnosis	ICD-10-CM
D57.00	Hb-SS disease with crisis, unspecified	Diagnosis	ICD-10-CM
D57.01	Hb-SS disease with acute chest syndrome	Diagnosis	ICD-10-CM
D57.02	Hb-SS disease with splenic sequestration	Diagnosis	ICD-10-CM
D57.03	Hb-SS disease with cerebral vascular involvement	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
D57.04	Hb-SS disease with dactylitis	Diagnosis	ICD-10-CM
D57.09	Hb-SS disease with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.1	Sickle-cell disease without crisis	Diagnosis	ICD-10-CM
D57.20	Sickle-cell/Hb-C disease without crisis	Diagnosis	ICD-10-CM
D57.211	Sickle-cell/Hb-C disease with acute chest syndrome	Diagnosis	ICD-10-CM
D57.212	Sickle-cell/Hb-C disease with splenic sequestration	Diagnosis	ICD-10-CM
D57.213	Sickle-cell/Hb-C disease with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.214	Sickle-cell/Hb-C disease with dactylitis	Diagnosis	ICD-10-CM
D57.218	Sickle-cell/Hb-C disease with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.219	Sickle-cell/Hb-C disease with crisis, unspecified	Diagnosis	ICD-10-CM
D57.3	Sickle-cell trait	Diagnosis	ICD-10-CM
D57.40	Sickle-cell thalassemia without crisis	Diagnosis	ICD-10-CM
D57.411	Sickle-cell thalassemia, unspecified, with acute chest syndrome	Diagnosis	ICD-10-CM
D57.412	Sickle-cell thalassemia, unspecified, with splenic sequestration	Diagnosis	ICD-10-CM
D57.413	Sickle-cell thalassemia, unspecified, with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.414	Sickle-cell thalassemia, unspecified, with dactylitis	Diagnosis	ICD-10-CM
D57.418	Sickle-cell thalassemia, unspecified, with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.419	Sickle-cell thalassemia, unspecified, with crisis	Diagnosis	ICD-10-CM
D57.42	Sickle-cell thalassemia beta zero without crisis	Diagnosis	ICD-10-CM
D57.431	Sickle-cell thalassemia beta zero with acute chest syndrome	Diagnosis	ICD-10-CM
D57.432	Sickle-cell thalassemia beta zero with splenic sequestration	Diagnosis	ICD-10-CM
D57.433	Sickle-cell thalassemia beta zero with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.434	Sickle-cell thalassemia beta zero with dactylitis	Diagnosis	ICD-10-CM
D57.438	Sickle-cell thalassemia beta zero with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.439	Sickle-cell thalassemia beta zero with crisis, unspecified	Diagnosis	ICD-10-CM
D57.44	Sickle-cell thalassemia beta plus without crisis	Diagnosis	ICD-10-CM
D57.451	Sickle-cell thalassemia beta plus with acute chest syndrome	Diagnosis	ICD-10-CM
D57.452	Sickle-cell thalassemia beta plus with splenic sequestration	Diagnosis	ICD-10-CM
D57.453	Sickle-cell thalassemia beta plus with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.454	Sickle-cell thalassemia beta plus with dactylitis	Diagnosis	ICD-10-CM
D57.458	Sickle-cell thalassemia beta plus with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.459	Sickle-cell thalassemia beta plus with crisis, unspecified	Diagnosis	ICD-10-CM
D57.80	Other sickle-cell disorders without crisis	Diagnosis	ICD-10-CM
D57.811	Other sickle-cell disorders with acute chest syndrome	Diagnosis	ICD-10-CM
D57.812	Other sickle-cell disorders with splenic sequestration	Diagnosis	ICD-10-CM
D57.813	Other sickle-cell disorders with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.814	Other sickle-cell disorders with dactylitis	Diagnosis	ICD-10-CM
D57.818	Other sickle-cell disorders with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.819	Other sickle-cell disorders with crisis, unspecified	Diagnosis	ICD-10-CM
D58.0	Hereditary spherocytosis	Diagnosis	ICD-10-CM
D58.1	Hereditary elliptocytosis	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
D58.2	Other hemoglobinopathies	Diagnosis	ICD-10-CM
D58.8	Other specified hereditary hemolytic anemias	Diagnosis	ICD-10-CM
D58.9	Hereditary hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D59.0	Drug-induced autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.1	Other autoimmune hemolytic anemias	Diagnosis	ICD-10-CM
D59.10	Autoimmune hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D59.11	Warm autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.12	Cold autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.13	Mixed type autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.19	Other autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.2	Drug-induced nonautoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.3	Hemolytic-uremic syndrome	Diagnosis	ICD-10-CM
D59.30	Hemolytic-uremic syndrome, unspecified	Diagnosis	ICD-10-CM
D59.31	Infection-associated hemolytic-uremic syndrome	Diagnosis	ICD-10-CM
D59.32	Hereditary hemolytic-uremic syndrome	Diagnosis	ICD-10-CM
D59.39	Other hemolytic-uremic syndrome	Diagnosis	ICD-10-CM
D59.4	Other nonautoimmune hemolytic anemias	Diagnosis	ICD-10-CM
D59.5	Paroxysmal nocturnal hemoglobinuria [Marchiafava-Micheli]	Diagnosis	ICD-10-CM
D59.6	Hemoglobinuria due to hemolysis from other external causes	Diagnosis	ICD-10-CM
D59.8	Other acquired hemolytic anemias	Diagnosis	ICD-10-CM
D59.9	Acquired hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D60.0	Chronic acquired pure red cell aplasia	Diagnosis	ICD-10-CM
D60.1	Transient acquired pure red cell aplasia	Diagnosis	ICD-10-CM
D60.8	Other acquired pure red cell aplasias	Diagnosis	ICD-10-CM
D60.9	Acquired pure red cell aplasia, unspecified	Diagnosis	ICD-10-CM
D61.01	Constitutional (pure) red blood cell aplasia	Diagnosis	ICD-10-CM
D61.02	Shwachman-Diamond syndrome	Diagnosis	ICD-10-CM
D61.09	Other constitutional aplastic anemia	Diagnosis	ICD-10-CM
D61.1	Drug-induced aplastic anemia	Diagnosis	ICD-10-CM
D61.2	Aplastic anemia due to other external agents	Diagnosis	ICD-10-CM
D61.3	Idiopathic aplastic anemia	Diagnosis	ICD-10-CM
D61.810	Antineoplastic chemotherapy induced pancytopenia	Diagnosis	ICD-10-CM
D61.811	Other drug-induced pancytopenia	Diagnosis	ICD-10-CM
D61.818	Other pancytopenia	Diagnosis	ICD-10-CM
D61.82	Myelophthisis	Diagnosis	ICD-10-CM
D61.89	Other specified aplastic anemias and other bone marrow failure syndromes	Diagnosis	ICD-10-CM
D61.9	Aplastic anemia, unspecified	Diagnosis	ICD-10-CM
D63.0	Anemia in neoplastic disease	Diagnosis	ICD-10-CM
D63.1	Anemia in chronic kidney disease	Diagnosis	ICD-10-CM
D63.8	Anemia in other chronic diseases classified elsewhere	Diagnosis	ICD-10-CM
D64.0	Hereditary sideroblastic anemia	Diagnosis	ICD-10-CM
D64.1	Secondary sideroblastic anemia due to disease	Diagnosis	ICD-10-CM
D64.2	Secondary sideroblastic anemia due to drugs and toxins	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
D64.3	Other sideroblastic anemias	Diagnosis	ICD-10-CM
D64.4	Congenital dyserythropoietic anemia	Diagnosis	ICD-10-CM
D64.81	Anemia due to antineoplastic chemotherapy	Diagnosis	ICD-10-CM
D64.89	Other specified anemias	Diagnosis	ICD-10-CM
D64.9	Anemia, unspecified	Diagnosis	ICD-10-CM
D75.81	Myelofibrosis	Diagnosis	ICD-10-CM
Asthma			
J45.20	Mild intermittent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.21	Mild intermittent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.22	Mild intermittent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.30	Mild persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.31	Mild persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.32	Mild persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.40	Moderate persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.41	Moderate persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.42	Moderate persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.50	Severe persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.51	Severe persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.52	Severe persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.901	Unspecified asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.902	Unspecified asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.909	Unspecified asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.990	Exercise induced bronchospasm	Diagnosis	ICD-10-CM
J45.991	Cough variant asthma	Diagnosis	ICD-10-CM
J45.998	Other asthma	Diagnosis	ICD-10-CM
Atrial Fibrillation			
I48.0	Paroxysmal atrial fibrillation	Diagnosis	ICD-10-CM
I48.1	Persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.11	Longstanding persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.19	Other persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.2	Chronic atrial fibrillation	Diagnosis	ICD-10-CM
I48.20	Chronic atrial fibrillation, unspecified	Diagnosis	ICD-10-CM
I48.21	Permanent atrial fibrillation	Diagnosis	ICD-10-CM
I48.3	Typical atrial flutter	Diagnosis	ICD-10-CM
I48.4	Atypical atrial flutter	Diagnosis	ICD-10-CM
I48.91	Unspecified atrial fibrillation	Diagnosis	ICD-10-CM
Benign Prostatic Hyperplasia			
N40.0	Benign prostatic hyperplasia without lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.1	Benign prostatic hyperplasia with lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.2	Nodular prostate without lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.3	Nodular prostate with lower urinary tract symptoms	Diagnosis	ICD-10-CM
Breast Cancer			
C50.011	Malignant neoplasm of nipple and areola, right female breast	Diagnosis	ICD-10-CM
C50.012	Malignant neoplasm of nipple and areola, left female breast	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
C50.019	Malignant neoplasm of nipple and areola, unspecified female breast	Diagnosis	ICD-10-CM
C50.021	Malignant neoplasm of nipple and areola, right male breast	Diagnosis	ICD-10-CM
C50.022	Malignant neoplasm of nipple and areola, left male breast	Diagnosis	ICD-10-CM
C50.029	Malignant neoplasm of nipple and areola, unspecified male breast	Diagnosis	ICD-10-CM
C50.111	Malignant neoplasm of central portion of right female breast	Diagnosis	ICD-10-CM
C50.112	Malignant neoplasm of central portion of left female breast	Diagnosis	ICD-10-CM
C50.119	Malignant neoplasm of central portion of unspecified female breast	Diagnosis	ICD-10-CM
C50.121	Malignant neoplasm of central portion of right male breast	Diagnosis	ICD-10-CM
C50.122	Malignant neoplasm of central portion of left male breast	Diagnosis	ICD-10-CM
C50.129	Malignant neoplasm of central portion of unspecified male breast	Diagnosis	ICD-10-CM
C50.211	Malignant neoplasm of upper-inner quadrant of right female breast	Diagnosis	ICD-10-CM
C50.212	Malignant neoplasm of upper-inner quadrant of left female breast	Diagnosis	ICD-10-CM
C50.219	Malignant neoplasm of upper-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.221	Malignant neoplasm of upper-inner quadrant of right male breast	Diagnosis	ICD-10-CM
C50.222	Malignant neoplasm of upper-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.229	Malignant neoplasm of upper-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.311	Malignant neoplasm of lower-inner quadrant of right female breast	Diagnosis	ICD-10-CM
C50.312	Malignant neoplasm of lower-inner quadrant of left female breast	Diagnosis	ICD-10-CM
C50.319	Malignant neoplasm of lower-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.321	Malignant neoplasm of lower-inner quadrant of right male breast	Diagnosis	ICD-10-CM
C50.322	Malignant neoplasm of lower-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.329	Malignant neoplasm of lower-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.411	Malignant neoplasm of upper-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.412	Malignant neoplasm of upper-outer quadrant of left female breast	Diagnosis	ICD-10-CM
C50.419	Malignant neoplasm of upper-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.421	Malignant neoplasm of upper-outer quadrant of right male breast	Diagnosis	ICD-10-CM
C50.422	Malignant neoplasm of upper-outer quadrant of left male breast	Diagnosis	ICD-10-CM
C50.429	Malignant neoplasm of upper-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.511	Malignant neoplasm of lower-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.512	Malignant neoplasm of lower-outer quadrant of left female breast	Diagnosis	ICD-10-CM
C50.519	Malignant neoplasm of lower-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.521	Malignant neoplasm of lower-outer quadrant of right male breast	Diagnosis	ICD-10-CM
C50.522	Malignant neoplasm of lower-outer quadrant of left male breast	Diagnosis	ICD-10-CM
C50.529	Malignant neoplasm of lower-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.611	Malignant neoplasm of axillary tail of right female breast	Diagnosis	ICD-10-CM
C50.612	Malignant neoplasm of axillary tail of left female breast	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
C50.619	Malignant neoplasm of axillary tail of unspecified female breast	Diagnosis	ICD-10-CM
C50.621	Malignant neoplasm of axillary tail of right male breast	Diagnosis	ICD-10-CM
C50.622	Malignant neoplasm of axillary tail of left male breast	Diagnosis	ICD-10-CM
C50.629	Malignant neoplasm of axillary tail of unspecified male breast	Diagnosis	ICD-10-CM
C50.811	Malignant neoplasm of overlapping sites of right female breast	Diagnosis	ICD-10-CM
C50.812	Malignant neoplasm of overlapping sites of left female breast	Diagnosis	ICD-10-CM
C50.819	Malignant neoplasm of overlapping sites of unspecified female breast	Diagnosis	ICD-10-CM
C50.821	Malignant neoplasm of overlapping sites of right male breast	Diagnosis	ICD-10-CM
C50.822	Malignant neoplasm of overlapping sites of left male breast	Diagnosis	ICD-10-CM
C50.829	Malignant neoplasm of overlapping sites of unspecified male breast	Diagnosis	ICD-10-CM
C50.911	Malignant neoplasm of unspecified site of right female breast	Diagnosis	ICD-10-CM
C50.912	Malignant neoplasm of unspecified site of left female breast	Diagnosis	ICD-10-CM
C50.919	Malignant neoplasm of unspecified site of unspecified female breast	Diagnosis	ICD-10-CM
C50.921	Malignant neoplasm of unspecified site of right male breast	Diagnosis	ICD-10-CM
C50.922	Malignant neoplasm of unspecified site of left male breast	Diagnosis	ICD-10-CM
C50.929	Malignant neoplasm of unspecified site of unspecified male breast	Diagnosis	ICD-10-CM
D05.00	Lobular carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.01	Lobular carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.02	Lobular carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.10	Intraductal carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.11	Intraductal carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.12	Intraductal carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.80	Other specified type of carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.81	Other specified type of carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.82	Other specified type of carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.90	Unspecified type of carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.91	Unspecified type of carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.92	Unspecified type of carcinoma in situ of left breast	Diagnosis	ICD-10-CM
Z17.0	Estrogen receptor positive status [ER+]	Diagnosis	ICD-10-CM
Z17.1	Estrogen receptor negative status [ER-]	Diagnosis	ICD-10-CM
Z19.1	Hormone sensitive malignancy status	Diagnosis	ICD-10-CM
Z19.2	Hormone resistant malignancy status	Diagnosis	ICD-10-CM
Z85.3	Personal history of malignant neoplasm of breast	Diagnosis	ICD-10-CM
Z86.000	Personal history of in-situ neoplasm of breast	Diagnosis	ICD-10-CM
History of Cardiac Arrest			
I46.2	Cardiac arrest due to underlying cardiac condition	Diagnosis	ICD-10-CM
I46.8	Cardiac arrest due to other underlying condition	Diagnosis	ICD-10-CM
I46.9	Cardiac arrest, cause unspecified	Diagnosis	ICD-10-CM
I97.120	Postprocedural cardiac arrest following cardiac surgery	Diagnosis	ICD-10-CM
I97.121	Postprocedural cardiac arrest following other surgery	Diagnosis	ICD-10-CM
I97.710	Intraoperative cardiac arrest during cardiac surgery	Diagnosis	ICD-10-CM
I97.711	Intraoperative cardiac arrest during other surgery	Diagnosis	ICD-10-CM
Z86.74	Personal history of sudden cardiac arrest	Diagnosis	ICD-10-CM
Chronic Kidney Disease			

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
A18.11	Tuberculosis of kidney and ureter	Diagnosis	ICD-10-CM
A52.75	Syphilis of kidney and ureter	Diagnosis	ICD-10-CM
B52.0	Plasmodium malariae malaria with nephropathy	Diagnosis	ICD-10-CM
E08.21	Diabetes mellitus due to underlying condition with diabetic nephropathy	Diagnosis	ICD-10-CM
E08.22	Diabetes mellitus due to underlying condition with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E08.29	Diabetes mellitus due to underlying condition with other diabetic kidney complication	Diagnosis	ICD-10-CM
E09.21	Drug or chemical induced diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E09.22	Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E09.29	Drug or chemical induced diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E10.21	Type 1 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E11.21	Type 2 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.29	Type 2 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E13.21	Other specified diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E13.29	Other specified diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
I12.0	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease	Diagnosis	ICD-10-CM
I12.9	Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.10	Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.11	Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
K76.7	Hepatorenal syndrome	Diagnosis	ICD-10-CM
M10.30	Gout due to renal impairment, unspecified site	Diagnosis	ICD-10-CM
M10.311	Gout due to renal impairment, right shoulder	Diagnosis	ICD-10-CM
M10.312	Gout due to renal impairment, left shoulder	Diagnosis	ICD-10-CM
M10.319	Gout due to renal impairment, unspecified shoulder	Diagnosis	ICD-10-CM
M10.321	Gout due to renal impairment, right elbow	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M10.322	Gout due to renal impairment, left elbow	Diagnosis	ICD-10-CM
M10.329	Gout due to renal impairment, unspecified elbow	Diagnosis	ICD-10-CM
M10.331	Gout due to renal impairment, right wrist	Diagnosis	ICD-10-CM
M10.332	Gout due to renal impairment, left wrist	Diagnosis	ICD-10-CM
M10.339	Gout due to renal impairment, unspecified wrist	Diagnosis	ICD-10-CM
M10.341	Gout due to renal impairment, right hand	Diagnosis	ICD-10-CM
M10.342	Gout due to renal impairment, left hand	Diagnosis	ICD-10-CM
M10.349	Gout due to renal impairment, unspecified hand	Diagnosis	ICD-10-CM
M10.351	Gout due to renal impairment, right hip	Diagnosis	ICD-10-CM
M10.352	Gout due to renal impairment, left hip	Diagnosis	ICD-10-CM
M10.359	Gout due to renal impairment, unspecified hip	Diagnosis	ICD-10-CM
M10.361	Gout due to renal impairment, right knee	Diagnosis	ICD-10-CM
M10.362	Gout due to renal impairment, left knee	Diagnosis	ICD-10-CM
M10.369	Gout due to renal impairment, unspecified knee	Diagnosis	ICD-10-CM
M10.371	Gout due to renal impairment, right ankle and foot	Diagnosis	ICD-10-CM
M10.372	Gout due to renal impairment, left ankle and foot	Diagnosis	ICD-10-CM
M10.379	Gout due to renal impairment, unspecified ankle and foot	Diagnosis	ICD-10-CM
M10.38	Gout due to renal impairment, vertebrae	Diagnosis	ICD-10-CM
M10.39	Gout due to renal impairment, multiple sites	Diagnosis	ICD-10-CM
M32.14	Glomerular disease in systemic lupus erythematosus	Diagnosis	ICD-10-CM
M32.15	Tubulo-interstitial nephropathy in systemic lupus erythematosus	Diagnosis	ICD-10-CM
M35.04	Sjogren syndrome with tubulo-interstitial nephropathy	Diagnosis	ICD-10-CM
M35.0A	Sjogren syndrome with glomerular disease	Diagnosis	ICD-10-CM
N01.0	Rapidly progressive nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N01.1	Rapidly progressive nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N01.2	Rapidly progressive nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N01.3	Rapidly progressive nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N01.4	Rapidly progressive nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N01.5	Rapidly progressive nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N01.6	Rapidly progressive nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N01.7	Rapidly progressive nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N01.8	Rapidly progressive nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N01.9	Rapidly progressive nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N01.A	Rapidly progressive nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N02.0	Recurrent and persistent hematuria with minor glomerular abnormality	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
N02.1	Recurrent and persistent hematuria with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N02.2	Recurrent and persistent hematuria with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N02.3	Recurrent and persistent hematuria with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N02.4	Recurrent and persistent hematuria with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N02.5	Recurrent and persistent hematuria with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N02.6	Recurrent and persistent hematuria with dense deposit disease	Diagnosis	ICD-10-CM
N02.7	Recurrent and persistent hematuria with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N02.8	Recurrent and persistent hematuria with other morphologic changes	Diagnosis	ICD-10-CM
N02.9	Recurrent and persistent hematuria with unspecified morphologic changes	Diagnosis	ICD-10-CM
N02.A	Recurrent and persistent hematuria with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N02.B1	Recurrent and persistent immunoglobulin A nephropathy with glomerular lesion	Diagnosis	ICD-10-CM
N02.B2	Recurrent and persistent immunoglobulin A nephropathy with focal and segmental glomerular lesion	Diagnosis	ICD-10-CM
N02.B3	Recurrent and persistent immunoglobulin A nephropathy with diffuse membranoproliferative glomerulonephritis	Diagnosis	ICD-10-CM
N02.B4	Recurrent and persistent immunoglobulin A nephropathy with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N02.B5	Recurrent and persistent immunoglobulin A nephropathy with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N02.B6	Recurrent and persistent immunoglobulin A nephropathy with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N02.B9	Other recurrent and persistent immunoglobulin A nephropathy	Diagnosis	ICD-10-CM
N03.0	Chronic nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N03.1	Chronic nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N03.2	Chronic nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N03.3	Chronic nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N03.4	Chronic nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N03.5	Chronic nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N03.6	Chronic nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N03.7	Chronic nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N03.8	Chronic nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
N03.9	Chronic nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N03.A	Chronic nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N04.0	Nephrotic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N04.1	Nephrotic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N04.2	Nephrotic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N04.20	Nephrotic syndrome with diffuse membranous glomerulonephritis, unspecified	Diagnosis	ICD-10-CM
N04.21	Primary membranous nephropathy with nephrotic syndrome	Diagnosis	ICD-10-CM
N04.22	Secondary membranous nephropathy with nephrotic syndrome	Diagnosis	ICD-10-CM
N04.29	Other nephrotic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N04.3	Nephrotic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N04.4	Nephrotic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N04.5	Nephrotic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N04.6	Nephrotic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N04.7	Nephrotic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N04.8	Nephrotic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N04.9	Nephrotic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N04.A	Nephrotic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N05.0	Unspecified nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N05.1	Unspecified nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N05.2	Unspecified nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N05.3	Unspecified nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N05.4	Unspecified nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N05.5	Unspecified nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N05.6	Unspecified nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N05.7	Unspecified nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N05.8	Unspecified nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N05.9	Unspecified nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N05.A	Unspecified nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N06.0	Isolated proteinuria with minor glomerular abnormality	Diagnosis	ICD-10-CM
N06.1	Isolated proteinuria with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N06.2	Isolated proteinuria with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N06.20	Isolated proteinuria with diffuse membranous glomerulonephritis, unspecified	Diagnosis	ICD-10-CM
N06.21	Primary membranous nephropathy with isolated proteinuria	Diagnosis	ICD-10-CM
N06.22	Secondary membranous nephropathy with isolated proteinuria	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
N06.29	Other isolated proteinuria with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N06.3	Isolated proteinuria with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N06.4	Isolated proteinuria with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N06.5	Isolated proteinuria with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N06.6	Isolated proteinuria with dense deposit disease	Diagnosis	ICD-10-CM
N06.7	Isolated proteinuria with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N06.8	Isolated proteinuria with other morphologic lesion	Diagnosis	ICD-10-CM
N06.9	Isolated proteinuria with unspecified morphologic lesion	Diagnosis	ICD-10-CM
N06.A	Isolated proteinuria with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N07.0	Hereditary nephropathy, not elsewhere classified with minor glomerular abnormality	Diagnosis	ICD-10-CM
N07.1	Hereditary nephropathy, not elsewhere classified with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N07.2	Hereditary nephropathy, not elsewhere classified with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N07.3	Hereditary nephropathy, not elsewhere classified with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N07.4	Hereditary nephropathy, not elsewhere classified with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N07.5	Hereditary nephropathy, not elsewhere classified with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N07.6	Hereditary nephropathy, not elsewhere classified with dense deposit disease	Diagnosis	ICD-10-CM
N07.7	Hereditary nephropathy, not elsewhere classified with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N07.8	Hereditary nephropathy, not elsewhere classified with other morphologic lesions	Diagnosis	ICD-10-CM
N07.9	Hereditary nephropathy, not elsewhere classified with unspecified morphologic lesions	Diagnosis	ICD-10-CM
N07.A	Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N08	Glomerular disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
N14.0	Analgesic nephropathy	Diagnosis	ICD-10-CM
N14.1	Nephropathy induced by other drugs, medicaments and biological substances	Diagnosis	ICD-10-CM
N14.11	Contrast-induced nephropathy	Diagnosis	ICD-10-CM
N14.19	Nephropathy induced by other drugs, medicaments and biological substances	Diagnosis	ICD-10-CM
N14.2	Nephropathy induced by unspecified drug, medicament or biological substance	Diagnosis	ICD-10-CM
N14.3	Nephropathy induced by heavy metals	Diagnosis	ICD-10-CM
N14.4	Toxic nephropathy, not elsewhere classified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
N15.0	Balkan nephropathy	Diagnosis	ICD-10-CM
N15.8	Other specified renal tubulo-interstitial diseases	Diagnosis	ICD-10-CM
N15.9	Renal tubulo-interstitial disease, unspecified	Diagnosis	ICD-10-CM
N16	Renal tubulo-interstitial disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
N18.1	Chronic kidney disease, stage 1	Diagnosis	ICD-10-CM
N18.2	Chronic kidney disease, stage 2 (mild)	Diagnosis	ICD-10-CM
N18.3	Chronic kidney disease, stage 3 (moderate)	Diagnosis	ICD-10-CM
N18.30	Chronic kidney disease, stage 3 unspecified	Diagnosis	ICD-10-CM
N18.31	Chronic kidney disease, stage 3a	Diagnosis	ICD-10-CM
N18.32	Chronic kidney disease, stage 3b	Diagnosis	ICD-10-CM
N18.4	Chronic kidney disease, stage 4 (severe)	Diagnosis	ICD-10-CM
N18.5	Chronic kidney disease, stage 5	Diagnosis	ICD-10-CM
N18.6	End stage renal disease	Diagnosis	ICD-10-CM
N18.9	Chronic kidney disease, unspecified	Diagnosis	ICD-10-CM
N25.1	Nephrogenic diabetes insipidus	Diagnosis	ICD-10-CM
N25.89	Other disorders resulting from impaired renal tubular function	Diagnosis	ICD-10-CM
N25.9	Disorder resulting from impaired renal tubular function, unspecified	Diagnosis	ICD-10-CM
N26.1	Atrophy of kidney (terminal)	Diagnosis	ICD-10-CM
N26.9	Renal sclerosis, unspecified	Diagnosis	ICD-10-CM
N99.0	Postprocedural (acute) (chronic) kidney failure	Diagnosis	ICD-10-CM
Q61.02	Congenital multiple renal cysts	Diagnosis	ICD-10-CM
Q61.11	Cystic dilatation of collecting ducts	Diagnosis	ICD-10-CM
Q61.19	Other polycystic kidney, infantile type	Diagnosis	ICD-10-CM
Q61.2	Polycystic kidney, adult type	Diagnosis	ICD-10-CM
Q61.3	Polycystic kidney, unspecified	Diagnosis	ICD-10-CM
Q61.4	Renal dysplasia	Diagnosis	ICD-10-CM
Q61.5	Medullary cystic kidney	Diagnosis	ICD-10-CM
Q61.8	Other cystic kidney diseases	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
Colorectal Cancer			
C18.0	Malignant neoplasm of cecum	Diagnosis	ICD-10-CM
C18.1	Malignant neoplasm of appendix	Diagnosis	ICD-10-CM
C18.2	Malignant neoplasm of ascending colon	Diagnosis	ICD-10-CM
C18.3	Malignant neoplasm of hepatic flexure	Diagnosis	ICD-10-CM
C18.4	Malignant neoplasm of transverse colon	Diagnosis	ICD-10-CM
C18.5	Malignant neoplasm of splenic flexure	Diagnosis	ICD-10-CM
C18.6	Malignant neoplasm of descending colon	Diagnosis	ICD-10-CM
C18.7	Malignant neoplasm of sigmoid colon	Diagnosis	ICD-10-CM
C18.8	Malignant neoplasm of overlapping sites of colon	Diagnosis	ICD-10-CM
C18.9	Malignant neoplasm of colon, unspecified	Diagnosis	ICD-10-CM
C19	Malignant neoplasm of rectosigmoid junction	Diagnosis	ICD-10-CM
C20	Malignant neoplasm of rectum	Diagnosis	ICD-10-CM
C49.A4	Gastrointestinal stromal tumor of large intestine	Diagnosis	ICD-10-CM
C49.A5	Gastrointestinal stromal tumor of rectum	Diagnosis	ICD-10-CM
D01.0	Carcinoma in situ of colon	Diagnosis	ICD-10-CM
D01.1	Carcinoma in situ of rectosigmoid junction	Diagnosis	ICD-10-CM
D01.2	Carcinoma in situ of rectum	Diagnosis	ICD-10-CM
Z85.030	Personal history of malignant carcinoid tumor of large intestine	Diagnosis	ICD-10-CM
Z85.038	Personal history of other malignant neoplasm of large intestine	Diagnosis	ICD-10-CM
Z85.040	Personal history of malignant carcinoid tumor of rectum	Diagnosis	ICD-10-CM
Z85.048	Personal history of other malignant neoplasm of rectum, rectosigmoid junction, and anus	Diagnosis	ICD-10-CM
Chronic Obstructive Pulmonary Disease (COPD) and Bronchiectasis			
J40	Bronchitis, not specified as acute or chronic	Diagnosis	ICD-10-CM
J41.0	Simple chronic bronchitis	Diagnosis	ICD-10-CM
J41.1	Mucopurulent chronic bronchitis	Diagnosis	ICD-10-CM
J41.8	Mixed simple and mucopurulent chronic bronchitis	Diagnosis	ICD-10-CM
J42	Unspecified chronic bronchitis	Diagnosis	ICD-10-CM
J43.0	Unilateral pulmonary emphysema [MacLeod's syndrome]	Diagnosis	ICD-10-CM
J43.1	Panlobular emphysema	Diagnosis	ICD-10-CM
J43.2	Centrilobular emphysema	Diagnosis	ICD-10-CM
J43.9	Emphysema, unspecified	Diagnosis	ICD-10-CM
J44.0	Chronic obstructive pulmonary disease with (acute) lower respiratory infection	Diagnosis	ICD-10-CM
J44.1	Chronic obstructive pulmonary disease with (acute) exacerbation	Diagnosis	ICD-10-CM
J44.81	Bronchiolitis obliterans and bronchiolitis obliterans syndrome	Diagnosis	ICD-10-CM
J44.89	Other specified chronic obstructive pulmonary disease	Diagnosis	ICD-10-CM
J44.9	Chronic obstructive pulmonary disease, unspecified	Diagnosis	ICD-10-CM
J47.0	Bronchiectasis with acute lower respiratory infection	Diagnosis	ICD-10-CM
J47.1	Bronchiectasis with (acute) exacerbation	Diagnosis	ICD-10-CM
J47.9	Bronchiectasis, uncomplicated	Diagnosis	ICD-10-CM
J98.2	Interstitial emphysema	Diagnosis	ICD-10-CM
J98.3	Compensatory emphysema	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
History of Coronary Angioplasty or Bypass			
00566	Anesthesia for direct coronary artery bypass grafting; without pump oxygenator	Procedure	CPT-4
00567	Anesthesia for direct coronary artery bypass grafting; with pump oxygenator	Procedure	CPT-4
02104Z3	Bypass Coronary Artery, One Artery from Coronary Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114Z3	Bypass Coronary Artery, Two Arteries from Coronary Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124Z3	Bypass Coronary Artery, Three Arteries from Coronary Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134Z3	Bypass Coronary Artery, Four or More Arteries from Coronary Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0270346	Dilation of Coronary Artery, One Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
027034Z	Dilation of Coronary Artery, One Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0270356	Dilation of Coronary Artery, One Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027035Z	Dilation of Coronary Artery, One Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0270366	Dilation of Coronary Artery, One Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027036Z	Dilation of Coronary Artery, One Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0270376	Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027037Z	Dilation of Coronary Artery, One Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703D6	Dilation of Coronary Artery, One Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02703DZ	Dilation of Coronary Artery, One Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02703E6	Dilation of Coronary Artery, One Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703EZ	Dilation of Coronary Artery, One Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703F6	Dilation of Coronary Artery, One Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703FZ	Dilation of Coronary Artery, One Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703G6	Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
02703GZ	Dilation of Coronary Artery, One Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703T6	Dilation of Coronary Artery, One Artery, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02703TZ	Dilation of Coronary Artery, One Artery with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02703Z6	Dilation of Coronary Artery, One Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
02703ZZ	Dilation of Coronary Artery, One Artery, Percutaneous Approach	Procedure	ICD-10-PCS
0270446	Dilation of Coronary Artery, One Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027044Z	Dilation of Coronary Artery, One Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0270456	Dilation of Coronary Artery, One Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027045Z	Dilation of Coronary Artery, One Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0270466	Dilation of Coronary Artery, One Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027046Z	Dilation of Coronary Artery, One Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0270476	Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027047Z	Dilation of Coronary Artery, One Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704D6	Dilation of Coronary Artery, One Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704DZ	Dilation of Coronary Artery, One Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704E6	Dilation of Coronary Artery, One Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704EZ	Dilation of Coronary Artery, One Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704F6	Dilation of Coronary Artery, One Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704FZ	Dilation of Coronary Artery, One Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704G6	Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704GZ	Dilation of Coronary Artery, One Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704T6	Dilation of Coronary Artery, One Artery, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
02704TZ	Dilation of Coronary Artery, One Artery with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704Z6	Dilation of Coronary Artery, One Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704ZZ	Dilation of Coronary Artery, One Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0271346	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
027134Z	Dilation of Coronary Artery, Two Arteries with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0271356	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027135Z	Dilation of Coronary Artery, Two Arteries with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0271366	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027136Z	Dilation of Coronary Artery, Two Arteries with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0271376	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027137Z	Dilation of Coronary Artery, Two Arteries with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713D6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02713DZ	Dilation of Coronary Artery, Two Arteries with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02713E6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713EZ	Dilation of Coronary Artery, Two Arteries with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713F6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713FZ	Dilation of Coronary Artery, Two Arteries with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713G6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713GZ	Dilation of Coronary Artery, Two Arteries with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713T6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02713TZ	Dilation of Coronary Artery, Two Arteries with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02713Z6	Dilation of Coronary Artery, Two Arteries, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
02713ZZ	Dilation of Coronary Artery, Two Arteries, Percutaneous Approach	Procedure	ICD-10-PCS
0271446	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027144Z	Dilation of Coronary Artery, Two Arteries with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0271456	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027145Z	Dilation of Coronary Artery, Two Arteries with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0271466	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027146Z	Dilation of Coronary Artery, Two Arteries with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0271476	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027147Z	Dilation of Coronary Artery, Two Arteries with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714D6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714DZ	Dilation of Coronary Artery, Two Arteries with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714E6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714EZ	Dilation of Coronary Artery, Two Arteries with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714F6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714FZ	Dilation of Coronary Artery, Two Arteries with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714G6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714GZ	Dilation of Coronary Artery, Two Arteries with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714T6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714TZ	Dilation of Coronary Artery, Two Arteries with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714Z6	Dilation of Coronary Artery, Two Arteries, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714ZZ	Dilation of Coronary Artery, Two Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0272346	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
027234Z	Dilation of Coronary Artery, Three Arteries with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0272356	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027235Z	Dilation of Coronary Artery, Three Arteries with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0272366	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027236Z	Dilation of Coronary Artery, Three Arteries with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0272376	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027237Z	Dilation of Coronary Artery, Three Arteries with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02723D6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02723DZ	Dilation of Coronary Artery, Three Arteries with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02723E6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02723EZ	Dilation of Coronary Artery, Three Arteries with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02723F6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02723FZ	Dilation of Coronary Artery, Three Arteries with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02723G6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02723GZ	Dilation of Coronary Artery, Three Arteries with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02723T6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02723TZ	Dilation of Coronary Artery, Three Arteries with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02723Z6	Dilation of Coronary Artery, Three Arteries, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
02723ZZ	Dilation of Coronary Artery, Three Arteries, Percutaneous Approach	Procedure	ICD-10-PCS
0272446	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027244Z	Dilation of Coronary Artery, Three Arteries with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0272456	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
027245Z	Dilation of Coronary Artery, Three Arteries with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0272466	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027246Z	Dilation of Coronary Artery, Three Arteries with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0272476	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027247Z	Dilation of Coronary Artery, Three Arteries with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724D6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724DZ	Dilation of Coronary Artery, Three Arteries with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724E6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724EZ	Dilation of Coronary Artery, Three Arteries with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724F6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724FZ	Dilation of Coronary Artery, Three Arteries with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724G6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724GZ	Dilation of Coronary Artery, Three Arteries with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724T6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724TZ	Dilation of Coronary Artery, Three Arteries with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724Z6	Dilation of Coronary Artery, Three Arteries, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724ZZ	Dilation of Coronary Artery, Three Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0273346	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
027334Z	Dilation of Coronary Artery, Four or More Arteries with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0273356	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027335Z	Dilation of Coronary Artery, Four or More Arteries with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
0273366	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027336Z	Dilation of Coronary Artery, Four or More Arteries with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0273376	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027337Z	Dilation of Coronary Artery, Four or More Arteries with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02733D6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02733DZ	Dilation of Coronary Artery, Four or More Arteries with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02733E6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02733EZ	Dilation of Coronary Artery, Four or More Arteries with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02733F6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02733FZ	Dilation of Coronary Artery, Four or More Arteries with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02733G6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02733GZ	Dilation of Coronary Artery, Four or More Arteries with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02733T6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02733TZ	Dilation of Coronary Artery, Four or More Arteries with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02733Z6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
02733ZZ	Dilation of Coronary Artery, Four or More Arteries, Percutaneous Approach	Procedure	ICD-10-PCS
0273446	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027344Z	Dilation of Coronary Artery, Four or More Arteries with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0273456	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027345Z	Dilation of Coronary Artery, Four or More Arteries with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0273466	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
027346Z	Dilation of Coronary Artery, Four or More Arteries with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0273476	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027347Z	Dilation of Coronary Artery, Four or More Arteries with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734D6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734DZ	Dilation of Coronary Artery, Four or More Arteries with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734E6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734EZ	Dilation of Coronary Artery, Four or More Arteries with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734F6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734FZ	Dilation of Coronary Artery, Four or More Arteries with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734G6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734GZ	Dilation of Coronary Artery, Four or More Arteries with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734T6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734TZ	Dilation of Coronary Artery, Four or More Arteries with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734Z6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734ZZ	Dilation of Coronary Artery, Four or More Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0644T	Transcatheter removal or debulking of intracardiac mass (eg, vegetations, thrombus) via suction (eg, vacuum, aspiration) device, percutaneous approach, with intraoperative reinfusion of aspirated blood, including imaging guidance, when performed	Procedure	CPT-3
33508	Endoscopy, surgical, including video-assisted harvest of vein(s) for coronary artery bypass procedure (List separately in addition to code for primary procedure)	Procedure	CPT-4
33509	Harvest of upper extremity artery, 1 segment, for coronary artery bypass procedure, endoscopic	Procedure	CPT-4
33510	Coronary artery bypass, vein only; single coronary venous graft	Procedure	CPT-4
33511	Coronary artery bypass, vein only; 2 coronary venous grafts	Procedure	CPT-4
33512	Coronary artery bypass, vein only; 3 coronary venous grafts	Procedure	CPT-4
33513	Coronary artery bypass, vein only; 4 coronary venous grafts	Procedure	CPT-4

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
33514	Coronary artery bypass, vein only; 5 coronary venous grafts	Procedure	CPT-4
33516	Coronary artery bypass, vein only; 6 or more coronary venous grafts	Procedure	CPT-4
33517	Coronary artery bypass, using venous graft(s) and arterial graft(s); single vein graft (List separately in addition to code for primary procedure)	Procedure	CPT-4
33518	Coronary artery bypass, using venous graft(s) and arterial graft(s); 2 venous grafts (List separately in addition to code for primary procedure)	Procedure	CPT-4
33519	Coronary artery bypass, using venous graft(s) and arterial graft(s); 3 venous grafts (List separately in addition to code for primary procedure)	Procedure	CPT-4
33520	Coronary Artery Bypass, Nonautogenous Graft (eg, Synthetic Or Cadaver); Single Graft	Procedure	CPT-4
33521	Coronary artery bypass, using venous graft(s) and arterial graft(s); 4 venous grafts (List separately in addition to code for primary procedure)	Procedure	CPT-4
33522	Coronary artery bypass, using venous graft(s) and arterial graft(s); 5 venous grafts (List separately in addition to code for primary procedure)	Procedure	CPT-4
33523	Coronary artery bypass, using venous graft(s) and arterial graft(s); 6 or more venous grafts (List separately in addition to code for primary procedure)	Procedure	CPT-4
33525	Coronary Artery Bypass, Nonautogenous Graft (eg, Synthetic Or Cadaver); Two Coronary Grafts	Procedure	CPT-4
33528	Coronary Artery Bypass, Nonautogenous Graft (eg, Synthetic Or Cadaver); Three Or More Coronary Grafts	Procedure	CPT-4
33530	Reoperation, coronary artery bypass procedure or valve procedure, more than 1 month after original operation (List separately in addition to code for primary procedure)	Procedure	CPT-4
33533	Coronary artery bypass, using arterial graft(s); single arterial graft	Procedure	CPT-4
33534	Coronary artery bypass, using arterial graft(s); 2 coronary arterial grafts	Procedure	CPT-4
33535	Coronary artery bypass, using arterial graft(s); 3 coronary arterial grafts	Procedure	CPT-4
33536	Coronary artery bypass, using arterial graft(s); 4 or more coronary arterial grafts	Procedure	CPT-4
33572	Coronary endarterectomy, open, any method, of left anterior descending, circumflex, or right coronary artery performed in conjunction with coronary artery bypass graft procedure, each vessel (List separately in addition to primary procedure)	Procedure	CPT-4
35500	Harvest of upper extremity vein, 1 segment, for lower extremity or coronary artery bypass procedure (List separately in addition to code for primary procedure)	Procedure	CPT-4
35600	Harvest of upper extremity artery, 1 segment, for coronary artery bypass procedure, open	Procedure	CPT-4
4110F	Internal mammary artery graft performed for primary, isolated coronary artery bypass graft procedure (CABG)	Procedure	CPT-2

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
92920	Percutaneous transluminal coronary angioplasty; single major coronary artery or branch	Procedure	CPT-4
92921	Percutaneous transluminal coronary angioplasty; each additional branch of a major coronary artery (List separately in addition to code for primary procedure)	Procedure	CPT-4
92924	Percutaneous transluminal coronary atherectomy, with coronary angioplasty when performed; single major coronary artery or branch	Procedure	CPT-4
92925	Percutaneous transluminal coronary atherectomy, with coronary angioplasty when performed; each additional branch of a major coronary artery (List separately in addition to code for primary procedure)	Procedure	CPT-4
92928	Percutaneous transcatheter placement of intracoronary stent(s), with coronary angioplasty when performed; single major coronary artery or branch	Procedure	CPT-4
92929	Percutaneous transcatheter placement of intracoronary stent(s), with coronary angioplasty when performed; each additional branch of a major coronary artery (List separately in addition to code for primary procedure)	Procedure	CPT-4
92933	Percutaneous transluminal coronary atherectomy, with intracoronary stent, with coronary angioplasty when performed; single major coronary artery or branch	Procedure	CPT-4
92934	Percutaneous transluminal coronary atherectomy, with intracoronary stent, with coronary angioplasty when performed; each additional branch of a major coronary artery (List separately in addition to code for primary procedure)	Procedure	CPT-4
92937	Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of intracoronary stent, atherectomy and angioplasty, including distal protection when performed; single	Procedure	CPT-4
92938	Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of intracoronary stent, atherectomy and angioplasty, including distal protection when performed; each ad	Procedure	CPT-4
92941	Percutaneous transluminal revascularization of acute total/subtotal occlusion during acute myocardial infarction, coronary artery or coronary artery bypass graft, any combination of intracoronary stent, atherectomy and angioplasty, including aspirati	Procedure	CPT-4
92943	Percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of intracoronary stent, atherectomy and angioplasty; single vessel	Procedure	CPT-4

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
92944	Percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of intracoronary stent, atherectomy and angioplasty; each additional coronary artery, co	Procedure	CPT-4
C9600	Percutaneous transcatheter placement of drug eluting intracoronary stent(s), with coronary angioplasty when performed; single major coronary artery or branch	Procedure	HCPCS
C9601	Percutaneous transcatheter placement of drug-eluting intracoronary stent(s), with coronary angioplasty when performed; each additional branch of a major coronary artery (list separately in addition to code for primary procedure)	Procedure	HCPCS
C9602	Percutaneous transluminal coronary atherectomy, with drug eluting intracoronary stent, with coronary angioplasty when performed; single major coronary artery or branch	Procedure	HCPCS
C9603	Percutaneous transluminal coronary atherectomy, with drug-eluting intracoronary stent, with coronary angioplasty when performed; each additional branch of a major coronary artery (list separately in addition to code for primary procedure)	Procedure	HCPCS
C9604	Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of drug-eluting intracoronary stent, atherectomy and angioplasty, including distal protection when perfo	Procedure	HCPCS
C9605	Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of drug-eluting intracoronary stent, atherectomy and angioplasty, including distal protection when perfo	Procedure	HCPCS
C9606	Percutaneous transluminal revascularization of acute total/subtotal occlusion during acute myocardial infarction, coronary artery or coronary artery bypass graft, any combination of drug-eluting intracoronary stent, atherectomy and angioplasty, inclu	Procedure	HCPCS
C9607	Percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of drug-eluting intracoronary stent, atherectomy and angioplasty; single vessel	Procedure	HCPCS
C9608	Percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of drug-eluting intracoronary stent, atherectomy and angioplasty; each additional corona	Procedure	HCPCS
S2205	Minimally invasive direct coronary artery bypass surgery involving mini-thoracotomy or mini-sternotomy surgery, performed under direct vision; using arterial graft(s), single coronary arterial graft	Procedure	HCPCS
S2206	Minimally invasive direct coronary artery bypass surgery involving mini-thoracotomy or mini-sternotomy surgery, performed under direct vision; using arterial graft(s), two coronary arterial grafts	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
S2207	Minimally invasive direct coronary artery bypass surgery involving mini-thoracotomy or mini-sternotomy surgery, performed under direct vision; using venous graft only, single coronary venous graft	Procedure	HCPCS
S2208	Minimally invasive direct coronary artery bypass surgery involving mini-thoracotomy or mini-sternotomy surgery, performed under direct vision; using single arterial and venous graft(s), single venous graft	Procedure	HCPCS
S2209	Minimally invasive direct coronary artery bypass surgery involving mini-thoracotomy or mini-sternotomy surgery, performed under direct vision; using two arterial grafts and single venous graft	Procedure	HCPCS
T82.2	Mechanical complication of coronary artery bypass graft and biological heart valve graft	Diagnosis	ICD-10-CM
T82.21	Mechanical complication of coronary artery bypass graft	Diagnosis	ICD-10-CM
T82.211	Breakdown (mechanical) of coronary artery bypass graft	Diagnosis	ICD-10-CM
T82.211A	Breakdown (mechanical) of coronary artery bypass graft, initial encounter	Diagnosis	ICD-10-CM
T82.211D	Breakdown (mechanical) of coronary artery bypass graft, subsequent encounter	Diagnosis	ICD-10-CM
T82.211S	Breakdown (mechanical) of coronary artery bypass graft, sequela	Diagnosis	ICD-10-CM
T82.212	Displacement of coronary artery bypass graft	Diagnosis	ICD-10-CM
T82.212A	Displacement of coronary artery bypass graft, initial encounter	Diagnosis	ICD-10-CM
T82.212D	Displacement of coronary artery bypass graft, subsequent encounter	Diagnosis	ICD-10-CM
T82.212S	Displacement of coronary artery bypass graft, sequela	Diagnosis	ICD-10-CM
T82.213	Leakage of coronary artery bypass graft	Diagnosis	ICD-10-CM
T82.213A	Leakage of coronary artery bypass graft, initial encounter	Diagnosis	ICD-10-CM
T82.213D	Leakage of coronary artery bypass graft, subsequent encounter	Diagnosis	ICD-10-CM
T82.213S	Leakage of coronary artery bypass graft, sequela	Diagnosis	ICD-10-CM
T82.218	Other mechanical complication of coronary artery bypass graft	Diagnosis	ICD-10-CM
T82.218A	Other mechanical complication of coronary artery bypass graft, initial encounter	Diagnosis	ICD-10-CM
T82.218D	Other mechanical complication of coronary artery bypass graft, subsequent encounter	Diagnosis	ICD-10-CM
T82.218S	Other mechanical complication of coronary artery bypass graft, sequela	Diagnosis	ICD-10-CM
Z95.1	Presence of aortocoronary bypass graft	Diagnosis	ICD-10-CM
Z95.5	Presence of coronary angioplasty implant and graft	Diagnosis	ICD-10-CM
Z98.61	Coronary angioplasty status	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
Non-Alzheimer's Dementia			
F01.50	Vascular dementia, unspecified severity, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F01.51	Vascular dementia, unspecified severity, with behavioral disturbance	Diagnosis	ICD-10-CM
F01.511	Vascular dementia, unspecified severity, with agitation	Diagnosis	ICD-10-CM
F01.518	Vascular dementia, unspecified severity, with other behavioral disturbance	Diagnosis	ICD-10-CM
F01.52	Vascular dementia, unspecified severity, with psychotic disturbance	Diagnosis	ICD-10-CM
F01.53	Vascular dementia, unspecified severity, with mood disturbance	Diagnosis	ICD-10-CM
F01.54	Vascular dementia, unspecified severity, with anxiety	Diagnosis	ICD-10-CM
F01.A0	Vascular dementia, mild, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F01.A11	Vascular dementia, mild, with agitation	Diagnosis	ICD-10-CM
F01.A18	Vascular dementia, mild, with other behavioral disturbance	Diagnosis	ICD-10-CM
F01.A2	Vascular dementia, mild, with psychotic disturbance	Diagnosis	ICD-10-CM
F01.A3	Vascular dementia, mild, with mood disturbance	Diagnosis	ICD-10-CM
F01.A4	Vascular dementia, mild, with anxiety	Diagnosis	ICD-10-CM
F01.B0	Vascular dementia, moderate, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F01.B11	Vascular dementia, moderate, with agitation	Diagnosis	ICD-10-CM
F01.B18	Vascular dementia, moderate, with other behavioral disturbance	Diagnosis	ICD-10-CM
F01.B2	Vascular dementia, moderate, with psychotic disturbance	Diagnosis	ICD-10-CM
F01.B3	Vascular dementia, moderate, with mood disturbance	Diagnosis	ICD-10-CM
F01.B4	Vascular dementia, moderate, with anxiety	Diagnosis	ICD-10-CM
F01.C0	Vascular dementia, severe, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F01.C11	Vascular dementia, severe, with agitation	Diagnosis	ICD-10-CM
F01.C18	Vascular dementia, severe, with other behavioral disturbance	Diagnosis	ICD-10-CM
F01.C2	Vascular dementia, severe, with psychotic disturbance	Diagnosis	ICD-10-CM
F01.C3	Vascular dementia, severe, with mood disturbance	Diagnosis	ICD-10-CM
F01.C4	Vascular dementia, severe, with anxiety	Diagnosis	ICD-10-CM
F02.80	Dementia in other diseases classified elsewhere, unspecified severity, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F02.81	Dementia in other diseases classified elsewhere, unspecified severity, with behavioral disturbance	Diagnosis	ICD-10-CM
F02.811	Dementia in other diseases classified elsewhere, unspecified severity, with agitation	Diagnosis	ICD-10-CM
F02.818	Dementia in other diseases classified elsewhere, unspecified severity, with other behavioral disturbance	Diagnosis	ICD-10-CM
F02.82	Dementia in other diseases classified elsewhere, unspecified severity, with psychotic disturbance	Diagnosis	ICD-10-CM
F02.83	Dementia in other diseases classified elsewhere, unspecified severity, with mood disturbance	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F02.84	Dementia in other diseases classified elsewhere, unspecified severity, with anxiety	Diagnosis	ICD-10-CM
F02.A0	Dementia in other diseases classified elsewhere, mild, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F02.A11	Dementia in other diseases classified elsewhere, mild, with agitation	Diagnosis	ICD-10-CM
F02.A18	Dementia in other diseases classified elsewhere, mild, with other behavioral disturbance	Diagnosis	ICD-10-CM
F02.A2	Dementia in other diseases classified elsewhere, mild, with psychotic disturbance	Diagnosis	ICD-10-CM
F02.A3	Dementia in other diseases classified elsewhere, mild, with mood disturbance	Diagnosis	ICD-10-CM
F02.A4	Dementia in other diseases classified elsewhere, mild, with anxiety	Diagnosis	ICD-10-CM
F02.B0	Dementia in other diseases classified elsewhere, moderate, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F02.B11	Dementia in other diseases classified elsewhere, moderate, with agitation	Diagnosis	ICD-10-CM
F02.B18	Dementia in other diseases classified elsewhere, moderate, with other behavioral disturbance	Diagnosis	ICD-10-CM
F02.B2	Dementia in other diseases classified elsewhere, moderate, with psychotic disturbance	Diagnosis	ICD-10-CM
F02.B3	Dementia in other diseases classified elsewhere, moderate, with mood disturbance	Diagnosis	ICD-10-CM
F02.B4	Dementia in other diseases classified elsewhere, moderate, with anxiety	Diagnosis	ICD-10-CM
F02.C0	Dementia in other diseases classified elsewhere, severe, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F02.C11	Dementia in other diseases classified elsewhere, severe, with agitation	Diagnosis	ICD-10-CM
F02.C18	Dementia in other diseases classified elsewhere, severe, with other behavioral disturbance	Diagnosis	ICD-10-CM
F02.C2	Dementia in other diseases classified elsewhere, severe, with psychotic disturbance	Diagnosis	ICD-10-CM
F02.C3	Dementia in other diseases classified elsewhere, severe, with mood disturbance	Diagnosis	ICD-10-CM
F02.C4	Dementia in other diseases classified elsewhere, severe, with anxiety	Diagnosis	ICD-10-CM
F03.90	Unspecified dementia, unspecified severity, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F03.91	Unspecified dementia, unspecified severity, with behavioral disturbance	Diagnosis	ICD-10-CM
F03.911	Unspecified dementia, unspecified severity, with agitation	Diagnosis	ICD-10-CM
F03.918	Unspecified dementia, unspecified severity, with other behavioral disturbance	Diagnosis	ICD-10-CM
F03.92	Unspecified dementia, unspecified severity, with psychotic disturbance	Diagnosis	ICD-10-CM
F03.93	Unspecified dementia, unspecified severity, with mood disturbance	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F03.94	Unspecified dementia, unspecified severity, with anxiety	Diagnosis	ICD-10-CM
F03.A0	Unspecified dementia, mild, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F03.A11	Unspecified dementia, mild, with agitation	Diagnosis	ICD-10-CM
F03.A18	Unspecified dementia, mild, with other behavioral disturbance	Diagnosis	ICD-10-CM
F03.A2	Unspecified dementia, mild, with psychotic disturbance	Diagnosis	ICD-10-CM
F03.A3	Unspecified dementia, mild, with mood disturbance	Diagnosis	ICD-10-CM
F03.A4	Unspecified dementia, mild, with anxiety	Diagnosis	ICD-10-CM
F03.B0	Unspecified dementia, moderate, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F03.B11	Unspecified dementia, moderate, with agitation	Diagnosis	ICD-10-CM
F03.B18	Unspecified dementia, moderate, with other behavioral disturbance	Diagnosis	ICD-10-CM
F03.B2	Unspecified dementia, moderate, with psychotic disturbance	Diagnosis	ICD-10-CM
F03.B3	Unspecified dementia, moderate, with mood disturbance	Diagnosis	ICD-10-CM
F03.B4	Unspecified dementia, moderate, with anxiety	Diagnosis	ICD-10-CM
F03.C0	Unspecified dementia, severe, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F03.C11	Unspecified dementia, severe, with agitation	Diagnosis	ICD-10-CM
F03.C18	Unspecified dementia, severe, with other behavioral disturbance	Diagnosis	ICD-10-CM
F03.C2	Unspecified dementia, severe, with psychotic disturbance	Diagnosis	ICD-10-CM
F03.C3	Unspecified dementia, severe, with mood disturbance	Diagnosis	ICD-10-CM
F03.C4	Unspecified dementia, severe, with anxiety	Diagnosis	ICD-10-CM
F05	Delirium due to known physiological condition	Diagnosis	ICD-10-CM
G13.8	Systemic atrophy primarily affecting central nervous system in other diseases classified elsewhere	Diagnosis	ICD-10-CM
G31.01	Pick's disease	Diagnosis	ICD-10-CM
G31.09	Other frontotemporal neurocognitive disorder	Diagnosis	ICD-10-CM
G31.1	Senile degeneration of brain, not elsewhere classified	Diagnosis	ICD-10-CM
G31.2	Degeneration of nervous system due to alcohol	Diagnosis	ICD-10-CM
G31.83	Neurocognitive disorder with Lewy bodies	Diagnosis	ICD-10-CM
G94	Other disorders of brain in diseases classified elsewhere	Diagnosis	ICD-10-CM
R41.81	Age-related cognitive decline	Diagnosis	ICD-10-CM
Depression			
F06.31	Mood disorder due to known physiological condition with depressive features	Diagnosis	ICD-10-CM
F06.32	Mood disorder due to known physiological condition with major depressive-like episode	Diagnosis	ICD-10-CM
F31.0	Bipolar disorder, current episode hypomanic	Diagnosis	ICD-10-CM
F31.10	Bipolar disorder, current episode manic without psychotic features, unspecified	Diagnosis	ICD-10-CM
F31.11	Bipolar disorder, current episode manic without psychotic features, mild	Diagnosis	ICD-10-CM
F31.12	Bipolar disorder, current episode manic without psychotic features, moderate	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F31.13	Bipolar disorder, current episode manic without psychotic features, severe	Diagnosis	ICD-10-CM
F31.2	Bipolar disorder, current episode manic severe with psychotic features	Diagnosis	ICD-10-CM
F31.30	Bipolar disorder, current episode depressed, mild or moderate severity, unspecified	Diagnosis	ICD-10-CM
F31.31	Bipolar disorder, current episode depressed, mild	Diagnosis	ICD-10-CM
F31.32	Bipolar disorder, current episode depressed, moderate	Diagnosis	ICD-10-CM
F31.4	Bipolar disorder, current episode depressed, severe, without psychotic features	Diagnosis	ICD-10-CM
F31.5	Bipolar disorder, current episode depressed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.60	Bipolar disorder, current episode mixed, unspecified	Diagnosis	ICD-10-CM
F31.61	Bipolar disorder, current episode mixed, mild	Diagnosis	ICD-10-CM
F31.62	Bipolar disorder, current episode mixed, moderate	Diagnosis	ICD-10-CM
F31.63	Bipolar disorder, current episode mixed, severe, without psychotic features	Diagnosis	ICD-10-CM
F31.64	Bipolar disorder, current episode mixed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.71	Bipolar disorder, in partial remission, most recent episode hypomanic	Diagnosis	ICD-10-CM
F31.73	Bipolar disorder, in partial remission, most recent episode manic	Diagnosis	ICD-10-CM
F31.75	Bipolar disorder, in partial remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.76	Bipolar disorder, in full remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.77	Bipolar disorder, in partial remission, most recent episode mixed	Diagnosis	ICD-10-CM
F31.78	Bipolar disorder, in full remission, most recent episode mixed	Diagnosis	ICD-10-CM
F31.81	Bipolar II disorder	Diagnosis	ICD-10-CM
F31.89	Other bipolar disorder	Diagnosis	ICD-10-CM
F31.9	Bipolar disorder, unspecified	Diagnosis	ICD-10-CM
F32.0	Major depressive disorder, single episode, mild	Diagnosis	ICD-10-CM
F32.1	Major depressive disorder, single episode, moderate	Diagnosis	ICD-10-CM
F32.2	Major depressive disorder, single episode, severe without psychotic features	Diagnosis	ICD-10-CM
F32.3	Major depressive disorder, single episode, severe with psychotic features	Diagnosis	ICD-10-CM
F32.4	Major depressive disorder, single episode, in partial remission	Diagnosis	ICD-10-CM
F32.5	Major depressive disorder, single episode, in full remission	Diagnosis	ICD-10-CM
F32.8	Other depressive episodes	Diagnosis	ICD-10-CM
F32.89	Other specified depressive episodes	Diagnosis	ICD-10-CM
F32.9	Major depressive disorder, single episode, unspecified	Diagnosis	ICD-10-CM
F32.A	Depression, unspecified	Diagnosis	ICD-10-CM
F33.0	Major depressive disorder, recurrent, mild	Diagnosis	ICD-10-CM
F33.1	Major depressive disorder, recurrent, moderate	Diagnosis	ICD-10-CM
F33.2	Major depressive disorder, recurrent severe without psychotic features	Diagnosis	ICD-10-CM
F33.3	Major depressive disorder, recurrent, severe with psychotic symptoms	Diagnosis	ICD-10-CM
F33.40	Major depressive disorder, recurrent, in remission, unspecified	Diagnosis	ICD-10-CM
F33.41	Major depressive disorder, recurrent, in partial remission	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F33.42	Major depressive disorder, recurrent, in full remission	Diagnosis	ICD-10-CM
F33.8	Other recurrent depressive disorders	Diagnosis	ICD-10-CM
F33.9	Major depressive disorder, recurrent, unspecified	Diagnosis	ICD-10-CM
F34.0	Cyclothymic disorder	Diagnosis	ICD-10-CM
F34.1	Dysthymic disorder	Diagnosis	ICD-10-CM
F43.21	Adjustment disorder with depressed mood	Diagnosis	ICD-10-CM
F43.23	Adjustment disorder with mixed anxiety and depressed mood	Diagnosis	ICD-10-CM
Diabetes			
E08.00	Diabetes mellitus due to underlying condition with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E08.01	Diabetes mellitus due to underlying condition with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E08.10	Diabetes mellitus due to underlying condition with ketoacidosis without coma	Diagnosis	ICD-10-CM
E08.11	Diabetes mellitus due to underlying condition with ketoacidosis with coma	Diagnosis	ICD-10-CM
E08.21	Diabetes mellitus due to underlying condition with diabetic nephropathy	Diagnosis	ICD-10-CM
E08.22	Diabetes mellitus due to underlying condition with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E08.29	Diabetes mellitus due to underlying condition with other diabetic kidney complication	Diagnosis	ICD-10-CM
E08.311	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.319	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.321	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3211	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3212	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3213	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3219	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.329	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3291	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3292	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E08.3293	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3299	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.331	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3311	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3312	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3313	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3319	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.339	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3391	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3392	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3393	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3399	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.341	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3411	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3412	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3413	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3419	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.349	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3491	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3492	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E08.3493	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3499	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.351	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3511	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3512	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3513	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3519	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.3521	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E08.3522	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E08.3523	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E08.3529	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E08.3531	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E08.3532	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E08.3533	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E08.3539	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E08.3541	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E08.3542	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E08.3543	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E08.3549	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E08.3551	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E08.3552	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E08.3553	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E08.3559	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E08.359	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3591	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3592	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3593	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3599	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.36	Diabetes mellitus due to underlying condition with diabetic cataract	Diagnosis	ICD-10-CM
E08.37X1	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E08.37X2	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E08.37X3	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E08.37X9	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E08.39	Diabetes mellitus due to underlying condition with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E08.40	Diabetes mellitus due to underlying condition with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E08.41	Diabetes mellitus due to underlying condition with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E08.42	Diabetes mellitus due to underlying condition with diabetic polyneuropathy	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E08.43	Diabetes mellitus due to underlying condition with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E08.44	Diabetes mellitus due to underlying condition with diabetic amyotrophy	Diagnosis	ICD-10-CM
E08.49	Diabetes mellitus due to underlying condition with other diabetic neurological complication	Diagnosis	ICD-10-CM
E08.51	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E08.52	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E08.59	Diabetes mellitus due to underlying condition with other circulatory complications	Diagnosis	ICD-10-CM
E08.610	Diabetes mellitus due to underlying condition with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E08.618	Diabetes mellitus due to underlying condition with other diabetic arthropathy	Diagnosis	ICD-10-CM
E08.620	Diabetes mellitus due to underlying condition with diabetic dermatitis	Diagnosis	ICD-10-CM
E08.621	Diabetes mellitus due to underlying condition with foot ulcer	Diagnosis	ICD-10-CM
E08.622	Diabetes mellitus due to underlying condition with other skin ulcer	Diagnosis	ICD-10-CM
E08.628	Diabetes mellitus due to underlying condition with other skin complications	Diagnosis	ICD-10-CM
E08.630	Diabetes mellitus due to underlying condition with periodontal disease	Diagnosis	ICD-10-CM
E08.638	Diabetes mellitus due to underlying condition with other oral complications	Diagnosis	ICD-10-CM
E08.641	Diabetes mellitus due to underlying condition with hypoglycemia with coma	Diagnosis	ICD-10-CM
E08.649	Diabetes mellitus due to underlying condition with hypoglycemia without coma	Diagnosis	ICD-10-CM
E08.65	Diabetes mellitus due to underlying condition with hyperglycemia	Diagnosis	ICD-10-CM
E08.69	Diabetes mellitus due to underlying condition with other specified complication	Diagnosis	ICD-10-CM
E08.8	Diabetes mellitus due to underlying condition with unspecified complications	Diagnosis	ICD-10-CM
E08.9	Diabetes mellitus due to underlying condition without complications	Diagnosis	ICD-10-CM
E09.00	Drug or chemical induced diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E09.01	Drug or chemical induced diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E09.10	Drug or chemical induced diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E09.11	Drug or chemical induced diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E09.21	Drug or chemical induced diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E09.22	Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E09.29	Drug or chemical induced diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E09.311	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.319	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.321	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3211	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3212	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3213	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3219	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.329	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3291	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3292	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3293	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3299	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.331	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3311	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3312	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3313	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3319	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.339	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3391	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3392	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E09.3393	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3399	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.341	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3411	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3412	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3413	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3419	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.349	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3491	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3492	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3493	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3499	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.351	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3511	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3512	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3513	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3519	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.3521	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E09.3522	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E09.3523	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E09.3529	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E09.3531	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E09.3532	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E09.3533	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E09.3539	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E09.3541	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E09.3542	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E09.3543	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E09.3549	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E09.3551	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E09.3552	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E09.3553	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E09.3559	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E09.359	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3591	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3592	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3593	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E09.3599	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.36	Drug or chemical induced diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E09.37X1	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E09.37X2	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E09.37X3	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E09.37X9	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E09.39	Drug or chemical induced diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E09.40	Drug or chemical induced diabetes mellitus with neurological complications with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E09.41	Drug or chemical induced diabetes mellitus with neurological complications with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E09.42	Drug or chemical induced diabetes mellitus with neurological complications with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E09.43	Drug or chemical induced diabetes mellitus with neurological complications with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E09.44	Drug or chemical induced diabetes mellitus with neurological complications with diabetic amyotrophy	Diagnosis	ICD-10-CM
E09.49	Drug or chemical induced diabetes mellitus with neurological complications with other diabetic neurological complication	Diagnosis	ICD-10-CM
E09.51	Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E09.52	Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E09.59	Drug or chemical induced diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E09.610	Drug or chemical induced diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E09.618	Drug or chemical induced diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E09.620	Drug or chemical induced diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E09.621	Drug or chemical induced diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E09.622	Drug or chemical induced diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E09.628	Drug or chemical induced diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E09.630	Drug or chemical induced diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E09.638	Drug or chemical induced diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E09.641	Drug or chemical induced diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E09.649	Drug or chemical induced diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E09.65	Drug or chemical induced diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E09.69	Drug or chemical induced diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E09.8	Drug or chemical induced diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E09.9	Drug or chemical induced diabetes mellitus without complications	Diagnosis	ICD-10-CM
E10.10	Type 1 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E10.11	Type 1 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E10.21	Type 1 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E10.311	Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.319	Type 1 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.321	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3211	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3212	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3213	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3219	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.329	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3291	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3292	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3293	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3299	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.331	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3311	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E10.3312	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3313	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3319	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.339	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3391	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3392	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3393	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3399	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.341	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3411	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3412	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3413	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3419	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.349	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3491	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3492	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3493	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3499	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.351	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3511	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3512	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3513	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E10.3519	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.3521	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E10.3522	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E10.3523	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E10.3529	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E10.3531	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E10.3532	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E10.3533	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E10.3539	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E10.3541	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E10.3542	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E10.3543	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E10.3549	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E10.3551	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E10.3552	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E10.3553	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E10.3559	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E10.359	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3591	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3592	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E10.3593	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3599	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.36	Type 1 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E10.37X1	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E10.37X2	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E10.37X3	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E10.37X9	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E10.39	Type 1 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E10.40	Type 1 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E10.41	Type 1 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E10.42	Type 1 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E10.43	Type 1 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E10.44	Type 1 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E10.49	Type 1 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E10.51	Type 1 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E10.52	Type 1 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E10.59	Type 1 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E10.610	Type 1 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E10.618	Type 1 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E10.620	Type 1 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E10.621	Type 1 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E10.622	Type 1 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E10.628	Type 1 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E10.630	Type 1 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E10.638	Type 1 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E10.641	Type 1 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E10.649	Type 1 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E10.65	Type 1 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E10.69	Type 1 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E10.8	Type 1 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E10.9	Type 1 diabetes mellitus without complications	Diagnosis	ICD-10-CM
E11.00	Type 2 diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E11.01	Type 2 diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E11.10	Type 2 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E11.11	Type 2 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E11.21	Type 2 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.29	Type 2 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E11.311	Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.319	Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.321	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3211	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3212	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3213	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3219	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.329	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3291	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3292	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3293	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3299	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.331	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3311	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3312	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3313	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3319	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.339	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3391	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3392	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E11.3393	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3399	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.341	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3411	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3412	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3413	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3419	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.349	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3491	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3492	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3493	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3499	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.351	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3511	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3512	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3513	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3519	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.3521	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E11.3522	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3523	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3529	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E11.3531	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E11.3532	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3533	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3539	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E11.3541	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E11.3542	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E11.3543	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E11.3549	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E11.3551	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E11.3552	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E11.3553	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E11.3559	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E11.359	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3591	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3592	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3593	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3599	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.36	Type 2 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E11.37X1	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E11.37X2	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E11.37X3	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E11.37X9	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E11.39	Type 2 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E11.40	Type 2 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E11.41	Type 2 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E11.42	Type 2 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E11.43	Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E11.44	Type 2 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E11.49	Type 2 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E11.51	Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E11.52	Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E11.59	Type 2 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E11.610	Type 2 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E11.618	Type 2 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E11.620	Type 2 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E11.621	Type 2 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E11.622	Type 2 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E11.628	Type 2 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E11.630	Type 2 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E11.638	Type 2 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E11.641	Type 2 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E11.649	Type 2 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E11.65	Type 2 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E11.69	Type 2 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E11.8	Type 2 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E11.9	Type 2 diabetes mellitus without complications	Diagnosis	ICD-10-CM
E13.00	Other specified diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E13.01	Other specified diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E13.10	Other specified diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E13.11	Other specified diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E13.21	Other specified diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E13.29	Other specified diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E13.311	Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.319	Other specified diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.321	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E13.3211	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3212	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3213	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3219	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.329	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3291	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3292	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3293	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3299	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.331	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3311	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3312	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3313	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3319	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.339	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3391	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3392	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3393	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3399	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.341	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3411	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3412	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E13.3413	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3419	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.349	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3491	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3492	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3493	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3499	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.351	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3511	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3512	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3513	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3519	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.3521	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E13.3522	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E13.3523	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E13.3529	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E13.3531	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E13.3532	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E13.3533	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E13.3539	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E13.3541	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E13.3542	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E13.3543	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E13.3549	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E13.3551	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E13.3552	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E13.3553	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E13.3559	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E13.359	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3591	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3592	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3593	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3599	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.36	Other specified diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E13.39	Other specified diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E13.40	Other specified diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E13.41	Other specified diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E13.42	Other specified diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E13.43	Other specified diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E13.44	Other specified diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E13.49	Other specified diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E13.51	Other specified diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E13.52	Other specified diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E13.59	Other specified diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E13.610	Other specified diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E13.618	Other specified diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E13.620	Other specified diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E13.621	Other specified diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E13.622	Other specified diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E13.628	Other specified diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E13.630	Other specified diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E13.638	Other specified diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E13.641	Other specified diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E13.649	Other specified diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E13.65	Other specified diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E13.69	Other specified diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E13.8	Other specified diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E13.9	Other specified diabetes mellitus without complications	Diagnosis	ICD-10-CM
Drug Abuse or Dependence			
F11.10	Opioid abuse, uncomplicated	Diagnosis	ICD-10-CM
F11.11	Opioid abuse, in remission	Diagnosis	ICD-10-CM
F11.120	Opioid abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.121	Opioid abuse with intoxication delirium	Diagnosis	ICD-10-CM
F11.122	Opioid abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.129	Opioid abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.13	Opioid abuse with withdrawal	Diagnosis	ICD-10-CM
F11.14	Opioid abuse with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.150	Opioid abuse with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.151	Opioid abuse with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.159	Opioid abuse with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.181	Opioid abuse with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.182	Opioid abuse with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.188	Opioid abuse with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.19	Opioid abuse with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F11.20	Opioid dependence, uncomplicated	Diagnosis	ICD-10-CM
F11.220	Opioid dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.221	Opioid dependence with intoxication delirium	Diagnosis	ICD-10-CM
F11.222	Opioid dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.229	Opioid dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.23	Opioid dependence with withdrawal	Diagnosis	ICD-10-CM
F11.24	Opioid dependence with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.250	Opioid dependence with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.251	Opioid dependence with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.259	Opioid dependence with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.281	Opioid dependence with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.282	Opioid dependence with opioid-induced sleep disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F11.288	Opioid dependence with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.29	Opioid dependence with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F11.90	Opioid use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F11.920	Opioid use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.921	Opioid use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F11.922	Opioid use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.929	Opioid use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.93	Opioid use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F11.94	Opioid use, unspecified with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.950	Opioid use, unspecified with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.951	Opioid use, unspecified with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.959	Opioid use, unspecified with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.981	Opioid use, unspecified with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.982	Opioid use, unspecified with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.988	Opioid use, unspecified with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.99	Opioid use, unspecified with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F12.10	Cannabis abuse, uncomplicated	Diagnosis	ICD-10-CM
F12.11	Cannabis abuse, in remission	Diagnosis	ICD-10-CM
F12.120	Cannabis abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.121	Cannabis abuse with intoxication delirium	Diagnosis	ICD-10-CM
F12.122	Cannabis abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.129	Cannabis abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.13	Cannabis abuse with withdrawal	Diagnosis	ICD-10-CM
F12.150	Cannabis abuse with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.151	Cannabis abuse with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.159	Cannabis abuse with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.180	Cannabis abuse with cannabis-induced anxiety disorder	Diagnosis	ICD-10-CM
F12.188	Cannabis abuse with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.19	Cannabis abuse with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.20	Cannabis dependence, uncomplicated	Diagnosis	ICD-10-CM
F12.220	Cannabis dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.221	Cannabis dependence with intoxication delirium	Diagnosis	ICD-10-CM
F12.222	Cannabis dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.229	Cannabis dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.250	Cannabis dependence with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.251	Cannabis dependence with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.259	Cannabis dependence with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.280	Cannabis dependence with cannabis-induced anxiety disorder	Diagnosis	ICD-10-CM
F12.288	Cannabis dependence with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.29	Cannabis dependence with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.90	Cannabis use, unspecified, uncomplicated	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F12.920	Cannabis use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.921	Cannabis use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F12.922	Cannabis use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.929	Cannabis use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.950	Cannabis use, unspecified with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.951	Cannabis use, unspecified with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.959	Cannabis use, unspecified with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.980	Cannabis use, unspecified with anxiety disorder	Diagnosis	ICD-10-CM
F12.988	Cannabis use, unspecified with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.99	Cannabis use, unspecified with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F13.10	Sedative, hypnotic or anxiolytic abuse, uncomplicated	Diagnosis	ICD-10-CM
F13.11	Sedative, hypnotic or anxiolytic abuse, in remission	Diagnosis	ICD-10-CM
F13.120	Sedative, hypnotic or anxiolytic abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.121	Sedative, hypnotic or anxiolytic abuse with intoxication delirium	Diagnosis	ICD-10-CM
F13.129	Sedative, hypnotic or anxiolytic abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.130	Sedative, hypnotic or anxiolytic abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.131	Sedative, hypnotic or anxiolytic abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F13.132	Sedative, hypnotic or anxiolytic abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F13.139	Sedative, hypnotic or anxiolytic abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.14	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.150	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.151	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.159	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.180	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.181	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.182	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.188	Sedative, hypnotic or anxiolytic abuse with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.19	Sedative, hypnotic or anxiolytic abuse with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.20	Sedative, hypnotic or anxiolytic dependence, uncomplicated	Diagnosis	ICD-10-CM
F13.220	Sedative, hypnotic or anxiolytic dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.221	Sedative, hypnotic or anxiolytic dependence with intoxication delirium	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F13.229	Sedative, hypnotic or anxiolytic dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.230	Sedative, hypnotic or anxiolytic dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.231	Sedative, hypnotic or anxiolytic dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F13.232	Sedative, hypnotic or anxiolytic dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F13.239	Sedative, hypnotic or anxiolytic dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.24	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.250	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.251	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.259	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.26	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting amnesic disorder	Diagnosis	ICD-10-CM
F13.27	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting dementia	Diagnosis	ICD-10-CM
F13.280	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.281	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.282	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.288	Sedative, hypnotic or anxiolytic dependence with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.29	Sedative, hypnotic or anxiolytic dependence with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.90	Sedative, hypnotic, or anxiolytic use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F13.920	Sedative, hypnotic or anxiolytic use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.921	Sedative, hypnotic or anxiolytic use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F13.929	Sedative, hypnotic or anxiolytic use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.930	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.931	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F13.932	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal with perceptual disturbances	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F13.939	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.94	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.950	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.951	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.959	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.96	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting amnesic disorder	Diagnosis	ICD-10-CM
F13.97	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting dementia	Diagnosis	ICD-10-CM
F13.980	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.981	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.982	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.988	Sedative, hypnotic or anxiolytic use, unspecified with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.99	Sedative, hypnotic or anxiolytic use, unspecified with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F14.10	Cocaine abuse, uncomplicated	Diagnosis	ICD-10-CM
F14.11	Cocaine abuse, in remission	Diagnosis	ICD-10-CM
F14.120	Cocaine abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.121	Cocaine abuse with intoxication with delirium	Diagnosis	ICD-10-CM
F14.122	Cocaine abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.129	Cocaine abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.13	Cocaine abuse, unspecified with withdrawal	Diagnosis	ICD-10-CM
F14.14	Cocaine abuse with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.150	Cocaine abuse with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.151	Cocaine abuse with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.159	Cocaine abuse with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.180	Cocaine abuse with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.181	Cocaine abuse with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.182	Cocaine abuse with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.188	Cocaine abuse with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.19	Cocaine abuse with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.20	Cocaine dependence, uncomplicated	Diagnosis	ICD-10-CM
F14.220	Cocaine dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.221	Cocaine dependence with intoxication delirium	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F14.222	Cocaine dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.229	Cocaine dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.23	Cocaine dependence with withdrawal	Diagnosis	ICD-10-CM
F14.24	Cocaine dependence with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.250	Cocaine dependence with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.251	Cocaine dependence with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.259	Cocaine dependence with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.280	Cocaine dependence with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.281	Cocaine dependence with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.282	Cocaine dependence with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.288	Cocaine dependence with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.29	Cocaine dependence with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.90	Cocaine use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F14.920	Cocaine use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.921	Cocaine use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F14.922	Cocaine use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.929	Cocaine use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.93	Cocaine use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F14.94	Cocaine use, unspecified with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.950	Cocaine use, unspecified with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.951	Cocaine use, unspecified with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.959	Cocaine use, unspecified with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.980	Cocaine use, unspecified with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.981	Cocaine use, unspecified with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.982	Cocaine use, unspecified with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.988	Cocaine use, unspecified with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.99	Cocaine use, unspecified with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F15.10	Other stimulant abuse, uncomplicated	Diagnosis	ICD-10-CM
F15.11	Other stimulant abuse, in remission	Diagnosis	ICD-10-CM
F15.120	Other stimulant abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.121	Other stimulant abuse with intoxication delirium	Diagnosis	ICD-10-CM
F15.122	Other stimulant abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.129	Other stimulant abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.13	Other stimulant abuse with withdrawal	Diagnosis	ICD-10-CM
F15.14	Other stimulant abuse with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.150	Other stimulant abuse with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F15.151	Other stimulant abuse with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.159	Other stimulant abuse with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.180	Other stimulant abuse with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.181	Other stimulant abuse with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.182	Other stimulant abuse with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.188	Other stimulant abuse with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.19	Other stimulant abuse with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.20	Other stimulant dependence, uncomplicated	Diagnosis	ICD-10-CM
F15.220	Other stimulant dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.221	Other stimulant dependence with intoxication delirium	Diagnosis	ICD-10-CM
F15.222	Other stimulant dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.229	Other stimulant dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.23	Other stimulant dependence with withdrawal	Diagnosis	ICD-10-CM
F15.24	Other stimulant dependence with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.250	Other stimulant dependence with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.251	Other stimulant dependence with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.259	Other stimulant dependence with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.280	Other stimulant dependence with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.281	Other stimulant dependence with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.282	Other stimulant dependence with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.288	Other stimulant dependence with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.29	Other stimulant dependence with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.90	Other stimulant use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F15.920	Other stimulant use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.921	Other stimulant use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F15.922	Other stimulant use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.929	Other stimulant use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.93	Other stimulant use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F15.94	Other stimulant use, unspecified with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.950	Other stimulant use, unspecified with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.951	Other stimulant use, unspecified with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.959	Other stimulant use, unspecified with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F15.980	Other stimulant use, unspecified with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.981	Other stimulant use, unspecified with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.982	Other stimulant use, unspecified with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.988	Other stimulant use, unspecified with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.99	Other stimulant use, unspecified with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F16.10	Hallucinogen abuse, uncomplicated	Diagnosis	ICD-10-CM
F16.11	Hallucinogen abuse, in remission	Diagnosis	ICD-10-CM
F16.120	Hallucinogen abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.121	Hallucinogen abuse with intoxication with delirium	Diagnosis	ICD-10-CM
F16.122	Hallucinogen abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F16.129	Hallucinogen abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.14	Hallucinogen abuse with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.150	Hallucinogen abuse with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.151	Hallucinogen abuse with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.159	Hallucinogen abuse with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.180	Hallucinogen abuse with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.183	Hallucinogen abuse with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.188	Hallucinogen abuse with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.19	Hallucinogen abuse with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.20	Hallucinogen dependence, uncomplicated	Diagnosis	ICD-10-CM
F16.220	Hallucinogen dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.221	Hallucinogen dependence with intoxication with delirium	Diagnosis	ICD-10-CM
F16.229	Hallucinogen dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.24	Hallucinogen dependence with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.250	Hallucinogen dependence with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.251	Hallucinogen dependence with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.259	Hallucinogen dependence with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.280	Hallucinogen dependence with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.283	Hallucinogen dependence with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.288	Hallucinogen dependence with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.29	Hallucinogen dependence with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.90	Hallucinogen use, unspecified, uncomplicated	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F16.920	Hallucinogen use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.921	Hallucinogen use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F16.929	Hallucinogen use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.94	Hallucinogen use, unspecified with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.950	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.951	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.959	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.980	Hallucinogen use, unspecified with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.983	Hallucinogen use, unspecified with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.988	Hallucinogen use, unspecified with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.99	Hallucinogen use, unspecified with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F18.10	Inhalant abuse, uncomplicated	Diagnosis	ICD-10-CM
F18.11	Inhalant abuse, in remission	Diagnosis	ICD-10-CM
F18.120	Inhalant abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.121	Inhalant abuse with intoxication delirium	Diagnosis	ICD-10-CM
F18.129	Inhalant abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.14	Inhalant abuse with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.150	Inhalant abuse with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.151	Inhalant abuse with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.159	Inhalant abuse with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.17	Inhalant abuse with inhalant-induced dementia	Diagnosis	ICD-10-CM
F18.180	Inhalant abuse with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.188	Inhalant abuse with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.19	Inhalant abuse with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.20	Inhalant dependence, uncomplicated	Diagnosis	ICD-10-CM
F18.220	Inhalant dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.221	Inhalant dependence with intoxication delirium	Diagnosis	ICD-10-CM
F18.229	Inhalant dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.24	Inhalant dependence with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.250	Inhalant dependence with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.251	Inhalant dependence with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.259	Inhalant dependence with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F18.27	Inhalant dependence with inhalant-induced dementia	Diagnosis	ICD-10-CM
F18.280	Inhalant dependence with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.288	Inhalant dependence with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.29	Inhalant dependence with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.90	Inhalant use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F18.920	Inhalant use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.921	Inhalant use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F18.929	Inhalant use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.94	Inhalant use, unspecified with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.950	Inhalant use, unspecified with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.951	Inhalant use, unspecified with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.959	Inhalant use, unspecified with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.97	Inhalant use, unspecified with inhalant-induced persisting dementia	Diagnosis	ICD-10-CM
F18.980	Inhalant use, unspecified with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.988	Inhalant use, unspecified with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.99	Inhalant use, unspecified with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F19.10	Other psychoactive substance abuse, uncomplicated	Diagnosis	ICD-10-CM
F19.11	Other psychoactive substance abuse, in remission	Diagnosis	ICD-10-CM
F19.120	Other psychoactive substance abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.121	Other psychoactive substance abuse with intoxication delirium	Diagnosis	ICD-10-CM
F19.122	Other psychoactive substance abuse with intoxication with perceptual disturbances	Diagnosis	ICD-10-CM
F19.129	Other psychoactive substance abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.130	Other psychoactive substance abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.131	Other psychoactive substance abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F19.132	Other psychoactive substance abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.139	Other psychoactive substance abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.14	Other psychoactive substance abuse with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.150	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.151	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.159	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.16	Other psychoactive substance abuse with psychoactive substance-induced persisting amnesic disorder	Diagnosis	ICD-10-CM
F19.17	Other psychoactive substance abuse with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F19.180	Other psychoactive substance abuse with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.181	Other psychoactive substance abuse with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.182	Other psychoactive substance abuse with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.188	Other psychoactive substance abuse with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.19	Other psychoactive substance abuse with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.20	Other psychoactive substance dependence, uncomplicated	Diagnosis	ICD-10-CM
F19.21	Other psychoactive substance dependence, in remission	Diagnosis	ICD-10-CM
F19.220	Other psychoactive substance dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.221	Other psychoactive substance dependence with intoxication delirium	Diagnosis	ICD-10-CM
F19.222	Other psychoactive substance dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F19.229	Other psychoactive substance dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.230	Other psychoactive substance dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.231	Other psychoactive substance dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F19.232	Other psychoactive substance dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.239	Other psychoactive substance dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.24	Other psychoactive substance dependence with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.250	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.251	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.259	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.26	Other psychoactive substance dependence with psychoactive substance-induced persisting amnesic disorder	Diagnosis	ICD-10-CM
F19.27	Other psychoactive substance dependence with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.280	Other psychoactive substance dependence with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.281	Other psychoactive substance dependence with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.282	Other psychoactive substance dependence with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F19.288	Other psychoactive substance dependence with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.29	Other psychoactive substance dependence with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.90	Other psychoactive substance use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F19.920	Other psychoactive substance use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.921	Other psychoactive substance use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F19.922	Other psychoactive substance use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F19.929	Other psychoactive substance use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.930	Other psychoactive substance use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.931	Other psychoactive substance use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F19.932	Other psychoactive substance use, unspecified with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.939	Other psychoactive substance use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.94	Other psychoactive substance use, unspecified with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.950	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.951	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.959	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.96	Other psychoactive substance use, unspecified with psychoactive substance-induced persisting amnesic disorder	Diagnosis	ICD-10-CM
F19.97	Other psychoactive substance use, unspecified with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.980	Other psychoactive substance use, unspecified with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.981	Other psychoactive substance use, unspecified with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.982	Other psychoactive substance use, unspecified with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.988	Other psychoactive substance use, unspecified with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.99	Other psychoactive substance use, unspecified with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
HZZZZZ	Detoxification Services for Substance Abuse Treatment	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
HZ30ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ31ZZZ	Individual Counseling for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ32ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ33ZZZ	Individual Counseling for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ34ZZZ	Individual Counseling for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ35ZZZ	Individual Counseling for Substance Abuse Treatment, Vocational	Procedure	ICD-10-PCS
HZ36ZZZ	Individual Counseling for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ37ZZZ	Individual Counseling for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ38ZZZ	Individual Counseling for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ39ZZZ	Individual Counseling for Substance Abuse Treatment, Continuing Care	Procedure	ICD-10-PCS
HZ3BZZZ	Individual Counseling for Substance Abuse Treatment, Spiritual	Procedure	ICD-10-PCS
HZ40ZZZ	Group Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ41ZZZ	Group Counseling for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ42ZZZ	Group Counseling for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ43ZZZ	Group Counseling for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ44ZZZ	Group Counseling for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ45ZZZ	Group Counseling for Substance Abuse Treatment, Vocational	Procedure	ICD-10-PCS
HZ46ZZZ	Group Counseling for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ47ZZZ	Group Counseling for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ48ZZZ	Group Counseling for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ49ZZZ	Group Counseling for Substance Abuse Treatment, Continuing Care	Procedure	ICD-10-PCS
HZ4BZZZ	Group Counseling for Substance Abuse Treatment, Spiritual	Procedure	ICD-10-PCS
HZ50ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ51ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ52ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ53ZZZ	Individual Psychotherapy for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ54ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ55ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Interactive	Procedure	ICD-10-PCS
HZ56ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ57ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ58ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ59ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Supportive	Procedure	ICD-10-PCS
HZ5BZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychoanalysis	Procedure	ICD-10-PCS
HZ5CZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychodynamic	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
HZ5DZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychophysiological	Procedure	ICD-10-PCS
HZ63ZZZ	Family Counseling for Substance Abuse Treatment	Procedure	ICD-10-PCS
HZ83ZZZ	Medication Management for Substance Abuse Treatment, Antabuse	Procedure	ICD-10-PCS
HZ86ZZZ	Medication Management for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
HZ88ZZZ	Medication Management for Substance Abuse Treatment, Psychiatric Medication	Procedure	ICD-10-PCS
HZ89ZZZ	Medication Management for Substance Abuse Treatment, Other Replacement Medication	Procedure	ICD-10-PCS
HZ93ZZZ	Pharmacotherapy for Substance Abuse Treatment, Antabuse	Procedure	ICD-10-PCS
HZ96ZZZ	Pharmacotherapy for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
HZ98ZZZ	Pharmacotherapy for Substance Abuse Treatment, Psychiatric Medication	Procedure	ICD-10-PCS
HZ99ZZZ	Pharmacotherapy for Substance Abuse Treatment, Other Replacement Medication	Procedure	ICD-10-PCS
O35.5XX0	Maternal care for (suspected) damage to fetus by drugs, not applicable or unspecified	Diagnosis	ICD-10-CM
O35.5XX1	Maternal care for (suspected) damage to fetus by drugs, fetus 1	Diagnosis	ICD-10-CM
O35.5XX2	Maternal care for (suspected) damage to fetus by drugs, fetus 2	Diagnosis	ICD-10-CM
O35.5XX3	Maternal care for (suspected) damage to fetus by drugs, fetus 3	Diagnosis	ICD-10-CM
O35.5XX4	Maternal care for (suspected) damage to fetus by drugs, fetus 4	Diagnosis	ICD-10-CM
O35.5XX5	Maternal care for (suspected) damage to fetus by drugs, fetus 5	Diagnosis	ICD-10-CM
O35.5XX9	Maternal care for (suspected) damage to fetus by drugs, other fetus	Diagnosis	ICD-10-CM
T40.0X1A	Poisoning by opium, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.0X2A	Poisoning by opium, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.0X3A	Poisoning by opium, assault, initial encounter	Diagnosis	ICD-10-CM
T40.0X4A	Poisoning by opium, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.0X5A	Adverse effect of opium, initial encounter	Diagnosis	ICD-10-CM
T40.0X5S	Adverse effect of opium, sequela	Diagnosis	ICD-10-CM
T40.1X1A	Poisoning by heroin, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.1X2A	Poisoning by heroin, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.1X3A	Poisoning by heroin, assault, initial encounter	Diagnosis	ICD-10-CM
T40.1X4A	Poisoning by heroin, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.2X1A	Poisoning by other opioids, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.2X2A	Poisoning by other opioids, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.2X3A	Poisoning by other opioids, assault, initial encounter	Diagnosis	ICD-10-CM
T40.2X4A	Poisoning by other opioids, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.3X1A	Poisoning by methadone, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.3X2A	Poisoning by methadone, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.3X3A	Poisoning by methadone, assault, initial encounter	Diagnosis	ICD-10-CM
T40.3X4A	Poisoning by methadone, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.3X5A	Adverse effect of methadone, initial encounter	Diagnosis	ICD-10-CM
T40.3X5S	Adverse effect of methadone, sequela	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
T40.411A	Poisoning by fentanyl or fentanyl analogs, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.412A	Poisoning by fentanyl or fentanyl analogs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.413A	Poisoning by fentanyl or fentanyl analogs, assault, initial encounter	Diagnosis	ICD-10-CM
T40.414A	Poisoning by fentanyl or fentanyl analogs, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.415A	Adverse effect of fentanyl or fentanyl analogs, initial encounter	Diagnosis	ICD-10-CM
T40.421A	Poisoning by tramadol, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.422A	Poisoning by tramadol, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.423A	Poisoning by tramadol, assault, initial encounter	Diagnosis	ICD-10-CM
T40.424A	Poisoning by tramadol, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.425A	Adverse effect of tramadol, initial encounter	Diagnosis	ICD-10-CM
T40.491A	Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.492A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.493A	Poisoning by other synthetic narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.494A	Poisoning by other synthetic narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.495A	Adverse effect of other synthetic narcotics, initial encounter	Diagnosis	ICD-10-CM
T40.4X1A	Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.4X2A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.4X3A	Poisoning by other synthetic narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.4X4A	Poisoning by other synthetic narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.601A	Poisoning by unspecified narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.602A	Poisoning by unspecified narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.603A	Poisoning by unspecified narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.604A	Poisoning by unspecified narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.691A	Poisoning by other narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.692A	Poisoning by other narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.693A	Poisoning by other narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.694A	Poisoning by other narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.711A	Poisoning by cannabis, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.721A	Poisoning by synthetic cannabinoids, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.7X1A	Poisoning by cannabis (derivatives), accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.8X1A	Poisoning by lysergide [LSD], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
T40.901A	Poisoning by unspecified psychodysleptics [hallucinogens], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.991A	Poisoning by other psychodysleptics [hallucinogens], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
Z71.51	Drug abuse counseling and surveillance of drug abuser	Diagnosis	ICD-10-CM
Endometrial Cancer			
C54.0	Malignant neoplasm of isthmus uteri	Diagnosis	ICD-10-CM
C54.1	Malignant neoplasm of endometrium	Diagnosis	ICD-10-CM
C54.2	Malignant neoplasm of myometrium	Diagnosis	ICD-10-CM
C54.3	Malignant neoplasm of fundus uteri	Diagnosis	ICD-10-CM
C54.8	Malignant neoplasm of overlapping sites of corpus uteri	Diagnosis	ICD-10-CM
C54.9	Malignant neoplasm of corpus uteri, unspecified	Diagnosis	ICD-10-CM
D07.0	Carcinoma in situ of endometrium	Diagnosis	ICD-10-CM
Z85.42	Personal history of malignant neoplasm of other parts of uterus	Diagnosis	ICD-10-CM
Glaucoma			
H40.011	Open angle with borderline findings, low risk, right eye	Diagnosis	ICD-10-CM
H40.012	Open angle with borderline findings, low risk, left eye	Diagnosis	ICD-10-CM
H40.013	Open angle with borderline findings, low risk, bilateral	Diagnosis	ICD-10-CM
H40.019	Open angle with borderline findings, low risk, unspecified eye	Diagnosis	ICD-10-CM
H40.021	Open angle with borderline findings, high risk, right eye	Diagnosis	ICD-10-CM
H40.022	Open angle with borderline findings, high risk, left eye	Diagnosis	ICD-10-CM
H40.023	Open angle with borderline findings, high risk, bilateral	Diagnosis	ICD-10-CM
H40.029	Open angle with borderline findings, high risk, unspecified eye	Diagnosis	ICD-10-CM
H40.041	Steroid responder, right eye	Diagnosis	ICD-10-CM
H40.042	Steroid responder, left eye	Diagnosis	ICD-10-CM
H40.043	Steroid responder, bilateral	Diagnosis	ICD-10-CM
H40.049	Steroid responder, unspecified eye	Diagnosis	ICD-10-CM
H40.051	Ocular hypertension, right eye	Diagnosis	ICD-10-CM
H40.052	Ocular hypertension, left eye	Diagnosis	ICD-10-CM
H40.053	Ocular hypertension, bilateral	Diagnosis	ICD-10-CM
H40.059	Ocular hypertension, unspecified eye	Diagnosis	ICD-10-CM
H40.10X0	Unspecified open-angle glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.10X1	Unspecified open-angle glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.10X2	Unspecified open-angle glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.10X3	Unspecified open-angle glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.10X4	Unspecified open-angle glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.1110	Primary open-angle glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1111	Primary open-angle glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1112	Primary open-angle glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1113	Primary open-angle glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1114	Primary open-angle glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1120	Primary open-angle glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1121	Primary open-angle glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1122	Primary open-angle glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
H40.1123	Primary open-angle glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1124	Primary open-angle glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1130	Primary open-angle glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1131	Primary open-angle glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1132	Primary open-angle glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1133	Primary open-angle glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1134	Primary open-angle glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1190	Primary open-angle glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1191	Primary open-angle glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1192	Primary open-angle glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1193	Primary open-angle glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1194	Primary open-angle glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.11X0	Primary open-angle glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.11X1	Primary open-angle glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.11X2	Primary open-angle glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.11X3	Primary open-angle glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.11X4	Primary open-angle glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.1210	Low-tension glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1211	Low-tension glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1212	Low-tension glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1213	Low-tension glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1214	Low-tension glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1220	Low-tension glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1221	Low-tension glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1222	Low-tension glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1223	Low-tension glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1224	Low-tension glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1230	Low-tension glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1231	Low-tension glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1232	Low-tension glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1233	Low-tension glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1234	Low-tension glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1290	Low-tension glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1291	Low-tension glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1292	Low-tension glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1293	Low-tension glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1294	Low-tension glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1310	Pigmentary glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1311	Pigmentary glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1312	Pigmentary glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1313	Pigmentary glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1314	Pigmentary glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1320	Pigmentary glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1321	Pigmentary glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
H40.1322	Pigmentary glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1323	Pigmentary glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1324	Pigmentary glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1330	Pigmentary glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1331	Pigmentary glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1332	Pigmentary glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1333	Pigmentary glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1334	Pigmentary glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1390	Pigmentary glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1391	Pigmentary glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1392	Pigmentary glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1393	Pigmentary glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1394	Pigmentary glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1410	Capsular glaucoma with pseudoexfoliation of lens, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1411	Capsular glaucoma with pseudoexfoliation of lens, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1412	Capsular glaucoma with pseudoexfoliation of lens, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1413	Capsular glaucoma with pseudoexfoliation of lens, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1414	Capsular glaucoma with pseudoexfoliation of lens, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1420	Capsular glaucoma with pseudoexfoliation of lens, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1421	Capsular glaucoma with pseudoexfoliation of lens, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1422	Capsular glaucoma with pseudoexfoliation of lens, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1423	Capsular glaucoma with pseudoexfoliation of lens, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1424	Capsular glaucoma with pseudoexfoliation of lens, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1430	Capsular glaucoma with pseudoexfoliation of lens, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1431	Capsular glaucoma with pseudoexfoliation of lens, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1432	Capsular glaucoma with pseudoexfoliation of lens, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1433	Capsular glaucoma with pseudoexfoliation of lens, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1434	Capsular glaucoma with pseudoexfoliation of lens, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1490	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1491	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, mild stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
H40.1492	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1493	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1494	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.151	Residual stage of open-angle glaucoma, right eye	Diagnosis	ICD-10-CM
H40.152	Residual stage of open-angle glaucoma, left eye	Diagnosis	ICD-10-CM
H40.153	Residual stage of open-angle glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.159	Residual stage of open-angle glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.20X0	Unspecified primary angle-closure glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.20X1	Unspecified primary angle-closure glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.20X2	Unspecified primary angle-closure glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.20X3	Unspecified primary angle-closure glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.20X4	Unspecified primary angle-closure glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.211	Acute angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.212	Acute angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.213	Acute angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.219	Acute angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.2210	Chronic angle-closure glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2211	Chronic angle-closure glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.2212	Chronic angle-closure glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.2213	Chronic angle-closure glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.2214	Chronic angle-closure glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.2220	Chronic angle-closure glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2221	Chronic angle-closure glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.2222	Chronic angle-closure glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.2223	Chronic angle-closure glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.2224	Chronic angle-closure glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.2230	Chronic angle-closure glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.2231	Chronic angle-closure glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.2232	Chronic angle-closure glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.2233	Chronic angle-closure glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.2234	Chronic angle-closure glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.2290	Chronic angle-closure glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2291	Chronic angle-closure glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.2292	Chronic angle-closure glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.2293	Chronic angle-closure glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.2294	Chronic angle-closure glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.231	Intermittent angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.232	Intermittent angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.233	Intermittent angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.239	Intermittent angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.241	Residual stage of angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
H40.242	Residual stage of angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.243	Residual stage of angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.249	Residual stage of angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.30X0	Glaucoma secondary to eye trauma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.30X1	Glaucoma secondary to eye trauma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.30X2	Glaucoma secondary to eye trauma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.30X3	Glaucoma secondary to eye trauma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.30X4	Glaucoma secondary to eye trauma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.31X0	Glaucoma secondary to eye trauma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.31X1	Glaucoma secondary to eye trauma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.31X2	Glaucoma secondary to eye trauma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.31X3	Glaucoma secondary to eye trauma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.31X4	Glaucoma secondary to eye trauma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.32X0	Glaucoma secondary to eye trauma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.32X1	Glaucoma secondary to eye trauma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.32X2	Glaucoma secondary to eye trauma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.32X3	Glaucoma secondary to eye trauma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.32X4	Glaucoma secondary to eye trauma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.33X0	Glaucoma secondary to eye trauma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.33X1	Glaucoma secondary to eye trauma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.33X2	Glaucoma secondary to eye trauma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.33X3	Glaucoma secondary to eye trauma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.33X4	Glaucoma secondary to eye trauma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.40X0	Glaucoma secondary to eye inflammation, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.40X1	Glaucoma secondary to eye inflammation, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.40X2	Glaucoma secondary to eye inflammation, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.40X3	Glaucoma secondary to eye inflammation, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.40X4	Glaucoma secondary to eye inflammation, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.41X0	Glaucoma secondary to eye inflammation, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.41X1	Glaucoma secondary to eye inflammation, right eye, mild stage	Diagnosis	ICD-10-CM
H40.41X2	Glaucoma secondary to eye inflammation, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.41X3	Glaucoma secondary to eye inflammation, right eye, severe stage	Diagnosis	ICD-10-CM
H40.41X4	Glaucoma secondary to eye inflammation, right eye, indeterminate	Diagnosis	ICD-10-CM
H40.42X0	Glaucoma secondary to eye inflammation, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.42X1	Glaucoma secondary to eye inflammation, left eye, mild stage	Diagnosis	ICD-10-CM
H40.42X2	Glaucoma secondary to eye inflammation, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.42X3	Glaucoma secondary to eye inflammation, left eye, severe stage	Diagnosis	ICD-10-CM
H40.42X4	Glaucoma secondary to eye inflammation, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.43X0	Glaucoma secondary to eye inflammation, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.43X1	Glaucoma secondary to eye inflammation, bilateral, mild stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
H40.43X2	Glaucoma secondary to eye inflammation, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.43X3	Glaucoma secondary to eye inflammation, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.43X4	Glaucoma secondary to eye inflammation, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.50X0	Glaucoma secondary to other eye disorders, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.50X1	Glaucoma secondary to other eye disorders, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.50X2	Glaucoma secondary to other eye disorders, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.50X3	Glaucoma secondary to other eye disorders, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.50X4	Glaucoma secondary to other eye disorders, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.51X0	Glaucoma secondary to other eye disorders, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.51X1	Glaucoma secondary to other eye disorders, right eye, mild stage	Diagnosis	ICD-10-CM
H40.51X2	Glaucoma secondary to other eye disorders, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.51X3	Glaucoma secondary to other eye disorders, right eye, severe stage	Diagnosis	ICD-10-CM
H40.51X4	Glaucoma secondary to other eye disorders, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.52X0	Glaucoma secondary to other eye disorders, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.52X1	Glaucoma secondary to other eye disorders, left eye, mild stage	Diagnosis	ICD-10-CM
H40.52X2	Glaucoma secondary to other eye disorders, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.52X3	Glaucoma secondary to other eye disorders, left eye, severe stage	Diagnosis	ICD-10-CM
H40.52X4	Glaucoma secondary to other eye disorders, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.53X0	Glaucoma secondary to other eye disorders, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.53X1	Glaucoma secondary to other eye disorders, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.53X2	Glaucoma secondary to other eye disorders, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.53X3	Glaucoma secondary to other eye disorders, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.53X4	Glaucoma secondary to other eye disorders, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.60X0	Glaucoma secondary to drugs, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.60X1	Glaucoma secondary to drugs, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.60X2	Glaucoma secondary to drugs, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.60X3	Glaucoma secondary to drugs, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.60X4	Glaucoma secondary to drugs, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.61X0	Glaucoma secondary to drugs, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.61X1	Glaucoma secondary to drugs, right eye, mild stage	Diagnosis	ICD-10-CM
H40.61X2	Glaucoma secondary to drugs, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.61X3	Glaucoma secondary to drugs, right eye, severe stage	Diagnosis	ICD-10-CM
H40.61X4	Glaucoma secondary to drugs, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.62X0	Glaucoma secondary to drugs, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.62X1	Glaucoma secondary to drugs, left eye, mild stage	Diagnosis	ICD-10-CM
H40.62X2	Glaucoma secondary to drugs, left eye, moderate stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
H40.62X3	Glaucoma secondary to drugs, left eye, severe stage	Diagnosis	ICD-10-CM
H40.62X4	Glaucoma secondary to drugs, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.63X0	Glaucoma secondary to drugs, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.63X1	Glaucoma secondary to drugs, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.63X2	Glaucoma secondary to drugs, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.63X3	Glaucoma secondary to drugs, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.63X4	Glaucoma secondary to drugs, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.811	Glaucoma with increased episcleral venous pressure, right eye	Diagnosis	ICD-10-CM
H40.812	Glaucoma with increased episcleral venous pressure, left eye	Diagnosis	ICD-10-CM
H40.813	Glaucoma with increased episcleral venous pressure, bilateral	Diagnosis	ICD-10-CM
H40.819	Glaucoma with increased episcleral venous pressure, unspecified eye	Diagnosis	ICD-10-CM
H40.821	Hypersecretion glaucoma, right eye	Diagnosis	ICD-10-CM
H40.822	Hypersecretion glaucoma, left eye	Diagnosis	ICD-10-CM
H40.823	Hypersecretion glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.829	Hypersecretion glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.831	Aqueous misdirection, right eye	Diagnosis	ICD-10-CM
H40.832	Aqueous misdirection, left eye	Diagnosis	ICD-10-CM
H40.833	Aqueous misdirection, bilateral	Diagnosis	ICD-10-CM
H40.839	Aqueous misdirection, unspecified eye	Diagnosis	ICD-10-CM
H40.89	Other specified glaucoma	Diagnosis	ICD-10-CM
H40.9	Unspecified glaucoma	Diagnosis	ICD-10-CM
H42	Glaucoma in diseases classified elsewhere	Diagnosis	ICD-10-CM
H44.511	Absolute glaucoma, right eye	Diagnosis	ICD-10-CM
H44.512	Absolute glaucoma, left eye	Diagnosis	ICD-10-CM
H44.513	Absolute glaucoma, bilateral	Diagnosis	ICD-10-CM
H44.519	Absolute glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H47.231	Glaucomatous optic atrophy, right eye	Diagnosis	ICD-10-CM
H47.232	Glaucomatous optic atrophy, left eye	Diagnosis	ICD-10-CM
H47.233	Glaucomatous optic atrophy, bilateral	Diagnosis	ICD-10-CM
H47.239	Glaucomatous optic atrophy, unspecified eye	Diagnosis	ICD-10-CM
Q15.0	Congenital glaucoma	Diagnosis	ICD-10-CM
Heart Failure			
I09.81	Rheumatic heart failure	Diagnosis	ICD-10-CM
I11.0	Hypertensive heart disease with heart failure	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I42.0	Dilated cardiomyopathy	Diagnosis	ICD-10-CM
I42.5	Other restrictive cardiomyopathy	Diagnosis	ICD-10-CM
I42.6	Alcoholic cardiomyopathy	Diagnosis	ICD-10-CM
I42.7	Cardiomyopathy due to drug and external agent	Diagnosis	ICD-10-CM
I42.8	Other cardiomyopathies	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I43	Cardiomyopathy in diseases classified elsewhere	Diagnosis	ICD-10-CM
I50.1	Left ventricular failure, unspecified	Diagnosis	ICD-10-CM
I50.20	Unspecified systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.21	Acute systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.22	Chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.23	Acute on chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.30	Unspecified diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.31	Acute diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.32	Chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.33	Acute on chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.40	Unspecified combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.41	Acute combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.42	Chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.43	Acute on chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.810	Right heart failure, unspecified	Diagnosis	ICD-10-CM
I50.811	Acute right heart failure	Diagnosis	ICD-10-CM
I50.812	Chronic right heart failure	Diagnosis	ICD-10-CM
I50.813	Acute on chronic right heart failure	Diagnosis	ICD-10-CM
I50.814	Right heart failure due to left heart failure	Diagnosis	ICD-10-CM
I50.82	Biventricular heart failure	Diagnosis	ICD-10-CM
I50.83	High output heart failure	Diagnosis	ICD-10-CM
I50.84	End stage heart failure	Diagnosis	ICD-10-CM
I50.89	Other heart failure	Diagnosis	ICD-10-CM
I50.9	Heart failure, unspecified	Diagnosis	ICD-10-CM
P29.0	Neonatal cardiac failure	Diagnosis	ICD-10-CM
Hyperlipidemia			
E78.0	Pure hypercholesterolemia	Diagnosis	ICD-10-CM
E78.00	Pure hypercholesterolemia, unspecified	Diagnosis	ICD-10-CM
E78.01	Familial hypercholesterolemia	Diagnosis	ICD-10-CM
E78.1	Pure hyperglyceridemia	Diagnosis	ICD-10-CM
E78.2	Mixed hyperlipidemia	Diagnosis	ICD-10-CM
E78.3	Hyperchylomicronemia	Diagnosis	ICD-10-CM
E78.4	Other hyperlipidemia	Diagnosis	ICD-10-CM
E78.41	Elevated Lipoprotein(a)	Diagnosis	ICD-10-CM
E78.49	Other hyperlipidemia	Diagnosis	ICD-10-CM
E78.5	Hyperlipidemia, unspecified	Diagnosis	ICD-10-CM
Hypertension			
H35.031	Hypertensive retinopathy, right eye	Diagnosis	ICD-10-CM
H35.032	Hypertensive retinopathy, left eye	Diagnosis	ICD-10-CM
H35.033	Hypertensive retinopathy, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
H35.039	Hypertensive retinopathy, unspecified eye	Diagnosis	ICD-10-CM
I10	Essential (primary) hypertension	Diagnosis	ICD-10-CM
I11.0	Hypertensive heart disease with heart failure	Diagnosis	ICD-10-CM
I11.9	Hypertensive heart disease without heart failure	Diagnosis	ICD-10-CM
I12.0	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease	Diagnosis	ICD-10-CM
I12.9	Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.10	Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.11	Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I15.0	Renovascular hypertension	Diagnosis	ICD-10-CM
I15.1	Hypertension secondary to other renal disorders	Diagnosis	ICD-10-CM
I15.2	Hypertension secondary to endocrine disorders	Diagnosis	ICD-10-CM
I15.8	Other secondary hypertension	Diagnosis	ICD-10-CM
I15.9	Secondary hypertension, unspecified	Diagnosis	ICD-10-CM
I1A.0	Resistant hypertension	Diagnosis	ICD-10-CM
I67.4	Hypertensive encephalopathy	Diagnosis	ICD-10-CM
N26.2	Page kidney	Diagnosis	ICD-10-CM
Ischemic Heart Disease			
I20.0	Unstable angina	Diagnosis	ICD-10-CM
I20.1	Angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I20.2	Refractory angina pectoris	Diagnosis	ICD-10-CM
I20.8	Other forms of angina pectoris	Diagnosis	ICD-10-CM
I20.81	Angina pectoris with coronary microvascular dysfunction	Diagnosis	ICD-10-CM
I20.89	Other forms of angina pectoris	Diagnosis	ICD-10-CM
I24.0	Acute coronary thrombosis not resulting in myocardial infarction	Diagnosis	ICD-10-CM
I24.1	Dressler's syndrome	Diagnosis	ICD-10-CM
I24.8	Other forms of acute ischemic heart disease	Diagnosis	ICD-10-CM
I24.81	Acute coronary microvascular dysfunction	Diagnosis	ICD-10-CM
I24.89	Other forms of acute ischemic heart disease	Diagnosis	ICD-10-CM
I25.10	Atherosclerotic heart disease of native coronary artery without angina pectoris	Diagnosis	ICD-10-CM
I25.110	Atherosclerotic heart disease of native coronary artery with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.111	Atherosclerotic heart disease of native coronary artery with angina pectoris with documented spasm	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I25.112	Atherosclerotic heart disease of native coronary artery with refractory angina pectoris	Diagnosis	ICD-10-CM
I25.118	Atherosclerotic heart disease of native coronary artery with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.119	Atherosclerotic heart disease of native coronary artery with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.3	Aneurysm of heart	Diagnosis	ICD-10-CM
I25.41	Coronary artery aneurysm	Diagnosis	ICD-10-CM
I25.42	Coronary artery dissection	Diagnosis	ICD-10-CM
I25.5	Ischemic cardiomyopathy	Diagnosis	ICD-10-CM
I25.6	Silent myocardial ischemia	Diagnosis	ICD-10-CM
I25.700	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.701	Atherosclerosis of coronary artery bypass graft(s), unspecified, with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.702	Atherosclerosis of coronary artery bypass graft(s), unspecified, with refractory angina pectoris	Diagnosis	ICD-10-CM
I25.708	Atherosclerosis of coronary artery bypass graft(s), unspecified, with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.710	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.711	Atherosclerosis of autologous vein coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.712	Atherosclerosis of autologous vein coronary artery bypass graft(s) with refractory angina pectoris	Diagnosis	ICD-10-CM
I25.718	Atherosclerosis of autologous vein coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.719	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.720	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.721	Atherosclerosis of autologous artery coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.722	Atherosclerosis of autologous artery coronary artery bypass graft(s) with refractory angina pectoris	Diagnosis	ICD-10-CM
I25.728	Atherosclerosis of autologous artery coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.729	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.730	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.731	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I25.732	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with refractory angina pectoris	Diagnosis	ICD-10-CM
I25.738	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.739	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.750	Atherosclerosis of native coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
I25.751	Atherosclerosis of native coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.752	Atherosclerosis of native coronary artery of transplanted heart with refractory angina pectoris	Diagnosis	ICD-10-CM
I25.758	Atherosclerosis of native coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.759	Atherosclerosis of native coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.760	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
I25.761	Atherosclerosis of bypass graft of coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.762	Atherosclerosis of bypass graft of coronary artery of transplanted heart with refractory angina pectoris	Diagnosis	ICD-10-CM
I25.768	Atherosclerosis of bypass graft of coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.769	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.790	Atherosclerosis of other coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.791	Atherosclerosis of other coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.792	Atherosclerosis of other coronary artery bypass graft(s) with refractory angina pectoris	Diagnosis	ICD-10-CM
I25.798	Atherosclerosis of other coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.799	Atherosclerosis of other coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.810	Atherosclerosis of coronary artery bypass graft(s) without angina pectoris	Diagnosis	ICD-10-CM
I25.811	Atherosclerosis of native coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM
I25.812	Atherosclerosis of bypass graft of coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM
I25.82	Chronic total occlusion of coronary artery	Diagnosis	ICD-10-CM
I25.83	Coronary atherosclerosis due to lipid rich plaque	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I25.84	Coronary atherosclerosis due to calcified coronary lesion	Diagnosis	ICD-10-CM
I25.85	Chronic coronary microvascular dysfunction	Diagnosis	ICD-10-CM
I25.89	Other forms of chronic ischemic heart disease	Diagnosis	ICD-10-CM
I25.9	Chronic ischemic heart disease, unspecified	Diagnosis	ICD-10-CM
Liver Disease CCW			
K70	Alcoholic liver disease	Diagnosis	ICD-10-CM
K70.0	Alcoholic fatty liver	Diagnosis	ICD-10-CM
K70.1	Alcoholic hepatitis	Diagnosis	ICD-10-CM
K70.10	Alcoholic hepatitis without ascites	Diagnosis	ICD-10-CM
K70.11	Alcoholic hepatitis with ascites	Diagnosis	ICD-10-CM
K70.2	Alcoholic fibrosis and sclerosis of liver	Diagnosis	ICD-10-CM
K70.3	Alcoholic cirrhosis of liver	Diagnosis	ICD-10-CM
K70.30	Alcoholic cirrhosis of liver without ascites	Diagnosis	ICD-10-CM
K70.31	Alcoholic cirrhosis of liver with ascites	Diagnosis	ICD-10-CM
K70.4	Alcoholic hepatic failure	Diagnosis	ICD-10-CM
K70.40	Alcoholic hepatic failure without coma	Diagnosis	ICD-10-CM
K70.41	Alcoholic hepatic failure with coma	Diagnosis	ICD-10-CM
K70.9	Alcoholic liver disease, unspecified	Diagnosis	ICD-10-CM
K71.0	Toxic liver disease with cholestasis	Diagnosis	ICD-10-CM
K71.11	Toxic liver disease with hepatic necrosis, with coma	Diagnosis	ICD-10-CM
K71.7	Toxic liver disease with fibrosis and cirrhosis of liver	Diagnosis	ICD-10-CM
K71.8	Toxic liver disease with other disorders of liver	Diagnosis	ICD-10-CM
K71.9	Toxic liver disease, unspecified	Diagnosis	ICD-10-CM
K72	Hepatic failure, not elsewhere classified	Diagnosis	ICD-10-CM
K72.0	Acute and subacute hepatic failure	Diagnosis	ICD-10-CM
K72.00	Acute and subacute hepatic failure without coma	Diagnosis	ICD-10-CM
K72.01	Acute and subacute hepatic failure with coma	Diagnosis	ICD-10-CM
K72.1	Chronic hepatic failure	Diagnosis	ICD-10-CM
K72.10	Chronic hepatic failure without coma	Diagnosis	ICD-10-CM
K72.11	Chronic hepatic failure with coma	Diagnosis	ICD-10-CM
K72.9	Hepatic failure, unspecified	Diagnosis	ICD-10-CM
K72.90	Hepatic failure, unspecified without coma	Diagnosis	ICD-10-CM
K72.91	Hepatic failure, unspecified with coma	Diagnosis	ICD-10-CM
K74	Fibrosis and cirrhosis of liver	Diagnosis	ICD-10-CM
K74.0	Hepatic fibrosis	Diagnosis	ICD-10-CM
K74.00	Hepatic fibrosis, unspecified	Diagnosis	ICD-10-CM
K74.01	Hepatic fibrosis, early fibrosis	Diagnosis	ICD-10-CM
K74.02	Hepatic fibrosis, advanced fibrosis	Diagnosis	ICD-10-CM
K74.1	Hepatic sclerosis	Diagnosis	ICD-10-CM
K74.2	Hepatic fibrosis with hepatic sclerosis	Diagnosis	ICD-10-CM
K74.3	Primary biliary cirrhosis	Diagnosis	ICD-10-CM
K74.4	Secondary biliary cirrhosis	Diagnosis	ICD-10-CM
K74.5	Biliary cirrhosis, unspecified	Diagnosis	ICD-10-CM
K74.6	Other and unspecified cirrhosis of liver	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
K74.60	Unspecified cirrhosis of liver	Diagnosis	ICD-10-CM
K74.69	Other cirrhosis of liver	Diagnosis	ICD-10-CM
K75.0	Abscess of liver	Diagnosis	ICD-10-CM
K75.1	Phlebitis of portal vein	Diagnosis	ICD-10-CM
K75.8	Other specified inflammatory liver diseases	Diagnosis	ICD-10-CM
K75.81	Nonalcoholic steatohepatitis (NASH)	Diagnosis	ICD-10-CM
K75.89	Other specified inflammatory liver diseases	Diagnosis	ICD-10-CM
K75.9	Inflammatory liver disease, unspecified	Diagnosis	ICD-10-CM
K76.0	Fatty (change of) liver, not elsewhere classified	Diagnosis	ICD-10-CM
K76.1	Chronic passive congestion of liver	Diagnosis	ICD-10-CM
K76.2	Central hemorrhagic necrosis of liver	Diagnosis	ICD-10-CM
K76.3	Infarction of liver	Diagnosis	ICD-10-CM
K76.5	Hepatic veno-occlusive disease	Diagnosis	ICD-10-CM
K76.6	Portal hypertension	Diagnosis	ICD-10-CM
K76.7	Hepatorenal syndrome	Diagnosis	ICD-10-CM
K76.8	Other specified diseases of liver	Diagnosis	ICD-10-CM
K76.81	Hepatopulmonary syndrome	Diagnosis	ICD-10-CM
K76.82	Hepatic encephalopathy	Diagnosis	ICD-10-CM
K76.89	Other specified diseases of liver	Diagnosis	ICD-10-CM
K76.9	Liver disease, unspecified	Diagnosis	ICD-10-CM
K77	Liver disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
K80.30	Calculus of bile duct with cholangitis, unspecified, without obstruction	Diagnosis	ICD-10-CM
K80.31	Calculus of bile duct with cholangitis, unspecified, with obstruction	Diagnosis	ICD-10-CM
K80.32	Calculus of bile duct with acute cholangitis without obstruction	Diagnosis	ICD-10-CM
K80.33	Calculus of bile duct with acute cholangitis with obstruction	Diagnosis	ICD-10-CM
K80.34	Calculus of bile duct with chronic cholangitis without obstruction	Diagnosis	ICD-10-CM
K80.35	Calculus of bile duct with chronic cholangitis with obstruction	Diagnosis	ICD-10-CM
K80.36	Calculus of bile duct with acute and chronic cholangitis without obstruction	Diagnosis	ICD-10-CM
K80.37	Calculus of bile duct with acute and chronic cholangitis with obstruction	Diagnosis	ICD-10-CM
K83.0	Cholangitis	Diagnosis	ICD-10-CM
R16.0	Hepatomegaly, not elsewhere classified	Diagnosis	ICD-10-CM
R16.2	Hepatomegaly with splenomegaly, not elsewhere classified	Diagnosis	ICD-10-CM
Z48.23	Encounter for aftercare following liver transplant	Diagnosis	ICD-10-CM
Z94.4	Liver transplant status	Diagnosis	ICD-10-CM
Liver Disease Extended			
K70	Alcoholic liver disease	Diagnosis	ICD-10-CM
K70.0	Alcoholic fatty liver	Diagnosis	ICD-10-CM
K70.1	Alcoholic hepatitis	Diagnosis	ICD-10-CM
K70.10	Alcoholic hepatitis without ascites	Diagnosis	ICD-10-CM
K70.11	Alcoholic hepatitis with ascites	Diagnosis	ICD-10-CM
K70.2	Alcoholic fibrosis and sclerosis of liver	Diagnosis	ICD-10-CM
K70.3	Alcoholic cirrhosis of liver	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
K70.30	Alcoholic cirrhosis of liver without ascites	Diagnosis	ICD-10-CM
K70.31	Alcoholic cirrhosis of liver with ascites	Diagnosis	ICD-10-CM
K70.4	Alcoholic hepatic failure	Diagnosis	ICD-10-CM
K70.40	Alcoholic hepatic failure without coma	Diagnosis	ICD-10-CM
K70.41	Alcoholic hepatic failure with coma	Diagnosis	ICD-10-CM
K70.9	Alcoholic liver disease, unspecified	Diagnosis	ICD-10-CM
K71	Toxic liver disease	Diagnosis	ICD-10-CM
K71.0	Toxic liver disease with cholestasis	Diagnosis	ICD-10-CM
K71.1	Toxic liver disease with hepatic necrosis	Diagnosis	ICD-10-CM
K71.10	Toxic liver disease with hepatic necrosis, without coma	Diagnosis	ICD-10-CM
K71.11	Toxic liver disease with hepatic necrosis, with coma	Diagnosis	ICD-10-CM
K71.2	Toxic liver disease with acute hepatitis	Diagnosis	ICD-10-CM
K71.3	Toxic liver disease with chronic persistent hepatitis	Diagnosis	ICD-10-CM
K71.4	Toxic liver disease with chronic lobular hepatitis	Diagnosis	ICD-10-CM
K71.5	Toxic liver disease with chronic active hepatitis	Diagnosis	ICD-10-CM
K71.50	Toxic liver disease with chronic active hepatitis without ascites	Diagnosis	ICD-10-CM
K71.51	Toxic liver disease with chronic active hepatitis with ascites	Diagnosis	ICD-10-CM
K71.6	Toxic liver disease with hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM
K71.7	Toxic liver disease with fibrosis and cirrhosis of liver	Diagnosis	ICD-10-CM
K71.8	Toxic liver disease with other disorders of liver	Diagnosis	ICD-10-CM
K71.9	Toxic liver disease, unspecified	Diagnosis	ICD-10-CM
K72	Hepatic failure, not elsewhere classified	Diagnosis	ICD-10-CM
K72.0	Acute and subacute hepatic failure	Diagnosis	ICD-10-CM
K72.00	Acute and subacute hepatic failure without coma	Diagnosis	ICD-10-CM
K72.01	Acute and subacute hepatic failure with coma	Diagnosis	ICD-10-CM
K72.1	Chronic hepatic failure	Diagnosis	ICD-10-CM
K72.10	Chronic hepatic failure without coma	Diagnosis	ICD-10-CM
K72.11	Chronic hepatic failure with coma	Diagnosis	ICD-10-CM
K72.9	Hepatic failure, unspecified	Diagnosis	ICD-10-CM
K72.90	Hepatic failure, unspecified without coma	Diagnosis	ICD-10-CM
K72.91	Hepatic failure, unspecified with coma	Diagnosis	ICD-10-CM
K73	Chronic hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM
K73.0	Chronic persistent hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM
K73.1	Chronic lobular hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM
K73.2	Chronic active hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM
K73.8	Other chronic hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM
K73.9	Chronic hepatitis, unspecified	Diagnosis	ICD-10-CM
K74	Fibrosis and cirrhosis of liver	Diagnosis	ICD-10-CM
K74.0	Hepatic fibrosis	Diagnosis	ICD-10-CM
K74.00	Hepatic fibrosis, unspecified	Diagnosis	ICD-10-CM
K74.01	Hepatic fibrosis, early fibrosis	Diagnosis	ICD-10-CM
K74.02	Hepatic fibrosis, advanced fibrosis	Diagnosis	ICD-10-CM
K74.1	Hepatic sclerosis	Diagnosis	ICD-10-CM
K74.2	Hepatic fibrosis with hepatic sclerosis	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
K74.3	Primary biliary cirrhosis	Diagnosis	ICD-10-CM
K74.4	Secondary biliary cirrhosis	Diagnosis	ICD-10-CM
K74.5	Biliary cirrhosis, unspecified	Diagnosis	ICD-10-CM
K74.6	Other and unspecified cirrhosis of liver	Diagnosis	ICD-10-CM
K74.60	Unspecified cirrhosis of liver	Diagnosis	ICD-10-CM
K74.69	Other cirrhosis of liver	Diagnosis	ICD-10-CM
K75	Other inflammatory liver diseases	Diagnosis	ICD-10-CM
K75.0	Abscess of liver	Diagnosis	ICD-10-CM
K75.1	Phlebitis of portal vein	Diagnosis	ICD-10-CM
K75.2	Nonspecific reactive hepatitis	Diagnosis	ICD-10-CM
K75.3	Granulomatous hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM
K75.4	Autoimmune hepatitis	Diagnosis	ICD-10-CM
K75.8	Other specified inflammatory liver diseases	Diagnosis	ICD-10-CM
K75.81	Nonalcoholic steatohepatitis (NASH)	Diagnosis	ICD-10-CM
K75.89	Other specified inflammatory liver diseases	Diagnosis	ICD-10-CM
K75.9	Inflammatory liver disease, unspecified	Diagnosis	ICD-10-CM
K76	Other diseases of liver	Diagnosis	ICD-10-CM
K76.0	Fatty (change of) liver, not elsewhere classified	Diagnosis	ICD-10-CM
K76.1	Chronic passive congestion of liver	Diagnosis	ICD-10-CM
K76.2	Central hemorrhagic necrosis of liver	Diagnosis	ICD-10-CM
K76.3	Infarction of liver	Diagnosis	ICD-10-CM
K76.4	Peliosis hepatis	Diagnosis	ICD-10-CM
K76.5	Hepatic veno-occlusive disease	Diagnosis	ICD-10-CM
K76.6	Portal hypertension	Diagnosis	ICD-10-CM
K76.7	Hepatorenal syndrome	Diagnosis	ICD-10-CM
K76.8	Other specified diseases of liver	Diagnosis	ICD-10-CM
K76.81	Hepatopulmonary syndrome	Diagnosis	ICD-10-CM
K76.82	Hepatic encephalopathy	Diagnosis	ICD-10-CM
K76.89	Other specified diseases of liver	Diagnosis	ICD-10-CM
K76.9	Liver disease, unspecified	Diagnosis	ICD-10-CM
K77	Liver disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
K80.30	Calculus of bile duct with cholangitis, unspecified, without obstruction	Diagnosis	ICD-10-CM
K80.31	Calculus of bile duct with cholangitis, unspecified, with obstruction	Diagnosis	ICD-10-CM
K80.32	Calculus of bile duct with acute cholangitis without obstruction	Diagnosis	ICD-10-CM
K80.33	Calculus of bile duct with acute cholangitis with obstruction	Diagnosis	ICD-10-CM
K80.34	Calculus of bile duct with chronic cholangitis without obstruction	Diagnosis	ICD-10-CM
K80.35	Calculus of bile duct with chronic cholangitis with obstruction	Diagnosis	ICD-10-CM
K80.36	Calculus of bile duct with acute and chronic cholangitis without obstruction	Diagnosis	ICD-10-CM
K80.37	Calculus of bile duct with acute and chronic cholangitis with obstruction	Diagnosis	ICD-10-CM
K83.0	Cholangitis	Diagnosis	ICD-10-CM
R16.0	Hepatomegaly, not elsewhere classified	Diagnosis	ICD-10-CM
R16.2	Hepatomegaly with splenomegaly, not elsewhere classified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
Z48.23	Encounter for aftercare following liver transplant	Diagnosis	ICD-10-CM
Z94.4	Liver transplant status	Diagnosis	ICD-10-CM
Liver Disease Procedures			
06L20ZZ	Occlusion of Gastric Vein, Open Approach	Procedure	ICD-10-PCS
06L23ZZ	Occlusion of Gastric Vein, Percutaneous Approach	Procedure	ICD-10-PCS
06L24ZZ	Occlusion of Gastric Vein, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
06L30ZZ	Occlusion of Esophageal Vein, Open Approach	Procedure	ICD-10-PCS
06L33ZZ	Occlusion of Esophageal Vein, Percutaneous Approach	Procedure	ICD-10-PCS
06L34ZZ	Occlusion of Esophageal Vein, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D9S30Z	Drainage of Greater Omentum with Drainage Device, Percutaneous Approach	Procedure	ICD-10-PCS
0D9S3ZZ	Drainage of Greater Omentum, Percutaneous Approach	Procedure	ICD-10-PCS
0D9S40Z	Drainage of Greater Omentum with Drainage Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D9S4ZZ	Drainage of Greater Omentum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D9T30Z	Drainage of Lesser Omentum with Drainage Device, Percutaneous Approach	Procedure	ICD-10-PCS
0D9T3ZZ	Drainage of Lesser Omentum, Percutaneous Approach	Procedure	ICD-10-PCS
0D9T40Z	Drainage of Lesser Omentum with Drainage Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D9T4ZZ	Drainage of Lesser Omentum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D9V30Z	Drainage of Mesentery with Drainage Device, Percutaneous Approach	Procedure	ICD-10-PCS
0D9V3ZZ	Drainage of Mesentery, Percutaneous Approach	Procedure	ICD-10-PCS
0D9V40Z	Drainage of Mesentery with Drainage Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D9V4ZZ	Drainage of Mesentery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D9W30Z	Drainage of Peritoneum with Drainage Device, Percutaneous Approach	Procedure	ICD-10-PCS
0D9W3ZZ	Drainage of Peritoneum, Percutaneous Approach	Procedure	ICD-10-PCS
0D9W40Z	Drainage of Peritoneum with Drainage Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D9W4ZZ	Drainage of Peritoneum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DL57DZ	Occlusion of Esophagus with Intraluminal Device, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DL58DZ	Occlusion of Esophagus with Intraluminal Device, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0W9F30Z	Drainage of Abdominal Wall with Drainage Device, Percutaneous Approach	Procedure	ICD-10-PCS
0W9F3ZZ	Drainage of Abdominal Wall, Percutaneous Approach	Procedure	ICD-10-PCS
0W9F40Z	Drainage of Abdominal Wall with Drainage Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0W9F4ZZ	Drainage of Abdominal Wall, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0W9G30Z	Drainage of Peritoneal Cavity with Drainage Device, Percutaneous Approach	Procedure	ICD-10-PCS
0W9G3ZZ	Drainage of Peritoneal Cavity, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
0W9G40Z	Drainage of Peritoneal Cavity with Drainage Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0W9G4ZZ	Drainage of Peritoneal Cavity, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0W9J30Z	Drainage of Pelvic Cavity with Drainage Device, Percutaneous Approach	Procedure	ICD-10-PCS
0W9J3ZZ	Drainage of Pelvic Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
Lung Cancer			
C34.00	Malignant neoplasm of unspecified main bronchus	Diagnosis	ICD-10-CM
C34.01	Malignant neoplasm of right main bronchus	Diagnosis	ICD-10-CM
C34.02	Malignant neoplasm of left main bronchus	Diagnosis	ICD-10-CM
C34.10	Malignant neoplasm of upper lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.11	Malignant neoplasm of upper lobe, right bronchus or lung	Diagnosis	ICD-10-CM
C34.12	Malignant neoplasm of upper lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.2	Malignant neoplasm of middle lobe, bronchus or lung	Diagnosis	ICD-10-CM
C34.30	Malignant neoplasm of lower lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.31	Malignant neoplasm of lower lobe, right bronchus or lung	Diagnosis	ICD-10-CM
C34.32	Malignant neoplasm of lower lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.80	Malignant neoplasm of overlapping sites of unspecified bronchus and lung	Diagnosis	ICD-10-CM
C34.81	Malignant neoplasm of overlapping sites of right bronchus and lung	Diagnosis	ICD-10-CM
C34.82	Malignant neoplasm of overlapping sites of left bronchus and lung	Diagnosis	ICD-10-CM
C34.90	Malignant neoplasm of unspecified part of unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.91	Malignant neoplasm of unspecified part of right bronchus or lung	Diagnosis	ICD-10-CM
C34.92	Malignant neoplasm of unspecified part of left bronchus or lung	Diagnosis	ICD-10-CM
D02.20	Carcinoma in situ of unspecified bronchus and lung	Diagnosis	ICD-10-CM
D02.21	Carcinoma in situ of right bronchus and lung	Diagnosis	ICD-10-CM
D02.22	Carcinoma in situ of left bronchus and lung	Diagnosis	ICD-10-CM
Z85.110	Personal history of malignant carcinoid tumor of bronchus and lung	Diagnosis	ICD-10-CM
Z85.118	Personal history of other malignant neoplasm of bronchus and lung	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
Obesity (Diagnosis or Procedure Codes)			
0D16079	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160J9	Bypass Stomach to Duodenum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JA	Bypass Stomach to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JB	Bypass Stomach to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160Z9	Bypass Stomach to Duodenum, Open Approach	Procedure	ICD-10-PCS
0D160ZA	Bypass Stomach to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D160ZB	Bypass Stomach to Ileum, Open Approach	Procedure	ICD-10-PCS
0D160ZL	Bypass Stomach to Transverse Colon, Open Approach	Procedure	ICD-10-PCS
0D16479	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164J9	Bypass Stomach to Duodenum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JA	Bypass Stomach to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JB	Bypass Stomach to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
0D164KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164Z9	Bypass Stomach to Duodenum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZA	Bypass Stomach to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZB	Bypass Stomach to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZL	Bypass Stomach to Transverse Colon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D16879	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168J9	Bypass Stomach to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JA	Bypass Stomach to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JB	Bypass Stomach to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168Z9	Bypass Stomach to Duodenum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZA	Bypass Stomach to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZB	Bypass Stomach to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZL	Bypass Stomach to Transverse Colon, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D19079	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
0D1907A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1907B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190JB	Bypass Duodenum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190Z9	Bypass Duodenum to Duodenum, Open Approach	Procedure	ICD-10-PCS
0D190ZA	Bypass Duodenum to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D190ZB	Bypass Duodenum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D19479	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1947A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1947B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194JB	Bypass Duodenum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194Z9	Bypass Duodenum to Duodenum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194ZA	Bypass Duodenum to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194ZB	Bypass Duodenum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D19879	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1987A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1987B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
0D198J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198JB	Bypass Duodenum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198Z9	Bypass Duodenum to Duodenum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198ZA	Bypass Duodenum to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198ZB	Bypass Duodenum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A07A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A07B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0JB	Bypass Jejunum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0ZA	Bypass Jejunum to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D1A0ZB	Bypass Jejunum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D1A47A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A47B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4JB	Bypass Jejunum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4ZA	Bypass Jejunum to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4ZB	Bypass Jejunum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
0D1A87A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A87B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8JB	Bypass Jejunum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZA	Bypass Jejunum to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZB	Bypass Jejunum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZH	Bypass Jejunum to Cecum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B07B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0JB	Bypass Ileum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0ZB	Bypass Ileum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D1B47B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4JB	Bypass Ileum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4ZB	Bypass Ileum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B87B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8JB	Bypass Ileum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8ZB	Bypass Ileum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8ZH	Bypass Ileum to Cecum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DB60Z3	Excision of Stomach, Open Approach, Vertical	Procedure	ICD-10-PCS
0DB60ZZ	Excision of Stomach, Open Approach	Procedure	ICD-10-PCS
0DB63Z3	Excision of Stomach, Percutaneous Approach, Vertical	Procedure	ICD-10-PCS
0DB63ZZ	Excision of Stomach, Percutaneous Approach	Procedure	ICD-10-PCS
0DB67Z3	Excision of Stomach, Via Natural or Artificial Opening, Vertical	Procedure	ICD-10-PCS
0DB67ZZ	Excision of Stomach, Via Natural or Artificial Opening	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
0DB68Z3	Excision of Stomach, Via Natural or Artificial Opening Endoscopic, Vertical	Procedure	ICD-10-PCS
0DB80ZZ	Excision of Small Intestine, Open Approach	Procedure	ICD-10-PCS
0DB90ZZ	Excision of Duodenum, Open Approach	Procedure	ICD-10-PCS
0DBB0ZZ	Excision of Ileum, Open Approach	Procedure	ICD-10-PCS
0DQ64ZZ	Repair Stomach, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DV64CZ	Restriction of Stomach with Extraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0F190Z3	Bypass Common Bile Duct to Duodenum, Open Approach	Procedure	ICD-10-PCS
0TRB07Z	Replacement of Bladder with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
43644	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and Roux-en-Y gastroenterostomy (roux limb 150 cm or less)	Procedure	CPT-4
43645	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and small intestine reconstruction to limit absorption	Procedure	CPT-4
43770	Laparoscopy, surgical, gastric restrictive procedure; placement of adjustable gastric restrictive device (eg, gastric band and subcutaneous port components)	Procedure	CPT-4
43842	Gastric restrictive procedure, without gastric bypass, for morbid obesity; vertical-banded gastroplasty	Procedure	CPT-4
43843	Gastric restrictive procedure, without gastric bypass, for morbid obesity; other than vertical-banded gastroplasty	Procedure	CPT-4
43845	Gastric restrictive procedure with partial gastrectomy, pylorus-preserving duodenoileostomy and ileoileostomy (50 to 100 cm common channel) to limit absorption (biliopancreatic diversion with duodenal switch)	Procedure	CPT-4
43846	Gastric restrictive procedure, with gastric bypass for morbid obesity; with short limb (150 cm or less) Roux-en-Y gastroenterostomy	Procedure	CPT-4
43847	Gastric restrictive procedure, with gastric bypass for morbid obesity; with small intestine reconstruction to limit absorption	Procedure	CPT-4
E66.01	Morbid (severe) obesity due to excess calories	Diagnosis	ICD-10-CM
E66.09	Other obesity due to excess calories	Diagnosis	ICD-10-CM
E66.1	Drug-induced obesity	Diagnosis	ICD-10-CM
E66.2	Morbid (severe) obesity with alveolar hypoventilation	Diagnosis	ICD-10-CM
E66.8	Other obesity	Diagnosis	ICD-10-CM
E66.9	Obesity, unspecified	Diagnosis	ICD-10-CM
K95.01	Infection due to gastric band procedure	Diagnosis	ICD-10-CM
K95.09	Other complications of gastric band procedure	Diagnosis	ICD-10-CM
K95.81	Infection due to other bariatric procedure	Diagnosis	ICD-10-CM
K95.89	Other complications of other bariatric procedure	Diagnosis	ICD-10-CM
O99.210	Obesity complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.211	Obesity complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.212	Obesity complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.213	Obesity complicating pregnancy, third trimester	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
O99.214	Obesity complicating childbirth	Diagnosis	ICD-10-CM
O99.215	Obesity complicating the puerperium	Diagnosis	ICD-10-CM
O99.840	Bariatric surgery status complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.841	Bariatric surgery status complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.842	Bariatric surgery status complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.843	Bariatric surgery status complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.844	Bariatric surgery status complicating childbirth	Diagnosis	ICD-10-CM
O99.845	Bariatric surgery status complicating the puerperium	Diagnosis	ICD-10-CM
Z68.30	Body mass index (BMI) 30.0-30.9, adult	Diagnosis	ICD-10-CM
Z68.31	Body mass index (BMI) 31.0-31.9, adult	Diagnosis	ICD-10-CM
Z68.32	Body mass index (BMI) 32.0-32.9, adult	Diagnosis	ICD-10-CM
Z68.33	Body mass index (BMI) 33.0-33.9, adult	Diagnosis	ICD-10-CM
Z68.34	Body mass index (BMI) 34.0-34.9, adult	Diagnosis	ICD-10-CM
Z68.35	Body mass index (BMI) 35.0-35.9, adult	Diagnosis	ICD-10-CM
Z68.36	Body mass index (BMI) 36.0-36.9, adult	Diagnosis	ICD-10-CM
Z68.37	Body mass index (BMI) 37.0-37.9, adult	Diagnosis	ICD-10-CM
Z68.38	Body mass index (BMI) 38.0-38.9, adult	Diagnosis	ICD-10-CM
Z68.39	Body mass index (BMI) 39.0-39.9, adult	Diagnosis	ICD-10-CM
Z68.41	Body mass index (BMI) 40.0-44.9, adult	Diagnosis	ICD-10-CM
Z68.42	Body mass index (BMI) 45.0-49.9, adult	Diagnosis	ICD-10-CM
Z68.43	Body mass index (BMI) 50-59.9, adult	Diagnosis	ICD-10-CM
Z68.44	Body mass index (BMI) 60.0-69.9, adult	Diagnosis	ICD-10-CM
Z68.45	Body mass index (BMI) 70 or greater, adult	Diagnosis	ICD-10-CM
Osteoporosis			
M80.00XA	Age-related osteoporosis with current pathological fracture, unspecified site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.011A	Age-related osteoporosis with current pathological fracture, right shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.012A	Age-related osteoporosis with current pathological fracture, left shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.019A	Age-related osteoporosis with current pathological fracture, unspecified shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.021A	Age-related osteoporosis with current pathological fracture, right humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.022A	Age-related osteoporosis with current pathological fracture, left humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.029A	Age-related osteoporosis with current pathological fracture, unspecified humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.031A	Age-related osteoporosis with current pathological fracture, right forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.032A	Age-related osteoporosis with current pathological fracture, left forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.039A	Age-related osteoporosis with current pathological fracture, unspecified forearm, initial encounter for fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M80.041A	Age-related osteoporosis with current pathological fracture, right hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.042A	Age-related osteoporosis with current pathological fracture, left hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.049A	Age-related osteoporosis with current pathological fracture, unspecified hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.051A	Age-related osteoporosis with current pathological fracture, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.052A	Age-related osteoporosis with current pathological fracture, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.059A	Age-related osteoporosis with current pathological fracture, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.061A	Age-related osteoporosis with current pathological fracture, right lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.062A	Age-related osteoporosis with current pathological fracture, left lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.069A	Age-related osteoporosis with current pathological fracture, unspecified lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.071A	Age-related osteoporosis with current pathological fracture, right ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.072A	Age-related osteoporosis with current pathological fracture, left ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.079A	Age-related osteoporosis with current pathological fracture, unspecified ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.08XA	Age-related osteoporosis with current pathological fracture, vertebra(e), initial encounter for fracture	Diagnosis	ICD-10-CM
M80.0AXA	Age-related osteoporosis with current pathological fracture, other site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.0B1A	Age-related osteoporosis with current pathological fracture, right pelvis, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.0B2A	Age-related osteoporosis with current pathological fracture, left pelvis, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.0B9A	Age-related osteoporosis with current pathological fracture, unspecified pelvis, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.80XA	Other osteoporosis with current pathological fracture, unspecified site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.811A	Other osteoporosis with current pathological fracture, right shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.812A	Other osteoporosis with current pathological fracture, left shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.819A	Other osteoporosis with current pathological fracture, unspecified shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.821A	Other osteoporosis with current pathological fracture, right humerus, initial encounter for fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M80.822A	Other osteoporosis with current pathological fracture, left humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.829A	Other osteoporosis with current pathological fracture, unspecified humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.831A	Other osteoporosis with current pathological fracture, right forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.832A	Other osteoporosis with current pathological fracture, left forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.839A	Other osteoporosis with current pathological fracture, unspecified forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.841A	Other osteoporosis with current pathological fracture, right hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.842A	Other osteoporosis with current pathological fracture, left hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.849A	Other osteoporosis with current pathological fracture, unspecified hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.851A	Other osteoporosis with current pathological fracture, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.852A	Other osteoporosis with current pathological fracture, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.859A	Other osteoporosis with current pathological fracture, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.861A	Other osteoporosis with current pathological fracture, right lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.862A	Other osteoporosis with current pathological fracture, left lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.869A	Other osteoporosis with current pathological fracture, unspecified lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.871A	Other osteoporosis with current pathological fracture, right ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.872A	Other osteoporosis with current pathological fracture, left ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.879A	Other osteoporosis with current pathological fracture, unspecified ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.88XA	Other osteoporosis with current pathological fracture, vertebra(e), initial encounter for fracture	Diagnosis	ICD-10-CM
M80.8AXA	Other osteoporosis with current pathological fracture, other site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.8B1A	Other osteoporosis with current pathological fracture, right pelvis, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.8B2A	Other osteoporosis with current pathological fracture, left pelvis, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.8B9A	Other osteoporosis with current pathological fracture, unspecified pelvis, initial encounter for fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M81.0	Age-related osteoporosis without current pathological fracture	Diagnosis	ICD-10-CM
M81.6	Localized osteoporosis [Lequesne]	Diagnosis	ICD-10-CM
M81.8	Other osteoporosis without current pathological fracture	Diagnosis	ICD-10-CM
Overweight			
E66.3	Overweight	Diagnosis	ICD-10-CM
Z68.25	Body mass index (BMI) 25.0-25.9, adult	Diagnosis	ICD-10-CM
Z68.26	Body mass index (BMI) 26.0-26.9, adult	Diagnosis	ICD-10-CM
Z68.27	Body mass index (BMI) 27.0-27.9, adult	Diagnosis	ICD-10-CM
Z68.28	Body mass index (BMI) 28.0-28.9, adult	Diagnosis	ICD-10-CM
Z68.29	Body mass index (BMI) 29.0-29.9, adult	Diagnosis	ICD-10-CM
Prostate Cancer			
C61	Malignant neoplasm of prostate	Diagnosis	ICD-10-CM
D07.5	Carcinoma in situ of prostate	Diagnosis	ICD-10-CM
Z85.46	Personal history of malignant neoplasm of prostate	Diagnosis	ICD-10-CM
Rheumatoid Arthritis/Osteoarthritis			
L40.50	Arthropathic psoriasis, unspecified	Diagnosis	ICD-10-CM
L40.51	Distal interphalangeal psoriatic arthropathy	Diagnosis	ICD-10-CM
L40.54	Psoriatic juvenile arthropathy	Diagnosis	ICD-10-CM
L40.59	Other psoriatic arthropathy	Diagnosis	ICD-10-CM
M05.00	Felty's syndrome, unspecified site	Diagnosis	ICD-10-CM
M05.011	Felty's syndrome, right shoulder	Diagnosis	ICD-10-CM
M05.012	Felty's syndrome, left shoulder	Diagnosis	ICD-10-CM
M05.019	Felty's syndrome, unspecified shoulder	Diagnosis	ICD-10-CM
M05.021	Felty's syndrome, right elbow	Diagnosis	ICD-10-CM
M05.022	Felty's syndrome, left elbow	Diagnosis	ICD-10-CM
M05.029	Felty's syndrome, unspecified elbow	Diagnosis	ICD-10-CM
M05.031	Felty's syndrome, right wrist	Diagnosis	ICD-10-CM
M05.032	Felty's syndrome, left wrist	Diagnosis	ICD-10-CM
M05.039	Felty's syndrome, unspecified wrist	Diagnosis	ICD-10-CM
M05.041	Felty's syndrome, right hand	Diagnosis	ICD-10-CM
M05.042	Felty's syndrome, left hand	Diagnosis	ICD-10-CM
M05.049	Felty's syndrome, unspecified hand	Diagnosis	ICD-10-CM
M05.051	Felty's syndrome, right hip	Diagnosis	ICD-10-CM
M05.052	Felty's syndrome, left hip	Diagnosis	ICD-10-CM
M05.059	Felty's syndrome, unspecified hip	Diagnosis	ICD-10-CM
M05.061	Felty's syndrome, right knee	Diagnosis	ICD-10-CM
M05.062	Felty's syndrome, left knee	Diagnosis	ICD-10-CM
M05.069	Felty's syndrome, unspecified knee	Diagnosis	ICD-10-CM
M05.071	Felty's syndrome, right ankle and foot	Diagnosis	ICD-10-CM
M05.072	Felty's syndrome, left ankle and foot	Diagnosis	ICD-10-CM
M05.079	Felty's syndrome, unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.09	Felty's syndrome, multiple sites	Diagnosis	ICD-10-CM
M05.10	Rheumatoid lung disease with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.111	Rheumatoid lung disease with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M05.112	Rheumatoid lung disease with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.119	Rheumatoid lung disease with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.121	Rheumatoid lung disease with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.122	Rheumatoid lung disease with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.129	Rheumatoid lung disease with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.131	Rheumatoid lung disease with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.132	Rheumatoid lung disease with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.139	Rheumatoid lung disease with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.141	Rheumatoid lung disease with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.142	Rheumatoid lung disease with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.149	Rheumatoid lung disease with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.151	Rheumatoid lung disease with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.152	Rheumatoid lung disease with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.159	Rheumatoid lung disease with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.161	Rheumatoid lung disease with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.162	Rheumatoid lung disease with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.169	Rheumatoid lung disease with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.171	Rheumatoid lung disease with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.172	Rheumatoid lung disease with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.179	Rheumatoid lung disease with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.19	Rheumatoid lung disease with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.20	Rheumatoid vasculitis with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.211	Rheumatoid vasculitis with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.212	Rheumatoid vasculitis with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.219	Rheumatoid vasculitis with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.221	Rheumatoid vasculitis with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.222	Rheumatoid vasculitis with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.229	Rheumatoid vasculitis with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.231	Rheumatoid vasculitis with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.232	Rheumatoid vasculitis with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.239	Rheumatoid vasculitis with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.241	Rheumatoid vasculitis with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.242	Rheumatoid vasculitis with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.249	Rheumatoid vasculitis with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.251	Rheumatoid vasculitis with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.252	Rheumatoid vasculitis with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.259	Rheumatoid vasculitis with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.261	Rheumatoid vasculitis with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M05.262	Rheumatoid vasculitis with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.269	Rheumatoid vasculitis with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.271	Rheumatoid vasculitis with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.272	Rheumatoid vasculitis with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.279	Rheumatoid vasculitis with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.29	Rheumatoid vasculitis with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.30	Rheumatoid heart disease with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.311	Rheumatoid heart disease with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.312	Rheumatoid heart disease with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.319	Rheumatoid heart disease with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.321	Rheumatoid heart disease with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.322	Rheumatoid heart disease with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.329	Rheumatoid heart disease with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.331	Rheumatoid heart disease with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.332	Rheumatoid heart disease with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.339	Rheumatoid heart disease with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.341	Rheumatoid heart disease with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.342	Rheumatoid heart disease with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.349	Rheumatoid heart disease with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.351	Rheumatoid heart disease with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.352	Rheumatoid heart disease with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.359	Rheumatoid heart disease with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.361	Rheumatoid heart disease with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.362	Rheumatoid heart disease with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.369	Rheumatoid heart disease with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.371	Rheumatoid heart disease with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.372	Rheumatoid heart disease with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.379	Rheumatoid heart disease with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.39	Rheumatoid heart disease with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.40	Rheumatoid myopathy with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.411	Rheumatoid myopathy with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.412	Rheumatoid myopathy with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.419	Rheumatoid myopathy with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.421	Rheumatoid myopathy with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.422	Rheumatoid myopathy with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M05.429	Rheumatoid myopathy with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.431	Rheumatoid myopathy with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.432	Rheumatoid myopathy with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.439	Rheumatoid myopathy with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.441	Rheumatoid myopathy with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.442	Rheumatoid myopathy with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.449	Rheumatoid myopathy with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.451	Rheumatoid myopathy with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.452	Rheumatoid myopathy with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.459	Rheumatoid myopathy with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.461	Rheumatoid myopathy with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.462	Rheumatoid myopathy with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.469	Rheumatoid myopathy with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.471	Rheumatoid myopathy with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.472	Rheumatoid myopathy with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.479	Rheumatoid myopathy with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.49	Rheumatoid myopathy with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.50	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.511	Rheumatoid polyneuropathy with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.512	Rheumatoid polyneuropathy with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.519	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.521	Rheumatoid polyneuropathy with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.522	Rheumatoid polyneuropathy with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.529	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.531	Rheumatoid polyneuropathy with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.532	Rheumatoid polyneuropathy with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.539	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.541	Rheumatoid polyneuropathy with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.542	Rheumatoid polyneuropathy with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.549	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.551	Rheumatoid polyneuropathy with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.552	Rheumatoid polyneuropathy with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.559	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.561	Rheumatoid polyneuropathy with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.562	Rheumatoid polyneuropathy with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.569	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M05.571	Rheumatoid polyneuropathy with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.572	Rheumatoid polyneuropathy with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.579	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.59	Rheumatoid polyneuropathy with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.60	Rheumatoid arthritis of unspecified site with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.611	Rheumatoid arthritis of right shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.612	Rheumatoid arthritis of left shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.619	Rheumatoid arthritis of unspecified shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.621	Rheumatoid arthritis of right elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.622	Rheumatoid arthritis of left elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.629	Rheumatoid arthritis of unspecified elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.631	Rheumatoid arthritis of right wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.632	Rheumatoid arthritis of left wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.639	Rheumatoid arthritis of unspecified wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.641	Rheumatoid arthritis of right hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.642	Rheumatoid arthritis of left hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.649	Rheumatoid arthritis of unspecified hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.651	Rheumatoid arthritis of right hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.652	Rheumatoid arthritis of left hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.659	Rheumatoid arthritis of unspecified hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.661	Rheumatoid arthritis of right knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.662	Rheumatoid arthritis of left knee with involvement of other organs and systems	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M05.669	Rheumatoid arthritis of unspecified knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.671	Rheumatoid arthritis of right ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.672	Rheumatoid arthritis of left ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.679	Rheumatoid arthritis of unspecified ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.69	Rheumatoid arthritis of multiple sites with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.70	Rheumatoid arthritis with rheumatoid factor of unspecified site without organ or systems involvement	Diagnosis	ICD-10-CM
M05.711	Rheumatoid arthritis with rheumatoid factor of right shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.712	Rheumatoid arthritis with rheumatoid factor of left shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.719	Rheumatoid arthritis with rheumatoid factor of unspecified shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.721	Rheumatoid arthritis with rheumatoid factor of right elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.722	Rheumatoid arthritis with rheumatoid factor of left elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.729	Rheumatoid arthritis with rheumatoid factor of unspecified elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.731	Rheumatoid arthritis with rheumatoid factor of right wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.732	Rheumatoid arthritis with rheumatoid factor of left wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.739	Rheumatoid arthritis with rheumatoid factor of unspecified wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.741	Rheumatoid arthritis with rheumatoid factor of right hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.742	Rheumatoid arthritis with rheumatoid factor of left hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.749	Rheumatoid arthritis with rheumatoid factor of unspecified hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.751	Rheumatoid arthritis with rheumatoid factor of right hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.752	Rheumatoid arthritis with rheumatoid factor of left hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.759	Rheumatoid arthritis with rheumatoid factor of unspecified hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.761	Rheumatoid arthritis with rheumatoid factor of right knee without organ or systems involvement	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M05.762	Rheumatoid arthritis with rheumatoid factor of left knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.769	Rheumatoid arthritis with rheumatoid factor of unspecified knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.771	Rheumatoid arthritis with rheumatoid factor of right ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.772	Rheumatoid arthritis with rheumatoid factor of left ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.779	Rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.79	Rheumatoid arthritis with rheumatoid factor of multiple sites without organ or systems involvement	Diagnosis	ICD-10-CM
M05.7A	Rheumatoid arthritis with rheumatoid factor of other specified site without organ or systems involvement	Diagnosis	ICD-10-CM
M05.80	Other rheumatoid arthritis with rheumatoid factor of unspecified site	Diagnosis	ICD-10-CM
M05.811	Other rheumatoid arthritis with rheumatoid factor of right shoulder	Diagnosis	ICD-10-CM
M05.812	Other rheumatoid arthritis with rheumatoid factor of left shoulder	Diagnosis	ICD-10-CM
M05.819	Other rheumatoid arthritis with rheumatoid factor of unspecified shoulder	Diagnosis	ICD-10-CM
M05.821	Other rheumatoid arthritis with rheumatoid factor of right elbow	Diagnosis	ICD-10-CM
M05.822	Other rheumatoid arthritis with rheumatoid factor of left elbow	Diagnosis	ICD-10-CM
M05.829	Other rheumatoid arthritis with rheumatoid factor of unspecified elbow	Diagnosis	ICD-10-CM
M05.831	Other rheumatoid arthritis with rheumatoid factor of right wrist	Diagnosis	ICD-10-CM
M05.832	Other rheumatoid arthritis with rheumatoid factor of left wrist	Diagnosis	ICD-10-CM
M05.839	Other rheumatoid arthritis with rheumatoid factor of unspecified wrist	Diagnosis	ICD-10-CM
M05.841	Other rheumatoid arthritis with rheumatoid factor of right hand	Diagnosis	ICD-10-CM
M05.842	Other rheumatoid arthritis with rheumatoid factor of left hand	Diagnosis	ICD-10-CM
M05.849	Other rheumatoid arthritis with rheumatoid factor of unspecified hand	Diagnosis	ICD-10-CM
M05.851	Other rheumatoid arthritis with rheumatoid factor of right hip	Diagnosis	ICD-10-CM
M05.852	Other rheumatoid arthritis with rheumatoid factor of left hip	Diagnosis	ICD-10-CM
M05.859	Other rheumatoid arthritis with rheumatoid factor of unspecified hip	Diagnosis	ICD-10-CM
M05.861	Other rheumatoid arthritis with rheumatoid factor of right knee	Diagnosis	ICD-10-CM
M05.862	Other rheumatoid arthritis with rheumatoid factor of left knee	Diagnosis	ICD-10-CM
M05.869	Other rheumatoid arthritis with rheumatoid factor of unspecified knee	Diagnosis	ICD-10-CM
M05.871	Other rheumatoid arthritis with rheumatoid factor of right ankle and foot	Diagnosis	ICD-10-CM
M05.872	Other rheumatoid arthritis with rheumatoid factor of left ankle and foot	Diagnosis	ICD-10-CM
M05.879	Other rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.89	Other rheumatoid arthritis with rheumatoid factor of multiple sites	Diagnosis	ICD-10-CM
M05.8A	Other rheumatoid arthritis with rheumatoid factor of other specified site	Diagnosis	ICD-10-CM
M05.9	Rheumatoid arthritis with rheumatoid factor, unspecified	Diagnosis	ICD-10-CM
M06.00	Rheumatoid arthritis without rheumatoid factor, unspecified site	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M06.011	Rheumatoid arthritis without rheumatoid factor, right shoulder	Diagnosis	ICD-10-CM
M06.012	Rheumatoid arthritis without rheumatoid factor, left shoulder	Diagnosis	ICD-10-CM
M06.019	Rheumatoid arthritis without rheumatoid factor, unspecified shoulder	Diagnosis	ICD-10-CM
M06.021	Rheumatoid arthritis without rheumatoid factor, right elbow	Diagnosis	ICD-10-CM
M06.022	Rheumatoid arthritis without rheumatoid factor, left elbow	Diagnosis	ICD-10-CM
M06.029	Rheumatoid arthritis without rheumatoid factor, unspecified elbow	Diagnosis	ICD-10-CM
M06.031	Rheumatoid arthritis without rheumatoid factor, right wrist	Diagnosis	ICD-10-CM
M06.032	Rheumatoid arthritis without rheumatoid factor, left wrist	Diagnosis	ICD-10-CM
M06.039	Rheumatoid arthritis without rheumatoid factor, unspecified wrist	Diagnosis	ICD-10-CM
M06.041	Rheumatoid arthritis without rheumatoid factor, right hand	Diagnosis	ICD-10-CM
M06.042	Rheumatoid arthritis without rheumatoid factor, left hand	Diagnosis	ICD-10-CM
M06.049	Rheumatoid arthritis without rheumatoid factor, unspecified hand	Diagnosis	ICD-10-CM
M06.051	Rheumatoid arthritis without rheumatoid factor, right hip	Diagnosis	ICD-10-CM
M06.052	Rheumatoid arthritis without rheumatoid factor, left hip	Diagnosis	ICD-10-CM
M06.059	Rheumatoid arthritis without rheumatoid factor, unspecified hip	Diagnosis	ICD-10-CM
M06.061	Rheumatoid arthritis without rheumatoid factor, right knee	Diagnosis	ICD-10-CM
M06.062	Rheumatoid arthritis without rheumatoid factor, left knee	Diagnosis	ICD-10-CM
M06.069	Rheumatoid arthritis without rheumatoid factor, unspecified knee	Diagnosis	ICD-10-CM
M06.071	Rheumatoid arthritis without rheumatoid factor, right ankle and foot	Diagnosis	ICD-10-CM
M06.072	Rheumatoid arthritis without rheumatoid factor, left ankle and foot	Diagnosis	ICD-10-CM
M06.079	Rheumatoid arthritis without rheumatoid factor, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.08	Rheumatoid arthritis without rheumatoid factor, vertebrae	Diagnosis	ICD-10-CM
M06.09	Rheumatoid arthritis without rheumatoid factor, multiple sites	Diagnosis	ICD-10-CM
M06.0A	Rheumatoid arthritis without rheumatoid factor, other specified site	Diagnosis	ICD-10-CM
M06.1	Adult-onset Still's disease	Diagnosis	ICD-10-CM
M06.20	Rheumatoid bursitis, unspecified site	Diagnosis	ICD-10-CM
M06.211	Rheumatoid bursitis, right shoulder	Diagnosis	ICD-10-CM
M06.212	Rheumatoid bursitis, left shoulder	Diagnosis	ICD-10-CM
M06.219	Rheumatoid bursitis, unspecified shoulder	Diagnosis	ICD-10-CM
M06.221	Rheumatoid bursitis, right elbow	Diagnosis	ICD-10-CM
M06.222	Rheumatoid bursitis, left elbow	Diagnosis	ICD-10-CM
M06.229	Rheumatoid bursitis, unspecified elbow	Diagnosis	ICD-10-CM
M06.231	Rheumatoid bursitis, right wrist	Diagnosis	ICD-10-CM
M06.232	Rheumatoid bursitis, left wrist	Diagnosis	ICD-10-CM
M06.239	Rheumatoid bursitis, unspecified wrist	Diagnosis	ICD-10-CM
M06.241	Rheumatoid bursitis, right hand	Diagnosis	ICD-10-CM
M06.242	Rheumatoid bursitis, left hand	Diagnosis	ICD-10-CM
M06.249	Rheumatoid bursitis, unspecified hand	Diagnosis	ICD-10-CM
M06.251	Rheumatoid bursitis, right hip	Diagnosis	ICD-10-CM
M06.252	Rheumatoid bursitis, left hip	Diagnosis	ICD-10-CM
M06.259	Rheumatoid bursitis, unspecified hip	Diagnosis	ICD-10-CM
M06.261	Rheumatoid bursitis, right knee	Diagnosis	ICD-10-CM
M06.262	Rheumatoid bursitis, left knee	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M06.269	Rheumatoid bursitis, unspecified knee	Diagnosis	ICD-10-CM
M06.271	Rheumatoid bursitis, right ankle and foot	Diagnosis	ICD-10-CM
M06.272	Rheumatoid bursitis, left ankle and foot	Diagnosis	ICD-10-CM
M06.279	Rheumatoid bursitis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.28	Rheumatoid bursitis, vertebrae	Diagnosis	ICD-10-CM
M06.29	Rheumatoid bursitis, multiple sites	Diagnosis	ICD-10-CM
M06.30	Rheumatoid nodule, unspecified site	Diagnosis	ICD-10-CM
M06.311	Rheumatoid nodule, right shoulder	Diagnosis	ICD-10-CM
M06.312	Rheumatoid nodule, left shoulder	Diagnosis	ICD-10-CM
M06.319	Rheumatoid nodule, unspecified shoulder	Diagnosis	ICD-10-CM
M06.321	Rheumatoid nodule, right elbow	Diagnosis	ICD-10-CM
M06.322	Rheumatoid nodule, left elbow	Diagnosis	ICD-10-CM
M06.329	Rheumatoid nodule, unspecified elbow	Diagnosis	ICD-10-CM
M06.331	Rheumatoid nodule, right wrist	Diagnosis	ICD-10-CM
M06.332	Rheumatoid nodule, left wrist	Diagnosis	ICD-10-CM
M06.339	Rheumatoid nodule, unspecified wrist	Diagnosis	ICD-10-CM
M06.341	Rheumatoid nodule, right hand	Diagnosis	ICD-10-CM
M06.342	Rheumatoid nodule, left hand	Diagnosis	ICD-10-CM
M06.349	Rheumatoid nodule, unspecified hand	Diagnosis	ICD-10-CM
M06.351	Rheumatoid nodule, right hip	Diagnosis	ICD-10-CM
M06.352	Rheumatoid nodule, left hip	Diagnosis	ICD-10-CM
M06.359	Rheumatoid nodule, unspecified hip	Diagnosis	ICD-10-CM
M06.361	Rheumatoid nodule, right knee	Diagnosis	ICD-10-CM
M06.362	Rheumatoid nodule, left knee	Diagnosis	ICD-10-CM
M06.369	Rheumatoid nodule, unspecified knee	Diagnosis	ICD-10-CM
M06.371	Rheumatoid nodule, right ankle and foot	Diagnosis	ICD-10-CM
M06.372	Rheumatoid nodule, left ankle and foot	Diagnosis	ICD-10-CM
M06.379	Rheumatoid nodule, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.38	Rheumatoid nodule, vertebrae	Diagnosis	ICD-10-CM
M06.39	Rheumatoid nodule, multiple sites	Diagnosis	ICD-10-CM
M06.80	Other specified rheumatoid arthritis, unspecified site	Diagnosis	ICD-10-CM
M06.811	Other specified rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M06.812	Other specified rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M06.819	Other specified rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M06.821	Other specified rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M06.822	Other specified rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M06.829	Other specified rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M06.831	Other specified rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M06.832	Other specified rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M06.839	Other specified rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M06.841	Other specified rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M06.842	Other specified rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M06.849	Other specified rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M06.851	Other specified rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M06.852	Other specified rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M06.859	Other specified rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M06.861	Other specified rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M06.862	Other specified rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M06.869	Other specified rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M06.871	Other specified rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M06.872	Other specified rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M06.879	Other specified rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.88	Other specified rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M06.89	Other specified rheumatoid arthritis, multiple sites	Diagnosis	ICD-10-CM
M06.8A	Other specified rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M06.9	Rheumatoid arthritis, unspecified	Diagnosis	ICD-10-CM
M08.00	Unspecified juvenile rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M08.011	Unspecified juvenile rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.012	Unspecified juvenile rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.019	Unspecified juvenile rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.021	Unspecified juvenile rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M08.022	Unspecified juvenile rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M08.029	Unspecified juvenile rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.031	Unspecified juvenile rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M08.032	Unspecified juvenile rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M08.039	Unspecified juvenile rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.041	Unspecified juvenile rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M08.042	Unspecified juvenile rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M08.049	Unspecified juvenile rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.051	Unspecified juvenile rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M08.052	Unspecified juvenile rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M08.059	Unspecified juvenile rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.061	Unspecified juvenile rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M08.062	Unspecified juvenile rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M08.069	Unspecified juvenile rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.071	Unspecified juvenile rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.072	Unspecified juvenile rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.079	Unspecified juvenile rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.08	Unspecified juvenile rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M08.09	Unspecified juvenile rheumatoid arthritis, multiple sites	Diagnosis	ICD-10-CM
M08.0A	Unspecified juvenile rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M08.1	Juvenile ankylosing spondylitis	Diagnosis	ICD-10-CM
M08.20	Juvenile rheumatoid arthritis with systemic onset, unspecified site	Diagnosis	ICD-10-CM
M08.211	Juvenile rheumatoid arthritis with systemic onset, right shoulder	Diagnosis	ICD-10-CM
M08.212	Juvenile rheumatoid arthritis with systemic onset, left shoulder	Diagnosis	ICD-10-CM
M08.219	Juvenile rheumatoid arthritis with systemic onset, unspecified shoulder	Diagnosis	ICD-10-CM
M08.221	Juvenile rheumatoid arthritis with systemic onset, right elbow	Diagnosis	ICD-10-CM
M08.222	Juvenile rheumatoid arthritis with systemic onset, left elbow	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M08.229	Juvenile rheumatoid arthritis with systemic onset, unspecified elbow	Diagnosis	ICD-10-CM
M08.231	Juvenile rheumatoid arthritis with systemic onset, right wrist	Diagnosis	ICD-10-CM
M08.232	Juvenile rheumatoid arthritis with systemic onset, left wrist	Diagnosis	ICD-10-CM
M08.239	Juvenile rheumatoid arthritis with systemic onset, unspecified wrist	Diagnosis	ICD-10-CM
M08.241	Juvenile rheumatoid arthritis with systemic onset, right hand	Diagnosis	ICD-10-CM
M08.242	Juvenile rheumatoid arthritis with systemic onset, left hand	Diagnosis	ICD-10-CM
M08.249	Juvenile rheumatoid arthritis with systemic onset, unspecified hand	Diagnosis	ICD-10-CM
M08.251	Juvenile rheumatoid arthritis with systemic onset, right hip	Diagnosis	ICD-10-CM
M08.252	Juvenile rheumatoid arthritis with systemic onset, left hip	Diagnosis	ICD-10-CM
M08.259	Juvenile rheumatoid arthritis with systemic onset, unspecified hip	Diagnosis	ICD-10-CM
M08.261	Juvenile rheumatoid arthritis with systemic onset, right knee	Diagnosis	ICD-10-CM
M08.262	Juvenile rheumatoid arthritis with systemic onset, left knee	Diagnosis	ICD-10-CM
M08.269	Juvenile rheumatoid arthritis with systemic onset, unspecified knee	Diagnosis	ICD-10-CM
M08.271	Juvenile rheumatoid arthritis with systemic onset, right ankle and foot	Diagnosis	ICD-10-CM
M08.272	Juvenile rheumatoid arthritis with systemic onset, left ankle and foot	Diagnosis	ICD-10-CM
M08.279	Juvenile rheumatoid arthritis with systemic onset, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.28	Juvenile rheumatoid arthritis with systemic onset, vertebrae	Diagnosis	ICD-10-CM
M08.29	Juvenile rheumatoid arthritis with systemic onset, multiple sites	Diagnosis	ICD-10-CM
M08.2A	Juvenile rheumatoid arthritis with systemic onset, other specified site	Diagnosis	ICD-10-CM
M08.3	Juvenile rheumatoid polyarthritis (seronegative)	Diagnosis	ICD-10-CM
M08.40	Pauciarticular juvenile rheumatoid arthritis, unspecified site	Diagnosis	ICD-10-CM
M08.411	Pauciarticular juvenile rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.412	Pauciarticular juvenile rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.419	Pauciarticular juvenile rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.421	Pauciarticular juvenile rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M08.422	Pauciarticular juvenile rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M08.429	Pauciarticular juvenile rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.431	Pauciarticular juvenile rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M08.432	Pauciarticular juvenile rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M08.439	Pauciarticular juvenile rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.441	Pauciarticular juvenile rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M08.442	Pauciarticular juvenile rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M08.449	Pauciarticular juvenile rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.451	Pauciarticular juvenile rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M08.452	Pauciarticular juvenile rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M08.459	Pauciarticular juvenile rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.461	Pauciarticular juvenile rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M08.462	Pauciarticular juvenile rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M08.469	Pauciarticular juvenile rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.471	Pauciarticular juvenile rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.472	Pauciarticular juvenile rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.479	Pauciarticular juvenile rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.48	Pauciarticular juvenile rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M08.4A	Pauciarticular juvenile rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M08.80	Other juvenile arthritis, unspecified site	Diagnosis	ICD-10-CM
M08.811	Other juvenile arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.812	Other juvenile arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.819	Other juvenile arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.821	Other juvenile arthritis, right elbow	Diagnosis	ICD-10-CM
M08.822	Other juvenile arthritis, left elbow	Diagnosis	ICD-10-CM
M08.829	Other juvenile arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.831	Other juvenile arthritis, right wrist	Diagnosis	ICD-10-CM
M08.832	Other juvenile arthritis, left wrist	Diagnosis	ICD-10-CM
M08.839	Other juvenile arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.841	Other juvenile arthritis, right hand	Diagnosis	ICD-10-CM
M08.842	Other juvenile arthritis, left hand	Diagnosis	ICD-10-CM
M08.849	Other juvenile arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.851	Other juvenile arthritis, right hip	Diagnosis	ICD-10-CM
M08.852	Other juvenile arthritis, left hip	Diagnosis	ICD-10-CM
M08.859	Other juvenile arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.861	Other juvenile arthritis, right knee	Diagnosis	ICD-10-CM
M08.862	Other juvenile arthritis, left knee	Diagnosis	ICD-10-CM
M08.869	Other juvenile arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.871	Other juvenile arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.872	Other juvenile arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.879	Other juvenile arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.88	Other juvenile arthritis, other specified site	Diagnosis	ICD-10-CM
M08.89	Other juvenile arthritis, multiple sites	Diagnosis	ICD-10-CM
M08.90	Juvenile arthritis, unspecified, unspecified site	Diagnosis	ICD-10-CM
M08.911	Juvenile arthritis, unspecified, right shoulder	Diagnosis	ICD-10-CM
M08.912	Juvenile arthritis, unspecified, left shoulder	Diagnosis	ICD-10-CM
M08.919	Juvenile arthritis, unspecified, unspecified shoulder	Diagnosis	ICD-10-CM
M08.921	Juvenile arthritis, unspecified, right elbow	Diagnosis	ICD-10-CM
M08.922	Juvenile arthritis, unspecified, left elbow	Diagnosis	ICD-10-CM
M08.929	Juvenile arthritis, unspecified, unspecified elbow	Diagnosis	ICD-10-CM
M08.931	Juvenile arthritis, unspecified, right wrist	Diagnosis	ICD-10-CM
M08.932	Juvenile arthritis, unspecified, left wrist	Diagnosis	ICD-10-CM
M08.939	Juvenile arthritis, unspecified, unspecified wrist	Diagnosis	ICD-10-CM
M08.941	Juvenile arthritis, unspecified, right hand	Diagnosis	ICD-10-CM
M08.942	Juvenile arthritis, unspecified, left hand	Diagnosis	ICD-10-CM
M08.949	Juvenile arthritis, unspecified, unspecified hand	Diagnosis	ICD-10-CM
M08.951	Juvenile arthritis, unspecified, right hip	Diagnosis	ICD-10-CM
M08.952	Juvenile arthritis, unspecified, left hip	Diagnosis	ICD-10-CM
M08.959	Juvenile arthritis, unspecified, unspecified hip	Diagnosis	ICD-10-CM
M08.961	Juvenile arthritis, unspecified, right knee	Diagnosis	ICD-10-CM
M08.962	Juvenile arthritis, unspecified, left knee	Diagnosis	ICD-10-CM
M08.969	Juvenile arthritis, unspecified, unspecified knee	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M08.971	Juvenile arthritis, unspecified, right ankle and foot	Diagnosis	ICD-10-CM
M08.972	Juvenile arthritis, unspecified, left ankle and foot	Diagnosis	ICD-10-CM
M08.979	Juvenile arthritis, unspecified, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.98	Juvenile arthritis, unspecified, vertebrae	Diagnosis	ICD-10-CM
M08.99	Juvenile arthritis, unspecified, multiple sites	Diagnosis	ICD-10-CM
M08.9A	Juvenile arthritis, unspecified, other specified site	Diagnosis	ICD-10-CM
M15.0	Primary generalized (osteo)arthritis	Diagnosis	ICD-10-CM
M15.1	Heberden's nodes (with arthropathy)	Diagnosis	ICD-10-CM
M15.2	Bouchard's nodes (with arthropathy)	Diagnosis	ICD-10-CM
M15.3	Secondary multiple arthritis	Diagnosis	ICD-10-CM
M15.4	Erosive (osteo)arthritis	Diagnosis	ICD-10-CM
M15.8	Other polyosteoarthritis	Diagnosis	ICD-10-CM
M15.9	Polyosteoarthritis, unspecified	Diagnosis	ICD-10-CM
M16.0	Bilateral primary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.10	Unilateral primary osteoarthritis, unspecified hip	Diagnosis	ICD-10-CM
M16.11	Unilateral primary osteoarthritis, right hip	Diagnosis	ICD-10-CM
M16.12	Unilateral primary osteoarthritis, left hip	Diagnosis	ICD-10-CM
M16.2	Bilateral osteoarthritis resulting from hip dysplasia	Diagnosis	ICD-10-CM
M16.30	Unilateral osteoarthritis resulting from hip dysplasia, unspecified hip	Diagnosis	ICD-10-CM
M16.31	Unilateral osteoarthritis resulting from hip dysplasia, right hip	Diagnosis	ICD-10-CM
M16.32	Unilateral osteoarthritis resulting from hip dysplasia, left hip	Diagnosis	ICD-10-CM
M16.4	Bilateral post-traumatic osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.50	Unilateral post-traumatic osteoarthritis, unspecified hip	Diagnosis	ICD-10-CM
M16.51	Unilateral post-traumatic osteoarthritis, right hip	Diagnosis	ICD-10-CM
M16.52	Unilateral post-traumatic osteoarthritis, left hip	Diagnosis	ICD-10-CM
M16.6	Other bilateral secondary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.7	Other unilateral secondary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.9	Osteoarthritis of hip, unspecified	Diagnosis	ICD-10-CM
M17.0	Bilateral primary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.10	Unilateral primary osteoarthritis, unspecified knee	Diagnosis	ICD-10-CM
M17.11	Unilateral primary osteoarthritis, right knee	Diagnosis	ICD-10-CM
M17.12	Unilateral primary osteoarthritis, left knee	Diagnosis	ICD-10-CM
M17.2	Bilateral post-traumatic osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.30	Unilateral post-traumatic osteoarthritis, unspecified knee	Diagnosis	ICD-10-CM
M17.31	Unilateral post-traumatic osteoarthritis, right knee	Diagnosis	ICD-10-CM
M17.32	Unilateral post-traumatic osteoarthritis, left knee	Diagnosis	ICD-10-CM
M17.4	Other bilateral secondary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.5	Other unilateral secondary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.9	Osteoarthritis of knee, unspecified	Diagnosis	ICD-10-CM
M18.0	Bilateral primary osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.10	Unilateral primary osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.11	Unilateral primary osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M18.12	Unilateral primary osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.2	Bilateral post-traumatic osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.30	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.31	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.32	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.4	Other bilateral secondary osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.50	Other unilateral secondary osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.51	Other unilateral secondary osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.52	Other unilateral secondary osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.9	Osteoarthritis of first carpometacarpal joint, unspecified	Diagnosis	ICD-10-CM
M19.011	Primary osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.012	Primary osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.019	Primary osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.021	Primary osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.022	Primary osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.029	Primary osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.031	Primary osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.032	Primary osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.039	Primary osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.041	Primary osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.042	Primary osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.049	Primary osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.071	Primary osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.072	Primary osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.079	Primary osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.09	Primary osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.111	Post-traumatic osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.112	Post-traumatic osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.119	Post-traumatic osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.121	Post-traumatic osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.122	Post-traumatic osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.129	Post-traumatic osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.131	Post-traumatic osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.132	Post-traumatic osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.139	Post-traumatic osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.141	Post-traumatic osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.142	Post-traumatic osteoarthritis, left hand	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M19.149	Post-traumatic osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.171	Post-traumatic osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.172	Post-traumatic osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.179	Post-traumatic osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.19	Post-traumatic osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.211	Secondary osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.212	Secondary osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.219	Secondary osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.221	Secondary osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.222	Secondary osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.229	Secondary osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.231	Secondary osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.232	Secondary osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.239	Secondary osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.241	Secondary osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.242	Secondary osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.249	Secondary osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.271	Secondary osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.272	Secondary osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.279	Secondary osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.29	Secondary osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.90	Unspecified osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.91	Primary osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.92	Post-traumatic osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.93	Secondary osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M45.0	Ankylosing spondylitis of multiple sites in spine	Diagnosis	ICD-10-CM
M45.1	Ankylosing spondylitis of occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M45.2	Ankylosing spondylitis of cervical region	Diagnosis	ICD-10-CM
M45.3	Ankylosing spondylitis of cervicothoracic region	Diagnosis	ICD-10-CM
M45.4	Ankylosing spondylitis of thoracic region	Diagnosis	ICD-10-CM
M45.5	Ankylosing spondylitis of thoracolumbar region	Diagnosis	ICD-10-CM
M45.6	Ankylosing spondylitis lumbar region	Diagnosis	ICD-10-CM
M45.7	Ankylosing spondylitis of lumbosacral region	Diagnosis	ICD-10-CM
M45.8	Ankylosing spondylitis sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M45.9	Ankylosing spondylitis of unspecified sites in spine	Diagnosis	ICD-10-CM
M45.A0	Non-radiographic axial spondyloarthritis of unspecified sites in spine	Diagnosis	ICD-10-CM
M45.A1	Non-radiographic axial spondyloarthritis of occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M45.A2	Non-radiographic axial spondyloarthritis of cervical region	Diagnosis	ICD-10-CM
M45.A3	Non-radiographic axial spondyloarthritis of cervicothoracic region	Diagnosis	ICD-10-CM
M45.A4	Non-radiographic axial spondyloarthritis of thoracic region	Diagnosis	ICD-10-CM
M45.A5	Non-radiographic axial spondyloarthritis of thoracolumbar region	Diagnosis	ICD-10-CM
M45.A6	Non-radiographic axial spondyloarthritis of lumbar region	Diagnosis	ICD-10-CM
M45.A7	Non-radiographic axial spondyloarthritis of lumbosacral region	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M45.A8	Non-radiographic axial spondyloarthritis of sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M45.AB	Non-radiographic axial spondyloarthritis of multiple sites in spine	Diagnosis	ICD-10-CM
M46.80	Other specified inflammatory spondylopathies, site unspecified	Diagnosis	ICD-10-CM
M46.81	Other specified inflammatory spondylopathies, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M46.82	Other specified inflammatory spondylopathies, cervical region	Diagnosis	ICD-10-CM
M46.83	Other specified inflammatory spondylopathies, cervicothoracic region	Diagnosis	ICD-10-CM
M46.84	Other specified inflammatory spondylopathies, thoracic region	Diagnosis	ICD-10-CM
M46.85	Other specified inflammatory spondylopathies, thoracolumbar region	Diagnosis	ICD-10-CM
M46.86	Other specified inflammatory spondylopathies, lumbar region	Diagnosis	ICD-10-CM
M46.87	Other specified inflammatory spondylopathies, lumbosacral region	Diagnosis	ICD-10-CM
M46.88	Other specified inflammatory spondylopathies, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M46.89	Other specified inflammatory spondylopathies, multiple sites in spine	Diagnosis	ICD-10-CM
M46.90	Unspecified inflammatory spondylopathy, site unspecified	Diagnosis	ICD-10-CM
M46.91	Unspecified inflammatory spondylopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M46.92	Unspecified inflammatory spondylopathy, cervical region	Diagnosis	ICD-10-CM
M46.93	Unspecified inflammatory spondylopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M46.94	Unspecified inflammatory spondylopathy, thoracic region	Diagnosis	ICD-10-CM
M46.95	Unspecified inflammatory spondylopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M46.96	Unspecified inflammatory spondylopathy, lumbar region	Diagnosis	ICD-10-CM
M46.97	Unspecified inflammatory spondylopathy, lumbosacral region	Diagnosis	ICD-10-CM
M46.98	Unspecified inflammatory spondylopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M46.99	Unspecified inflammatory spondylopathy, multiple sites in spine	Diagnosis	ICD-10-CM
M47.011	Anterior spinal artery compression syndromes, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.012	Anterior spinal artery compression syndromes, cervical region	Diagnosis	ICD-10-CM
M47.013	Anterior spinal artery compression syndromes, cervicothoracic region	Diagnosis	ICD-10-CM
M47.014	Anterior spinal artery compression syndromes, thoracic region	Diagnosis	ICD-10-CM
M47.015	Anterior spinal artery compression syndromes, thoracolumbar region	Diagnosis	ICD-10-CM
M47.016	Anterior spinal artery compression syndromes, lumbar region	Diagnosis	ICD-10-CM
M47.019	Anterior spinal artery compression syndromes, site unspecified	Diagnosis	ICD-10-CM
M47.021	Vertebral artery compression syndromes, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.022	Vertebral artery compression syndromes, cervical region	Diagnosis	ICD-10-CM
M47.029	Vertebral artery compression syndromes, site unspecified	Diagnosis	ICD-10-CM
M47.10	Other spondylosis with myelopathy, site unspecified	Diagnosis	ICD-10-CM
M47.11	Other spondylosis with myelopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.12	Other spondylosis with myelopathy, cervical region	Diagnosis	ICD-10-CM
M47.13	Other spondylosis with myelopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.14	Other spondylosis with myelopathy, thoracic region	Diagnosis	ICD-10-CM
M47.15	Other spondylosis with myelopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.16	Other spondylosis with myelopathy, lumbar region	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M47.20	Other spondylosis with radiculopathy, site unspecified	Diagnosis	ICD-10-CM
M47.21	Other spondylosis with radiculopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.22	Other spondylosis with radiculopathy, cervical region	Diagnosis	ICD-10-CM
M47.23	Other spondylosis with radiculopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.24	Other spondylosis with radiculopathy, thoracic region	Diagnosis	ICD-10-CM
M47.25	Other spondylosis with radiculopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.26	Other spondylosis with radiculopathy, lumbar region	Diagnosis	ICD-10-CM
M47.27	Other spondylosis with radiculopathy, lumbosacral region	Diagnosis	ICD-10-CM
M47.28	Other spondylosis with radiculopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.811	Spondylosis without myelopathy or radiculopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.812	Spondylosis without myelopathy or radiculopathy, cervical region	Diagnosis	ICD-10-CM
M47.813	Spondylosis without myelopathy or radiculopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.814	Spondylosis without myelopathy or radiculopathy, thoracic region	Diagnosis	ICD-10-CM
M47.815	Spondylosis without myelopathy or radiculopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.816	Spondylosis without myelopathy or radiculopathy, lumbar region	Diagnosis	ICD-10-CM
M47.817	Spondylosis without myelopathy or radiculopathy, lumbosacral region	Diagnosis	ICD-10-CM
M47.818	Spondylosis without myelopathy or radiculopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.819	Spondylosis without myelopathy or radiculopathy, site unspecified	Diagnosis	ICD-10-CM
M47.891	Other spondylosis, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.892	Other spondylosis, cervical region	Diagnosis	ICD-10-CM
M47.893	Other spondylosis, cervicothoracic region	Diagnosis	ICD-10-CM
M47.894	Other spondylosis, thoracic region	Diagnosis	ICD-10-CM
M47.895	Other spondylosis, thoracolumbar region	Diagnosis	ICD-10-CM
M47.896	Other spondylosis, lumbar region	Diagnosis	ICD-10-CM
M47.897	Other spondylosis, lumbosacral region	Diagnosis	ICD-10-CM
M47.898	Other spondylosis, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.899	Other spondylosis, site unspecified	Diagnosis	ICD-10-CM
M47.9	Spondylosis, unspecified	Diagnosis	ICD-10-CM
M48.8X1	Other specified spondylopathies, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M48.8X2	Other specified spondylopathies, cervical region	Diagnosis	ICD-10-CM
M48.8X3	Other specified spondylopathies, cervicothoracic region	Diagnosis	ICD-10-CM
M48.8X4	Other specified spondylopathies, thoracic region	Diagnosis	ICD-10-CM
M48.8X5	Other specified spondylopathies, thoracolumbar region	Diagnosis	ICD-10-CM
M48.8X6	Other specified spondylopathies, lumbar region	Diagnosis	ICD-10-CM
M48.8X7	Other specified spondylopathies, lumbosacral region	Diagnosis	ICD-10-CM
M48.8X8	Other specified spondylopathies, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M48.8X9	Other specified spondylopathies, site unspecified	Diagnosis	ICD-10-CM
Smoking (Diagnosis or Procedure Codes)			
1034F	Current tobacco smoker (CAD, CAP, COPD, PV) (DM)	Procedure	CPT-2

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
4001F	Tobacco use cessation intervention, pharmacologic therapy (COPD, CAD, CAP, PV, Asthma) (DM) (PV)	Procedure	CPT-2
4004F	Patient screened for tobacco use and received tobacco cessation intervention (counseling, pharmacotherapy, or both), if identified as a tobacco user (PV, CAD)	Procedure	CPT-2
99406	Smoking and tobacco use cessation counseling visit; intermediate, greater than 3 minutes up to 10 minutes	Procedure	CPT-4
99407	Smoking and tobacco use cessation counseling visit; intensive, greater than 10 minutes	Procedure	CPT-4
F17.200	Nicotine dependence, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F17.201	Nicotine dependence, unspecified, in remission	Diagnosis	ICD-10-CM
F17.203	Nicotine dependence unspecified, with withdrawal	Diagnosis	ICD-10-CM
F17.208	Nicotine dependence, unspecified, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.209	Nicotine dependence, unspecified, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.210	Nicotine dependence, cigarettes, uncomplicated	Diagnosis	ICD-10-CM
F17.211	Nicotine dependence, cigarettes, in remission	Diagnosis	ICD-10-CM
F17.213	Nicotine dependence, cigarettes, with withdrawal	Diagnosis	ICD-10-CM
F17.218	Nicotine dependence, cigarettes, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.219	Nicotine dependence, cigarettes, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.223	Nicotine dependence, chewing tobacco, with withdrawal	Diagnosis	ICD-10-CM
F17.228	Nicotine dependence, chewing tobacco, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.229	Nicotine dependence, chewing tobacco, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.290	Nicotine dependence, other tobacco product, uncomplicated	Diagnosis	ICD-10-CM
F17.291	Nicotine dependence, other tobacco product, in remission	Diagnosis	ICD-10-CM
F17.293	Nicotine dependence, other tobacco product, with withdrawal	Diagnosis	ICD-10-CM
F17.298	Nicotine dependence, other tobacco product, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.299	Nicotine dependence, other tobacco product, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
G0436	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intermediate, greater than 3 minutes, up to 10 minutes	Procedure	HCPCS
G0437	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intensive, greater than 10 minutes	Procedure	HCPCS
G9016	Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) [demo project code only]	Procedure	HCPCS
G9276	Documentation that patient is a current tobacco user	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
G9458	Patient documented as tobacco user and received tobacco cessation intervention (must include at least one of the following: advice given to quit smoking or tobacco use, counseling on the benefits of quitting smoking or tobacco use, assistance with or	Procedure	HCPCS
O99.330	Smoking (tobacco) complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.331	Smoking (tobacco) complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.332	Smoking (tobacco) complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.333	Smoking (tobacco) complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.334	Smoking (tobacco) complicating childbirth	Diagnosis	ICD-10-CM
O99.335	Smoking (tobacco) complicating the puerperium	Diagnosis	ICD-10-CM
S4995	Smoking cessation gum	Procedure	HCPCS
S9075	Smoking cessation treatment	Procedure	HCPCS
S9453	Smoking cessation classes, nonphysician provider, per session	Procedure	HCPCS
T65.221A	Toxic effect of tobacco cigarettes, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T65.222A	Toxic effect of tobacco cigarettes, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.223A	Toxic effect of tobacco cigarettes, assault, initial encounter	Diagnosis	ICD-10-CM
T65.224A	Toxic effect of tobacco cigarettes, undetermined, initial encounter	Diagnosis	ICD-10-CM
Z71.6	Tobacco abuse counseling	Diagnosis	ICD-10-CM
Z87.891	Personal history of nicotine dependence	Diagnosis	ICD-10-CM
Stroke/Transient Ischemic Attack (TIA)			
G45.0	Vertebro-basilar artery syndrome	Diagnosis	ICD-10-CM
G45.1	Carotid artery syndrome (hemispheric)	Diagnosis	ICD-10-CM
G45.2	Multiple and bilateral precerebral artery syndromes	Diagnosis	ICD-10-CM
G45.3	Amaurosis fugax	Diagnosis	ICD-10-CM
G45.8	Other transient cerebral ischemic attacks and related syndromes	Diagnosis	ICD-10-CM
G45.9	Transient cerebral ischemic attack, unspecified	Diagnosis	ICD-10-CM
G46.0	Middle cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.1	Anterior cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.2	Posterior cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.3	Brain stem stroke syndrome	Diagnosis	ICD-10-CM
G46.4	Cerebellar stroke syndrome	Diagnosis	ICD-10-CM
G46.5	Pure motor lacunar syndrome	Diagnosis	ICD-10-CM
G46.6	Pure sensory lacunar syndrome	Diagnosis	ICD-10-CM
G46.7	Other lacunar syndromes	Diagnosis	ICD-10-CM
G46.8	Other vascular syndromes of brain in cerebrovascular diseases	Diagnosis	ICD-10-CM
G97.31	Intraoperative hemorrhage and hematoma of a nervous system organ or structure complicating a nervous system procedure	Diagnosis	ICD-10-CM
G97.32	Intraoperative hemorrhage and hematoma of a nervous system organ or structure complicating other procedure	Diagnosis	ICD-10-CM
I60.00	Nontraumatic subarachnoid hemorrhage from unspecified carotid siphon and bifurcation	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I60.01	Nontraumatic subarachnoid hemorrhage from right carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.02	Nontraumatic subarachnoid hemorrhage from left carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.10	Nontraumatic subarachnoid hemorrhage from unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I60.11	Nontraumatic subarachnoid hemorrhage from right middle cerebral artery	Diagnosis	ICD-10-CM
I60.12	Nontraumatic subarachnoid hemorrhage from left middle cerebral artery	Diagnosis	ICD-10-CM
I60.2	Nontraumatic subarachnoid hemorrhage from anterior communicating artery	Diagnosis	ICD-10-CM
I60.20	Nontraumatic subarachnoid hemorrhage from unspecified anterior communicating artery	Diagnosis	ICD-10-CM
I60.21	Nontraumatic subarachnoid hemorrhage from right anterior communicating artery	Diagnosis	ICD-10-CM
I60.22	Nontraumatic subarachnoid hemorrhage from left anterior communicating artery	Diagnosis	ICD-10-CM
I60.30	Nontraumatic subarachnoid hemorrhage from unspecified posterior communicating artery	Diagnosis	ICD-10-CM
I60.31	Nontraumatic subarachnoid hemorrhage from right posterior communicating artery	Diagnosis	ICD-10-CM
I60.32	Nontraumatic subarachnoid hemorrhage from left posterior communicating artery	Diagnosis	ICD-10-CM
I60.4	Nontraumatic subarachnoid hemorrhage from basilar artery	Diagnosis	ICD-10-CM
I60.50	Nontraumatic subarachnoid hemorrhage from unspecified vertebral artery	Diagnosis	ICD-10-CM
I60.51	Nontraumatic subarachnoid hemorrhage from right vertebral artery	Diagnosis	ICD-10-CM
I60.52	Nontraumatic subarachnoid hemorrhage from left vertebral artery	Diagnosis	ICD-10-CM
I60.6	Nontraumatic subarachnoid hemorrhage from other intracranial arteries	Diagnosis	ICD-10-CM
I60.7	Nontraumatic subarachnoid hemorrhage from unspecified intracranial artery	Diagnosis	ICD-10-CM
I60.8	Other nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I60.9	Nontraumatic subarachnoid hemorrhage, unspecified	Diagnosis	ICD-10-CM
I61.0	Nontraumatic intracerebral hemorrhage in hemisphere, subcortical	Diagnosis	ICD-10-CM
I61.1	Nontraumatic intracerebral hemorrhage in hemisphere, cortical	Diagnosis	ICD-10-CM
I61.2	Nontraumatic intracerebral hemorrhage in hemisphere, unspecified	Diagnosis	ICD-10-CM
I61.3	Nontraumatic intracerebral hemorrhage in brain stem	Diagnosis	ICD-10-CM
I61.4	Nontraumatic intracerebral hemorrhage in cerebellum	Diagnosis	ICD-10-CM
I61.5	Nontraumatic intracerebral hemorrhage, intraventricular	Diagnosis	ICD-10-CM
I61.6	Nontraumatic intracerebral hemorrhage, multiple localized	Diagnosis	ICD-10-CM
I61.8	Other nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I61.9	Nontraumatic intracerebral hemorrhage, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I62.00	Nontraumatic subdural hemorrhage, unspecified	Diagnosis	ICD-10-CM
I62.01	Nontraumatic acute subdural hemorrhage	Diagnosis	ICD-10-CM
I62.02	Nontraumatic subacute subdural hemorrhage	Diagnosis	ICD-10-CM
I62.9	Nontraumatic intracranial hemorrhage, unspecified	Diagnosis	ICD-10-CM
I63.00	Cerebral infarction due to thrombosis of unspecified precerebral artery	Diagnosis	ICD-10-CM
I63.011	Cerebral infarction due to thrombosis of right vertebral artery	Diagnosis	ICD-10-CM
I63.012	Cerebral infarction due to thrombosis of left vertebral artery	Diagnosis	ICD-10-CM
I63.013	Cerebral infarction due to thrombosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.019	Cerebral infarction due to thrombosis of unspecified vertebral artery	Diagnosis	ICD-10-CM
I63.02	Cerebral infarction due to thrombosis of basilar artery	Diagnosis	ICD-10-CM
I63.031	Cerebral infarction due to thrombosis of right carotid artery	Diagnosis	ICD-10-CM
I63.032	Cerebral infarction due to thrombosis of left carotid artery	Diagnosis	ICD-10-CM
I63.033	Cerebral infarction due to thrombosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.039	Cerebral infarction due to thrombosis of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.09	Cerebral infarction due to thrombosis of other precerebral artery	Diagnosis	ICD-10-CM
I63.10	Cerebral infarction due to embolism of unspecified precerebral artery	Diagnosis	ICD-10-CM
I63.111	Cerebral infarction due to embolism of right vertebral artery	Diagnosis	ICD-10-CM
I63.112	Cerebral infarction due to embolism of left vertebral artery	Diagnosis	ICD-10-CM
I63.113	Cerebral infarction due to embolism of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.119	Cerebral infarction due to embolism of unspecified vertebral artery	Diagnosis	ICD-10-CM
I63.12	Cerebral infarction due to embolism of basilar artery	Diagnosis	ICD-10-CM
I63.131	Cerebral infarction due to embolism of right carotid artery	Diagnosis	ICD-10-CM
I63.132	Cerebral infarction due to embolism of left carotid artery	Diagnosis	ICD-10-CM
I63.133	Cerebral infarction due to embolism of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.139	Cerebral infarction due to embolism of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.19	Cerebral infarction due to embolism of other precerebral artery	Diagnosis	ICD-10-CM
I63.20	Cerebral infarction due to unspecified occlusion or stenosis of unspecified precerebral arteries	Diagnosis	ICD-10-CM
I63.211	Cerebral infarction due to unspecified occlusion or stenosis of right vertebral artery	Diagnosis	ICD-10-CM
I63.212	Cerebral infarction due to unspecified occlusion or stenosis of left vertebral artery	Diagnosis	ICD-10-CM
I63.213	Cerebral infarction due to unspecified occlusion or stenosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.219	Cerebral infarction due to unspecified occlusion or stenosis of unspecified vertebral artery	Diagnosis	ICD-10-CM
I63.22	Cerebral infarction due to unspecified occlusion or stenosis of basilar artery	Diagnosis	ICD-10-CM
I63.231	Cerebral infarction due to unspecified occlusion or stenosis of right carotid arteries	Diagnosis	ICD-10-CM
I63.232	Cerebral infarction due to unspecified occlusion or stenosis of left carotid arteries	Diagnosis	ICD-10-CM
I63.233	Cerebral infarction due to unspecified occlusion or stenosis of bilateral carotid arteries	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I63.239	Cerebral infarction due to unspecified occlusion or stenosis of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.29	Cerebral infarction due to unspecified occlusion or stenosis of other precerebral arteries	Diagnosis	ICD-10-CM
I63.30	Cerebral infarction due to thrombosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.311	Cerebral infarction due to thrombosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.312	Cerebral infarction due to thrombosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.313	Cerebral infarction due to thrombosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.319	Cerebral infarction due to thrombosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.321	Cerebral infarction due to thrombosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.322	Cerebral infarction due to thrombosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.323	Cerebral infarction due to thrombosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.329	Cerebral infarction due to thrombosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.331	Cerebral infarction due to thrombosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.332	Cerebral infarction due to thrombosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.333	Cerebral infarction due to thrombosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.339	Cerebral infarction due to thrombosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.341	Cerebral infarction due to thrombosis of right cerebellar artery	Diagnosis	ICD-10-CM
I63.342	Cerebral infarction due to thrombosis of left cerebellar artery	Diagnosis	ICD-10-CM
I63.343	Cerebral infarction due to thrombosis of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.349	Cerebral infarction due to thrombosis of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.39	Cerebral infarction due to thrombosis of other cerebral artery	Diagnosis	ICD-10-CM
I63.40	Cerebral infarction due to embolism of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.411	Cerebral infarction due to embolism of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.412	Cerebral infarction due to embolism of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.413	Cerebral infarction due to embolism of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.419	Cerebral infarction due to embolism of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.421	Cerebral infarction due to embolism of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.422	Cerebral infarction due to embolism of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.423	Cerebral infarction due to embolism of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.429	Cerebral infarction due to embolism of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.431	Cerebral infarction due to embolism of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.432	Cerebral infarction due to embolism of left posterior cerebral artery	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I63.433	Cerebral infarction due to embolism of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.439	Cerebral infarction due to embolism of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.441	Cerebral infarction due to embolism of right cerebellar artery	Diagnosis	ICD-10-CM
I63.442	Cerebral infarction due to embolism of left cerebellar artery	Diagnosis	ICD-10-CM
I63.443	Cerebral infarction due to embolism of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.449	Cerebral infarction due to embolism of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.49	Cerebral infarction due to embolism of other cerebral artery	Diagnosis	ICD-10-CM
I63.50	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.511	Cerebral infarction due to unspecified occlusion or stenosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.512	Cerebral infarction due to unspecified occlusion or stenosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.513	Cerebral infarction due to unspecified occlusion or stenosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.519	Cerebral infarction due to unspecified occlusion or stenosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.521	Cerebral infarction due to unspecified occlusion or stenosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.522	Cerebral infarction due to unspecified occlusion or stenosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.523	Cerebral infarction due to unspecified occlusion or stenosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.529	Cerebral infarction due to unspecified occlusion or stenosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.531	Cerebral infarction due to unspecified occlusion or stenosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.532	Cerebral infarction due to unspecified occlusion or stenosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.533	Cerebral infarction due to unspecified occlusion or stenosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.539	Cerebral infarction due to unspecified occlusion or stenosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.541	Cerebral infarction due to unspecified occlusion or stenosis of right cerebellar artery	Diagnosis	ICD-10-CM
I63.542	Cerebral infarction due to unspecified occlusion or stenosis of left cerebellar artery	Diagnosis	ICD-10-CM
I63.543	Cerebral infarction due to unspecified occlusion or stenosis of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.549	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebellar artery	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I63.59	Cerebral infarction due to unspecified occlusion or stenosis of other cerebral artery	Diagnosis	ICD-10-CM
I63.6	Cerebral infarction due to cerebral venous thrombosis, nonpyogenic	Diagnosis	ICD-10-CM
I63.8	Other cerebral infarction	Diagnosis	ICD-10-CM
I63.81	Other cerebral infarction due to occlusion or stenosis of small artery	Diagnosis	ICD-10-CM
I63.89	Other cerebral infarction	Diagnosis	ICD-10-CM
I63.9	Cerebral infarction, unspecified	Diagnosis	ICD-10-CM
I67.841	Reversible cerebrovascular vasoconstriction syndrome	Diagnosis	ICD-10-CM
I67.848	Other cerebrovascular vasospasm and vasoconstriction	Diagnosis	ICD-10-CM
I67.89	Other cerebrovascular disease	Diagnosis	ICD-10-CM
I97.810	Intraoperative cerebrovascular infarction during cardiac surgery	Diagnosis	ICD-10-CM
I97.811	Intraoperative cerebrovascular infarction during other surgery	Diagnosis	ICD-10-CM
I97.820	Postprocedural cerebrovascular infarction following cardiac surgery	Diagnosis	ICD-10-CM
I97.821	Postprocedural cerebrovascular infarction following other surgery	Diagnosis	ICD-10-CM

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
Obesity	
benzphetamine HCl	Regimex
benzphetamine HCl	benzphetamine
diethylpropion HCl	diethylpropion
liraglutide	Saxenda
liraglutide	Victoza 2-Pak
liraglutide	Victoza 3-Pak
liraglutide	liraglutide
lorcaserin HCl	Belviq
lorcaserin HCl	Belviq XR
naltrexone HCl/bupropion HCl	Contrave
orlistat	Alli
orlistat	Xenical
phendimetrazine tartrate	phendimetrazine tartrate
phentermine HCl	Adipex-P
phentermine HCl	Lomaira
phentermine HCl	phentermine
phentermine HCl/topiramate	Qsymia
semaglutide	Ozempic
semaglutide	Wegovy
tirzepatide	Mounjaro
tirzepatide	Zepbound
Smoking	
nicotine	Nicoderm CQ
nicotine	Nicotrol
nicotine	Nicotrol NS
nicotine	nicotine
nicotine bitartrate	Nicotine Tartrate
nicotine polacrilex	Nicorelief
nicotine polacrilex	Nicorette
nicotine polacrilex	Quit 2
nicotine polacrilex	Quit 4
nicotine polacrilex	Stop Smoking Aid
nicotine polacrilex	nicotine (polacrilex)
nicotine polacrilex	nicotine polacrilex (bulk)
varenicline tartrate	Chantix
varenicline tartrate	Chantix Continuing Month Box
varenicline tartrate	Chantix Starting Month Box
varenicline tartrate	Tyrvaya
varenicline tartrate	varenicline tartrate

Appendix F. Specifications Used in this Request

An execution of the Cohort Identification and Descriptive Analysis (CIDA) tool, version 14.2.0, was requested to investigate utilization and uptake of New Molecular Entities (NMEs) approved in year 2018 in the Sentinel Distributed Database (SDD). This is a type five analysis in the Query Request Package (QRP) documentation. Aggregate level data only was returned. One run of the program was performed.

Query Reriod: January 1, 2018 - December 31, 2024
Coverage Requirement: Medical and Drug Coverage
Minimum Pre-Index Enrollment Days: 183 days
Minimum Post-Index Required Days: 0 days
Enrollment Gap: 45 days
Age Groups: 0-17, 18-24, 25-40, 41-64, 65+ years
Sex: M, F
Other Demographic Restrictions: Not Applicable
Stratifications: Age group, Sex, Calendar Month (for Figures only)
Data Restrictions: None
Chart Availability Restriction Indicator: N
Envelope Macro: Reclassify encounters during inpatient stay as inpatient
Freeze Data: N
Drop Censor Output Indicator: Y (Indicates if counts of episodes censored by death and query end should be excluded from output to prevent death small cells from being sent to SOC.)

Exposure									
Scenario	Index Exposure	Cohort Definition	Type 5 Exposure Washout Period	Care Setting and Diagnosis Position Requirements	Treatment Episode Gap Type	Exposure Episode Gap	Exposure Episode Extension Period	Create Baseline Table?	End At-Risk Period at Evidence of
1	mogamulizumab-kpkc	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
2	patisiran	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
3	segesterone acetate and ethinyl estradiol vaginal system	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
4	migalastat	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
5	stiripentol	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F. Specifications Used in this Request

Exposure									
Scenario	Index Exposure	Cohort Definition	Type 5 Exposure Washout Period	Care Setting and Diagnosis Position Requirements	Treatment Episode Gap Type	Exposure Episode Gap	Exposure Episode Extension Period	Create Baseline Table?	End At-Risk Period at Evidence of
6	cenegermin-bkbj	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
7	lanadelumab	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
8	eravacycline	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
9	doravirine	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
10	moxetumomab pasudotox-tdfk	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
11	fremanezumab-vfrm	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
12	duvelisib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
13	galcanezumab-gnlm	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
14	dacomitinib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F. Specifications Used in this Request

Exposure									
Scenario	Index Exposure	Cohort Definition	Type 5 Exposure Washout Period	Care Setting and Diagnosis Position Requirements	Treatment Episode Gap Type	Exposure Episode Gap	Exposure Episode Extension Period	Create Baseline Table?	End At-Risk Period at Evidence of
15	cemiplimab-rwlc	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
16	sarecycline	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
17	omadacycline	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
18	elapegademase-lvlr	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
19	inotersen	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
20	talazoparib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
21	baloxavir marboxil	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
22	lorlatinib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
23	revefenacin	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F. Specifications Used in this Request

Exposure									
Scenario	Index Exposure	Cohort Definition	Type 5 Exposure Washout Period	Care Setting and Diagnosis Position Requirements	Treatment Episode Gap Type	Exposure Episode Gap	Exposure Episode Extension Period	Create Baseline Table?	End At-Risk Period at Evidence of
24	rifamycin	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
25	emapalumab-lzsg	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
26	glasdegib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
27	larotrectinib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
28	amifampridine	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
29	gilteritinib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
30	prucalopride	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
31	calaspargase pegol-mknl	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
32	tagraxofusp-erzs	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F. Specifications Used in this Request

Exposure									
Scenario	Index Exposure	Cohort Definition	Type 5 Exposure Washout Period	Care Setting and Diagnosis Position Requirements	Treatment Episode Gap Type	Exposure Episode Gap	Exposure Episode Extension Period	Create Baseline Table?	End At-Risk Period at Evidence of
33	ravulizumab	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
International Classification of Diseases, Ninth Revision (ICD-9), International Classification of Diseases, Tenth Revision (ICD-10), Healthcare Common Procedure Coding System (HCPCS), and CPT (Current Procedural Terminology) codes are provided by Optum360. National Drug Codes (NDCs) are checked against FirstDataBank's FDBMedKnowledge®									

Appendix G. Baseline Characteristics Used in this Request

Baseline Characteristics									
Covariate Name	Covariate Number	Code Category	Complex Covariate Components	Care Setting and Diagnosis Position Requirements	Number of Instances the Covariate Should be Found in Evaluation Period	Covariate Evaluation Period Start	Covariate Evaluation Period End	Forced Supply to Attach to a Code <i>(only applies to RX codes)</i>	Lookback Period Date Only
<i>Chronic Conditions Data Warehouse</i>									
Acute Myocardial Infarction	1	DX		IPP, IPS	1	-183	-1	N/A	Y
Alzheimer's Disease	2	DX		Any	1	-183	-1	N/A	Y
Non-Alzheimer's Dementia	3	DX		Any	1	-183	-1	N/A	Y
Atrial Fibrillation	4	DX		IPP, IPS	1	-183	-1	N/A	Y
	5	DX		AV*, ED*, OA*	2	-183	-1	N/A	Y
	6	CC	4 or 5		1			N/A	Y
Diabetes	7	DX		IP*, IS*	1	-183	-1	N/A	Y
	8	DX		AV*, ED*, OA*	2	-183	-1	N/A	Y
	9	CC	7 or 8		1			N/A	Y
Heart Failure	10	DX		IP*, AV*, ED*, OA*	1	-183	-1	N/A	Y
Hyperlipidemia	11	DX		IP*, IS*	1	-183	-1	N/A	Y
	12	DX		AV*, ED*, OA*	2	-183	-1	N/A	Y
	13	CC	11 or 12		1			N/A	Y
Hypertension	14	DX		IP*, IS*	1	-183	-1	N/A	Y
	15	DX		AV*, ED*, OA*	2	-183	-1	N/A	Y
	16	CC	14 or 15		1			N/A	Y
Depression	17	DX		Any	1	-183	-1	N/A	Y
Ischemic Heart Disease	18	DX		Any	1	-183	-1	N/A	Y
Rheumatoid Arthritis/Osteoarthritis	19	DX		Any	2	-183	-1	N/A	Y
Stroke/Transient Ishemic Attack (TIA)	20	DX		IP*	1	-183	-1	N/A	Y
	21	DX		AV*, ED*, OA*	2	-183	-1	N/A	Y
	22	CC	20 or 21		1			N/A	Y
Breast Cancer	23	DX		IP*, IS*	1	-183	-1	N/A	Y
	24	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	25	CC	23 or 24		1			N/A	Y
Colorectal Cancer	26	DX		IP*, IS*	1	-183	-1	N/A	Y
	27	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	28	CC	26 or 27		1			N/A	Y
Prostate Cancer	29	DX		IP*, IS*	1	-183	-1	N/A	Y
	30	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	31	CC	29 or 30		1			N/A	Y
Lung Cancer	32	DX		IP*, IS*	1	-183	-1	N/A	Y
	33	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	34	CC	32 or 33		1			N/A	Y
Endometrial Cancer	35	DX		IP*, IS*	1	-183	-1	N/A	Y
	36	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	37	CC	35 or 36		1			N/A	Y
Acquired Hypothyroidism	38	DX		IP*, IS*,	1	-183	-1	N/A	Y
	39	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	40	CC	38 or 39		1			N/A	Y
Anemia	41	DX		Any	1	-183	-1	N/A	Y
Asthma	42	DX		IP*, IS*,	1	-183	-1	N/A	Y
	43	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	44	CC	42 or 43		1			N/A	Y

Appendix G. Baseline Characteristics Used in this Request

Baseline Characteristics									
Covariate Name	Covariate Number	Code Category	Complex Covariate Components	Care Setting and Diagnosis Position Requirements	Number of Instances the Covariate Should be Found in Evaluation Period	Covariate Evaluation Period Start	Covariate Evaluation Period End	Forced Supply to Attach to a Code <i>(only applies to RX codes)</i>	Lookback Period Date Only
Benign Prostatic Hyperplasia	45	DX		IP*, IS*,	1	-183	-1	N/A	Y
	46	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	47	CC	45 or 46		1			N/A	Y
Chronic Kidney Disease	48	DX		IP*, IS*,	1	-183	-1	N/A	Y
	49	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	50	CC	48 or 49		1			N/A	Y
Chronic Obstructive Pulmonary Disease (COPD) and Bronchiectasis	51	DX		IP*, IS*,	1	-183	-1	N/A	Y
	52	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	53	CC	51 or 52		1			N/A	Y
Glaucoma	54	DX		AV*, ED*, OA*	1	-183	-1	N/A	Y
Osteoporosis	55	DX		IP*, IS*,	1	-183	-1	N/A	Y
	56	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	57	CC	55 or 56		1			N/A	Y
Other									
Obesity (Diagnosis or Procedure Codes)	58	DX, PX		Any	1	-183	-1	N/A	Y
Obesity (Dispensing Codes)	59	RX		Any	1	-183	-1	N/A	Y
Overweight	60	DX		Any	1	-183	-1	N/A	Y
Smoking (Diagnosis or Procedure Codes)	61	DX, PX		Any	1	-183	-1	N/A	Y
Smoking (Dispensing Codes)	62	RX		Any	1	-183	-1	N/A	Y
Alcohol Abuse or Dependence	63	DX, PX		Any	1	-183	-1	N/A	Y
Drug Abuse or Dependence	64	DX, PX		Any	1	-183	-1	N/A	Y
History of Cardiac Arrest	65	DX		Any	1	-183	-1	N/A	Y
History of Coronary Angioplasty or Bypass	66	DX		Any	1	-183	-1	N/A	Y
Liver Disease CCW	67	DX		IP*, IS*	1	-183	-1	N/A	Y
	68	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	69	CC	67 or 68		1			N/A	Y
	70	PX		AV*	1	-183	-1	N/A	Y
	71	DX		AV*	1	-183	-1	N/A	Y
	72	CC	70 and 71		1			N/A	Y
	73	PX		ED*	1	-183	-1	N/A	Y
	74	DX		ED*	1	-183	-1	N/A	Y
	75	CC	73 and 74		1			N/A	Y
	76	PX		OA*	1	-183	-1	N/A	Y
	77	DX		OA*	1	-183	-1	N/A	Y
	78	CC	76 and 77		1			N/A	Y
	79	PX		IS*	1	-183	-1	N/A	Y
	80	DX		IS*	1	-183	-1	N/A	Y
	81	CC	79 and 80		1			N/A	Y
	82	CC	69 or 72 or 75 or 78 or		1			N/A	Y

Appendix G. Baseline Characteristics Used in this Request

Baseline Characteristics									
Covariate Name	Covariate Number	Code Category	Complex Covariate Components	Care Setting and Diagnosis Position Requirements	Number of Instances the Covariate Should be Found in Evaluation Period	Covariate Evaluation Period Start	Covariate Evaluation Period End	Forced Supply to Attach to a Code (only applies to RX codes)	Lookback Period Date Only
Liver Disease Extended	83	DX	83 or 84	IP*, IS*,	1	-183	-1	N/A	Y
	84	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	85	CC			1			N/A	Y
	86	PX	86 and 87	AV*	1	-183	-1	N/A	Y
	87	DX		AV*	1	-183	-1	N/A	Y
	88	CC			1			N/A	Y
	89	PX	89 and 90	ED*	1	-183	-1	N/A	Y
	90	DX		ED*	1	-183	-1	N/A	Y
	91	CC			1			N/A	Y
	92	PX	92 and 93	OA*	1	-183	-1	N/A	Y
	93	DX		OA*	1	-183	-1	N/A	Y
	94	CC			1			N/A	Y
	95	PX	95 and 96	IS*	1	-183	-1	N/A	Y
	96	DX		IS*	1	-183	-1	N/A	Y
	97	CC			1			N/A	Y
	98	CC	85 or 88 or 91 or 94 or		1			N/A	Y

The wildcard symbol () can be used to represent 'any' values of either the care setting or principal discharge diagnosis flag. Wildcard does not restrict a specific principal diagnosis position. The principal discharge diagnosis flag is only relevant for

N/A means Not Applicable.

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a

Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential,

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' =

RX: Drug code

DX: Diagnosis code

PX: Procedure code

CC: Complex covariates (multiple

COVARNUM values are used to define a covariate)

IP*: inpatient hospital stays, any diagnoses

IS*: non-acute institutional stays, any diagnoses

ED*: emergency department encounters


AV*: ambulatory visits

OA*: other ambulatory visits

N: Lookback period should search for evidence of a date or an interval

Y: Lookback period should search for evidence of a date only

Appendix H. Diagram Detailing the Design of the Request

Cohort Design for Part 2 QF-8901¹

¹ Includes all valid exposure during the query period; only the first valid episode's incidence is assessed using the washout period.

² 33 scenarios defined on initiation of NMEs approved in 2018 part 2 (one scenario per NME); Cohort entry date = first dispensing date for qualifying NME.

³ Baseline characteristics:

Window I: Age, Sex, Race, Hispanic Ethnicity, Year

Window II: Chronic conditions warehouse (CCW), alcohol abuse or dependence, drug abuse or dependence, history of cardiac arrest, history of coronary angioplasty or bypass, obesity, overweight, and smoking, Liver Disease CCW, Liver Disease Extended

⁴ Censoring: earliest of death, disenrollment, data partner data end date, query end date